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ABSTRACT 
 
Background: Hyperinsulinaemic hypoglycaemia (HH) is characterized by unregulated 
secretion of insulin in the presence of hypoglycaemia. Mutations in nine different genes 
(ABCC8, KCNJ11, GLUD1, HNF4A, HNF1A, GCK, HADH, SLC16A1 and UCP2) have so 
far been identified as a cause of HH. Mutations in ABCC8 and KCNJ11, which encode the 
sulfonylurea receptor 1 (SUR1) and potassium inward-rectifying 6.2 (Kir6.2) subunits of 
ATP-sensitive potassium channel (KATP channel), are the most common cause of HH. At 
least two (possibly more) well-described histological subtypes are associated with HH: a 
focal form and a diffuse form. Diffuse HH are most commonly due to recessive and dominant 
mutations in ABCC8 and KCNJ11. Focal HH results due to somatic loss of the maternal 11p 
allele (11p15.1 to 11p15.5) involving the ABCC8 and KCNJ11 region in patients with 
paternally inherited mutation in ABCC8 or KCNJ11. HH can be transient and resolve within 
few weeks. Transient HH is seen in association with intrauterine growth restriction, maternal 
diabetes mellitus, perinatal asphyxia, erythroblastosis fetalis, maternal administration of 
sulfonylureas, and intravenous glucose infusions during labour. In large series of HH 
patients, the underlying genetic cause was not identified in approximately 50% of the 
patients. Whole-exome sequencing is a powerful and cost-effective tool for identifying 
genetic basis of diseases. It involves sequencing the protein coding regions of the human 
genome.  
Aim: To identify novel genetic mechanisms of HH. To functionally characterize two novel 
KATP channel mutations associated with a unique clinical phenotype.  
Patients: Four patients had protein-sensitive HH with normal serum ammonia. Two families 
(one consanguineous and one non-consanguineous) had two affected siblings with HH. All 
these patients had negative molecular genetics for ABCC8, KCNJ11, GLUD1 and HADH. 
One patient had a unique phenotype of HH and cardiac arrhythmias. In addition, three 
patients had two novel KATP channel mutations associated with a unique clinical phenotype 
(transient HH and combined focal/diffuse HH).  
Methods: Whole-exome sequencing (WES) was performed on nine patients (from seven 
families), their parents and unaffected siblings to identify novel, deleterious gene variants.  
Based on the available biological information, two novel gene variants (p.F108del K2P17 and 
p.A422V Kv6.2) were considered potential disease causing. The mutations were created in 
plasmid constructs containing the WT cDNA sequence for KCNK17 (K2P17) and KCNG2 
(Kv6.2) using site-directed mutagenesis. These constructs were transfected into HEK293 
cells, which were studied by whole-cell patch clamping. Two novel KATP channel mutations 
(p.T1516M SUR1 and p.*391Rext*94 Kir6.2) were also studied. For studying the 
p.*391Rext*94 Kir6.2 mutation, the WT human cDNA and 3ʹ′UTR sequence of KCNJ11 was 
cloned into pcDNA 3.1 vector. The KATP channel mutations were created in plasmid 
construct containing the WT cDNA sequence for ABCC8/KCNJ11 using site-directed 
mutagenesis. These constructs were transfected into HEK293 cells, which were then studied 
by whole-cell patch clamping. The p.*391Rext*94 Kir6.2 is a non-stop mutation and the 
transcripts can undergo degradation by non-stop decay phenomenon. The presence of p. 
*391Rext*94 Kir6.2 mutant transcript in the pancreatic tissue of the affected patient was 
studied by cDNA sequencing and Western blotting on the patient’s pancreatic tissue extracted 
RNA and protein fraction respectively.  
Results: WES identified two potential disease-causing heterozygous gene variants 
(p.F108del K2P17 and p.A422V Kv6.2) in a family with a phenotype of HH and cardiac 
arrhythmia, which were confirmed by Sanger sequencing. Whole-cell patch clamping 
experiments on HEK293 cells proved both variants to be pathogenic under heterozygous 
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expression. Whole-cell patch clamping experiments on the two novel KATP channel mutations 
(p.T1516M SUR1 and p.*391Rext*94 Kir6.2) was indicative of pathogenic nature of the 
mutation. Analysis of the pancreatic tissue, obtained at surgery from the patient with non-stop 
KCNJ11 mutation (p.*391Rext*94 Kir6.2), by cDNA sequencing and Western blotting 
established the presence of transcript and protein with non-stop mutation.  
Conclusions:  Mutations in KCNK17 (K2P17) and KCNG2 (Kv6.2) are potential novel genetic 
mechanisms for HH and cardiac arrhythmias. More patients with similar phenotype need to 
be screened for mutations in these two genes. A novel mechanism for HH (combined focal 
and diffuse HH phenotype) and molecular basis for a transient type of HH was identified.  
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CHAPTER 1 
 
 
 
 
GLUCOSE PHYSIOLOGY, 
REGULATION OF INSULIN 
SECRETION AND 
HYPERINSULINAEMIC 
HYPOGLYCAEMIA  
 2 
 
1.1	  SUMMARY	  OF	  CHAPTER	  1	  
 
Chapter 1 provides an introduction to glucose physiology, regulation of insulin secretion, 
ATP-sensitive potassium channels (KATP), and hyperinsulinaemic hypoglycaemia (HH).  This 
chapter opens with a brief description of the physiological mechanisms of glucose regulation, 
followed by introduction to KATP channels. This then leads into detailed description of the 
clinical condition “hyperinsulinaemic hypoglycaemia”, its causes, clinical presentation, 
diagnosis, histological subtypes and management.  
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1.2	  GLUCOSE	  PHYSIOLOGY	  
 
1.2.1	  Introduction	  
 
Glucose is one of the principal energy substrates and provides about one-half of the total 
energy requirements of the human body. It is the predominant metabolic fuel for the brain. As 
the brain can neither store more than a few minutes supply of glucose nor synthesize glucose, 
its function is solely dependent on maintenance of normal glucose level in the circulation. To 
avoid problems from impairment of brain function due to diminished supply of glucose 
(seizures, unconsciousness, and permanent brain damage or [rarely] death), physiological 
mechanisms have evolved to maintain blood glucose level in the normal range. An 
abnormally reduced level of glucose in the blood is referred to as hypoglycaemia. It is a 
medical emergency and can produce symptoms due to neuroglycopenia.  
 
1.2.2	  Physiological	  Mechanisms	  Regulating	  Blood	  Glucose	  
Concentration	  
 
Blood glucose concentration is tightly regulated by maintaining a balance between the rate of 
glucose entry into the circulation and the rate of glucose removal from the circulation. This 
equilibrium is maintained by a complex interplay of glucose, insulin and counter-regulatory 
hormones that include glucagon, catecholamines, growth hormone and cortisol.  
 
1.2.2.1	  Glucose	  Production	  and	  Utilization	  
 
There are three sources of glucose flux in to the circulation:  
• Absorption from intestine following digestion of dietary carbohydrates,  
• Breakdown of stored glycogen into glucose in liver (glycogenolysis) and  
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• Formation of glucose from non-carbohydrate sources in liver and kidney 
(gluconeogenesis).  
 
Glycogenolysis occurs in liver and muscle in response to glucagon and/or adrenaline 
secretion. Glycogenolysis in the muscles provides glucose to be utilized by the muscles only 
whereas liver glycogenolysis maintains the blood glucose concentration in the first few hours 
after the meal and provides the brain with a ready source of glucose.  
 
Gluconeogenesis, which mainly occurs in the liver and to some extent in the kidneys, is 
responsible for maintaining blood glucose concentrations during prolonged fasting. The rate 
of gluconeogenesis is controlled by the concentrations of the available glucogenic substrates 
(alanine, lactate, glycerol etc.) and the activities of certain unidirectional enzymes, such as 
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase and glucose-6-
phosphatase (G6Pase). The activity of the key gluconeogenic enzymes is regulated by 
transcriptional and non-transcriptional mechanisms by key hormones, particularly insulin, 
glucagon and glucocorticoids (Beale et al., 1984, Christ et al., 1988).  
 
In the fasted state, insulin levels decrease while glucagon secretion increases resulting in 
increased gluconeogenesis. Glucagon treatment has been shown to result in increased PEPCK 
mRNA levels in the liver or hepatocytes (Beale et al., 1984, Christ et al., 1988, Iynedjian et 
al., 1985). In the fed state, insulin concentration increases, which suppresses 
gluconeogenesis.  
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Figure 1.1: Schematic showing glucose production by glycogenolysis (liver) and 
gluconeogenesis (liver and kidney) and peripheral glucose utilisation 
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In contrast to glucose production (which occurs only in liver and kidneys), glucose utilisation 
is by nearly all peripheral tissues. Glucose enters the cells in these tissues via two different 
types of carrier proteins in the cell membrane, the sodium-coupled glucose transporters 
(SGLT) and glucose transport facilitators (GLUT) (Mueckler, 1990). The distribution of 
these transporters varies in different tissues depending upon the requirement of the tissues 
(Mueckler, 1990). After entry into the cells, glucose can undergo three metabolic fates: 
1. Glycolysis – catabolism of glucose in the cells to produce adenosine triphosphate 
(ATP).  
2. Glycogenesis – conversion of glucose into glycogen for storage (in the liver and 
muscle). 
3. Conversion to fatty acids and storage as triglycerides (in adipose tissue). 
These fates are dependent upon the blood glucose concentration, length of fasting and the 
hormonal milieu. Among the various hormones that play a role, the principal hormone is 
insulin.  
 
 
1.2.2.2	  Insulin	  	  
 
Insulin is a 51 amino acids long polypeptide hormone produced in the β-cells of the 
pancreatic islets of Langerhans. It is encoded by the INS gene on chromosome 11. It consists 
of two chains (A & B) that are connected by disulfide bridges and has a molecular weight of 
5.8kDa. When first synthesized, insulin is a single polypeptide called preproinsulin. A 24 
amino acid signal peptide is cleaved off preproinsulin as it is translocated into the lumen of 
rough endoplasmic reticulum (RER), forming proinsulin. In the RER, proinsulin is folded 
into the correct conformation before transported to the Golgi apparatus. Proinsulin undergoes 
further maturation through the action of peptidases. The peptidases cleave proinsulin at 2 
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positions, releasing a fragment (C-peptide). The 2-peptide chains (the B- and A- chains) 
linked by 2 disulfide bonds form the active insulin. The resulting active insulin is packaged 
inside mature granules in the β-cells.   
 
Insulin receptor is a tyrosine kinase transmembrane receptor and is composed of two α and β 
subunits. Insulin binds to the extracellular portion of the α-subunits of the insulin receptor. 
The ligand binding causes a conformation change and activates the kinase domain on the 
intracellular portion of the β-subunits. The activated kinase domain autophosphorylates 
tyrosine residues on the c-terminus of the receptor as well as tyrosine residues in the IRS-1 
(insulin receptor substrate-1), IRS-2 and IRS-3 proteins. This activates protein kinase B 
through the intermediate steps of activation of phosphoinositol-3-kinase and production of 
phosphoinositol 1,4,5-triphosphate (PIP3) (Combettes-Souverain and Issad, 1998, Houslay 
and Siddle, 1989, Rhodes and White, 2002). Activation of protein kinase B results in 
activation of glycogen synthase and increase in GLUT4 transporters in the plasma membrane. 
Insulin action is terminated by endocytosis and degradation of the receptor bound to insulin 
as well as dephosphorylation of the tyrosine residues by tyrosine phosphatases (Combettes-
Souverain and Issad, 1998, Rhodes and White, 2002).  
 
In addition to β-cells, the islets of Langerhans have α-, δ-, ε- and pancreatic polypeptide (PP) 
cells as well. The average size of a human islet is between 50 to 400 µm in diameter and 
there are approximately one million such islets in a human pancreas interspersed between 
pancreatic exocrine tissue (Nam et al., 2010, Permutt et al., 1984). The β-cells comprise 
around 50-80% of the islet and are situated in the centre of the human islets. They are 
surrounded by α-cells, which secrete glucagon. The δ-cells and PP cells secrete somatostatin 
and pancreatic polypeptide respectively.  
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The α-, β-, δ- and PP cells are able to communicate with each other through the extracellular 
spaces and gap junctions. This enables them to influence the action of each other. For 
example, the secretion of insulin by the β-cells suppresses the secretion of glucagon from the 
α-cells.  
 
1.2.2.2.1	  Regulation	  of	  Insulin	  Secretion	  
 
The main regulator of insulin secretion is the blood glucose concentration, although it is 
modified by other nutrients (amino acids and fatty acids), circulating hormones and the 
autonomic nervous system, as well as local paracrine and autocrine signals (Ahren, 2000, Li 
et al., 2002, Redmon et al., 1994). 
 
Under normal physiological conditions the metabolism of glucose is intricately translated 
into signals regulating insulin secretion in pancreatic β-cells (Dunne et al., 2004).   
 
Glucose enters the pancreatic β-cells through facilitative glucose transporters, especially the 
glucose transporter 2 (GLUT 2) and is converted to glucose-6-phosphate by an islet specific 
enzyme glucokinase (Johnson et al., 1990).  In addition to pancreatic β-cells, glucokinase is 
also expressed in liver, gut and brain. GLUT2 has high Km for glucose (approximately 40 
mmol/l) which allows glucose transport across pancreatic β-cell membrane in proportion to 
the blood glucose concentrations (Gould et al., 1991). Glucokinase itself also plays a unique 
role in acting as a glucose sensor providing a link between the extracellular glucose 
concentration and the metabolism of glucose in the β-cell (Matschinsky, 1996).  When the 
blood glucose concentration is high, the activity of glucokinase increases thereby increasing 
the signal regulating the insulin production from the β-cell.  Similarly as the blood glucose 
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concentration decreases, less glucose transports across GLUT2 transporter and the activity of 
glucokinase is reduced. These events decrease the signal for insulin production and hence 
serum insulin becomes undetectable in adults at plasma glucose concentrations below 
3mmol/l (Cryer, 1993, Cryer et al., 2009).  
 
The pancreatic β-cell possesses a unique signal transduction system, which links the 
metabolism of the fuel stimulus to initiate insulin secretion, the so called “stimulus-response 
coupling”(Malaisse et al., 1979).  Glucose is the most important fuel involved in the 
stimulus-response coupling mechanism.  This stimulus response-coupling event is controlled 
by ATP-sensitive potassium channels (KATP) located in the pancreatic β-cell membrane, 
which are discussed later in this chapter. 
 
1.2.2.3	  Glucagon	  
 
Glucagon is a 29- amino acid peptide hormone processed from proglucagon. It plays a critical 
role in maintaining glucose homeostasis. Released from pancreatic α-cells in response to low 
circulating blood glucose, it acts via a seven-transmembrane G protein-coupled receptor 
consisting of 485 amino acids. The binding of glucagon activates Gsα, which leads to 
activation of adenylate cyclase, increase in intracellular cAMP levels, and subsequent 
activation of protein kinase A (PKA) (Jiang and Zhang, 2003). Activated PKA 
phosphorylates and activates glycogen phosphorylase kinase which in turn phosphorylates 
and activates glycogen phosphorylase (Jiang and Zhang, 2003). The activated glycogen 
phosphorylase results in increased glycogen breakdown (glycogenolysis) and production of 
glucose 6-phosphate (G-6-P). Additionally, glucagon has been shown to upregulate the 
transcription of glucose-6-phosphatase (G-6-Pase) gene and increase G-6-Pase activity 
(Striffler et al., 1984). Through these mechanisms, glucagon potentiates glycogenolysis. 
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By inducing the phosphorylation of glycogen synthase, a key enzyme in glycogenesis, 
glucagon inhibits its activity (Ciudad et al., 1984, Ramachandran et al., 1983). Inactivation of 
glycogen synthase reduces glycogen synthesis and accordingly, increases the pool of glucose 
for hepatic output into blood.  
 
Glucagon regulates blood glucose by also affecting glucose metabolism (increasing 
gluconeogenesis and decreasing glycolysis). Glucagon has been noticed to increase the 
PEPCK mRNA level in the liver (Beale et al., 1984, Christ et al., 1988, Iynedjian et al., 
1985). PEPCK catalyzes the rate-limiting step of conversion of oxaloacetate into 
phosphoenol pyruvate in the pathway of hepatic gluconeogenesis.  
 
Through phosphorylation of the bifunctional enzyme 6-phosphofructo-2-kinase (PFK-2)/ 
fructose-2,6-bisphosphatase (FBPase) by PKA, glucagon results in simultaneous inhibition 
PFK-2 and activation of FBPase (Kurland and Pilkis, 1995, Okar and Lange, 1999). These 
events reduce the intracellular levels of fructose-2,6-bisphosphate [F(2,6)P2]. As F(2,6)P2 is 
an allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1), glucagon relieves the 
inhibition of FBPase-1, which catalyzes an important step in gluconeogenesis.  
 
Glucagon inhibits glycolysis by inhibiting pyruvate kinase and phosphofructokinase-1 (PFK-
1) (Castano et al., 1979, Veneziale et al., 1976). Glucagon inhibits the transcription of the 
pyruvate kinase gene and augments the degradation of pyruvate kinase mRNA.  
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1.2.3	  KATP	  Channels	  
 
Dean and Matthews were the first to record electrical activity in the pancreatic β-cells (Dean 
et al., 1975). They found that the membrane potential of β-cells was glucose dependent. In 
the absence of glucose, the β-cells were hyperpolarized or silent. On exposure to high 
concentration of glucose, these cells depolarized. With the advent of patch clamp technique, 
the K+ channel responsible for this electrical activity was identified in isolated rat pancreatic 
β-cells. This channel was found to be active at the resting potential and was inhibited by 
glucose (Ashcroft et al., 1984). This glucose sensitive K+ channel was shown to be identical 
to the K+ channel identified in cardiac myocytes that was blocked by elevation of intracellular 
ATP (Rorsman and Trube, 1985). 
 
1.2.3.1	  Structure	  of	  KATP	  channel	  
 
KATP channels are expressed in many tissues (such as cardiomyocytes, pancreatic beta cells, 
skeletal muscles, vascular smooth muscles, adipose tissue, glial cells, and neurons). 
Functional KATP channels are now known to be octameric protein structures composed of 
four Kir6.x subunits that form the channel pore, surrounded by four sulfonylurea receptors 
(SURs) that regulate the channel pore activity (Figure 1.2).  
 
Kir6.2 was identified by screening a human genomic library and the MIN6 cDNA library by 
using Kir6.1 cDNA as a probe (Inagaki et al., 1995). However no significant KATP channel 
currents were noticed when mouse Kir6.2 alone was expressed alone in COS-1 cells, 
HEK239 cells or Xenopus laevis oocytes. When co-expressed with SUR1, weakly inward 
rectifying K+ currents were elicited. This channel activity could be inhibited by ATP and 
glibenclamide. This indicated that the pancreatic β-cell KATP channel comprises of two 
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subunits, SUR1 and Kir6.2. The 4:4 subunit stoichiometry of KATP channel was suggested by 
Inagaki and colleagues on the basis of optimum activity of KATP channels when SUR1 and 
Kir6.2 subunits were co expressed with-a molar ratio of 1:1 (Inagaki et al., 1995).   
 
The Kir6.x subunits (either Kir6.1 or Kir6.2) belong to the superfamily of weak inwardly 
rectifying, voltage independent potassium (K+) channels. These channels allow large K+ flux 
at potentials negative to the equilibrium potential of potassium (EK), but permit less current 
flow at more positive potentials (Lopatin et al., 1994). This characteristic, along with their 
voltage independence, makes Kir channels one of the major regulators of resting membrane 
potential. Furthermore, as KATP channels have the unique capability to respond to ATP/ADP 
levels, they are well suited to be the ideal cell metabolic sensors. Hence, KATP channels are 
able to regulate the membrane excitability in response to the metabolic status of the cell. This 
allows KATP channels to regulate many cellular functions, such as insulin secretion, 
excitability and cytoprotection.  
 
Each Kir6.2 subunit has two transmembrane (TM) domains (TM1 and TM2), which are 
linked by a pore-forming region (H5) on the extracellular side (Figure 1.3) (Martin et al., 
2013). The four TM2 domains of the four Kir6.2 subunits form the channel pore and the H5 
region serves as the potassium selectivity filter. The amino and carboxyl terminals are both 
found cytoplasmically, and join together to form the cytoplasmic domain that is responsible 
for channel gating and ATP binding (Martin et al., 2013). Unlike other Kir subunits, it lacks 
the S4 voltage sensor region that is critical for gating in all voltage dependent calcium (Ca2+), 
sodium (Na+) and potassium (K+) channels. Therefore, KATP channels are constitutively 
active if other regulatory mechanisms, such as SUR subunits, or ATP are absent.  
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SUR was first cloned from rat insulinoma (RINm5F) and hamster insulin-secreting tumor cell 
(HIT T15) λ phage libraries (Aguilar-Bryan et al., 1995). The open reading frame of hamster 
and rat SUR cDNA was found to encode proteins of 1582 amino acids. Northern (RNA) blot 
analysis of polyadenylated mRNA isolated from KATP channel expressing cell lines showed 
the presence of an approximately 5000-nucleotide transcript. A Blast search with nucleotide 
and amino acid sequence identified SUR sequence to be similar to cystic fibrosis 
transmembrane conductance regulator (CFTR) and multidrug resistance (MDR) proteins. 
This indicated that the SUR1 regulatory subunit belongs to the ATP-binding cassette (ABC) 
family (Aguilar-Bryan et al., 1995). The search also revealed two putative nucleotide-binding 
domains. These two domains had strong similarity to the 230- to 240- amino acid nucleotide-
binding folds (NBFs) found in other members of the ABC superfamily. The sequence of two 
NBFs extended beyond the Walker “A” and “B” consensus sequences identified in ATP or 
ADP binding enzymes (Walker et al., 1982). 
 
Each SUR1 subunit is now known to have 17 transmembrane regions, grouped into three 
transmembrane domains (TMDs) (Figure 1.3) (Martin et al., 2013). TMD1 (TM6-11) and 
TMD2 (TM12-17) are conserved among members of the ABC family. TMD0 (TM1-5) is 
unique to SUR, and is essential for trafficking Kir6.2 subunits to the membrane surface.  
 
The two NBFs are present on the cytoplasmic side. The NBF-1 is present between TMD1 and 
TMD2, and NBF-2 is present after TMD2. As crystal structure of NBFs from bacterial ABC 
proteins proved NBFs as dimers, it was thought that the nucleotide-binding site of SUR is 
formed where NBF-1 and NBF-2 interacts (Hung et al., 1998). Matsuo et al. demonstrated 
that both NBFs are involved in nucleotide binding (Matsuo et al., 1999). The authors 
demonstrated that NBF-1 of SUR1 binds 8-azido-ATP strongly and the binding is 
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magnesium-independent, and NBF-2 binds 8-azido-ATP weakly and the binding is 
magnesium-dependent. They also suggested that NBF-2 might have ATPase activity. 
 
In euglycaemic conditions, KATP channels are open which allows potassium efflux from the 
pancreatic β-cell. This keeps the β-cell membrane at a negative potential at which the voltage 
gated calcium (Ca2+) channels are closed. An increase in the blood glucose concentration 
leads to production of ATP. The increase in the ATP/ADP ratio triggers closure of the KATP 
channels leading to the depolarization of the β-cell membrane. This in turn leads to the 
opening of the voltage gated Ca2+ channels and Ca2+ ions influx. The entry of calcium ions 
triggers exocytosis of insulin (Dunne and Petersen, 1991) (Figure 1.4) .  
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Figure 1.2: Schematic of KATP channel. Each KATP channel has four Kir6.2 subunits in the 
centre, which form the pore of the channel, and four regulatory SUR1 subunits.   
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Figure 1.3: Schematic of Kir6.2 and Sulfonylurea Receptor Type 1 (SUR1) subunits of KATP channel. Kir6.2, the pore-forming subunit has two 
transmembrane (TM) domains (M1 and M2), which are linked by a pore-forming region (H5) on the extracellular side. SUR1 subunit has 17 
transmembrane regions, grouped into three transmembrane domains (TMDs) – TMD0 (TM1-5), TMD1 (TM6-11) and TMD2 (TM12-17). SUR1 
subunit has two cytosolic nucleotide-binding domains (NBD) which has conserved sequences including the Walker A and Walker B motifs. 
Both Kir6.2 and SUR1 subunits have an endoplasmic reticulum retaining recognition sequence (RKR).  
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Figure 1.4: Physiology of Insulin Secretion – In proportion to blood glucose concentration, 
glucose enters the pancreatic β-cell through GLUT2 transporter. ATP is produced by glucose 
metabolism, which is sensed by KATP channels leading to channel closure. The closure of 
KATP channels results in membrane depolarization that opens the voltage gated Ca2+ channels. 
Entry of Ca2+ ions leads to insulin exocytosis, which reduces the blood glucose concentration.  
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1.2.3.2	  KATP	  Channel	  Gates	  
 
There is evidence for two independent types of gates in the KATP channel. One is a fast, 
ligand independent gate, which confers selectivity to particular ions (Proks et al., 2001). The 
second is a slow, ligand-dependent gate. The widely accepted hypothesis is that this gate 
involves a hinged motion of M2 (second transmembrane domain of Kir6.2) (Nichols, 2006).  
 
 
1.2.3.3	  Regulation	  of	  KATP	  Channels	  by	  ATP	  
 
The open state probability of the KATP channel was reduced by the application of ATP to the 
intracellular surface of excised membrane patches to such an extent that 10-50µM ATP 
produced half-maximal inhibition and millimolar concentrations caused complete block 
(Cook and Hales, 1984). With this high ATP sensitivity, it was expected that KATP channel 
would always be closed unless there are additional channel regulators present in the β-cells as 
well. A number of nucleotides were reported which influenced channel activity in the 
presence of ATP. Most interest was focused on the actions of ADP as concentrations of ATP 
and ADP change reciprocally as glucose is metabolized. In inside-out patch experiments 
where physiological concentrations of both ATP and ADP were used, KATP channel activity 
could be recorded even in the presence of millimolar concentrations of ATP, which had 
previously shown complete inhibition of KATP channel activity (Dunne and Petersen, 1986, 
Kakei et al., 1986). These findings suggested that ATP/ADP ratio may be more important 
than ATP alone in KATP channel activity regulation.  
 
  
 19 
 
1.2.3.4	  Regulation	  of	  KATP	  Channels	  by	  Phospholipids	  
 
In 1996, Fan and Makielski reported that anionic phospholipids activated KATP channels in 
pancreatic β-cells, cardiac myocytes, skeletal muscle cells and a cloned KATP composed of 
SUR/Kir6.2 stably expressed in a mammalian cell line (Fan and Makielski, 1997). Polyvalent 
cations and enzymatic treatment with phospholipases that reduced the negative charge on 
phospholipids antagonized the effect on KATP channel activation. The authors also 
demonstrated that mutation of two positively charged amino acid residues at the C-terminus 
of Kir6.2 reduced the activating effects of phospholipids. It was proposed that metabolism of 
anionic phospholipids in the membrane may be novel mechanism of regulation of KATP 
channels.  
 
Shyng and Nichols subsequently demonstrated in inside out patch clamp experiments in 
COSm6 cells expressing Kir6.2/SUR1 that phosphatidylinositol decreased ATP sensitivity of 
the KATP channels (Shyng and Nichols, 1998).  
 
1.2.3.5	   Mechanism	   of	   KATP	   Channel	   Regulation	   by	   ATP	   and	  
Phosphatidylinositol	  phosphates	  (PIPs)	  
 
The cytoplasmic domains of Kir6.2 subunit provide the binding sites for ATP and 
phosphatidylinositol 4,5-bisphosphate (PIP2) (Baukrowitz et al., 1998, Shyng and Nichols, 
1998). Molecular modeling predicts four ATP-binding sites on KATP channel; one on each 
Kir6.2 subunit. Unliganded subunits are relatively unstable and at any time, Kir6.2 subunit 
can either bind to ATP or PIP2. In the absence of ATP, wild-type Kir6.2 subunits are bound 
to membrane PIP2 and are in the open state. Binding of ATP to the Kir6.2 subunit will trap it 
in the close state. The ATP concentration in energized cells is two to three orders of 
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magnitude higher than the association constant of wild-type Kir6.2 subunit (∼10µM). Hence 
the expected open probability of wild-type Kir6.2 subunit for most cells would be negligible 
without the stimulatory effects of Mg-nucleotides at the SUR subunit.  
 
Mutagenesis studies have suggested candidate residues in Kir6.2 subunit for the ATP-binding 
site. John et al. reported that mutations of three positively charged residues, R50, K185 and 
R201, impair the ability of ATP to close the KATP channel (John et al., 2003). The mutations 
did not affect the open probability in the absence of ATP, suggesting the role of these 
residues in ATP binding.  
 
The amino acid residues (Arg54, Arg176, Arg177 and Arg206), which potentially interact 
with PIP2, are near the ATP binding site and appropriately located to interact with PIP2 (John 
et al., 2003). Close location of ATP and PIP2 location sites are consistent with the proposed 
‘negative heterotropic’ interaction of the two ligands in channel regulation.  
 
Although Kir6.2 subunit provides the inhibitory binding site for ATP, the site for activation 
of KATP channel is on NBFs of SUR. It is hypothesized that the nucleotide-bound NBF-1 and 
NBF-2 dimer is the catalytically active species. ATP labeling studies revealed high 
magnesium dependence for nucleotide binding of NBF-2, providing indirect evidence that 
SUR NBF hydrolyze ATP and this hydrolysis overcome the inhibitory effect of ATP on 
Kir6.2 (Matsuo et al., 2000a).  
 
Evidence of activation of KATP channels by orthovandate and inhibition of KATP channels by 
beryllium fluoride gives weight to the hypothesis that ATP hydrolysis underlies channel 
activation. Orthovandate and beryllium fluoride are γ-phosphate analogs that stabilize the 
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ATPase cycle in distinct conformations. Orthovandate stabilized NBD2 ATPase cycle in a 
post hydrolytic conformation whereas beryllium fluoride in prehydrolytic conformation 
(Zingman et al., 2001).  
 
However decreased MgADP stimulation of KATP channels in mutations affecting residues that 
have drastic effects on ATP hydrolysis suggests that ATP hydrolysis is an epiphenomenon 
and that preferential binding of MgADP at nucleotide-binding site of SUR1 is the activator of 
the channel.  
 
 
 
1.2.3.6	  KATP	  Channel	  Independent	  Insulin	  Secretion	  
 
Although KATP channels have an essential role in linking the metabolism of glucose to the 
secretion of insulin, there is now evidence that there may well be other mechanisms of insulin 
secretion, the so-called KATP channel independent pathways of insulin secretion (Gembal et 
al., 1993, Aizawa et al., 1994, Straub et al., 2001). 
 
In a study on mouse islets, depolarisation of the membrane by increasing the concentration of 
extracellular K+ from 4.8 to 30 mM could induce Ca2+ influx and insulin release even in the 
presence of diazoxide. This K+-induced insulin release was dose-dependently increased by 
glucose. Based on these observations, the authors concluded the existence of KATP channel 
independent mechanism by which glucose can control insulin release (Gembal et al., 1993).  
 
In a study on islets isolated from pancreas of a patient with KATP channel mutation, although 
understandably tolbutamide (KATP channel blocker) failed to cause insulin secretion, glucose 
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readily promoted insulin release. No rise in intracellular free calcium concentration over 
basal values was noticed either with glucose or tolbutamide (Straub et al., 2001).  
Komatsu et al. demonstrated the insulinotropic action of glucose, in the presence of a phorbol 
ester (phorbol 12-myristate 13-acetate; PMA) and forskolin (adenylate cyclase activator), in 
Ca2+ depleted rat pancreatic islets. This action could be blocked by norepinephrine, a 
physiological inhibitor of insulin secretion, suggesting presence of KATP- and Ca2+-
independent pathway (Komatsu et al., 1995). Based on these observations, it can be 
concluded that either there are two different KATP-independent pathways or elevated 
intracellular free calcium concentration and activated protein kinase A and C lead to a 
common KATP-independent pathway (Komatsu et al., 1995).  
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1.3	  HYPERINSULINAEMIC	  HYPOGLYCAEMIA	  (HH)	  
 
Hyperinsulinaemic hypoglycaemia (HH) is characterized by unregulated secretion of insulin 
in the presence of hypoglycaemia. HH occurs in all age groups (neonates, children and 
adults) but due to different mechanisms. In the newborn and infancy periods it is a major 
cause of persistent and recurrent hypoglycaemia associated with hypoglycaemic brain injury 
(Aynsley-Green et al., 2000).  
 
Under normal physiological state, the pancreatic β-cells secrete the appropriate amount of 
insulin to maintain normoglycaemia. The unregulated insulin secretion in HH drives glucose 
into the insulin sensitive tissues especially skeletal muscle, adipose tissue and liver causing 
profound hypoglycaemia. This is compounded by the fact that insulin simultaneously inhibits 
glycogenolysis (glycogen breakdown), gluconeogenesis (glucose production from non-
carbohydrate sources), lipolysis and ketogenesis. In view of the inhibitory insulin action on 
lipolysis and ketogenesis, the brain glucopaenia is accompanied by the lack of alternative 
substrates such as ketone bodies and lactate. It is under these conditions that the risk of brain 
damage is highest. 
 
 
1.3.1	  Causes	  Of	  HH	  (Table	  1.1)	  
1.3.1.1	  Transient	  HH:	  	  
HH, which resolves within few weeks, has been reported in association with intrauterine 
growth restriction, maternal diabetes mellitus (gestational or insulin-dependent), perinatal 
asphyxia, erythroblastosis fetalis, maternal administration of sulfonylureas, and intravenous 
glucose infusions during labour. Occasionally, no known risk factors are present in transient 
 24 
 
HH cases (Yap et al., 2004). Transient HH can be protracted in some patients, requiring 
treatment with diazoxide for months (Fafoula et al., 2006, Arya et al., 2013). 
 
1.3.1.2	  HH	  due	  to	  defects	  in	  pancreatic	  β-­‐cell	  KATP	  channels	  
1.3.1.2.1	  Recessive	  KATP	  Channel	  Mutations	  
Given the key role of pancreatic β-cell KATP channels in regulating insulin secretion it is no 
surprise that genetic defects in the genes regulating the function of these channels lead to 
severe forms of HH. Glaser et al first suggested the link between HH and KATP channels. 
With linkage analysis in 15 families (12 Ashkenazi Jewish, 2 consanguineous Arab and 1 
non-Jewish Caucasian), Glaser et al. mapped familial hyperinsulinism to chromosome 11p14-
15.1 (Glaser et al., 1994).  
 
With the cloning of sulfonylurea receptor (SUR) gene in 1995, a regulator of insulin 
secretion, Thomas et al mapped this gene to 11p15.1 by fluorescence in situ hybridization 
(FISH) (Thomas et al., 1995). They identified two separate SUR gene splice site mutations in 
HH affected individuals from nine different families. Both mutations resulted in disruption of 
the putative NBD2 of the SUR protein (Thomas et al., 1995).  
 
A homozygous point mutation in Kir6.2 (L147P) was subsequently reported in a child 
severely affected with HH (Thomas et al., 1996).  
 
Recessive inactivating mutations in KATP channel subunits are now the most common cause 
of HH. In a study of genotype-phenotype correlation of 300 patients with congenital 
hyperinsulinism, Kapoor et al. reported recessively inherited KATP channel mutations in 63 
patients (Kapoor et al., 2013). In another recent study of 417 patients with congenital 
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hyperinsulinism, 84 patients had recessively inherited KATP mutations (Snider et al., 2013). 
As mentioned earlier, KATP channel is a heteromultimeric complex of at least two proteins 
designated SUR1 (ABCC8 gene) and Kir6.2 (KCNJ11 gene). So far, over 150 mutations have 
been identified in the ABCC8 and 25 in KCNJ11. These include missense, frame shift, 
nonsense, insertions/deletions, splice site and regulatory mutations, either present in 
homozygous or compound heterozygous state. In the Ashkenazi Jewish population, two 
common (F1388del and c.3992-9G4A) mutations account for 90% of all cases of congenital 
HH (Nestorowicz et al., 1996, Thomas et al., 1995). 
  
The molecular basis of recessive inactivating ABCC8 and KCNJ11 mutations involves 
multiple defects in KATP channel biogenesis and turnover, in channel trafficking from the 
endoplasmic reticulum and Golgi apparatus to the plasma membrane and alterations of 
channels in response to both nucleotide regulation and open state frequency (Cartier et al., 
2001a, Partridge et al., 2001a, Shyng et al., 1998, Dunne et al., 1997). There are two different 
classes of these loss-of-function mutations. In class I, all KATP channels are absent from the 
β-cell plasma membrane, resulting in no KATP current. The most common class I mutations 
are those leading to defects in trafficking. In class II mutations, KATP channels are present in 
the membrane (although less than normal) but show reduced sensitivity to Mg-nucleotide 
activation or reduced intrinsic channel open probability (Dunne et al., 2004).   
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Table 1.1: Causes of HH 
 
Common Perinatal Risk factors for HH ( Likely to be transient) 
Maternal diabetes mellitus (gestational and insulin dependent) 
IUGR 
Perinatal asphyxia 
Rhesus isoimmunisation 
Congenital Hyperinsulinism (Identified Gene mutations ) 
ABCC8 
KCNJ11 
GLUD1  
GCK  
HADH 
HNF4A 
HNF1A 
SLC16A1  
UCP2 
Metabolic Causes 
Congenital disorders of glycosylation (CDG), Type 1a/b/d 
Tyrosinaemia type I. 
Syndromic Causes 
Beckwith-Wiedemann 
Kabuki 
Trisomy 13 
Central Hypoventilation Syndrome  
Leprechaunism ( insulin resistance syndrome) 
Mosaic Turner 
Soto 
Usher 
Timothy 
Costello 
Miscellaneous causes 
Noninsulinoma pancreatogenous hypoglycaemia (Adults) 
Factitious Hypoglycaemia 
Insulinoma 
Insulin autoimmune syndrome  
Post Prandial HH after Post gastric bypass surgery for obesity (Adults) 
Non Islet cells tumor hypoglycemia (NICTH) (Adults) 
Dumping syndrome 
Drug induced (Oral antidiabetic drug (sulfonylurea, glinides, biguanides), Beta Blockers.  
Antiarrhythmic drugs (quinine). 
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1.3.1.2.1.1	  Defect	  in	  Biogenesis	  and	  Turnover	  
 
Crane and Aguilar-Bryan determined the lifetimes of SUR1 and Kir6.2 with pulse-labeling 
methods (Crane and Aguilar-Bryan, 2004). They estimated the half-life of SUR1 (expressed 
alone) to be approximately 25.5 hours. On the other hand, Kir6.2 turnover was biphasic. 
Approximately 60% was lost with t1/2 of 36 minutes. The remaining converted to a long-
lived species (t1/2 ∼26 hours). When Kir6.2 and SUR1 were co-expressed, the fast-
degradation of Kir6.2 was not noticed. The half-life of KATP channels was estimated to be 
∼7.3 hours.  
Some mutations in KATP channel subunits affect the association with their partners resulting 
in rapid degradation. Two examples of such mutations are Kir6.2 W91R and SUR1ΔF1388.  
 
1.3.1.2.1.2	  Defect	  in	  Channel	  Trafficking	  
 
Correct trafficking and cell surface expression of KATP channels requires the tripeptide 
endoplasmic reticulum (ER) retention signal sequence (RKR; Arg-Lys-Arg), present in both 
the SUR1 and Kir6.2 subunits, to be shielded. When expressed alone, the two proteins (SUR1 
and Kir6.2) are retained in the ER because of exposure of the RKR signal. When SUR1 and 
Kir6.2 coexpress and associate to form an octameric channel complex, the ER-retention 
signal in both subunits is shielded and the channel complex is able to traffic to the cell 
surface. 
 
The RKR motif in SUR1 is in a cytoplasmic segment right before the first nucleotide-binding 
fold (NBF-1). The RKR motif in Kir6.2 is near the C-terminus. The discovery that when 
expressed alone, c-terminal truncated Kir6.2 allowed potassium currents allowed the mapping 
of RKR motif in Kir6.2 sequence (Tucker et al., 1997, Zerangue et al., 1999). 
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Mutations in KATP channels can cause HI by affecting the trafficking of the channels to the 
cell surface. Cartier et al. demonstrated that F1388 in SUR1 is critical for normal trafficking 
and function of KATP channels by uncovering the defective trafficking as the underlying 
molecular mechanism of PHHI in SUR1ΔF1388 (Cartier et al., 2001b).  
 
Other mutations that affect trafficking include SUR1 L1544P and SUR1 R1394H (Partridge 
et al., 2001b, Taschenberger et al., 2002). Conti et al. mutated the two N-glycosylation 
residues (Asn10 and Asn1050) and noticed ER retention of the mutant channels (Conti et al., 
2002). The authors suggested that SUR1 glycosylation is a key element for correct trafficking 
of KATP channels.  
 
1.3.1.2.1.3	  Defects	  of	  Channel	  Regulation	  
 
SUR1 regulates the conductance of Kir6.2 through interaction with intracellular nucleotides. 
SUR1 has two nucleotide-binding folds (NBF-1 and NBF-2). Several mutations affect the 
sensitivity to changes in the ATP/ADP ratio and result in loss of ADP dependent activation of 
KATP channels (Shyng et al., 1998, Matsuo et al., 2000b). Loss of ADP dependent gating 
results in the constitutive closure of the KATP channel and persistent membrane depolarization 
of the β-cell. Examples of mutations that result in defective channel regulation are R1420C, 
T1139M and R1215Q.  
 
Overall, these mutations result in a loss-of-function of KATP channels in the pancreatic β-cell, 
leading to constitutive exocytosis of insulin-containing secretory vesicles.  
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Recessive inactivating mutations in ABCC8 and KCNJ11 usually cause severe HH, which in 
the vast majority of patients is unresponsive to medical treatment with diazoxide. However, 
some compound heterozygote mutations may be milder and may respond to treatment with 
diazoxide (Dekel et al., 2002). 
 
1.3.1.2.2	  Dominant	  acting	  KATP	  channel	  mutations	  
The first description of dominant acting KATP channel mutation was from Huopio et al 
(Huopio et al., 2000). The authors identified a heterozygous E1506K (E1507K based on the 
1582 amino acid transcript NM_000352.3) in seven related patients with congenital 
hyperinsulinism (CHI) and their mothers. All the patients were successfully managed with 
diazoxide.  
 
Linkage and haplotype analysis was suggestive of a dominant pattern of inheritance in this 
large multi-generation pedigree. Using an allele frequency of 0.03 (corresponding to the 
frequency of the conserved haplotype), the two-point linkage analysis yielded LOD scores of 
6.00 at θ = 0 and 3.83 at θ = 0.045 for the dominant and recessive models respectively.  
 
Experiments in oocytes injected with Kir6.2/SUR1-WT and Kir6.2/SUR1-E1507K revealed 
that SUR1-E1507K could form functional channels with Kir6.2. However these channels 
were insensitive to metabolic inhibition (equivalent to hypoglycaemia in the clinical setting) 
but could be opened by diazoxide. Experiments with injecting 1:1 mixture of WT and 
E1507K mutant indicated that this mutation does not have a dominant negative effect.  
 
Thornton et al. reported a heterozygous SUR1 mutation (delSer1387) in a family with 
dominantly inherited hyperinsulinism affecting five individuals in three generations 
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(Thornton et al., 2003). With surface immunofluorescence studies, it was shown that 
delSer1387 SUR1 mutant protein could form KATP channels with Kir6.2 protein but exhibited 
no rubidium efflux in response to metabolic inhibition and diazoxide. However when 
equimolar mixture of delSer1387 and wild-type SUR1 cDNA was used, surface expression 
and rubidium efflux was similar to control.  
 
Pinney et al. characterized 14 dominantly inherited KATP channel mutations with surface 
expression and inside-out patch clamping (Pinney et al., 2008). All of the mutations were 
single amino acid changes: 13 were amino acid substitutions and 1 was a single amino acid 
deletion. Eleven were ABCC8 mutations and 3 were KCNJ11 mutations. The authors noticed 
that these mutations (SUR1 as well as Kir6.2) had no or only mild effects on biogenesis and 
expression of the channel. However, the SUR1 mutant channels had significantly diminished 
or completely abolished response to MgADP and diazoxide. Kir6.2 mutants had dramatically 
reduced channel open probability or were non-conducting. Under simulated heterozygous 
conditions, presence of the WT ABCC8 or KCNJ11 allele resulted in partial channel response 
to changes in ATP/ADP ratio and to diazoxide. There data suggested dominant inactivating 
mutations to result in much milder phenotype than that of patients with recessive inactivating 
mutations (Huopio et al., 2000).  
 
In 2011, dominant acting KATP mutations resulting in diazoxide-unresponsive disease were 
reported. Flanagan et al. reported three ABCC8 mutations (D1506E, G1485E, and M1544K) 
in five patients (Flanagan et al., 2011a). The mutation arose either de novo or one of the 
parents who carried the mutation was also affected.  All five patients had severe 
hyperinsulinaemic hypoglycaemia and were unresponsive to maximum doses of diazoxide. 
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Histological analysis of the pancreatic material from four patients showed similar changes to 
that seen in recessive acting ABCC8 mutations.  
 
In the same year, MacMullen et al. reported 13 different monoallelic missense ABCC8 
mutations associated with diazoxide-unresponsive disease (Macmullen et al., 2011). 
Expression of these mutations in COSm6 cells revealed normal trafficking of channels but 
severely impaired responses to MgADP or diazoxide. The responses were significantly lower 
than the ABCC8 mutations studied by their group that caused diazoxide-responsive disease.  
 
To summarize, dominant acting KATP channel mutations can cause diazoxide-responsive or 
diazoxide-unresponsive disease depending on the responses of the channel subunits to 
MgADP or diazoxide. The normal trafficking of channel subunits is retained.  
 
1.3.1.3	  HH	  due	  to	  gain	  of	  function	  mutation	  in	  the	  GLUD1	  gene	  
 
Zammarchi et al. and Weinzimer et al. reported a group of patients with hyperinsulinism and 
concomitant hyperammonaemia (Weinzimer et al., 1997, Zammarchi et al., 1996). Stanley et 
al. studied eight such patients and noticed increased activity of glutamate dehydrogenase 
(GDH) enzyme in lymphoblasts prepared from peripheral blood lymphocytes from these 
patients (Stanley et al., 1998a). All these eight patients had heterozygous mutation in the 
proposed allosteric domain of the glutamate dehydrogenase enzyme.  
 
GDH is an intramitochondrial enzyme that is encoded by GLUD1 gene on the chromosome 
10q23.3. It catalyzes the oxidative deamination of glutamate to α-ketoglutarate, which enters 
Krebs’s cycle and results in ATP production. The enzyme is allosterically inhibited by ATP 
and GTP, and allosterically activated by leucine (Fahien et al., 1988). Mutations in GLUD1 
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reduce the sensitivity of GDH to allosteric inhibition by GTP and ATP (Stanley et al., 1998a). 
This results in increased activity of GDH.  
 
GDH is widely distributed at high levels in the pancreas, liver, brain, kidney, heart and lungs. 
In pancreatic β-cells, the resulting increased ATP/ADP ratio due to increased GDH activity 
consequently activates KATP channels, with subsequent cell depolarization and insulin release 
(Stanley, 2004). 
 
Increased GDH activity in liver may lead to hyperammonaemia because of excessive 
ammonia production and impaired urea cycle activity. Reduced concentrations of glutamate 
will reduce the synthesis of N-acetylglutamate, an essential activator of carbamoyl-phosphate 
synthetase, the first step in the conversion of ammonia to urea. Recent animal model studies 
suggest the role of renal ammoniagenesis due to activation of GDH as a source of 
hyperammonaemia in these patients (Treberg et al., 2010).  
 
Mutations in GLUD1 gene are the second most common congenital form of HH (HI/HA 
syndrome)(Stanley et al., 1998b).  
 
The GLUD1 gene mapped to the 10q23.3 region contains 13 exons encoding a 505 amino 
acid mature enzyme. Mutations causing HI/HA syndrome have been identified in the GTP 
allosteric region of the enzyme encoded by exons 11 and 12 of the GLUD1 gene, as well as in 
the GTP binding site encoded by exons 6 and 7 (MacMullen et al., 2001, Stanley et al., 
2000). 
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The major clinical feature of children with HI/HA syndrome is recurrent episodes of 
symptomatic HH. These may occur with fasting or can be provoked by protein feeding, as 
leucine is an allosteric activator of GDH. Some carriers can be asymptomatic, resulting from 
incomplete expression of enzyme abnormality (Palladino and Stanley, 2010).  
 
Hyperammonaemia, a characteristic biochemical marker of HI/HA syndrome, is typically 
mild to moderate (up to 3-5 times the upper limit of normal). It is resistant to detoxification 
compounds (sodium benzoate, sodium phenylbutyrate, N-carbamylglutamate) or protein-
restricted diet (Palladino and Stanley, 2010). 
 
Children with HI/HA syndrome appear to have epilepsy more frequently as compared to 
other congenital forms of HH (Raizen et al., 2005, Kapoor et al., 2009a, Bahi-Buisson et al., 
2008). The increased frequency of epilepsy is thought to be either the result of a) 
hypoglycaemic brain injury due to recurrent hypoglycaemia or b) chronic hyperammonaemia 
or c) decreased concentrations of glutamine and the neurotransmitter γ-aminobutyric acid 
(GABA) in the brain due to raised GDH activity. Over activity of GDH in the brain may lead 
to a decrease in glutamate availability for glutamate decarboxylase and GABA synthesis, 
which results, in turn, in altered GABA concentration (Bahi-Buisson et al., 2008). However, 
measurements of GABA and other neurotransmitters in CSF of these patients have been 
normal (Bahi-Buisson et al., 2008). Finally, mutations in the GTP binding site tend to be 
more frequently associated with epilepsy than those in the allosteric domain (Bahi-Buisson et 
al., 2008, Kapoor et al., 2009a).  
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1.3.1.4	  HH	  due	  to	  gain	  of	  function	  mutation	  in	  the	  GCK	  gene	  
 
Glucokinase (GCK) is a key regulatory enzyme in the pancreatic β-cells. It plays a crucial 
role in the regulation of insulin secretion and is referred to as the pancreatic β-cell sensor 
(Matschinsky, 1996). Its unique kinetics of low affinity for glucose (high Km) and no 
inhibition by its end product glucose-6-phosphate helps in modulation of its activity in 
relation to the concentration of glucose over a range of physiological glucose concentrations 
(4-15mmol/L). Hence pancreatic β-cells are able to increase their rate of glucose metabolism 
in response to a rise in the extracellular glucose concentration.  
 
Activating (or gain of function) mutations in GCK increase the affinity of GCK for glucose 
and alter the threshold for glucose stimulated insulin secretion (Davis et al., 1999). Thus 
insulin continues to be produced at lower blood glucose concentrations. All reported 
activated mutations cluster in the allosteric activator site of the enzyme. There is no evidence 
of increased gene expression as a likely cause HH.  
 
GCK mutations can lead to a variable phenotype, ranging from asymptomatic hypoglycaemia 
to medically unresponsive HH, with majority causing mild diazoxide responsive HH (Cuesta-
Munoz et al., 2004, Christesen et al., 2002, Dullaart et al., 2004, Thornton et al., 1998). In a 
large study, activating GCK mutations accounted for  ∼ 7% of medically responsive HH 
(Christesen et al., 2008).  
 
1.3.1.5	  Transcription	  factors	  and	  HH	  
 
The hepatocyte nuclear factor 4α (HNF-4α), encoded by HNF4A, is a member of the nuclear 
receptor (NR) family of transcription factors. The HNF4A gene is highly expressed in the 
liver, kidney, gut, and pancreatic islets and is thought to play an important role in the 
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development and function of these organs (Sladek et al., 1990). Other transcription factors 
important for the development of the pancreas include HNF-1α and HNF-1β (Xanthopoulos 
et al., 1991). These along with HNF-4α are thought to play a crucial role in expression of 
several genes involved in glucose stimulated insulin secretion.  
 
Heterozygous mutations in HNF4A have been reported to lead to a dominantly inherited 
condition with a dual phenotype of HH in the neonatal period and MODY1 in the adult life 
(Kapoor et al., 2008, Pearson et al., 2007). Pearson et al generated a mouse model with β-cell 
specific HNF4A deletion. By studying these β-HNF4A-KO mice, they identified significantly 
elevated insulin concentrations in late gestation β-HNF4A-KO embryos and significantly 
higher insulin/glucose ratios in β-HNF4A-KO versus control mice in the neonatal period. 
They did not find any difference in the expression of genes implicated in human 
hyperinsulinaemic hypoglycaemia (ABCC8, KCNJ11, SCHAD, GCK and GLUD1) in β-
HNF4A-KO mice.  
 
The exact mechanism behind HH in HNF4A mutations is unclear. Gupta and colleagues, in a 
conditional knockout of HNF4A mouse model, noticed 60% reduction in the expression of 
the potassium channel subunit Kir6.2. They also demonstrated that the KCNJ11 gene is a 
transcriptional target of HNF4A (Gupta et al., 2005). The other possible mechanism is HNF-
4α deficiency leads to lower levels of PPARα (peroxisomal proliferator-activated receptor 
alpha), which is important for insulin regulation (Gremlich et al., 2005).  
 
Clinically HNF4A mutations are characterized by an early neonatal presentation of HH and 
macrosomia. The severity may range from mild transient hypoglycaemia not needing 
medication to persistent HH requiring treatment with diazoxide for up to 8 years (Kapoor et 
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al., 2008). In all reported cases, the HH improved with age and responded to diazoxide. A 
variable penetrance is often observed within families, demonstrated by absence of neonatal 
HH in some HNF4A mutation carriers. A family history of diabetes is a useful indicator of an 
HNF4A gene mutation, however its absence should not preclude HNF4A sequencing in 
patients with diazoxide responsive HH (Kapoor et al., 2008). The reason for the differences 
in clinical presentations is not currently understood; though, it is likely that other genetic and 
environmental factors may inﬂuence the severity of the disease. The HNF4A mutation 
phenotype may extend beyond β-cells of pancreas and include liver glycogenosis and renal 
Fanconi tubulopathy (Stanescu et al., 2012).  
 
A recent report described two cases with diazoxide responsive HH associated with mutations 
in HNF1A (Stanescu et al., 2012). The phenotype described is very similar to HNF4A 
mutations – macrosomia, early neonatal presentation and diazoxide responsiveness.  
 
 
1.3.1.6	  HH	  and	  defects	  in	  the	  mitochondrial	  oxidation	  enzyme	  Short	  chain	  3	  
Hydroxyacyl-­‐coenzyme	  A	  dehydrogenase	  (SCHAD)	  
 
Short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) catalyzes the penultimate step 
in fatty acid β-oxidation in the mitochondria. It is encoded by HADH, which is highly 
expressed in the pancreatic β-cells. Short chain 3-hydroxyacyl-CoA dehydrogenase 
(SCHAD) deficiency is a recently described disorder of mitochondrial fatty acid β-oxidation 
(Clayton et al., 2001, Hussain et al., 2005b, Molven et al., 2004). Unlike other inherited 
defects of fatty acid β-oxidation, the main clinical feature of this metabolic disease is HH.  
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A number of studies have demonstrated that HADH has a pivotal role in regulating insulin 
secretion (Hardy et al., 2007b, Martens et al., 2007). Recently, the mechanism behind 
unregulated insulin secretion in SCHAD deficiency is becoming clear. These patients were 
noticed to be severely protein sensitive, suggesting an amino acid triggered unknown 
pathway of insulin release (Kapoor et al., 2009b). Subsequently hadh -/- knockout mice 
studies demonstrated protein-protein interactions between HADH and glutamate 
dehydrogenase (GDH) (Li et al., 2010). Similar interactions have been reported in human 
control lymphoblast, which are lost in patients with HADH mutations (Heslegrave et al., 
2012). Studies on isolated islets showed an increase in the affinity of GDH for its substrate α-
ketoglutarate. It is therefore likely that HADH mutations cause HH by activation of GDH via 
loss of inhibitory regulation of GDH by HADH.  
 
Metabolic profile in affected individuals may reveal a raised plasma hydroxyl-butyryl-
carnitine and urinary 3-hydroxyglutarate levels. However, the reason why not all patients 
show abnormal organic acid proﬁles or defects in acylcarnitine metabolism is unclear. Most 
cases reported to date are from consanguineous families (Flanagan et al., 2011b). Hence 
sequencing of HADH is recommended in patients with diazoxide responsive CHI who come 
from consanguineous families and do not have an identifiable mutation in the 
ABCC8/KCNJ11 genes.  
 
 
 
1.3.1.7	  Exercise-­‐induced	  hyperinsulinism	  (EIHI)	  
 
Exercise-induced hyperinsulinism (EIHI) is an autosomal dominant disorder in which 
strenuous physical exercise causes inappropriate insulin secretion in affected individuals, 
leading to hypoglycemia. Heterozygous gain-of-function mutations in the solute carrier 
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family 16, member 1 (SLC16A1) that encodes monocarboxylate transporter 1 (MCT1; 
required for trans-membrane transport of pyruvate and lactate) causes exercise induced 
hyperinsulinism (Meissner et al., 2005, Ishihara et al., 1999, Otonkoski et al., 2003). 
 
In normal individuals, expression of the pyruvate transporter (MCT1) is specifically silenced 
in pancreatic β-cells, despite nearly universal expression across other tissues (Ishihara et al., 
1999). Affected patients have symptoms due to activating mutations in the SLC16A1 
promoter in β-cells. Increased expression of MCT1 thus renders the plasma membrane 
permeable to lactate and pyruvate, allowing the latter to inappropriately stimulate insulin 
secretion (Ishihara et al., 1999). Affected patients do not normally experience fasting 
hypoglycemia. During exercise pyruvate is generated along with lactate by muscle, thereby 
stimulating inappropriate insulin secretion from the pancreatic β-cell despite low blood 
glucose levels. The mechanism highlights the importance of MCT1 absence from these cells 
for the normal control of insulin secretion. Although the HH is usually quite severe in these 
patients, specific treatment is not usually needed as avoiding strenuous exercise may prevent 
hypoglycaemic episodes. 
 
 
1.3.2	  Clinical	  Presentation	  Of	  HH	  
 
Most common and severe presentation of HH is during the neonatal period. The presenting 
symptoms of hypoglycaemia may be very non-specific (irritability, poor feeding and 
lethargy) and severe (seizures and coma). Typically these infants are macrosomic and require 
very high dextrose infusion rate to maintain normoglycaemia (blood glucose > 3.5mmol/l). 
Transient forms of HH are observed in in infants born to mothers with diabetes mellitus 
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(insulin dependent or gestational), those who have sustained perinatal asphyxia or those with 
intrauterine growth restriction (IUGR). In these groups of infants the HH tends to resolve 
after few weeks or months.  
 
HH may also be the presenting feature in some developmental syndromes such as Beckwith-
Wiedemann syndrome (BWS), Soto’s syndrome and rare metabolic conditions such as 
congenital disorder of glycosylation (CDG). Of these, the commonest is BWS. HH in the vast 
majority of patients with BWS is transient and resolves spontaneously. The other clinical 
features of BWS include prenatal and/or postnatal overgrowth, macroglossia, anterior 
abdominal wall defects, organomegaly, hemihypertrophy, ear lobe creases, helical pits, and 
renal tract abnormalities (Choufani et al., 2010). 
 
During infancy and childhood, the presentation of HH may be very subtle and difficult to 
diagnose. The presenting symptoms before 1 year of age are seizures, episodes of drowsiness 
or excitability. After 1 year, the symptoms are typical of hypoglycaemia; pallor, faint, 
tachycardia and sweating, seizures.  
 
Patients with HH due to GLUD1 mutations (HI/HA syndrome) demonstrate two 
characteristic features. Firstly, they show marked sensitivity to dietary protein (leucine), and 
symptoms of hypoglycaemia become manifest or aggravated following a protein-rich meal, 
rather than a fast (Kapoor et al., 2009a). Secondly, they typically show mild to moderate 
asymptomatic hyperammonaemia. Hypoglycaemia is usually not as severe as that seen in HH 
due to KATP channels defects. Children with HI/HA syndrome show good response to therapy 
with diazoxide and in some cases protein restricted diet. In addition, these children usually 
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are not macrosomic at birth and their hypoglycaemia is often not recognized before several 
months of age. 
 
HH may be observed postprandially, for example, in the dumping syndrome. The “dumping 
syndrome” is classically observed in infants following gastro-esophageal surgery (Veit et al., 
1994). In exercise induced HH symptoms of hypoglycaemia occur within the 30 minutes 
following a short period of anaerobic exercise.  
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1.3.3	  Diagnosis	  And	  Investigations	  (Table	  1.2)	  
 
The diagnosis of HH is based on clinical presentation and detection of characteristic 
biochemical profile of hypoketonaemic, hypofattyacidaemic hypoglycaemia arising from the 
anabolic effects of excessive insulin action at the time of hypoglycaemia. Certain clinical 
clues for diagnosis of HH include macrosomia or severe IUGR, and high glucose requirement 
(>8 mg/kg min, normal range 4-6 mg/kg min) to maintain normoglycaemia. 
 
Characteristic metabolic profile can either be identified during spontaneous hypoglycaemia or 
hypoglycaemia induced by provocation tests (controlled fast/ exercise/protein ingestion). 
However, provocation test should only be done within a controlled environment with 
appropriate monitoring as this can be potentially life threatening. Laboratory ﬁndings at time 
of hypoglycaemia would unveil inappropriately elevated insulin and inappropriately low 
beta-hydroxybutyrate and free fatty acids. Plasma insulin levels may not be dramatically 
elevated (Al-Otaibi et al., 2013). Under normal physiological conditions, insulin production 
is switched off during hypoglycaemic state. As insulin release is pulsatile and has a short 
half- life, measurement of C-peptide (which has a longer half-life and reflects the endogenous 
insulin production) can prove to be more helpful when the diagnosis is in doubt.  
 
Additional supportive evidence can be provided by a positive glycaemic response to 
intramuscular/ intravenous glucagon at the time of hypoglycaemia (a clear increment in blood 
glucose of >1.5mmol/L despite severe hypoglycaemia), a positive glycaemic response to 
octreotide and a decreased serum levels of insulin-like growth factor-binding protein 1 
(IGFBP-1) (as insulin suppresses the transcription of IGFBP-1 gene (Hussain et al., 2005a, 
Finegold et al., 1980, Levitt Katz et al., 1997).  
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Table 1.2: Diagnostic Findings of HH 
 
Blood glucose  < 3mmol/l on Glucose infusion rate of >8mg/kg/min 
 
Factor  Result in HH 
Blood Samples Insulin Detectable or elevated 
C-peptide Detectable or elevated 
Free fatty acids Inappropriately low 
β-hydroxybutyrate Inappropriately low 
Acetoacetate Inappropriately low 
Lactic acid Normal 
Hydroxybutyryl Carnitine Elevated in HADH 
deficiency.  
Amino acids Low 
Ammonia Elevated in HI/HA syndrome 
Cortisol Elevated due to 
hypoglycaemia 
IGFBP-1 Low  
 
 
Urine Samples 
Ketone bodies  Negative 
Reducing substances Negative 
C-peptide Elevated 
3-hydroxyglutarate  Elevated in HADH 
deficiency. 
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A low serum cortisol and/or growth hormone levels at the time of hypoglycaemia is not 
diagnostic of cortisol or growth hormone deﬁciency (Hussain et al., 2003). Appropriate 
stimulation tests are required to confirm cortisol or growth hormone deﬁciency.  
 
In the persistent rare forms of CHI, certain specific diagnostic ﬁndings can suggest likely 
underlying genetic diagnosis. Elevated serum ammonia and HH imply HI/HA syndrome 
(GDH-HH) (Stanley, 2004). However, normal ammonia concentrations do not necessarily 
exclude GDH-HH. In these patients with “activating” GLUD1 mutations, hypoglycaemia 
may occur after ingestion of leucine- or protein-rich meal and can be provoked by performing 
a protein/leucine provocation test (Hsu et al., 2001, MacMullen et al., 2001).  
 
Abnormal plasma acylcarnitine profile (elevated 3-hydroxtbutyryl-carnitine) and urine 
organic acids (3-hydroxyglutarate in urine) characterize HADH-HH (Clayton et al., 2001). If 
HH is related to exercise, consider performing an exercise provocation test or pyruvate load 
test (Otonkoski et al., 2003). An exercise test with submaximal to maximal exercise over 10 
minutes is diagnostic. 
 
In patients with mutations in HNF4A and UCP2, there are no speciﬁc laboratory ﬁndings. 
HNF4A mutations are associated with a considerable increase in birth weight, macrosomia 
and family history of MODY (Kapoor et al., 2008, Pearson et al., 2007). However, prenatal 
hyperinsulinism due to other genetic causes may also increase the birth weight. Family 
history of MODY and postprandial HH may denote GCK-HH.  
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1.3.4	  Histological	  Subtypes	  And	  Underlying	  Molecular	  Basis	  of	  HH	  	  
 
Despite identical clinical presentation, at least two (possibly more) well described 
histological types are associated with HH: a focal form and a diffuse form (Figure 1.5) 
(Rahier et al., 2000). In diffuse form, all of the islets of Langerhans throughout the pancreas 
are enlarged and contain distinctly hypertrophied insulin producing cells. Focal form is 
characterized by nodular hyperplasia of islet-like cell clusters, including ductuloinsular 
complexes and giant β-cell nuclei surrounded by a histologically and functionally normal 
pancreatic tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Schematic of focal and diffuse hyperinsulinism. A Focal lesion at the junction of 
head and body of pancreas B Diffuse disease affecting the islets throughout the pancreas 
  
A"
B"
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These two subtypes have different underlying genetic mechanisms. The most common causes 
of diffuse HH are recessive and dominant mutations in ABCC8 and KCNJ11. The focal form 
has a unique genetic aetiology and involves two independent events – the inheritance of a 
paternal mutation in ABCC8 or KCNJ11, and somatic loss of the maternal 11p allele (11p15.1 
to 11p15.5) involving the ABCC8 and KCNJ11 region within the focal lesion (Verkarre et al., 
1998). This region includes two clusters of genes. The first cluster corresponds to 11p15.5 
region that contains an imprinted domain. The maternal LOH leads to an imbalance between 
the maternally expressed tumor suppressor genes H19 and CDKN1C, and the paternally 
expressed growth factor IGF2 (Fournet et al., 2001). The second cluster of genes in 11p15.1 
region includes the ABCC8 and KCNJ11 genes. Hence maternal LOH of the 11p15 region 
will lead to paternal uniparental disomy unmasking the paternally inherited KATP channel 
mutation. These events form the basis of unregulated insulin secretion and focal increased 
proliferation of β-cells evolving into a focal adenomatous hyperplasia. The focal disease is 
mostly sporadic in origin; however a familial case has been reported in literature (Ismail et 
al., 2011).  
 
Sempoux et al. recently described a novel histological form of PHHI (Sempoux et al., 2011). 
This particular form was characterized by the presence of two types of islets: large islets with 
β-cells with large cytoplasm and enlarged nuclei, and shrunken islets with β-cells with little 
cytoplasm and small nuclei. Large islets had hyperactive β-cells, characterized by large 
proinsulin antibody-labeled Golgi, strong labeling for insulin mRNA by insitu hybridization 
(ISH) and faint labeling of the antiinsulin antibody. Shrunken islets had resting β-cells, 
characterized by punctate proinsulin antibody-stained Golgi and strong antiinsulin antibody 
staining. This morphological entity was not associated with genomic mutations in ABCC8, 
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KCNJ11 and GCK, or 11p15 deletion. The abnormal hyperfunctional islets were most often 
confined to few adjacent lobules.  
Recently, the same authors studied the insulin secretion by pancreatic fragments from six of 
the 14 patients described with a novel histopathological form (Henquin et al., 2013). The 
authors showed that β-cells of the hyperfunctional islets have functionally normal KATP 
channels. The β-cells were noticed to be inappropriately sensitive to glucose in in vitro 
studies of pancreatic fragments. Addition of only 1mmol/L glucose consistently induced a 
large peak in insulin secretion, with no or little further effect with subsequent increase in 
glucose. Subsequent studies with immunohistochemistry and genetic analysis identified 
undue expression of low-Km hexokinase I (HK-I) or to an activating mutation in glucokinase 
in hyperfunctional islets only.   
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1.3.4.1	  Differentiation	  Between	  Diffuse	  And	  Focal	  Hyperinsulinism	  
 
The outcome in children with congenital HH is dependent on distinguishing between diffuse 
and focal hyperinsulinism. Medically unresponsive diffuse hyperinsulinism requires near-
total pancreatectomy with a very high risk of iatrogenic diabetes mellitus later in life. Focal 
hyperinsulinism can be treated with partial pancreatectomy if the region of focal 
adenomatous islet-cell hyperplasia can be identified.  
 
De Lonlay-Debeney et al. studied 52 neonates with hyperinsulinism referred for pancreatic 
surgery with transhepatic catheterization of the portal vein and selective catheterization of the 
pancreatic vein to locate the sites of insulin hypersecretion (de Lonlay-Debeney et al., 1999). 
The authors collected samples of venous blood from the head, the isthmus, the body and the 
tail of the pancreas for measurements of plasma glucose, insulin and c-peptide. Focal 
hyperinsulinism patients had high plasma insulin and c-peptide concentration in one or 
several samples from contiguous areas, with low concentrations from the remaining samples. 
Diffuse hyperinsulinism patients had high plasma insulin and c-peptide concentration in all 
samples. Pancreatic catheterization successfully localized the focal lesion in 17 out of 19 
neonates with histologically confirmed focal adenomatous hyperplasia. Among the 26 
neonates with diffuse hyperinsulinism who underwent pancreatic catheterization, the 
diagnosis was correctly established in 17 patients. In 7 patients with diffuse hyperinsulinism, 
the result of pancreatic catheterization was suspected of localized hyperinsulinism; however 
the intraoperative histologic testing revealed diffuse β-cell hyperfunction. 
 
Although pancreatic venous sampling was found useful in some centres, it was not widely 
accepted because of being invasive and technically demanding. In 2006, Otonkoski et al. 
described a non-invasive technique 18F-DOPA Positron Emission Tomography for diagnosis 
 48 
 
of focal hyperinsulinism of infancy (Otonkoski et al., 2006). Any patient with a visually clear 
[18F] hot spot in the pancreas with maximum uptake (standardized uptake values) measuring 
≥ 1.5 times the maximum pancreatic tracer concentration elsewhere was defined as having 
focal disease. Based on this cut-off, 18F-DOPA PET correctly identified focal disease in five 
patients.  
 
The principle of this imaging technique is based on the fact that pancreatic islets take up L-
DOPA and convert it into dopamine using the enzyme DOPA decarboxylase, which is 
expressed in islet cells. 18F-DOPA is an analogue of DOPA and thus the positron-emitting 
compound is useful for tracking the uptake of this dopamine precursor. Both diffuse and focal 
diseases have a high DOPA decarboxylase activity. 
Apart from differentiating diffuse and focal disease, 18F-DOPA PET/CT simultaneously 
permits precise preoperative localization of the lesion (Hardy et al., 2007a, Laje et al., 2013, 
Ribeiro et al., 2007). A recent meta-analysis reported the pooled sensitivity and specificity of 
18F-DOPA PET/CT in differentiating between focal and diffuse HH as 89% (95% CI: 81–
95%) and 98% (95% CI: 89–100%), respectively (Treglia et al., 2012). The pooled accuracy 
in localizing focal HH was 80% (95% CI: 71–88%). 
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1.3.5	  Management	  
 
1.3.5.1	  Medical	  management	  
 
The goal of treatment in patients with HH is to maintain normoglycaemia (blood glucose 
levels between 3.5–6  mmol/L). Intravenous dextrose infusion of up to 15–25  mg/kg/min 
through an established central venous access may be required to maintain normoglycaemia in 
neonates with severe forms of HH. This should be supported with enteral feeding to maintain 
orality. It is important to note that orality is often affected possibly due to disturbed feeding 
pattern and gastro-esophageal reflux, often inducing feeding refusal behavior. Frequent 
monitoring of blood glucose levels is required. 
Diazoxide	  
 
Once the diagnosis of HH has been confirmed, medical therapy with diazoxide should be 
initiated, and within the first week of diagnosis, the response to diazoxide would give an 
indication of the need for further evaluation and surgical intervention. 
In all newborns and infants diagnosed with HH, diazoxide (KATP channel opener) is the first-
line medical therapy. Diazoxide is administered orally at a starting dose of 5  mg/kg/day in 3 
divided doses. The dose can be increased by 5  mg/kg/day every 48  h to an effective and 
tolerated dose (the maximal dose rate is 15  mg/kg/d). The responsiveness to diazoxide is 
determined by a) appropriate fasting tolerance for age; b) feed volume and frequency normal 
for age; c) normal blood glucose levels at the end of the fast. 
The use of diazoxide is often limited by its side effects. The most common side effects of 
diazoxide are hypertrichosis and fluid retention (especially in the newborn), followed by 
hyperuricaemia, tachycardia, leukopenia, and feeding problems. In newborns, the drug is 
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given in conjunction with the thiazide diuretic chlorothiazide (5–10  mg/kg per day in 2 
divided doses), which reduces water retention. If the dose of diazoxide falls below 
5  mg/kg/day, a trial off diazoxide should be considered under medical observation in the 
hospital setting. In those with less severe HH (HH associated with perinatal stress or IUGR), 
it may be preferable to start at a lower dose (2–3  mg/kg/day) of diazoxide. 
Diazoxide is an agonist of the KATP channel and a dose range of (5–15  mg/kg/day) is usually 
effective in all forms of congenital HH, except those caused by autosomal recessive 
mutations in the ABCC8 and KCNJ11 genes (Aynsley-Green et al., 2000). A functional KATP 
channel is required for diazoxide to exert an effect. Hence patients with focal or diffuse KATP 
HH do not respond to therapy with diazoxide. Patients with GDH-HH, SCHAD-HH, HNF4A 
and transient HH typically respond well to diazoxide. Patients with GCK-HH have a variable 
response to diazoxide and some may require surgery (Cuesta-Munoz et al., 2004). 
Patients unresponsive to maximum doses of diazoxide need urgent genetic analysis to 
identify those who should undergo 18F-DOPA-PET/CT in search of a focal lesion. Those with 
a paternally inherited ABCC8/KCNJ11 mutation are likely to have a focal lesion. While these 
investigations are carried out, normoglycaemia should be achieved with second-line 
medications. 
Octreotide	  
 
Octreotide is the second line of medical therapy for HH. Octreotide inhibits insulin secretion 
by activation of somatostatin receptor-2 and -5 and inhibition of calcium mobilization in β-
cells (De Leon and Stanley, 2007). Octreotide is administered subcutaneously every 6–8  h, 
beginning at a low dose (5  µg/kg/day) and titrating up to a maximum of 30  µg/kg/day. 
Necrotizing enterocolitis is a rare but potentially life-threatening adverse effect of octreotide 
and therefore, it must be used with caution in neonates (Laje et al., 2010). In most patients, 
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there is transient hyperglycaemic response to the initial doses of octreotide. However 
desensitization can occur after 2–3 doses, requiring increasing doses (tachyphylaxis) that in 
some patients makes this drug unsuitable for long-term use. There are reports suggesting that 
continuous subcutaneous octreotide infusion can overcome tachyphylaxis and lead to 
reduction in the dosage required as compared to when given by multiple daily injections 
(Vezzosi et al., 2005, Yorifuji et al., 2013). 
Newer	  Medical	  Therapies	  
 
Treatment with long acting preparations of octreotide has been reported to be successful in 
older children and needs more research to prove efficacy in younger group of patients (Le 
Quan Sang et al., 2012, Modan-Moses et al., 2011). In combination with frequent feeding, it 
may be a long-term treatment option either alone or in conjunction with diazoxide (Le Quan 
Sang et al., 2012). In diazoxide unresponsive patients, glucagon can be given along with 
octreotide, as a continuous intravenous infusion as a rescue therapy to help maintain 
normoglycaemia (Mohnike et al., 2008). 
GLP-1 receptor may be a new therapeutic target in future for children with KATP HH. In a 
mouse model of KATP HH (SUR-1–/–), treatment with exendin-(9–39) (GLP-1 receptor 
antagonist) had been shown to result in improved fasting blood glucose levels (De Leon et 
al., 2008). The authors’ findings suggested cAMP may have a role in KATP HH as cAMP 
content in SUR-1–/– was reduced by exendin-(9–39) both basally and when stimulated by the 
amino acids (De Leon et al., 2008). More recently, in a randomized, open-labeled, 2-period 
crossover pilot clinical study involving 9 human subjects with KATP HH, it was shown that 
significantly higher nadir blood glucose levels were observed with exendin-(9–39) as 
compared to placebo. These findings propose that GLP-1 and its receptor may play a role in 
the regulation of fasting glycaemia in KATP HH (Calabria et al., 2012). 
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Senniappan et al recently described the successful use of mTOR inhibitor sirolimus in the 
management of diazoxide and octreotide unresponsive HH (Senniappan et al., 2014). The 
authors treated four consecutive HH patients, who were unresponsive to the maximum doses 
of diazoxide and octreotide, with sirolimus and noticed improved glycaemia. A possible 
underlying mechanism of β-cell hyperplasia and HH is constitutive activation of mTOR 
pathway. Inhibitors of mTOR and mTOR kinase have also been shown to improve glycaemia 
in insulinoma patients, who have a similar pathophysiology (Bourcier et al., 2009, Kulke et 
al., 2009).  
 
1.3.5.2.	  Surgical	  management	  
 
The indications for surgery in HH patients include medically unresponsive diffuse disease 
and confirmed focal disease on 18F-DOPA-PET/CT scan. Despite the huge advances in 
diagnosing and accurately localizing focal lesions preoperatively with novel imaging 
techniques such as 18F-DOPA-PET/CT there is still a potential for ambiguity. Therefore, it is 
very important to have an experienced surgeon, endocrinologist, as well as pathologists 
trained in evaluating intraoperative frozen sections to confirm the focal lesions, which aid in 
guiding the extent of the surgery. 
Infants with diffuse disease require a near-total pancreatectomy (95–98% removal) to control 
the HH. They might require additional therapy post-operatively with diazoxide, octreotide, 
and/or frequent feedings to maintain normoglycaemia. Laparoscopic pancreatectomy is a new 
approach to the diagnosis and management of patients with congenital HH associated with 
less operative trauma and faster recovery than traditional laparotomy (Al-Shanafey, 2009, 
Pierro and Nah, 2011).  
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1.4	  AIMS	  OF	  THE	  PROJECT	  
 
Previous research under Prof Khalid Hussain at Great Ormond Street Hospital, London has 
recruited 300 patients with CHI (Figure 1.6). Depending upon responsiveness to diazoxide 
treatment, the patients were broadly classified into diazoxide responsive (183) and diazoxide 
unresponsive (105).  Molecular genetic analysis performed at University of Exeter Medical 
School confirmed the underlying genetic aetiology in 51 (27.8%) diazoxide responsive and 
92 (87.6%) diazoxide unresponsive patients.  
 
Within this large cohort of patients, there are some patients with unique complex phenotypes 
(protein sensitive HH with normal ammonia, HH and renal cysts, HH and cerebellar 
dysfunction with normal imaging) and no identified genetic aetiology. Additionally, there are 
consanguineous and non-consanguineous families with two affected siblings with no 
identified genetic aetiology.  
 
The aims of this project were: 
1. To recruit patients with complex forms of HH with no identified genetic aetiology for 
detailed clinical and biochemical phenotyping of these patients.  
 
2. To study these patients with homozygosity mapping and whole-exome sequencing 
techniques to identify potential novel genetic mechanisms of HH based on the 
available biological information. 
 
 
3. Based on the function of the gene, functionally characterize the mutation by 
appropriate laboratory techniques. 
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4. To functionally characterize two novel KATP mutations associated with unique clinical 
phenotypes (transient HH; combined focal and diffuse HH phenotype). 
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n = 35 
(GLUD1 = 16, HNF4A = 
7, KCNJ11 = 1, ABCC8 = 
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n = 2 
(All ABCC8) 
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n	  =	  2 
Figure 1.6: Summary of the genotypes of a cohort of 300 
patients with congenital HH (Kapoor et al. Eur J 
Endocrinol. 2013 Mar 15; 168(4):557-64) 
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Chapter 2 
 
 
 
 
 
 
 
 
GENERAL METHODS  
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2.1	  SUMMARY	  OF	  CHAPTER	  2	  	  
 
In chapter 2, various molecular biology techniques used in this project such as homozygosity 
mapping, whole-exome sequencing, site-directed mutagenesis, molecular cloning, RNA and 
protein extraction from the pancreatic tissue, Western blotting etc., are discussed. Dr Kerra 
Pearce from UCL Genomics Department performed the homozygosity mapping. Oxford 
Gene Technology carried out the whole-exome sequencing of the patients recruited in this 
project. Dr Sofia Rahman, post-doctoral fellow in Professor Khalid Hussain’s laboratory, 
performed Western blotting.  
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2.2	  HOMOZYGOSITY	  MAPPING	  
 
A genomic region is considered to be homozygous when the nucleotide (A, C, G or T) 
present at corresponding positions on the homologous chromosomes are identical. There are 
numerous positions in the genomic sequence, which differ in the single nucleotide sequence 
between corresponding positions on the paired chromosomes. These are referred as single 
nucleotide polymorphisms (SNPs).  
 
Individuals born of consanguineous marriages show long stretches where the nucleotides at 
SNP sites are identical on the homologous chromosomes (homozygous regions). The size of 
the homozygous region will depend on the degree of inbreeding. If the parents are first 
cousins, then 1/16 of their offspring’s genome will be homozygous. If they were second 
cousins then the homozygous genome amongst their offspring would be 1/64. More outbred 
populations have shorter shared homozygous regions. 
 
Homozygosity mapping (HZM) is a powerful technique for identifying the genes underlying 
rare autosomal recessive diseases in consanguineous families. The technique was first 
suggested by Lander and Botstein in 1987 (Lander and Botstein, 1987). This technique is 
based on identifying the regions of homozygosity and searching these regions for the 
causative gene.  The homozygous regions in the affected individual can be identified by SNP 
arrays. Homozygous regions in the affected siblings can then be compared and overlapping 
regions are likely to carry the causal gene.  
 
The fundamental principle underlying HZM is that in children born to consanguineous 
marriages, and affected with an autosomal recessive condition, a common homozygous 
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region spanning the disease locus will be inherited in all affected individuals; and this region 
will be “identical by descent”.  
 
 
Figure 2.1 Principle of Homozygosity Mapping: In children born to consanguineous 
marriages, and affected with an autosomal recessive condition, a common homozygous 
region spanning the disease locus will be inherited in all affected individuals.  
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2.3	  EXOME	  SEQUENCING	  
 
Exome sequencing involves sequencing the protein coding regions of the human genome. It 
is a powerful and cost-effective tool for identifying genetic basis of diseases. There are 
several reasons to choose exome sequencing above genome sequencing in search of rare 
alleles underlying Mendelian diseases. First, positional cloning studies that have focused on 
protein-coding sequences have, when adequately powered, identified disease-causing variants 
for a number of monogenic diseases (Antonarakis and Beckmann, 2006). Second, most 
alleles that are known to underlie Mendelian disorders disrupt protein-coding sequences. 
Third, a significant percentage of rare, protein-altering variants, such as missense or nonsense 
single-base substitutions or small insertion-deletions, are predicted to have functional 
consequences and/or to be deleterious (Kryukov et al., 2007). In view of the above reasons, 
exome sequencing is likely to identify variants that are deleterious for the function of the 
protein.  
One particular challenge for exome sequencing has been how best to define the regions of the 
genome that constitutes the exome (Bamshad et al., 2011). Considerable uncertainty remains 
regarding which sequences of the human genome truly are protein coding. Nevertheless, all 
existing targets have limitations.  
1. Our knowledge of all truly protein-coding exons in the genome is still incomplete, so 
current capture probes are designed to target known exons and will not capture 
genomic regions which have not been identified to be protein coding so far.  
2. The efficiency of capture probes varies considerably, and some exonic sequences are 
not captured by the probes altogether.  
3. All templates are not sequenced with equal efficiency, and not all sequences can be 
aligned to the reference genome so as to allow base calling.  
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4. Finally, whether important genomic sequences other than exons should be targeted in 
the capture probe design (for example, microRNAs (miRNAs), promoters and ultra-
conserved elements).  
Despite these caveats, exome sequencing is rapidly proving to be a powerful new strategy for 
finding the cause of known or suspected Mendelian disorders for which the genetic basis has 
yet to be discovered (Johnson et al., 2010, Bilguvar et al., 2010, Walsh et al., 2010). 
2.3.1	  Workflow	  for	  exome	  sequencing	  
 
The basic steps for exome sequencing are shown in the figures 2.2 and 2.3. The steps include 
sample preparation, hybridization, sequencing and alignment to the human reference genome. 
 
2.3.1.1	  Sample	  preparation:	  
 
The samples were prepared according to Agilent’s SureSelect Protocol Version 1.2. The 
genomic DNA was sheared with the target peak for base pair size of 200, which was then 
confirmed using a DNA 1000 Bioanalyzer assay. The ends of the sheared DNA were repaired 
with T4 DNA Polymerase and Klenow enzyme. This was followed by addition of ‘A’ bases 
to the 3´ ends of the DNA fragments. The DNA fragments with 3´ overhanging ‘A’ bases 
were ligated with adapters with 3´ overhanging ‘T’ bases. The sample was then run on an 
agarose gel and the region of the gel that contained fragments in the 200 to 300 bp range was 
excised. The DNA was purified from the gel and amplified with two primers that annealed to 
the ends of the adaptors. Following PCR, the genomic DNA purity and quantity was checked 
on the spectrophotometer. A minimum of 500 ng is required for the next step of 
hybridization. The quality was assessed with Agilent 2100 Bioanalyzer to verify a single peak 
in the size range of 200 to 300 nucleotides.  
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2.3.1.2	  Hybridization:	  
 
SureSelect Oligo Capture Library Mix (Biotinylated RNA Library Baits) is mixed with the 
genomic DNA sample (prepared in the previous step) in the presence of hybridization 
buffers. RNA Baits will hybridize with the complementary DNA fragments present in the 
prepared genomic sample. The hybridization mixture is then added to the solution containing 
Streptavidin coated magnetic beads. Streptavidin has an extraordinarily high affinity for 
biotin. With the use of a magnet, DNA fragments, which hybridized with the Biotinylated 
RNA library baits, can be separated from the rest of the DNA fragments on the magnetic 
beads. The beads are then washed and RNA is digested. The DNA is amplified and then 
sequenced. 
 
2.3.1.3	  Sequencing:	  
 
Sequencing was performed on the Illumina HiSeq2000 platform. The read files (Fastq) were 
generated from the sequencing platform via the manufacturer’s proprietary software. The 
reads were mapped to their location in the most recent build of the human genome 
(hg19/b37) using the Burrows-Wheeler Aligner (BWA) package.  
Local realignment of the mapped reads around potential insertion/deletion (indel) sites was 
carried out with the Genome Analysis Tool Kit (GATK) version 1.6 This algorithm ensures 
that the alignment has the minimum number of mismatching bases across the reads, the 
biggest effect of this is to reduce false-positive SNP calls around indels, and accurately 
determine indel length.   
Duplicate reads were marked using Picard version 1.83. This removes reads likely to be the 
result of PCR bias. Such PCR artifacts can introduce false positive SNP calls. Reads are not 
removed from the alignment but are not considered further in the analysis. 
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Base quality (Phred scale) scores were recalibrated using GATK's covariance recalibration. 
This improves the accuracy of the base quality metrics, which in turn improves the quality of 
variant calls.  SNP and indel variants were called using the GATK Unified Genotyper for 
each sample. SNP novelty is determined against dbSNP release 135. 
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2.3.2	  Identifying	  causal	  alleles	  
 
One of the demanding aspects of using exome sequencing to find novel disease genes 
for either Mendelian or complex traits is identifying disease-related alleles among the 
background of non-pathogenic polymorphism and sequencing errors. On average, 
exome sequencing identifies ~24,000 single nucleotide variants (SNVs) in African 
American samples and ~20,000 in European American samples. More than 95% of 
these variants are already known as polymorphisms in human populations (Bamshad 
et al., 2011). 
 
Factors which govern strategies to be used in finding causal alleles against this 
background of non-pathogenic polymorphism include: the mode of inheritance of a 
trait; the pedigree or population structure; whether a phenotype arises owing to de 
novo or inherited variants; and the extent of locus heterogeneity for a trait. Such 
factors also influence both the sample size needed to provide adequate power to detect 
trait-associated alleles and the selection of the most successful analytical framework. 
 
The main approaches for identifying causal variants in exome-sequencing data are 
below: 
2.3.2.1	   Discrete	   filtering: This approach relies on identifying rare alleles or 
novel alleles in the same gene shared among a small number of unrelated or closely 
related affected individuals. The identified shared variants among affected individuals 
are filtered for novelty against a set of polymorphisms that are available in public 
databases (dbSNP and 1000 Genome Project) and/or those found in a set of 
unaffected individuals (i.e. controls). This ‘discrete filtering’ step is used to reduce the 
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number of candidate genes by assuming that any allele found in the ‘filter set’ cannot 
be causative. This approach reduces the number of candidate genes drastically 
because only a small fraction (∼ 2% on average) of the single nucleotide variants 
(SNVs) identified in an individual by exome sequencing is novel.  
 
 
 
Figure 2.4: Sequencing and filtering across multiple unrelated, affected individuals 
(indicated by the three colored circles) 
 
This assumption that the filter set contains no alleles from individuals with the 
phenotype can be problematic for two reasons. First, dbSNP is ‘contaminated’ with a 
small but appreciable number of pathogenic alleles. Second, as the number of 
sequenced exomes and genomes increases, the filtering of observed alleles in dbSNP 
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should take into account the minor allele frequency (MAF) as otherwise truly 
pathogenic alleles that are segregating in the general population at low but 
appreciable frequencies will be eliminated. This risk is especially relevant for 
recessive disorders, in which carrier status (heterozygous) will not result in a 
phenotype but will be present in the control population at a low frequency. Analysis 
of recessive disorders in which the maximum MAF is set at 1% is still well powered. 
Alternatively, discrete filtering with a maximum MAF >1% can be carried out using a 
substantially larger sample size and/or in conjunction with pedigree-based 
approaches.  
 
 
 
Figure 2.5 Sequencing and filtering among multiple affected individuals from within 
a pedigree (shaded circles and squares) to identify a gene with a novel variant in a 
shared region of the genome 
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A lower MAF cutoff of 0.1% is helpful for dominant disorders, as the estimated 
prevalence of the disorder (generally well below 0.1%) provides an upper bound on 
the MAF. However, if the number of novel variants with lower MAFs in a sample 
population is high, it will be difficult to identify the causal gene. This limitation 
highlights the importance of having control SNP data from the same populations as 
the one from which cases were sampled.  
	  
2.3.2.2	   Stratifying	   candidates	   after	   discrete	   filtering: To reduce the 
number of potential variants to a sizeable number, candidate alleles after filtering 
against SNP databases can be further stratified on the basis of their predicted impact 
or deleteriousness.  
 
Alleles can be stratified by their functional class. Frameshift mutations, nonsense 
mutations and mutations which disrupt the canonical splice sites are more likely to be 
causal as compared to missense variants. However, this is an oversimplification that is 
insensitive to causal alleles that do not directly alter protein-coding sequences or 
canonical splice sites.  
 
Additionally, candidate alleles can be stratified by existing biological or functional 
information about a gene; for example, alleles with a predicted role in a biological 
pathway which can explain the phenotype or alleles which are known to interact with 
genes or proteins that are known to cause a similar phenotype. 
 
Another approach for stratifying candidate alleles is to use quantitative estimates that 
have functional impact. There are sequences that show high conservation among 
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different species and mutations in these are likely to be pathogenic. Sites that have 
experienced purifying selection can be identified by quantifying rates of mammalian 
evolution at the nucleotide level.  
 
Approaches that stratify non-synonymous alleles [for example SIFT, Polymorphism 
Phenotyping (PolyPhen2) and Multivariate Analysis of Protein polymorphism 
(MAPP)] also explore the predicted changes in proteins caused by specific amino acid 
substitutions. 
 
All of the above strategies enrich for functional sites at which observed variants are 
more likely to affect phenotype.  
 
Use of pedigree Information: For Mendelian phenotypes, the pedigree information 
can be used to substantially narrow the genomic search space for candidate causal 
alleles. However, exome sequencing may not need to be performed on every 
individual in a pedigree. Depending on the frequency of a disease-causing allele and 
the nature of the relationship between the individuals, the most informative 
individuals can be chosen for exome sequencing. For very rare alleles, the probability 
of identity-by-descent given identity-by-state is high even among distantly related 
individuals.  
 
The mapping data are also helpful in deciding the individuals who should be exome-
sequenced from a pedigree. In the absence of mapping data, the two most distantly 
related individuals with the phenotype of interest should be sequenced to substantially 
restrict the number of shared candidate alleles. 
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When mapping data are available, the most efficient strategy is to sequence those 
affected individuals whose overlapping haplotype produces the smallest shared 
genomic region. If the haplotype shared by all affected individuals is sufficiently 
short, then sequencing a single individual may be enough. For consanguineous 
pedigrees with suspected recessive node of inheritance, sequencing the individual 
with the smallest region (or regions) of homozygosity, as determined by the genome-
wide genotyping data, should be sufficient. In each of these instances, exome 
sequencing is merely used as a replacement for Sanger sequencing of all the genes in 
a crucial interval.  
 
For identifying de novo coding mutations, an approach that involves sequencing of 
parent-child trios is extremely efficient as it is highly unlikely that the proband will 
have multiple de novo events occurring within a specific gene (or within a gene 
family or pathway) (Nachman and Crowell, 2000, Vissers et al., 2010). This study 
design may be especially relevant to gene discovery in disorders where most cases are 
sporadic (that is, the parents are unaffected) and when a dominant mode of 
inheritance is likely (for example, when there are few instances of parent-to-child 
transmission) or substantial locus heterogeneity is expected. Despite the fact that 
identifying Mendelian inconsistencies in which the proband has a variant that is not 
called in either parent is unequivocal, more than 70% of these inconsistencies turn out 
to be false negatives that result from failure to call the corresponding germline 
variants in one or the other parent. This is likely to become less of an issue as the 
variant callers improve. 
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Figure 2.6: Sequencing parent-child trios for identifying de novo mutations  
 
2.3.3	  Technical	  and	  analytical	  limitations: Exome sequencing followed 
by discrete filtering has been the most rewarding strategy for establishing a novel 
disease gene, often with the aid of mapping data (Gilissen et al., 2010, Lalonde et al., 
2010, Simpson et al., 2011, Hoischen et al., 2010). However, how often this approach 
has been unsuccessful is challenging to work out, as negative results are rarely 
reported. Failure can result for many reasons, most of which can be broadly 
considered as either technical or analytical.  
 
Technical failure can occur because: part or all of the causative gene is not included in 
the target definition and capture is not designed for this region; there may be 
inadequate depth of sequencing of the region that contains a causal variant (for 
example, because of poor capture or poor sequencing); the causal variant may have 
been covered but not accurately called due to the presence of a small but complex 
indel (Bamshad et al., 2011).  Mismapping of the sequence reads or errors in 
alignment to the reference sequence may result in false variants in a gene.  
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Analytical failures may result from the limitations and assumptions of discrete 
filtering. Genetic heterogeneity limits the power of discrete filtering. For example, if 
the disease is caused by mutations in a number of different genes (genetic 
heterogeneity), more than one gene in the sample population will have disease-
causing alleles (Bamshad et al., 2011). Several other genes may also carry neutral 
mutations in as many cases, depending on the sample size. Hence it may become 
extremely difficult to separate the causal alleles from the non-causal alleles unless a 
large number of cases are sequenced.  
 
No variant calling due to the presence of disease-causing alleles in the comparative 
set, and reduced penetrance will result in a reduced signal-to-noise ratio. This 
problem is very similar to genetic heterogeneity. False-positive calls (true variant in 
the genes but not responsible for the phenotype) will result in detection of candidate 
genes that cannot logically be eliminated by filtering alone. 
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2.4	  RNA	  EXTRACTION	  
 
A small section of the pancreatic tissue removed during surgery of the patient with 
heterozygous non-stop KCNJ11 mutation had been stored at -80ºC in RNAlater. 
RNAlater is an RNA stabilization reagent that stabilizes RNA in tissue samples and 
preserves the gene expression profile. RNA was extracted from the stored pancreatic 
tissue according to the following steps: 
1. The pancreatic tissue was thawed on ice and rinsed with ice-cold phosphate 
buffer saline. The tissue was then homogenized in 1 ml trizol reagent in a 
sterilium and was incubated at room temperature for 5 minutes.  
2. The homogenized mixture was transferred in a 1.5 ml microcentrifuge tube 
and mixed with chloroform (200 µL). The microcentrifuge tube was vortexed 
to ensure complete mixing. The mixture was incubated for another 5 minutes 
at room temperature.  
3. The sample was centrifuged at 12,000 rpm for 15 minutes at 4ºC.  At the end 
of centrifuge step, the sample was separated into different layers. 
4. The superficial aqueous layer was carefully transferred to a new 1.5ml 
microcentrifuge tube.  
5. Isopropanol (ice cold; 500 µL) was added to the microcentrifuge tube 
containing the aqueous layer and mixed by vortexing. The mixture was 
centrifuged at 12,000 rpm for 30 minutes at 4ºC. This resulted in pellet 
formation. 
6. The supernatant was discarded and the pellet was washed with 70% ethanol 
twice.  
7. After the second ethanol wash, the pellet was air-dried. 
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8. Nuclease free water (NFW; 30 µL) was added to the pellet and gently mixed. 
The mixture was incubated at 55ºC for 10 minutes. 
9. The sample was immediately transferred to ice and the concentration of RNA 
and its quality determined by NanoDrop TM 1000 Spectrophotometer (Thermo 
Scientific).  
10. The RNA concentration obtained was 3736 ng/µL and OD260/280 of the RNA 
sample was 1.81. The ratio of absorbance at 260 and 280 nm is used to assess 
the purity of the sample.  
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2.5	  REVERSE	  TRANSCRIPTASE	  –	  POLYMERASE	  CHAIN	  REACTION	  
(RT-­‐PCR)	  
 
RT-PCR is a technique to detect RNA expression in the tissue. To ensure the 
transcript encoded by the KCNJ11 allele with a non-stop mutation is not degraded by 
non-stop decay phenomenon, RT-PCR was performed on the RNA extracted from the 
pancreatic tissue. The synthesized cDNA was sequenced to confirm the presence of 
both KCNJ11transcripts in the pancreatic tissue.  
SuperScript® III First-Strand Synthesis System (Invitrogen) was used for RT-PCR. 
SuperScript III reverse transcriptase is a thermostable variant of MMLV (Moloney 
Murine Leukaemia Virus) reverse transcriptase and also has reduced RNaseH activity, 
which increased the yield of first-strand cDNA.  
 
The steps for RT-PCR technique were as follows: 
1. The following mixture (RNA/primer) was prepared in a 0.5mL tube 
Table 2.1: RNA/Primer mixture for RT-PCR technique 
Component Amount 
Total RNA (3736 ng/µL) 0.27 µL (1 µg) 
Random Hexamers (50ng/µL) 1 µL 
10 mM dNTP mix 1 µL 
Double distilled water 7.73 µL (to make total volume of 10 µL) 
 
2. The RNA/primer mixture tube was incubated at 65ºC for 5 minutes, and then 
on ice for at least 1 minute. 
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3. The cDNA Synthesis Mix was prepared as shown below: 
Table 2.2: cDNA Synthesis Mix Reaction 
Component Amount 
10X RT buffer 2 µL 
25 mM MgCl2 4 µL 
0.1 M DTT 2 µL 
RNaseOUT (40 U/µL) 1 µL 
SuperScript III RT (200U/µL) 1 µL 
 
4. The cDNA Synthesis Mix (10 µL) and RNA/primer Mix (10 µL) were gently 
mixed in a 0.5 µL tube, followed by a brief centrifugation. 
5. The mixture was then cycled in a thermocycler according to the following 
settings: 
Table 2.3: Thermocycler Settings for RT-PCR technique 
Temperature Duration 
25 ºC 10 minutes 
50 ºC 50 minutes 
85ºC 5 minutes 
 
6. The cDNA synthesis reaction was then used for PCR using the following 
primers to amplify the region around the stop codon position of KCNJ11.  
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Table 2.4: Primers sequence for KCNJ11 sequencing 
Primer Sequence 
Forward TACTGGAAGCTCTGACCCTC 
Reverse TGCCTTGTAACACCCTGGAT 
 
7. The PCR products were sequenced to detect the presence of both KCNJ11 
alleles.  
2.6	  PROTEIN	  EXTRACTION	  FROM	  PANCREATIC	  TISSUE	  
 
For Western blotting to confirm the presence of larger Kir6.2 protein translated from 
KCNJ11 allele carrying the non-stop mutation, protein was extracted from the 
pancreatic tissue according to the following steps: 
1. Tissue lysis buffer was prepared in a 1.5 mL microcentrifuge tube as follows: 
Table 2.5: Preparation of Tissue Lysis Buffer 
Component Amount 
10X RIPA Buffer 100 µL 
Protease inhibitor 100 µL 
Double distilled water 800 µL 
RIPA buffer is a lysis buffer used to lyse cells and tissue for 
Radioimmunoprecipitation assay. It contains the ionic detergents SDS and sodium 
deoxycholate. 
2. The pancreatic tissue sample was washed with ice-cold phosphate buffer 
saline.  
3. The pancreatic tissue was placed in 300 µL of tissue lysis buffer (prepared 
above) in a small container and homogenized.  
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4. The homogenized tissue was placed on ice for 30 minutes and then transferred 
into a 1.5 mL microcentrifuge tube.  
5. The tissue sample was centrifuged at 10,000g for 10 minutes at 4ºC.  
6. After centrifugation, the supernatant layer was carefully transferred to a new 
1.5 mL microcentrifuge tube. This layer contained the protein fraction of the 
tissue.  
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2.7	  PROTEIN	  QUANTIFICATION	  
 
The Thermo Scientific Pierce BCA Protein Assay was used for protein quantification 
in the sample extracted from the pancreatic tissue.  
2.7.1	  Principle:	  	  
 
This assay utilizes the property of protein to reduce Cu2+ to Cu+ in an alkaline 
medium (the biuret reaction). The cuprous cation (Cu+) is then detected 
calorimetrically using a reagent contained bicinchoninic acid (BCA).  Two molecules 
of BCA chelate one cuprous ion to form a purple-colored reaction product. This 
reaction product exhibits a strong absorbance at 562nm that is nearly linear with 
increasing protein concentrations over a broad range (20-2000µg/mL).  
As the extent of color formation is not merely proportional to sum of individual color-
producing functional groups, the protein concentrations are reported with reference to 
standards of a common protein such as bovine serum albumin (BSA). 
2.7.2	  Method:	  	  
 
1. The BCA working reagent (WR) was prepared by mixing Reagent A and 
Reagent B in the ratio 50:1 (50 parts of Reagent A with 1 part of Reagent B). 
The following formula was used to determine the total volume of WR 
required: 
(# Standards + # unknowns) × (# replicates) × (Volume of WR per sample) = 
total volume WR required.  
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2. The diluted albumin (BSA) standards were prepared as shown below: 
Table 2.6: Preparation of diluted albumin standards for protein quantitation 
Vial Volume of BSA 
(µL) 
Volume of Diluent 
(µL) 
Final BSA Concentration 
(µg/mL) 
A 300 0 2000 
B 210 70 1500 
C 140 140 1000 
D 70 of vial B dilution 70 750 
E 140 of vial C dilution 140 500 
F 140 of vial E dilution 140 250 
G 0 200 0 = Blank 
 
3. 10 µL of each prepared BSA standards and 4 different dilutions (1:1, 1:2, 1:4 
and 1:8) of protein sample extracted from pancreatic tissue was pipetted into a 
microplate well in triplicates. 
4. 200 µL of BCA WR prepared above was added to each well.  
5. The microplate was thoroughly mixed on a plate shaker for 30 seconds. 
6. The plate was covered and incubated at 37ºC for 30 minutes. 
7. The plate was then cooled to room temperature and the absorbance was 
measured at 584nm.  
8. The average 584nm absorbance measurement of the blank standard replicates 
was subtracted from the measurements of all other individual standard and 
unknown sample replicates.  
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9. The average blank-corrected 584nm measurement of each BSA standard was 
plotted against its concentration in µg/mL to get a standard curve. This curve 
was used to determine the protein concentration in the sample extracted from 
the pancreatic tissue of the patient (15.22mg/mL).  
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2.8	  WESTERN	  BLOTTING	  
 
Western blotting was performed to detect the presence of two different molecular 
weight Kir6.2 proteins in the pancreatic tissue of the patient with a non-stop KCNJ11 
mutation.  
Technique:	  
 
Invitrogen’s Xcell SureLock Mini-Cell Electrophoresis System was used for Western 
blotting.  
Gel Electrophoresis: The inner chamber was filled with 200 mL 1× NuPAGE 
(Polyacrylamide) SDS running buffer with antioxidant and the outer chamber was 
filled with 600 mL 1× NuPAGE SDS running buffer. The pancreatic tissue sample 
(20 µg) was mixed in Laemmli buffer to a final protein concentration of 1 µg/µL and 
the mixture was loaded in the well of the pre-cast gel along with a control pancreatic 
tissue sample (20 µg) and molecular markers, and run at 150V for 1 hour at room 
temperature. The control pancreatic tissue sample was from a patient with HH with no 
mutation in ABCC8/KCNJ11 who had undergone pancreatectomy at GOSH. This step 
resulted in separation of proteins based on their molecular weight.  
Transfer by Electroblotting: After electrophoresis, the gel was removed from the 
cassette and a nitrocellulose membrane (pre-soaked with 1× NuPAGE Transfer Buffer 
with 10% methanol) was placed on top of the gel. The gel/membrane assembly was 
sandwiched between filter paper and blotting pads on either side. This was placed in 
the Xcell II Blot Module, with the gel closest to the cathode plate. During the 
assembly, any trapped air was removed. The blot module was filled with 1× NuPAGE 
Transfer Buffer and the outer buffer chamber was filled with deionized water. The 
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transfer was run at 30V for 2 hours. This step resulted in the transfer of proteins from 
the gel to the nitrocellulose membrane.  
Ponceau S Staining: The nitrocellulose membrane was washed in 1× PBST (1× PBS 
in 0.1% Tween) and then placed in Ponceau S solution for few seconds to detect the 
successful transfer of polypeptide bands from the gel to the membrane. The 
membrane was then repeatedly washed with double distilled water until the stain of 
Ponceau S was removed.  
Subsequent steps were performed after putting the nitrocellulose membrane in a 50 ml 
falcon.  
Blocking: The nitrocellulose membrane was blocked using 5%milk/PBST solution on 
a roller for 1 hour. The proteins in the blocking solution attached to all places on the 
membrane where the target proteins have not attached during the transfer. 
 
Detection: The membrane was incubated with the primary Kir6.2 antibody (raised in 
goat) in a concentration of 1:500, diluted in 10 ml of 5% milk/PBST solution, for 1 
hour on a roller. After 1 hour, the membrane was washed three times with 1× PBST. 
Following wash steps, the membrane was incubated with the secondary antibody 
(conjugated to HRP [Horseradish Peroxidase] enzyme) in a concentration of 1:20,000, 
diluted in 10 ml of 5% milk/PBST solution. The membrane was repeatedly washed 
again to remove unbound antibody and incubated with ECL (enhanced 
chemiluminescent) substrate for 4 minutes. The excess ECL solution was blotted off 
and the membrane was wrapped in a clear plastic wrap.  
 
The HRP enzyme catalyze the oxidation of luminol with emission of low intensity 
light at 428nm that is enhanced in the presence of enhancers in ECL solution. The 
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intensity of the light is proportional to the amount of HRP, which is proportional to 
the amount of protein in the blot.  
By comparing polypeptide bands in the sample pancreatic tissue and control 
pancreatic tissue and estimating the size of polypeptides with the molecular weight 
markers, the presence of an additional higher molecular weight Kir6.2 polypeptide 
was determined.   
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2.9	  MOLECULAR	  CLONING	  
	  	  
The molecular cloning is a technique to assemble recombinant DNA molecules. In 
this project, human KCNJ11 gene was inserted into pcDNA3.1 Zeo+ plasmid. The 
vector with mouse KCNJ11 cDNA insert is commercially available. However the 
commercially available vector contains only the cDNA sequence of the KCNJ11. The 
patient studied had a heterozygous non-stop mutation, which resulted in insertion of 
an extra 94 amino acids into the Kir6.2 protein sequence. To replicate the gene 
sequence in in-vitro experiments, a plasmid construct with an insert of coding region 
and 3´ UTR sequence of KCNJ11 in the multiple cloning site of pcDNA3.1 Zeo+ 
vector was prepared according to the following steps: 
1. Designing primers with restriction enzyme sites on the ends 
2. PCR amplification of the insert (cDNA of interest) 
3. Gel purification 
4. Double Restriction digest of the empty vector and PCR product 
5. Phosphatase treatment of Recipient Plasmid Double Restriction Digest 
Reaction 
6. PCR purification 
7. Ligation 
8. Transformation 
9. Isolation of plasmid DNA from the bacterial cells 
10. Confirmation of the cloning of the cDNA of interest in the plasmid by 
diagnostic restriction digest and sequencing 
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2.9.1	  Primer	  Design	  for	  Cloning	  PCR	  reaction	  
 
The forward and reverse primers (oligonucleotides) were designed using the 
Primer3web version 4.0.0 (http://bioinfo.ut.ee/primer3/). The entire coding sequence 
of KCNJ11 with flanking UTR (untranslated regulatory) sequences was pasted in the 
Primer3web software. The designed primers by the Prmer3web with no SNPs (single 
nucleotide polymorphisms) in their sequences were selected by using the SNPCheck3 
software 
(https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm;jsessionid=72BF23547E16DA70
F16FDE86FE1124B3).  The sequences of the forward and reverse primers are shown 
in table 2.7.  
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GCCGCCCAGGCTGCCCCACAGCAGTAGCAGGTGTTAAACTGTGCTCCTTTCCTGCCGAGG 
CCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAATGAGAGGGAGTCTGAGCTTCCATCAG 
ATTGTCAAAGGATTCAAGACTAAGATTAAGAGCATCCCCCAAAGAGAAGCAGCTGCAGGT 
TGAGAAGTCCTCGGACCGCCTAATTTCCGCCAGCCCTGGGATTGGTGGCGCCGCCTCTCA 
GCGCCTCCTTTCCCGGGGAACCTGCAAACCTGGCGCGGCCGAGAGGCGGATTACTGACCC 
AAATACGGATGGGGATATTGGGGGAGGGGAGCCAGGGCGACAGGGCGGCGGCCCCAGACT 
GGGAGGGCGGGTCACAGATCCCTCCCAGCCCCCCACTTTCGTAGAGCGTGGGCAGGAGGA 
ACCTCTGGGTTCCGCGGATCAGAAAAACTCCAAAGGCCGGGTTGTGAGTCCCGGGAGGGG 
AGGTGGAGGGCGGGGGCGGGGAGGGGCGCGGGAGGGGCGGGGGCTTGCTCCGGCCCCGCC 
CCCTGCGCTCCGGTGCAGGTCGGGCTCCCCCTGGCGGTCCCCGGCCCCGTTCCTCTCCTC 
GTGCGCCCCCCTCCCGCCGTCCTAGACCCCTGCCTAGCCCAGGTCGGTCTCCGCGGACCC 
ACGGACGGACAGACAGACGGGAGGACGGCCAGCCGCGAGCGCCCGGGCGGCGGGAGGGGG 
CGGGGAGGCGACGGCCGTGGCGTGAGGAGCAGGAGCAGGTGCAGCGGCGGCGGCGGGCGG 
GGCCGGGACCCGGCGCGGAGCGGGAGCCGCGGCGCGGGCGGGCGGCAGGGACCGGGAGGC 
CGCGACTCGGAGTCAGCCCCGCCGGGTCGCGCGCAGGTCCGGGGAGCCGCGGTTGAGCCG 
GGTGGGGTGGTGACTCCAGAGAACGCAGGATCCCAAGGAGACAGAGAGGACGAGAGCTGG 
AGGGGGATCCGGAAAGCGGCGGGGGCGCTCCGGGAGGGGTGGAGTAGGACATAGGGGGCG 
CACCTGGAGGAGAGACGGGGCGGGGGTGGCCAGGACCTGAGCTGGAGCCTGGGAGCCCGA 
AGGCCAGACAGGTGAGGCGGGAGACCCGGAGGTGGGGGTGAGGTCCGGTTAGTGGGAGAG 
ATCCGGAGGTGTTAAGTTCTGAGCTGGGCTGGGAAGGCAGGCTGGGCGGGGAGAAGGGCT 
CTTAGCGGGAGGCCCAGGGGTGGTCAGCTGGTGGGGGAAGCTGGGGGAGGACGCAGGGCC 
AGGTGGAGAGCCGGCAGGGTTGGGGGCTCCCTAGGCGCCAGGCAGGTGGGCTCAAGGGTG 
AGGCTGTTTTTTTTGTTTTGTTTTTTGTTTTTGAGACGGAGTCTCGCTCTGTCGCCCAGG 
CTGGAGTGCAGTGGCGTGATCTTGGCTCACTGCAACCTCCGCCTCTCGGGTTCAAGCGAT 
TCTCCTGCCTCAGCTTCCTGAGTAGCTGGGATTACAGGTGCGCACCACCATGCCCGGCTA 
ACTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGTCAGGCTGGTCTCGAACTC 
CTGACCTAGTGATCTGCCCTCCTCAGCCTCCCAACGTACTGGGATTACAGGCGTGAGCCA 
CCGCGCCCGGCCTGAGGCTGGTATTAAGAAGTGAAGTGGGACCCAGGTGGAGGTAAGGAA 
GAGTCTGGTGGGGAGTTATCTCAGAAGTGAGGCCAGCACAGGCTGAGTGCAGCCCCAGGG 
TGAGAAGGTGCCCACCGAGAGGACTCTGCAGTGAGGCCCTAGGCCACGTCCGAGGGGTGC 
CTCCGATGGGGGAAGCCCCTCCCTGGGGGTCACCGGAGCCATGCTGTCCCGCAAGGGCAT 
CATCCCCGAGGAATACGTGCTGACACGCCTGGCAGAGGACCCTGCCAAGCCCAGGTACCG 
TGCCCGCCAGCGGAGGGCCCGCTTTGTGTCCAAGAAAGGCAACTGCAACGTGGCCCACAA 
GAACATCCGGGAGCAGGGCCGCTTCCTGCAGGACGTGTTCACCACGCTGGTGGACCTCAA 
GTGGCCACACACATTGCTCATCTTCACCATGTCCTTCCTGTGCAGCTGGCTGCTCTTCGC 
CATGGCCTGGTGGCTCATCGCCTTCGCCCACGGTGACCTGGCCCCCAGCGAGGGCACTGC 
TGAGCCCTGTGTCACCAGCATCCACTCCTTCTCGTCTGCCTTCCTTTTCTCCATTGAGGT 
CCAAGTGACTATTGGCTTTGGGGGGCGCATGGTGACTGAGGAGTGCCCACTGGCCATCCT 
GATCCTCATCGTGCAGAACATCGTGGGGCTCATGATCAACGCCATCATGCTTGGCTGCAT 
CTTCATGAAGACTGCCCAAGCCCACCGCAGGGCTGAGACCCTCATCTTCAGCAAGCATGC 
GGTGATCGCCCTGCGCCACGGCCGCCTCTGCTTCATGCTACGTGTGGGTGACCTCCGCAA 
GAGCATGATCATCAGCGCCACCATCCACATGCAGGTGGTACGCAAGACCACCAGCCCCGA 
GGGCGAGGTGGTGCCCCTCCACCAGGTGGACATCCCCATGGAGAACGGCGTGGGTGGCAA 
CAGCATCTTCCTGGTGGCCCCGCTGATCATCTACCATGTCATTGATGCCAACAGCCCACT 
CTACGACCTGGCACCCAGCGACCTGCACCACCACCAGGACCTCGAGATCATCGTCATCCT 
GGAAGGCGTGGTGGAAACCACGGGCATCACCACCCAGGCCCGCACCTCCTACCTGGCCGA 
TGAGATCCTGTGGGGCCAGCGCTTTGTGCCCATTGTAGCTGAGGAGGACGGACGTTACTC 
TGTGGACTACTCCAAGTTTGGCAACACCGTCAAAGTGCCCACACCACTCTGCACGGCCCG 
CCAGCTTGATGAGGACCACAGCCTACTGGAAGCTCTGACCCTCGCCTCAGCCCGCGGGCC 
CCTGCGCAAGCGCAGCGTGCCCATGGCCAAGGCCAAGCCCAAGTTCAGCATCTCTCCAGA 
TTCCCTGTCCTGAGCCATGGTCTCTCGGGCCCCCCACACGCGTGTGTACACACGGACCAT 
GTGGTATGTAGCCCGGCCAGGGCCTGGTGTGAGGCTGGGCCAGCCTCAGCTCAGCCTCCC 
CCTGCTGCTCATCCAGGGTGTTACAAGGCACTTGTCACTATGCTATTTCTGGCCTCAGCA 
GGAACCTGTACTGGGTTATTTTTGTCCCTGCTCCTCCCAACCCAATTCAGGACTGGCTCA 
CCCCTCTCCCCCGCCCAAGGCTGCAGAGGCTGTGGGAGGTACTGGGCCCTAGAGCTGTGC 
GTCCAGCCAGTCCTGGGTCCCCACGATTGACCAGCCACACTCTGGGCCGGTGGCTGGGGA 
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AGAACAATCCCCGAGGGCTGCTGCTTTGCGTCTGTGGCTCCAAGAAGTGCCTGTGGTCAG 
GCCCCAGCTCTACTTGGTCCCTGAAAAAGCACCTGGCTAAGGGCTGGGCCTGGCCAGCAG 
GGAGGGCAGTTGATGAGAGAGGGTGTTCCCGCTGGAGGGTTGGTGCTGTGGAGCCTACAC 
CGGCAGGGACAGCCTGGGGCTGACAGGGCTCCCCTCCGAGGGCCAGTTTCAGGTCTGGAA 
GGGGAGGAAGCAGGGGAAGGTGACCTGAGGAGGCTCGGCTTTGTAGAGCCCCGCTCAGGC 
ACAGGGAGGAGGAGATGCCAGGGCTCCTGCCTTTTGCCACATCGGCCTCGTGCAGTGAGG 
GCTCTGTGGGCTGGGGCTGCTGCCCCTGCCTACCTCCTGCCTGTCCCCAGAGGCTGAGGA 
GAGGGGGTACTGTGCCCACCACACATGATTAGGCCTCAGACCCAACTCTGGTCCTGGCTC 
CACAACAGTGGCTGCCACTCACTTTGTCCAGAAGGTGGCTTGGGGGTGGATATCTTTGGG 
TTGCTGGAAAAGGTGTGGGAAGGTTCAGGATGGTGGGAGGGACTGAGGTCCCTGAGGTGA 
AGAGGCCCTTGGTCCTGACGGGTTTGACCCGTGCCTGGACCCTTGGAGCAGTGTTGTGTG 
AACTTGCCTAGAACTCTGCCTTCTCCGTTGTCAATAAAGCCTCCCCCTCATGACCTAAAC 
TCTGGGCTTTTCTTGCTGGGGAGGCAGCAAGCATGCTGGTGGGAAGGGAGGCAGGGACTG 
GCAGCTGCCACCCCCTTCAAGAGGCGCCATAGACCCTAGCGGGGAGGGCAGGGGAGGGAC 
GGAAGGCTGGCACCTCTTCCACCAGTTCAGGGGGACTTTCCCCTCTCCTGTCTCAGGTGG 
CCCAGCCCTGTCAGCCTGTCTGGCCAACTCAGCCTTTGGGCACTCACCAGGCTTTGCAGC 
CCTGGGCTCTGTCTCTACTCCCAGGGACCTGCTGGAAGGCTGGAGTGCCCAGGGAGAGGT 
ATAGAGGTGTCATAGGCATTAGTGTAGTAATTGGAGCACTAACTCTCGAGCCAACTGCCT 
GGGTTCGAATCCTGGCTCTAGCTGTATGACTTTTGTCAAGTAACTTAGCCTCTCTGTGTC 
TCAGTTGCCTCTTCTATAACATGGATGCTAATAGTACCTACCTCATAGAATTGTTTTGGA 
AGTAAATGAAAAATATGTAAAATGCTGAAGTGCCTGGTCTACAGTAAGTGCTCAATAAAT 
GTTAACTATTGTGATTGCTGCTGAATCAGCTACATGCTGAGGAAACGGCCAAA 
 
 
 
Figure 2.7: Sequence of human KCNJ11 gene from Ensembl genome browser. The 
start and end of the coding sequence is shown by the grey highlighted sequence. The 
start and end of the sequence amplified with PCR for cloning into the vector is shown 
by red underlined sequence (included in the PCR insert). The normal stop codon is 
highlighted by the red font. The next stop codon in the sequence (TAG) is shown in 
the green font.  
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 Sequence 
Forward Primer TAGGATCCGCCGCCATGCTGTCCCGCAAGGGCAT 
Reverse Primer TAGAATTCCTAGGGCCCAGTACCTCCCA 
 
Table 2.7: Sequences of the forward and reverse primers used to clone KCNJ11 
sequence into the vector pcDNA3.1 Zeo+. The recognition site sequences of type II 
restriction endonucleases BamH1 (from Bacillus amyloliquefaciens) and EcoR1 
(from Escherichia coli) are underlined with red and green colour respectively. The 
sequence underlined with blue colour in the forward primer sequence is the Kozak 
sequence.  
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2.9.2	  PCR	  Amplification	  Of	  The	  Region	  Of	  Interest	  
 
The coding sequence and 279 nucleotides in the 3’UTR sequence of KCNJ11 was 
amplified by PCR using a high fidelity taq polymerase (Pfu Turbo DNA Polymerase). 
The reaction ingredients are shown in table 2.8. The reaction ingredients were mixed 
in 200µL PCR tubes on ice. 
Ingredient Amount per reaction (50 µL) 
10X cloned Pfu reaction buffer 5.0 µL 
dNTPs 10mM 1.25 µL 
DNA template (100 ng/µL) 1.0 µL 
Forward primer (100 ng/µL) 1.0 µL 
Reverse primer (100 ng/µL) 1.0 µL 
Pfu Turbo DNA Polymerase (2.5U/µL) 1.0 µL (2.5 U) 
ddH2O (Double distilled water) 39.75 µL 
 
Table 2.8: Reaction Ingredients for Cloning PCR Reaction 
 
Following the preparation of the reaction mixture, the DNA region of interest was 
amplified by running the PCR reaction. PCR is a widely used scientific technique for 
exponentially amplifying a small number of DNA copies by several magnitudes, 
ultimately producing millions of copies of a specific DNA region. PCR involves three 
stages described below, which are repeated in multiple cycles of heating and cooling 
of the DNA containing reaction mixture. With each cycle, the copies of DNA double 
from the previous stage. The PCR protocol used for cloning is shown in table 2.9.  
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Steps Temperature Duration Number of cycles  
Initial 
Denaturation 
95ºC 2 minutes 1 
Denaturation 95ºC 30 seconds 30 
Primer Annealing 56ºC 30 seconds 
Extension 72 ºC 4 minutes 
Final Extension 72 ºC 10 minutes 1 
 
Table 2.9: Thermocycler Settings for Cloning PCR Reaction 
 
2.9.3	  Gel	  Electrophoresis	  
 
Following PCR amplification, the reaction mixture was analyzed on a 1% agarose gel. 
The gel was made by mixing 1.5g of agarose powder with 150ml of 1X TBE (Tris 
Borate EDTA) in a 500 ml glass bottle. The solution was heated in a microwave till 
the agarose powder was completely dissolved. Ethidium bromide (3 µL) was added to 
the solution and the mixture is then poured into a gel tray. The gel was then allowed 
to solidify for 30 minutes. The gel was placed in the gel electrophoresis tank filled 
with TBE buffer. If required, more TBE buffer was added to ensure complete 
submersion of the gel in the TBE buffer. The wells in the gel were loaded with 
mixture of loading dye and PCR product (10 µL Loading dye and 50 µL PCR 
product). A DNA ladder was loaded in an adjacent well to allow identification of the 
size of the PCR product. A voltage of 80 volts was applied for 60 minutes to allow the 
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migration and separation of the DNA molecules according to their size. The gel was 
visualized under the UV light to identify the bands from PCR product.  
2.9.4	  Gel	  Purification	  of	  the	  PCR	  Insert	  
 
QIAquick gel extraction protocol was used for DNA extraction from the agarose gel 
according to the following steps: 
1. The DNA fragment was excised from the agarose gel with a clean and sharp 
scalpel.  
2. The agarose gel was weighed and three volumes of Buffer QG were added for 
1 volume of gel.  
3. The mixture was then incubated at 50ºC for 10 minutes to solubilize agarose 
completely. The colour of the mixture remained similar to the colour of Buffer 
QG without dissolved agarose.  
4. The mixture was then transferred to QIAquick column and centrifuged at 
≥10,000 × g (∼13,000 rpm) for 1 minute. 
5. The flow-through was discarded and QIAquick column was placed in the 
same collection tube and centrifuged for another 1 minute.  
6. Buffer PE (750 µL) was added to the QIAquick column and centrifuged for 1 
minute. The flow-through was discarded and QIAquick column was placed in 
the same collection tube and centrifuged for another 1 minute.  
7. QIAquick column was then placed in a clean 1.5ml microcentrifuge tube. 
Double distilled water (ddH2O; 30 µL) was added to the center of the 
QIAquick membrane and allowed to stand for 1 minute before centrifuging for 
another 1 minute.  
8. The DNA concentration in the eluate was 6ng/µL.  	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2.9.5	  Double	  Restriction	  Enzyme	  Digest	  	  
 
Following the purification of the DNA region of insert, which had recognition sites 
for restriction enzymes at either ends, the next step in cloning is to set up the 
restriction digest of the PCR product as well as the recipient plasmid (pcDNA3.1 
Zeo+). The double restriction digest was performed in a volume of 20 µL on 100ng of 
PCR product and 1 µg of recipient plasmid using 5 units of enzyme as shown in table 
2.10.  
Table 2.10: Restriction Digest Reaction 
PCR product double restriction digest Recipient Plasmid (pcDNA3.1 Zeo+) 
double restriction digest 
Reaction volume 20 µL Reaction volume 20 µL 
Restriction 
Enzyme 10×  
Buffer 
2.0 µL Restriction Enzyme 
10× Buffer 
2.0 µL 
Bovine Serum 
Albumin (BSA) 
0.2 µL Bovine Serum 
Albumin (BSA) 
0.2 µL 
EcoR1 Restriction 
Enzyme (10 u/ µL) 
0.5 µL EcoR1 Restriction 
Enzyme (10 u/ µL) 
0.5 µL 
BamH1 
Restriction 
Enzyme (10 u/ µL) 
0.5 µL BamH1 Restriction 
Enzyme (10 u/ µL) 
0.5 µL 
PCR product (6ng/ 
µL) 
16.8 µL (100ng) Recipient Plasmid 
(1 µg/ µL) 
1 µL (1 µg) 
ddH2O - ddH2O 15.8 ddH2O 
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After preparing the reactions as mentioned in the table, the reaction mixture was 
incubated at 37ºC for 1 hour.  
2.9.6	  Phosphatase	  treatment	  of	  Recipient	  Plasmid	  Double	  
Restriction	  Digest	  Reaction	  
 
To avoid the problem of ligation of the ends of the recipient plasmid during the ligase 
reaction, the recipient plasmid restriction digest reaction was treated with Antarctic 
phosphatase. It catalyzes the removal of 5´ phosphate from DNA and RNA, which is 
required for ligation reaction. The reaction was prepared as shown in table 2.11. 
 
Table 2.11: Antarctic Phosphatase Reaction Ingredients 
Ingredient Volume 
Recipient plasmid double restriction 
digest reaction mixture 
20 µL 
Antarctic phosphatase 10×  Buffer 2.5 µL 
Antarctic phosphatase (5U/µL) 1 µL 
ddH2O 1.5 µL 
 
The above reaction mixture was incubated at 37ºC for 15 minutes.  
 
2.9.7	  PCR	  Purification	  	  
 
The two reaction mixtures from the previous steps (phosphatase treatment of recipient 
plasmid double restriction digest and double restriction enzyme digest of PCR 
product) were subjected to purification to remove enzymes. The steps of the PCR 
purification step were as below: 
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1. Five volumes of Buffer PB were added to 1 volume of the reaction mixture 
and mixed. The colour of the mixture remained similar (yellow) to the colour 
of Buffer PB.  
2. The above mixture was poured into the QIAquick column held in a 2ml 
collection tube and centrifuged at ≥10,000 × g (∼13,000 rpm).  
3. The flow-through was discarded and 0.75ml Buffer PE was added to the 
QIAquick column and centrifuged for another 1 minute.  
4. After discarding the flow-through again, the QIAquick column was 
centrifuged once more to remove residual wash buffer (Buffer PE).  
5. QIAquick column was then placed in a clean 1.5 ml microcentrifuge tube and 
30 µL of ddH2O was added to the center of the QIAquick membrane. 
QIAquick column was centrifuged for another 1 minute after letting it stand 
for 1 minute.  
6. The DNA concentration in the eluate from recipient plasmid reaction mixture 
was 23 ng/ µL and from the PCR reaction digest was 6ng/µL.  
 
2.9.8	  Ligation	  Reaction	  
 
The next step, after cutting the PCR product and recipient plasmid with restriction 
enzymes to generate the cohesive ends, is to ligate the two products together using T4 
DNA Ligase. The molar ratio of recipient plasmid: PCR insert DNA in cloning can be 
1:1, 1:3 or 3:1. I used 1:3 ratio of recipient plasmid: PCR insert during ligation. 
Typical ligation reactions use 100-200 ng of plasmid DNA and are 10µL reactions. 
The formula to calculate the mass of PCR insert DNA in a ligation reaction is 
!!  !"  !"#$%&'  ×!"  !"#$  !"  !"#$%&!"  !"#$  !"  !"#$%&'   ×𝑚𝑜𝑙𝑎𝑟  𝑟𝑎𝑡𝑖𝑜  𝑜𝑓   !"#$%&!"#$%&'     = 𝑛𝑔  𝑜𝑓  𝑖𝑛𝑠𝑒𝑟𝑡  
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For 100ng of plasmid DNA, I had to use 77 ng of insert DNA according to the above 
formula (ng of plasmid = 100ng, kb size of insert = 1.4, kb size of the plasmid = 5.4). 100  𝑛𝑔  𝑝𝑙𝑎𝑠𝑚𝑖𝑑  ×1.4  𝑘𝑏  𝑖𝑛𝑠𝑒𝑟𝑡5.4  𝑘𝑏  𝑝𝑙𝑎𝑠𝑚𝑖𝑑   ×   31   = 77  𝑛𝑔  𝑖𝑛𝑠𝑒𝑟𝑡   
However I would not have been able to fit this amount in a 10 µL reaction as the 
concentration of recipient plasmid and insert DNA was less. Hence I carried out the 
ligation reaction using 50 ng of recipient plasmid DNA. 50  𝑛𝑔  𝑝𝑙𝑎𝑠𝑚𝑖𝑑  ×1.4  𝑘𝑏  𝑖𝑛𝑠𝑒𝑟𝑡5.4  𝑘𝑏  𝑝𝑙𝑎𝑠𝑚𝑖𝑑   ×   31   = 38.5  𝑛𝑔 
The ligation reaction was prepared according to table 2.12.  
Table 2.12: Ligation Reaction Ingredients 
Ingredient Volume (10 µL Reaction) 
Recipient plasmid DNA (23ng/µL) 2.2 µL (50 ng) 
PCR Insert DNA (6ng/ µL) 6.4 µL (38.5 µL) 
Ligase 10×  Buffer 1 µL 
T4 DNA Ligase (3U/ µL) 0.4 µL (1.2U) 
 
The ligation reaction mixture was incubated at room temperature for 3 hours and then 
chilled on ice. This was followed by transformation of 5 µL of the reaction mixture 
into competent cells.  
 
  
 98 
 
2.9.9	  Transformation	  	  
 
The ligation reaction mixture (5 µL) was transformed into AG1 competent cells. AG1 
competent cells are high transformation efficiency derivatives of DH1 cells. The 
transformation protocol used is described below: 
1. Two 14-ml BD Falcon polypropylene round-bottom tubes were pre-chilled on 
ice. SOC medium was kept on the heat block set at 42ºC. 
2. AG1 cells were removed from -80ºC storage and thawed on ice. The cells (100 
µL) were aliquoted into the pre-chilled round-bottom tubes.  
3. The β-mercaptoethanol (β-ME) reagent (1.7 µL) was added to each aliquot of 
cells. β-ME increases the transformation efficiency. 
4.  The tubes were gently swirled every 2 minutes for a total of 10 minutes while 
on ice. 
5. The ligation reaction mixture (5 µL) was added to one aliquot of cells. The 
pUC18 control plasmid (1 µL) was added to the other aliquot as a control for 
transformation efficacy.  
6. The tubes were gently swirled and then incubated on ice for another 30 
minutes. 
7. The tubes were submerged in the 42ºC water bath for 45 seconds. The 
duration of this step is critical as optimal transformation efficiency is observed 
when cells are heat-pulsed for 45-50 seconds.  
8. Following the heat-pulse, the tubes were immediately incubated on ice for 2 
minutes. 
9. Preheated SOC medium (0.9 ml; from step 1) was added to each tube. The 
tubes were then incubated at 37ºC for 1 hour with shaking at 225-250 rpm.  
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10. The transformation mixture was plated on LB-ampicillin agar plates. Different 
volumes (50 µL, 100 µL and 200 µL) of the transformation mixture were 
plated on each LB-ampicillin agar plate used. For the pUC18 control 
transformation, 5 µL of the transformation mixture was plated on the LB-
ampicillin agar plate. 
11. The plates were incubated overnight at 37ºC.  
12. Approximately 100 colonies were noticed on the LB-ampicillin agar plate 
used for plating ligation reaction transformation mixture.  
 
2.9.10	  Starter	  Cultures	  and	  Miniprep	  
 
Eight colonies were picked from the ligation-reaction transformation mixture plated 
agar plate with sterile pipette tips. Each colony was transferred into a 15 ml falcon 
containing 3-5 ml of autoclaved LB media with ampicillin at a concentration of 
50µg/mL. These starter cultures were incubated at 37ºC overnight with shaking at 
225-250 rpm.  
 
The following morning, a miniprep was carried out on all the successful overnight 
starter cultures (turbid looking LB media due to growth of bacteria containing 
plasmid for antibiotic resistance) using the QIAprep Spin Miniprep Kit (Qiagen). This 
technique purifies plasmid DNA and the procedure is based on alkaline lysis of 
bacterial cells followed by adsorption of DNA onto silica in the presence of high salt. 
Bacteria are lysed under alkaline conditions, and the lysate is subsequently 
neutralized and adjusted to high-salt binding conditions, ready for purification on the 
QIAprep silica-gel membrane. The optimized buffers in the lysis procedure combined 
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with the unique silica-gel membrane ensure that only DNA will be adsorbed, while 
RNA, cellular proteins, and metabolites are not retained on the membrane but are 
found in the flow-through. Salts are efficiently removed by a brief wash step with 
Buffer PE. High-quality plasmid DNA is then eluted from the QIAprep column with 
Buffer EB or water.  
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2.9.11	  Diagnostic	  Restriction	  Digest	  
 
Following isolation of plasmid DNA, a diagnostic restriction digest was performed 
with an endonuclease EcoN1 (isolated from E.coli) to confirm the cloning of KCNJ11 
into pcDNA3.1 Zeo+ vector. EcoN1 is predicted to cut the plasmid, pcDNA3.1 Zeo+ 
with KCNJ11 insert between BamH1 and EcoR1 recognition sites, at two positions 
and generate two fragments of sizes 648 bp and 6221 bp. The gel image of the 
diagnostic restriction digest is shown in figure. 
2.9.12	  Verification	  of	  Plasmid	  by	  Sequencing	  
 
As PCR based cloning carries the risk of insertion of mutations depending on the 
fidelity of DNA polymerase used, the entire KCNJ11 insert in the vector pcDNA3.1 
Zeo+ was sequenced to confirm no mutations have been inserted by error. The 
sequences of the oligonucleotides used to sequence the insert are shown in the table.  
 
Table 2.13: Primers Sequence for Sequencing of KCNJ11 insert in pcDNA3.1 vector 
Oligonucleotide Sequence 
T7 Promoter TAATACGACTCACTATAGG 
KCNJ11_F TACTGGAAGCTCTGACCCTC 
KCNJ11_R TGCCTTGTAACACCCTGGAT 
BGH Reverse TAGAAGGCACAGTCGAGG 
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2.10	  SITE	  DIRECTED	  MUTAGENESIS	  
 
In vitro site-directed mutagenesis is an invaluable technique for carrying out vector 
modification. QuikChange Site-Directed Mutagenesis Kit allows site-specific 
mutagenesis in double-stranded DNA (dsDNA) plasmid. It can be used to make point 
mutations, deletions and insertions with greater than 80% efficiency.  
 
Principle:  
The basic principle of this technique is that two synthetic oligonucleotide primers 
containing the desired mutation are designed, which will anneal to the complementary 
strands of the double-stranded DNA (dsDNA) vector. These primers will then be 
extended by a high fidelity DNA polymerase (PfuTurbo DNA Polymerase) in a 
temperature cycler. This extension will result in incorporation of the oligonucleotide 
primers, which carried the mutation, in the dsDNA vector. Subsequent treatment with 
a specific endonuclease, Dpn I, will digest the parental DNA template and leave 
behind the mutated synthesized nicked DNA vector. The final step is transformation 
of the mutated DNA vector in the XL1-Blue supercompetent cells.  
 
The steps are described in more details below: 
2.10.1	  Alignment	  of	  human	  and	  hamster	  ABCC8	  sequence	  	  
 
For studying ABCC8 mutation, the plasmid pcDNA3.1 Zeo+ with inserted hamster 
ABCC8 sequence was used. To identify the corresponding position of the mutation 
identified in my patient in the hamster SUR1 sequence, the human ABCC8 cDNA 
sequence was aligned with the hamster SUR1 ABCC8 sequence (Cricetus cricetus) 
using the Clustal programme.  
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For KCNJ11 and KCNK17 mutations identified in the patients studied in this thesis, 
the plasmids with human clone were used.  The plasmid containing KCNJ11 was 
constructed as explained above, whereas the KCNK17 plasmid was purchased from 
Thermofisher Scientific Biosciences.  
2.10.2	  Mutagenic	  Primer	  Design	  
 
The mutagenic primers were designed according to the following guidelines from the 
QuikChange Site-Directed Mutagenesis Kit. 
1. Both of the mutagenic primers must contained the desired mutation and anneal 
to the same sequence on opposite strands of the plasmid. 
2. Primers should be between 25 and 45 bases in length. 
3.  Melting temperature (Tm) of the primers as estimated by the following 
formula should be ≥78ºC.  
𝑇𝑚   = 81.5  + 0.41 %𝐺𝐶 −   675𝑁   −%  𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ 
N is the primer length in bases 
%GC and % mismatch must be whole numbers 
4. For primers designed to introduce insertions or deletions, the following 
formula should be used. 
𝑇𝑚 = 81.5+ 0.41 %𝐺𝐶 −   675 𝑁 
N does not include the bases, which are being inserted or deleted 
5. The desired mutation should be in the middle of the primer with ∼10-15 bases 
of correct sequence on both sides 
6. Optimally, the primers should have a minimum GC content of 40% and should 
terminate in one or more C or G bases.  
 104 
 
The mutagenic primers were ordered from Sigma Aldrich and were supplied in a 
lyophilized form. The primers were dissolved in appropriate volume to ddH2O to 
prepare a stock solution of 100 µM. The working primer solution (5 µM) was 
prepared by diluting 10 µL of the primer stock solution with 190 µL of ddH2O. The 
stock solution was stored at -20ºC and the working solution at 4ºC.   
The sequences of the mutagenic primers used to insert mutations are shown in table 
2.14.  
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Mutagenic Primers Primer Sequence 
KCNJ11_Primer 1 CTCTCCAGATTCCCTGTCCCGAGCCATGGTCTCTCGGG 
KCNJ11_Primer 2 CCCGAGAGACCATGGCTCGGGACAGGGAATCTGGAGAG 
KCNK17_Primer 1 GCTCGTGGGCTCCTTCTTTTCTGTGTCCACCATCAC 
KCNK17_Primer 2 GTGATGGTGGACACAGAAAAGAAGGAGCCCACGAGC 
KCNG2_Primer 1 CAAGGAGCAGCAGCAGCGCGTGGCCAGCCCCGAGCCGGC 
KCNG2_Primer 2 GCCGGCTCGGGGCTGGCCACGCGCTGCTGCTGCTCCTTG 
ABCC8_Primer 1 CCTCCATCGACATGGCTATGGAGAACATCCTCCAGAAG 
ABCC8_Primer 2 CTTCTGGAGGATGTTCTCCATAGCCATGTCGATGGAGG 
 
Table 2.14: Mutagenic Primers used to insert mutations in the genes carried in the 
vector 
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2.10.3	  Site-­‐Directed	  Mutagenesis	  (SDM)	  Reaction	  
 
The SDM reaction was prepared on ice in thin-walled PCR tubes utilizing the 
designed mutagenic primers and the double-stranded DNA vector containing the 
wild-type gene as shown in table 2.15.   
Table 2.15: SDM Reaction Preparation 
Reagent Amount 
10×  Reaction Buffer 5 µL 
dsDNA template 50 ng 
(volume varied with the concentration) 
Oligonucleotide Primer #1 125 ng 
Oligonucleotide Primer #2  125 ng 
dNTP mix 1 µL 
ddH2O To a final volume of 50 µL 
PfuTurbo DNA Polymerase (2.5 U/ µL) 1 µL 
 
After preparing the SDM reaction, it was cycled 16 times in a thermal cycler 
according to the settings shown in table 2.16. 
Segment Cycles Temperature Time 
1 1 95ºC 30 seconds 
2 16 95ºC 30 seconds 
55ºC 1 minute 
68ºC 1 minute/kb of plasmid length 
Table 2.16: Thermocycler Settings for QuikChange SDM Method 
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2.10.4	  Digestion	  
 
After the thermal cycling, the SDM reaction was placed on ice for 2 minutes. To the 
50 µL of the reaction mixture, Dpn I restriction enzyme (1 µL; 10 u/µL) was added 
and mixed thoroughly first by pipetting and then spinning the mixture in a 
microcentrifuge for 1 minute. The reactions were then incubated at 37ºC for 1 hour. 
Dpn I restriction enzyme digests the methylated parental DNA and leaves behind the 
mutation-containing synthesized DNA.  
2.10.5	  Transformation	  
 
The next step is to transform the XL1-Blue Supercompetent cells with the Dpn I 
digested SDM reaction. The supercompetent cells are gently thawed on ice and 
aliquoted (50 µL) into prechilled 14-ml BD Falcon polypropylene round-bottom 
tubes. The Dpn I treated SDM reaction (1-4 µL) was transferred into an aliquot of 
supercompetent cells. The reaction mixture is gently swirled and incubated on ice for 
30 minutes. After 30 minutes, the transformation reactions were heat-pulsed for 45 
seconds by immersing the round-bottom tubes in 42ºC water bath. The reactions were 
then placed on ice for 2 minutes and 900 µL of preheated SOC medium (42ºC) was 
added. Afterwards, the reaction mixtures were incubated at 37ºC for 1 hour with 
shaking at 225-250 rpm.  
2.10.6	  Inoculating	  Agar	  Plates	  
 
The LB-ampicillin agar plates were plated with varying volumes of the transformation 
reaction mixture. The transformation mixture was pipetted on the LB-ampicillin agar 
plates and was spread with a sterile glass spreader. The plates were air-dried for 5-10 
minutes and then incubated upside down in an incubator at 37ºC for >16 hours.  
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2.10.7	  Starter	  Cultures	  and	  Mini	  Prep	  
 
Colonies were picked with sterile pipette tips and inoculated into 15 ml falcons 
containing 3-5 ml of autoclaved LB media with ampicillin at a concentration of 
50µg/mL. These starter cultures were incubated at 37ºC overnight with shaking at 
225-250 rpm. A mini prep was carried out on all the successful starter cultures as 
described above under the technique of molecular cloning.  
2.10.8	  Sequencing	  	  
 
After the isolation of plasmid DNA using the miniprep technique, sequencing was 
performed to confirm the insertion of the mutation in the plasmid as well as to ensure 
no mutations at other sites in the gene of interest have been generated during thermal 
cycling. The sequences of the primers used for sequencing the entire gene are shown 
in table 2.17. 
 
 
Table 2.17: Primers Sequence for sequencing of the entire gene insert in the vector 
Primers Sequence 
pCMV-SPORT6-KCNK17 vector 
 
KCNK17_attB1 ACAAGTTTGTACAAAAAAGCAGG 
KCNK17_T7 Promoter AATACGACTCACTATAGGG 
KCNK17_1F CTTCCAGCGCGACAAGTG 
KCNK17_1R AAAGAAGAAGGAGCCCACGA 
KCNK17_2F CCGCCTCTTCTGCATCTTCT 
KCNK17_2R CTGGGAGGGGTTCATTCCAA 
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Primers Sequence 
pCMV-XL4-KCNG2 vector 
KCNG2_VP1.5 GGACTTTCCAAAATGTCG 
KCNG2_XL39 ATTAGGACAAGGCTGGTGGG 
KCNG2_1F GAGTTCTTCTTCGACCGCAG 
KCNG2_1R GGTCTCCAGCACGAACAGG 
KCNG2_2F CGTGTCCGTGTCCTTCGT 
KCNG2_2R AGGTGTGGAAGATGGAGGTG 
KCNG2_Reverse TCAGCGCCCTGCCCGCACCC 
pcDNA3.1-KCNJ11 vector 
KCNJ11_T7 Promoter AATACGACTCACTATAGGG 
KCNJ11_BGH reverse TAGAAGGCACAGTCGAGG 
KCNJ11_F TACTGGAAGCTCTGACCCTC 
KCNJ11_R TGCCTTGTAACACCCTGGAT 
pcDNA3.1-ABCC8 vector 
 
ABCC8 cDNA_1F ATGCCCTTGGCCTTCTGCGG 
ABCC8 cDNA_1R CACACAAGGACGAAGAGCAA 
ABCC8 cDNA_1Fʹ′ CCTCAACAACGGCTGCTT 
ABCC8 cDNA_1Rʹ′ ATGTTGCTGCTTGTGGAGGT 
ABCC8 cDNA_2F GGGCTTCTGGTGATCCTGTA 
ABCC8 cDNA_2R ATCCCAAAGATGCAGAGTGG 
ABCC8 cDNA_3F TGATCCTCAGCAGCACATTC 
ABCC8 cDNA_3R CACGCCCACAATGATCTGTA 
ABCC8 cDNA_3.1F CTTTCTGTGCCCAAACCTCT 
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Primers Sequence 
ABCC8 cDNA_3.1F CTCCCACGCATACAGTTTGA 
ABCC8 cDNA_4F TGAAGCAGACCAACGAGATG 
ABCC8 cDNA_4R CCGATGATCTGGACACAGAA 
Covers_G716D_F GGTTGTGAACCGCAAACG 
Covers_G716D_R TGGTTTCTGAGATGCGTAGG 
ABCC8 cDNA_5F CAGGACCAAGAGCTGGAGAA 
ABCC8 cDNA_5R CACGGGTGTGACATAGGAGA 
ABCC8 cDNA_6F TCGGATATCAGGAGCAGAGG 
ABCC8 cDNA_6R TGAGATGGCTCTGAGGCTTT 
ABCC8 cDNA_7F ATGCCTTGATGGTCTCCAAC 
ABCC8 cDNA_7R GCAGATCCCGATCTTCTGC 
ABCC8 cDNA_7Fʹ′ CCCCCATGAGGTTCTTTGA 
ABCC8 cDNA_7Rʹ′ CAGGTTCCTCACCATCCAGT 
ABCC8 cDNA_8F CGTGAGGAAGACCAGCATCT 
ABCC8 cDNA_8R CTGTCCTTCTGGCTGAGGAG 
ABCC8 cDNA_8Fʹ′ GAAGCATGTCAACACCCTCA 
ABCC8 cDNA_8Rʹ′  CAGGATAGCACCCCTCTTGA 
 
2.10.9	  Transformation	  into	  AG1	  Competent	  Cells	  
 
After the confirmation of the sequence of the insert in the vector, the plasmid DNA 
obtained after the mini prep step was transformed into AG1 competent cells according 
to the steps explained under the technique of molecular cloning. 
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2.10.10	  Maxi-­‐prep	  
 
Endo-Free Plasmid Maxi Kit (Qiagen) was used to perform maxi-preps after 
retransformation according to the manufacturer’s instructions. This technique is based 
on the principle of alkaline lysis of the bacterial cells followed by binding of the 
plasmid DNA to Qiagen Anion-Exchange Resin under appropriate low salt and pH 
conditions. Plasmid DNA is eluted in a high-salt buffer and then concentrated and 
desalted by isopropanol precipitation. This technique can yield up to 500 µg of 
plasmid DNA ready for transfection.  
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Chapter 3  
 
 
 
CLINICAL ASPECTS AND 
WHOLE-EXOME SEQUENCING 
RESULTS OF THE PATIENTS 
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3.1.	  RECRUITING	  PATIENTS	  WITH	  CONGENITAL	  HH	  
 
A cohort of 12 patients from 9 families was recruited into this project during the three 
years, based on their characteristic clinical phenotype. All patients were being 
managed by Professor Khalid Hussain at Great Ormond Street Hospital NHS Trust, 
London. Personal data (name, date of birth, gender and ethnic background) and 
detailed phenotypic data were collected on these patients. The phenotypic information 
included clinical information (age at presentation, birth weight, gestational age, 
presenting symptoms, family history of hypoglycaemia/diabetes mellitus, and 
consanguinity, and responsiveness to diazoxide) and biochemical information (results 
of controlled diagnostic fast and protein loading test). Information on histology was 
collected if the patient required pancreatectomy for management of HH. Eight 
patients have had molecular genetic testing done for ABCC8, KCNJ11, HNF4A and 
GLUD1 at University of Exeter Medical School, Exeter and were negative for 
mutations in known genes associated with the clinical phenotype.  
One patient had not undergone molecular genetic testing but had a unique phenotype. 
Another three patients recruited in this project were found to have novel heterozygous 
KATP channel mutations. Two second-degree cousins had an ABCC8 mutation and one 
patient had a KCNJ11 mutation. 
 
3.2	  ETHICS	  
 
Ethical approval was obtained for this study (R&D ID: 06BC06) from the ethical 
committee of Great Ormond Street Hospital and UCL Institute of Child Health.  
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FAMILY A 
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3.3	  CLINICAL	  INFORMATION	  (FAMILY	  A)	  
 
This Caucasian non-consanguineous family had two maternal half-sisters with 
congenital HH. The pedigree of this family is shown in figure 3.1. The elder sister 
was born at term gestation with a birth weight of 4500g. She presented with 
hypoglycaemic seizures at 1 year of age and investigations confirmed HH. She was 
commenced on diazoxide to which she was unresponsive. Blood glucose profile and 
controlled fasting studies on diazoxide revealed persistent hypoglycaemia with 
inappropriately elevated serum insulin concentrations. Management with regular 
daytime feeds and continuous overnight feeds along with maximum doses of 
Octreotide (30 micrograms/kg/day in 4 divided doses) was unsuccessful. In view of 
suboptimal control with medical management, she underwent near-total 
pancreatectomy at the age of 4 years and 8 months. Histological examination of the 
pancreatic tissue confirmed diffuse disease. 
 
The younger sister, aged 2 years, presented in the neonatal period with severe 
hypoglycaemia. She was born by emergency LSCS at 37+6 weeks of gestation with a 
birth weight of 4195 grams. She required high glucose infusion to maintain stable 
blood glucose (≥3.5mmol/l). Investigations confirmed HH. She showed a good 
response (defined as age appropriate fasting tolerance with no episodes of 
hypoglycaemia) to diazoxide (5 mg/kg/d) in the initial few months after diagnosis. 
However with increasing age, she required increased doses of diazoxide in view of 
recurrent hypoglycaemia on blood glucose profile.  
 
The mother also suffered from hypoglycaemia in infancy and developed diabetes 
mellitus in her early 30’s.  
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Figure 3.1: Pedigree of Family A. The two affected probands are maternal half-sisters 
 
 
  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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The results of the controlled diagnostic fast of the two affected siblings are shown in 
table 3.1.  
 
 
Table 3.1: Controlled Diagnostic Fast of the affected patients (Family A) 
Investigation Patient 1 Patient 2 Normal Reference 
Blood glucose 
(mmol/l) 
3.1 2.7 3.5 – 5.5 
Serum Insulin (mU/l) 2.9 19.4 < 2 mU/l in the presence 
of hypoglycaemia 
C-peptide (pmol/l)  432 <94 pmol/l in the 
presence of 
hypoglycaemia 
Non-esterified fatty 
acids (mmol/l) 
0.9  0.84 – 2.74 
β-hydroxybutyrate 
(mmol/l) 
0.77  0.22 – 2.34 
Ammonia (mmol/l) 27  < 40 
Lactate (mmol/l) 1.05  0.7 – 2.1 
Plasma Cortisol 
(nmol/l) 
353 221  
Carnitine profile Normal   
Plasma amino acids Normal   
Urine organic acids Normal   
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3.4	  WHOLE-­‐EXOME	  SEQUENCING	  RESULTS	  (FAMILY	  A)	  
 
In this family, whole-exome sequencing was performed on the mother and her three children 
(two affected and one unaffected).  Assuming a dominant inheritance pattern, filters were 
applied to whole-exome data as shown in figure 3.2. 
 
 
Figure 3.2: Dominant Variant Analysis of Whole-Exome Sequencing Data of Family A 
(*Novel variants include variants present in at least 1% minor allele frequency in 1000 
Genomes Project, Complete Genomics genomes and NHLBI ESP exomes excluded; ** 
Predicted deleterious variants included variants which were non-synonymous coding, splice 
site, frameshift, stop gain; *** Variants present in heterozygous state in affected siblings and 
mother and not present in unaffected sibling) 
 
The potential candidate gene variants and their locations in family A are shown in table 3.2  
  
65667	  
•  Total Variants in four family 
members 
1667	   •  Novel variants* 
578	   •  Predicted deleterious** 
13	   •  Genetic Analysis*** 
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Table 3.2: List Of Genes With Novel, Predicted Deleterious Variants In Heterozygous State 
Shared Between Mother And Two Affected Siblings, And Not Present In Unaffected Sibling 
(Family A)  
Gene Chromosome Position Protein Variant 
KCNN3 1 154842199 p.Q77_Q80dup 
APOB 1 21229265 p.I3492T 
PRSS56 2 233386683 p.P87Aa 
SH3TC2 5 148389857 p.R1101fs*15 
RABL6 9 139728262 p.G266R 
ZEB1 10 31810733 p.P757S 
CCDC33 15 74564056 p.G187R 
EFTUD1 15 82532853 p.P141L 
POLG 15 89876827 p.Q54_Q55dup 
RNF135 17 29325810 p.Q301fs*34 
TRIM25 17 54991137 p.N71K 
WDR62 19 36558261 p.F206del 
LMTK3 19 49001897 p.G839A 
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A brief description of these genes is presented next. From the available biological 
information about these genes, the phenotype of HH could not be explained with variations in 
these genes.  
 
KCNN3 (Potassium channel, Calcium activated, intermediate/small conductance, 
subfamily N, member 3) 
These channels are responsible for afterhyperpolarization phase in vertebrate neurons (Kohler 
et al., 1996). In situ hybridization studies have shown wide expression of mRNA encoding 
these channels in rat brain. By experimental silencing of KCNN3 gene, no overt phenotype 
was seen whereas overexpression induced abnormal respirations in response to hypoxia as 
well as compromised parturition (Bond et al., 2000).  
 
APOB (Apolipoprotein B) 
Apolipoprotein B is the main lipoprotein on chylomicrons and low density lipoproteins 
(LDLs). Allelic variants in APOB have been associated with the phenotype of 
hypercholesterolemia and hypobetalipoproteinemia (Linton et al., 1993, Soria et al., 1989). 
 
PRSS56 (Protease, Serine, 56) 
Mutations in PRSS56 gene have been associated with an autosomal recessive condition, 
isolated posterior micropthalmos (Gal et al., 2011).  
 
SH3TC2 (SH3 Domain and Tetratricopeptide Repeat Domain 2) 
Mutations in SH3TC2 are linked with Charcot-Marie-Tooth disease, type 4C (Senderek et al., 
2003).  
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RABL6 (Partner of ARF) 
RABL6 encodes for a 729-amino acid human protein, which has an N-terminal GTP-binding 
domain, followed by a RAB-like domain, 2 proline-rich sequences, and a C-terminal nuclear 
localization signal (Tompkins et al., 2006). This has been shown to bind p19 (ARF) isoform 
of CDKN2A in in-vitro and in-vivo binding assays. The knockdown of RABL6 function 
resulted in increased cell proliferation (Tompkins et al., 2006).  
 
ZEB1 (Zinc finger E box-binding homeobox 1) 
Heterozygous mutations in ZEB1 have been reported in association with a phenotype of 
Fuch’s endothelial corneal dystrophy (Krafchak et al., 2005).  
 
CCDC33 (Coiled-coil domain containing 33) 
CCDC33 protein contains 3 coiled-coil domains, a C2-domain, 2 ER membrane retention 
signal-like motifs and 2 putative peroxisomal targeting signals type 2 (Kaczmarek et al., 
2009).  Its expression was predominantly seen in the testis in mouse model (Kaczmarek et al., 
2009).  
 
EFTUD1 (Elongation factor Tu GTP binding domain containing 1) 
The protein encoded by EFTUD1 has a role in the biogenesis of the 60S ribosomal subunit as 
well as in the translational activation of the ribosomes (Finch et al., 2011).  
 
POLG (Polymerase, DNA, Gamma) 
Mutations in POLG are associated with phenotypes of mitochondrial DNA depletion 
syndrome and progressive external ophthalmoplegia (Naviaux and Nguyen, 2004, Schulte et 
al., 2009).   
 122 
 
RNF135 (Ring finger protein 135) 
Mutations in RNF135 have been reported in association with a phenotype of macrocephaly, 
macrosomia and facial dysmorphism syndrome (Douglas et al., 2007). 
 
TRIM25 (Tripartite Motif-containing protein 25) 
TRIM25 encodes a RING-finger dependent ubiquitin ligase (E3), also known as estrogen-
responsive finger protein (EFP). EFP is essential for the normal estrogen-induced cell 
proliferation as evidenced by significant underdeveloped uterus in EFP-/- mice (Orimo et al., 
1999). Loss of EFP function in mouse embryonic fibroblasts has been shown to lead to 
increased levels of a negative cell cycle regulator, 14-3-3-sigma explaining tumors generated 
by EFP-overexpressing breast cancer MCF7 cells in ovariectomized athymic mice in the 
absence of estrogen (Urano et al., 2002).  
 
WDR62 (WD Repeat-containing protein 62) 
Mutations in WDR62 are associated with a phenotype of primary autosomal recessive 
microcephaly (Bilguvar et al., 2010).  
 
LMTK3 (Lemur tyrosine kinase 3) 
LMTK3, a member of LMTK family of protein kinases, is predominantly expressed in brain. 
LMTK3(-/-) mice display pronounced locomotor hyperactivity, reduced anxiety and 
decreased depression, along with increased dopamine turnover in the striata, as compared to 
the wild-type control mice (Inoue et al., 2014).  
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FAMILIES B, C, G and H  
(PROTEIN SENSITIVE HH) 
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3.5	  CLINICAL	  INFORMATION	  (FAMILY	  B)	  
 
Proband B presented at 1year and 7 months of age with 9 months history of vacant episodes 
associated with floppiness. Initial investigations performed in local hospital suggested HH. 
She was born at 41+4 weeks of gestation weighing 3430g. She is the second child of non-
consanguineous parents, with an unaffected older brother aged 10 years. The pedigree of the 
family B is shown in figure 3.3. 
 
On controlled diagnostic fast at initial presentation, she developed hypoglycaemia at ∼10 
hours. At the time of hypoglycaemia, she had appropriately suppressed serum insulin with 
appropriate mobilization of free fatty acids and β-hydroxybutyrate (Table 3.3). Investigations 
for other causes of hypoglycaemia (cortisol insufficiency, glycogen storage diseases) were 
non-contributory.  
 
She was further investigated with oral protein loading test. Following a fast for 4 hours, oral 
protein load (1.5g/kg body weight) was given in the form of a standard protein powder 
(Vitalopro) dissolved in water.  Serum insulin and blood glucose investigations were 
performed at -30, 0, +30 and +60 minutes. As is evident from table 3.4, she demonstrated HH 
at +60 minutes. She responded well to diazoxide treatment and did not have further vacant 
episodes.  
 
Molecular genetic analysis for ABCC8, KCNJ11 and GLUD1 did not identify any mutation.  
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Figure 3.3: The pedigree chart of Family B 
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Table 3.3: Controlled Diagnostic Fast (Proband B) 
Investigations Start of Fast End of Fast 
Blood glucose (mmol/L) 3.2 2.2 
Serum Insulin (mU/L) 4.7 <2.0 
Non-esterified free fatty 
acids (mmol/L) 
0.19 1.39 
β-hydroxybutyrate 
(mmol/L) 
<0.05 1.45 
Lactate (mmol/L) 0.9  
Cortisol (nmol/L) 205 214 
Growth hormone (µg/L) 0.2 0.8 
Ammonia (mmol/L) 2  
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Table 3.4: Protein Load Test (Family B) 
 Before diazoxide On diazoxide 
Time (min) Glucose  
(mmol/l) 
Insulin  
(mU/l) 
Glucose  
(mmol/l) 
Insulin  
(mU/l) 
-30 3.0 <2.0   
0 2.7 <2.0 4.1 <2.0 
+30 2.9 <2.0 3.8 <2.0 
+60 2.1 3.8 3.1 <2.0 
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3.6	  CLINICAL	  INFORMATION	  (FAMILY	  C)	  
 
Proband C presented with recurrent episodes of vacant staring and floppiness at 4 months of 
age. She was born to non-consanguineous parents after normal pregnancy and delivery 
(Figure 3.4). Her development was normal. MRI brain and EEG were normal. Antiepileptic 
treatment with sodium valproate showed no response. Further investigations confirmed the 
diagnosis of HH (Table 3.5). Her glucagon stimulation test evidently shows presence of 
stored liver glycogen, which was not released because of hyperinsulinism despite 
development of hypoglycaemia. Her serum ammonia repeated was normal. Molecular genetic 
testing for ABCC8, KCNJ11, GLUD1 and GCK was negative.  
 
Table 3.5: Controlled Diagnostic Fast and Glucagon stimulation test (Proband C) 
Investigation Results 
Blood glucose 1.4 mmol/L 
Serum Insulin 10.8 mU/L 
Non-esterified fatty acids 0.14 mmol/L 
Beta-hydroxybutyrate <0.05 mmol/L 
Glucagon stimulation test 
Blood glucose before Glucagon 
Blood glucose after 30 minutes 
 
1 mmol/L 
4 mmol/L 
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Protein load test confirmed protein sensitive HH. The results of the protein load test are 
shown in table 3.6. 
 
 
Table 3.6: Protein Load Test (Proband C) 
Time (min) Blood glucose (mmol/l) Serum Insulin (mU/l) 
0 4.3 4.6 
30 3.4 44.2 
60 2.8 31.8 
90 2.9 30.9 
120 3.1 30.4 
 
 
Figure 3.4: The pedigree chart of Family C:
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3.7	  CLINICAL	  INFORMATION	  (FAMILY	  G)	  
Proband G was born at a gestational age of 38 weeks with a birth weight of 2800 grams to 
non-consanguineous Caucasian parents. There was no documented history of hypoglycaemia 
in the neonatal period. He presented at the age of 8 months with generalized tonic-clonic 
convulsion associated with hypoglycaemia. Investigations revealed a varying fasting 
tolerance. The results of one of the controlled diagnostic fast are shown in table 3.7. 
 
Table 3.7: Controlled diagnostic Fast (Proband G) 
Investigation Result 
Blood Glucose (mmol/L) 1.8 
Serum Insulin (mU/L) <2.0 
C-peptide (pmol/L) <94 
Serum Cortisol (nmol/L) 212 
Serum Growth hormone (ng/mL) 0.3 
Non-esterified fatty acids (mmol/L) 1.26 
Beta-hydroxybutyrate (mmol/L) 0.11 
Serum Ammonia (mmol/L) 23 
Serum Lactate (mmol/L) 1.1 
Plasma Amino acids Normal 
Urine Organic acids Normal 
Serum Carnitine profile Normal 
 
The results of Protein load test with 1.5g/kg of Maxipro are shown in table 3.8.  
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Table 3.8: Protein Load test (Proband G) 
Time (minutes) Blood Glucose (mmol/L) Serum Insulin (mU/L) 
-30 3.4 2.6 
0 4.2 2.4 
+30 3.4 12.5 
+60 3.0 14.2 
+90 2.8 14.8 
 
He was commenced on Diazoxide (5mg/kg/day). Following the commencement of diazoxide, 
he was able to fast appropriately for his age with no episodes of random hypoglycaemia. 
Sequencing of ABCC8, KCNJ11, GLUD1 and HADH genes was normal. At the age of 4 ½ 
years, the proband continues to show protein sensitive HH and is being successfully managed 
with a small dose of diazoxide.  
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3.8	  CLINICAL	  INFORMATION	  (FAMILY	  H)	  
 
The proband in family H was born at term gestation to Caucasian non-consanguineous 
parents with a birth weight of 3600g. He presented with history of recurrent episodes of 
floppiness, unresponsiveness, jerking of limbs and sweating. During one of these episodes, 
his blood glucose was recorded as low (1.1mmol/L). On controlled provocation fast, there 
was no obvious cause for hypoglycaemia. The results of controlled provocation fast are 
shown in table 3.9.  
 
Table 3.9: Controlled Diagnostic Fast (Proband H) 
Investigation Result 
Blood Glucose (mmol/L) 2.4 
Serum Insulin (mU/L) <2.0 
C-peptide (pmol/L) <94 
Serum Cortisol (nmol/L) 469 
Serum Growth hormone (ng/mL) 0.3 
Non-esterified fatty acids (mmol/L) 1.96 
Beta-hydroxybutyrate (mmol/L) 0.66 
Serum Ammonia (mmol/L) 23 
Serum Lactate (mmol/L) 1.1 
Plasma Amino acids Normal 
Urine Organic acids Normal 
Serum Carnitine profile Normal 
 
Further investigations with protein loading test confirmed the diagnosis of protein sensitive 
HH.  The results of protein loading test are shown in table 3.10 
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Table 3.10: Protein Load Test (Proband H) 
Time (minutes) Blood Glucose (mmol/L) Serum Insulin (mU/L) 
-30 3.5 <2.0 
0 3.7 4.3 
+30 3.2 56.5 
+60 1.5 53.5 
 
He showed remarkable clinical improvement with diazoxide (10mg/kg/day). Sequencing of 
ABCC8, KCNJ11, GLUD1 and HADH genes was normal. 
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3.9	  WHOLE-­‐EXOME	  SEQUENCING	  RESULTS	  FAMILIES	  B,	  C,	  G	  AND	  H	  
(PROTEIN	  SENSITIVE	  HH)	  
 
Whole-Exome sequencing was performed on the probands (4), their unaffected parents (8) 
and siblings (1).  
3.9.1	  Recessive	  Inheritance	  Analysis	  
 
Assuming a recessive inheritance, the filtering strategy applied to whole-exome sequencing 
data on four probands with protein sensitive HH is shown in figure 3.5.   
 
 
Figure 3.5: Recessive Variant Analysis Of Four Probands With Protein Sensitive HH 
(*Novel variants include variants present in at least 3% minor allele frequency in 1000 
Genomes Project, Complete Genomics genomes and NHLBI ESP exomes excluded; ** 
Predicted deleterious variants included non-synonymous coding, splice site, frameshift, stop 
gain variants; *** Variants present in homozygous/compound heterozygous state in at least 2 
of the four case samples and none of the controls [parents and unaffected siblings]) 
174503	   •  Total Variants in four families 
28955	   •  Novel variants* 
10590	   •  Predicted deleterious** 
2	   •  Genetic Analysis*** 
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The two genes with variants identified through autosomal recessive analysis are shown in 
table 3.11.  
 
Table 3.11: Novel Recessive Predicted Deleterious Variants In At Least 2 Of The Four 
Probands With Protein Sensitive HH And None Of The Unaffected Parents And Siblings 
Gene Chromosome Position Protein Variant 
NOTCH4 6 32191658 p.L16dup 
HLA-DRB5 6 32489766/32489856 p.F96L/p.D66N 
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NOTCH4 (Notch [Drosophila] homolog 4) 
 
The NOTCH4 gene encodes a member of Notch family. The members of this family are 
transmembrane proteins with an extracellular domain consisting of multiple epidermal 
growth factor-like (EGF) repeats, and an intracellular domain of various different types (Li et 
al., 1998). In Drosophilia, the members of Notch family interacts with its cell-bound ligands 
(delta, serrate) and this interaction plays a key role in development. In humans, Notch4 
functions as a receptor for membrane bound ligands Jagged 1, Jagged 2 and Delta 1 (Gray et 
al., 1999). Upon binding with its ligand, the intracellular domain (NICD) is released from the 
transmembrane domain.  The NICD activates the transcription of genes downstream and 
affects the differentiation, proliferation and apoptosis (Jarriault et al., 1995). In situ 
hybridization has revealed that primarily endothelial cells express Notch4 transcripts in 
embryonic and adult life (Uyttendaele et al., 1996).   
 
By studying the Notch-4 deficienct mouse, Krebs et al. concluded that Notch4 and Notch1 
genes have partially overlapping roles during embryogenesis (Krebs et al., 2000). Mutants 
mice with constitutive overexpression of Notch4 developed brain arteriovenous 
malformations, suggesting Notch pathway to be an inhibitor of vessel sprouting (Murphy et 
al., 2008).  
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3.9.2	  Dominant	  inheritance	  Analysis	  	  
 
 
Considering possibility of dominant disease in pedigrees with protein sensitive HH, filters 
were applied to exome sequencing data of trios (proband and both parents) to identify de 
novo heterozygous deleterious variants.  The results of filtering for dominant variants are 
shown in the figures 3.6, 3.7, 3.8 and 3.9. The novel de novo exonic variants in probands B, 
C, G and H are shown in table 3.12. 
 
 
 
 
 
 
 
Figure 3.6: De Novo Variant Analysis Of Proband B (* Novel variants include variants 
present in at least 3% minor allele frequency in 1000 Genomes Project, Complete Genomics 
genomes and NHLBI ESP exomes excluded; ** Predicted deleterious variants included non-
synonymous coding, splice site, frameshift, stop gain variants) 
 
60709	   •  Variants in Proband B 
5276	   •  Novel Variants* 
2406	   •  Predicted Deleterious** 
4	   •  De novo variants 
1	   •  Exonic Variant 
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Figure 3.7: De Novo Variant Analysis Of Proband C (* Novel variants include variants 
present in at least 3% minor allele frequency in 1000 Genomes Project, Complete Genomics 
genomes and NHLBI ESP exomes excluded; ** Predicted deleterious variants included non-
synonymous coding, splice site, frameshift, stop gain variants)  
 
 
  
61398	   •  Variants in Proband C   
5779	   •  Novel Variants* 
2817	   •  Predicted Deleterious** 
8	   •  De novo variants  
2	   •  Exonic Variants 
 139 
 
 
 
Figure 3.8: De Novo Variant Analysis Of Proband G (* Novel variants include variants 
present in at least 3% minor allele frequency in 1000 Genomes Project, Complete Genomics 
genomes and NHLBI ESP exomes excluded; ** Predicted deleterious variants included non-
synonymous coding, splice site, frameshift, stop gain variants) 
 
  
117780	   •  Variants in Proband G 
11581	   •  Novel Variants* 
3310	   •  Predicted Deleterious** 
22	   •  De novo variants 
3	   •  Exonic Variant 
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Figure 3.9: De Novo Variant Analysis Of Proband H (* Novel variants include variants 
present in at least 3% minor allele frequency in 1000 Genomes Project, Complete Genomics 
genomes and NHLBI ESP exomes excluded; ** Predicted deleterious variants included non-
synonymous coding, splice site, frameshift, stop gain variants) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117158	   •  Variants in Proband H 
11223	   •  Novel Variants* 
3146	   •  Predicted Deleterious** 
15	   •  De novo variants 
4	   •  Exonic Variant 
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Table 3.12: List Of Novel Predicted Deleterious De Novo Variants In Probands With Protein 
Sensitive HH 
 
Gene Gene Region Chromosome Variant 
Position 
Protein 
Proband B 
TNFSF12 Exonic 17 7463171 p.S116P 
Proband C 
AIM1L Exonic 1 26671690 p.S487P 
CAMKK2 Exonic 12 121678327 p.G539fs*4 
Proband G 
PRIM2 Exonic 6 57398226 p.G310V 
RCOR1 Exonic 14 103059287 p.A22_A28del 
SNRPB Exonic 20 2443385 p.P193_G194del 
Proband H 
LGALS8 Splice site 1 236714292 p.?? 
HLA-DRB5 Exonic 6 32489766 p.F96L 
TMEM67 Exonic 8 94793924 p.I258M,p.I339M 
 
 
 
Out of these variants identified by the recessive and dominant inheritance filtering strategy in 
four probands with protein sensitive HH, no variant could explain the phenotype of protein 
sensitive HH based on the biological information known about these genes. A brief 
description of the genes in which predicted deleterious variants were found is shown below.  
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TNFSF12 (Tumor Necrosis Factor [Ligand] Superfamily, Member 12) 
This gene codes for a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. 
The encoded protein has a role in apoptosis, angiogenesis and induction of other 
inflammatory cytokines (Chicheportiche et al., 1997). 
 
AIM1L (Absent In Melanoma 1-Like) 
AIM1L codes for Absent In Melanoma 1-Like protein. AIM1 expression was reported to be 
associated with the experimental reversal of tumorigenicity of human malignant melanoma 
(Ray et al., 1997). Not much knowledge is available about this gene.  
 
CAMKK2 (Calcium/Calmodulin-Dependent Protein Kinase Kinase 2, Beta) 
Using RT-PCR, Nagase et al. detected high expression of CAMKK2 in lung and ovaries 
(Nagase et al., 1998). A very low expression was detected in pancreas. Human CAMKK2 
was found to phosphorylate CAMK1 and activate its kinase activity in the presence of 
Ca2+/calmodulin (Hsu et al., 1998). Calmodulin-dependent kinases (CAMK) are a family of 
serine/threonine kinases that are responsible for many of the second messenger effects of 
Ca2+ (Anderson et al., 1998). Most CAMKs are expressed ubiquitously.  
 
PRIM2 (Primase, DNA, Polypeptide 2 [58kDa]) 
This gene encodes a subunit of enzyme, DNA primase. DNA primase plays an important role 
in DNA replication by synthesizing small RNA primers for the Okazaki fragments (Shiratori 
et al., 1995).  
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RCOR1 (REST Corepressor 1) 
The RCOR1 gene encodes a functional corepressor required for regulation of neural-specific 
gene expression. By association with REST (RE1-Silencing Transcription Factor), RCOR1 
recruits molecular machinery for silencing neuronal-specific genes (Lunyak et al., 2002).  
 
SNRPB (Small Nuclear Ribonucleoprotein Polypeptides B and B1)  
The SNRPB protein is one of the several nuclear proteins found in small ribonucleoprotein 
particles (snRNPs) (van Dam et al., 1989). These snRNPs are involved in pre-mRNA 
splicing.  
 
LGALS8 (Lectin, Galactoside-Binding, Soluble, 8)  
This gene encodes an animal lectin (carbohydrate-binding protein) that binds with beta-
galactoside. They have conserved carbohydrate recognition domains. These lectins have a 
role in cell-cell adhesion, cell signaling and cell migration. LGALS8 is expressed in the 
intestinal tract where the protein recognizes and kills E.coli expressing blood group antigen 
(Stowell et al., 2010). 
 
HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) 
HLA-DRB5 belongs to the HLA class II beta chain paralogues.  The class II molecules are 
expressed in antigen presenting cells and present peptides on the cell surface for recognition 
by the CD4 T-cells. The class II molecule is a heterodimer of an alpha (DRA) and a beta 
(DRB) chain (Tieber et al., 1986). The polymorphisms within the beta chain determine the 
peptide binding specificities.  
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TMEM67 (Transmembrane Protein 67) 
This gene has been linked to the phenotypes of Meckel syndrome 3, Joubert syndrome 6 and 
modifier of Bardet-Biedl syndrome 14 (Baala et al., 2007, Leitch et al., 2008, Smith et al., 
2006). The highest expression of TMEM67 was detected in spinal cord and moderate levels in 
adrenal tissue, brain and kidney by real-time quantitative PCR analysis of human embryonic 
tissues (Smith et al., 2006).  
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3.10	  CLINICAL	  INFORMATION	  (FAMILY	  D)	  
 
This consanguineous family had two siblings (probands D1 and D2) with congenital HH. The 
pedigree of the family D is shown in figure 3.10. The elder sibling (proband D1), aged 8 
years, presented at 4 months of age with hypoglycaemic seizures. She was born at term 
gestation weighing 2450 grams. Investigations confirmed HH (table 3.13) with elevated 
serum ammonia. She showed good response to diazoxide treatment.  
Table 3.13: Controlled Diagnostic Fast (Family D) 
Investigations Proband D1 Proband D2 
Blood glucose (mmol/L) 1.7 2.1 
Serum Insulin (mU/L) 5.6 2.9 
Acetoacetate (mmol/L) <0.05 <0.05 
Beta-hydroxyl butyrate 
(mmol/L) 
<0.05 <0.05 
Lactate (mmol/L) 2.94 1.3 
Serum Ammonia (µmol/L) 140; 169 163; 159 
Plasma amino acids Increased concentrations of 
tyrosine, methionine and 
proline 
Increased concentrations of 
Arginine, reduced 
concentration of valine 
Urine aminoacids Generalized aminoaciduria Dibasic aminoaciduria 
Carnitine (Free and Total) Normal Normal 
Acyl carnitines Normal Normal 
 
Further investigations showed normal glutamate dehydrogenase (GDH) activity and normal 
inhibition by GTP. Molecular genetic analysis was negative for ABCC8, KCNJ11, HADH and 
GLUD1.   
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The younger sibling (proband D2), currently aged 3 ½ years, was born at 37 weeks gestation 
weighing 2660 grams. She was given frequent feeds in view of the history of hypoglycaemia 
in the elder sister. At 5 months of age, she presented with lethargy and floppiness in the 
postprandial period. Investigations confirmed HH (table) with elevated serum ammonia. She 
showed good response to management with uncooked cornstarch and diazoxide. The younger 
sibling also had primary hypothyroidism and required thyroxine replacement.  
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Figure 3.10: The pedigree chart of Family D: 
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3.11	  HOMOZYGOSITY	  MAPPING	  RESULTS	  (FAMILY	  D)	  
 
As this is a consanguineous pedigree, homozygosity mapping was done to locate the shared 
homozygous regions between two affected siblings, which were not shared with the 
unaffected sibling (Table 3.14). The two largest homozygous shared regions (14.5Mb and 
4.73Mb) were on chromosome 3 and chromosome 19 respectively (Figure 3.11).  
 
Table 3.14: Shared Homozygous Region Between Affected Siblings, Which Is Not Shared 
With Unaffected Sibling (Family D) 
Chromosome Start End Size (Mb) 
Chr2 97358437 98637504 1.279067 
Chr2 117912256 119006422 1.094166 
Chr2 139489497 140900604 1.411107 
Chr3 98367525 99387903 1.020378 
Chr3 126935726 141484860 14.549134 
Chr4 47682174 48931655 1.249481 
Chr4 60536829 61860937 1.324108 
Chr5 128747841 132181800 3.433959 
Chr8 47060977 49190984 2.130007 
Chr14 80441297 80468443 0.027146 
Chr18 31945534 33040875 1.095341 
Chr19 35002775 39734923 4.732148 
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Figure 7.8: B-allele frequency plot for chromosome 3 
 
 
Figure 3.11: B-allele frequency plot showing the shared homozygous regions (highlighted in 
green) on chromosome 3. Samples 1 and 2 are the affected siblings, and sample 3 is the 
unaffected sibling. The shared homozygous region is between base pair position 126935726 
and 141484860, and spans 14.54 Mb.  
  
1 
2 
3 
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3.12	  WHOLE-­‐EXOME	  SEQUENCING	  RESULTS	  (FAMILY	  D)	  
 
In this family, four siblings (two affected and two unaffected) were studied with whole-
exome sequencing. In view of consanguinity, filters were applied as outlined in figure 3.12 to 
the whole-exome sequencing data to determine autosomal recessive variants.  
 
 
Figure 3.12: Recessive Variant Analysis Of Four Siblings (Two Affected And Two 
Unaffected) From Family D (* Novel variants include variants present in at less than 3% 
minor allele frequency in 1000 Genomes Project, Complete Genomics genomes and NHLBI 
ESP exomes excluded; ** Predicted deleterious variants included non-synonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in homozygous state in the 
affected siblings and not in the unaffected siblings) 
 
The novel, predicted deleterious, autosomal recessive variants in family D are shown in table 
3.15. With the available biological information about these genes, the phenotype of HH with 
these variants could not be explained. A very brief description about these genes is presented 
next.  
  
166429	   •  Variants in family  
17967	   •  Novel Variants* 
3014	   •  Predicted Deleterious** 
6	   •  Genetic analysis*** 
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Table 3.15: List Of Novel, Predicted Deleterious, Autosomal Recessive Variants In Family D 
Gene Chromosome Position Variant Phenotype 
SLCO2A1 3 133666113 p.V428F √ 
AMOTL2 3 134090292 p.C53Y  
FAM187B 19 35719234 p.H117R  
ZNF793 19 38027957 p.I133V  
GGN 19 38876725 p.P393S  
PAPL 19 39591453 p.L256S  
 
 
AMOTL2 (Angiomotin-like 2) 
Knockdown experiments in zebrafish and in cultured human umbilical vein endothelial cells 
indicated role of Amotl2 in polarity, migration and proliferation of angiogenic endothelial 
cells (Wang et al., 2011). Motin family members (AMOT, AMOTL1 and AMOTL2) were 
shown to be involved in regulation of Wnt/β-catenin signaling (Li et al., 2012).  
 
FAM187B (Family with Sequence Similarity 187, Member B) 
This encodes a predicted single-pass transmembrane protein. No information is available in 
the literature regarding the function of the gene.  
 
ZNF793 (Zinc finger protein 793) 
ZNF793 belongs to the Krueppel C2H2-type zinc-finger protein family. It contains 6 C2H2 
zinc-finger domains one Krueppel associated box domain (Ota et al., 2004). Based on the 
protein sequence, this is likely to be involved in transcriptional regulation.  
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GGN (Gametogenetin, Mouse, Homolog of) 
A similar mouse gene was expressed only in testis and ovary. By yeast 2-hybrid analysis, it 
was shown that proteins encoded by mouse GGN gene, GGN1 and GGN3, interacted with 
Pog (Proliferation of germ cells) protein (Lu and Bishop, 2003).  
 
PAPL (Purple Acid Phosphatase, Long form) 
PAPL is a member of a family of binuclear metallohydrolases, Purple Acid Phosphatases 
(PAP). A member with similar genomic sequence, ACP5 (Phosphatase, Acid, Type 5, 
Tartrate-Resistant) is associated with a phenotype of spondyloenchondrodysplasia with 
immune dysregulation (Briggs et al., 2011).   
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3.13	  CLINICAL	  INFORMATION	  (FAMILY	  J)	  
 
Proband J was born at 36 weeks to non-consanguineous Caucasian parents weighing 2750g 
after induction of labour. She presented with history of palpitations from early childhood. 
Investigations revealed multiple types of tachyarrhythmia (sinus tachycardia, 
Supraventricular tachycardia, atrial flutter). She underwent catheter ablation for 
supraventricular tachycardia. She continued to have episodes of ventricular tachyarrhythmia 
and required implantation of defibrillator.  
 
Along with cardiac arrhythmias, she also presented history of symptoms of hypoglycaemia 
within few hours of meals. Her glucose tolerance test revealed very high serum insulin 
measurements within 30 minutes of glucose load.  
 
There was history of similar symptoms in her mother. Her younger sister displayed similar 
symptoms but unfortunately died due to unrelated cause.  
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Figure 3.13: The pedigree chart of Family J 
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3.14	  WHOLE-­‐EXOME	  SEQUENCING	  RESULTS	  (FAMILY	  J)	  
 
In this family, the proband and her mother were studied with whole-exome sequencing. This 
family has a unique phenotype of HH and cardiac arrhythmias. A number of other family 
members had similar clinical phenotype. Assuming a dominant inheritance, filtering strategy 
applied to the whole-exome sequencing data of this family is shown in figure 3.14. 
 
 
Figure 3.14: Filtering Strategy For Whole-Exome Sequencing Data Of Family J (* Novel 
variants include variants present in at least 3% minor allele frequency in 1000 Genomes 
Project, Complete Genomics genomes and NHLBI ESP exomes excluded; ** Predicted 
deleterious variants included non-synonymous coding, splice site, frameshift, stop gain 
variants; *** Variants present in heterozygous state in the proband and her mother; **** 
Variants with biological role related to the clinical phenotype of hyperinsulinaemic 
hypoglycaemia and cardiac arrhythmias) 
 
The potential candidate genes and their locations are shown in table 3.16. A brief description 
about these genes is presented next.  
 
63570	   •  Variants in family  
3679	   •  Novel Variants* 
676	   •  Predicted Deleterious** 
297	   •  Genetic analysis*** 
24	   •  Biological context**** 
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Table 3.16: List Of Novel Predicted Deleterious Heterozygous Variants In Family J 
Gene Chromosome Position Variant Phenotype 
NBPF10 1 144871755 p.V1736E  
TTN 2 179596554 p.Y4439C √ 
FN1 2 216251538 p.R1405W √ 
MST1 3 49721812 p.R651*  
HAVCR1 5 156479569 p.T155_T159del  
HLA-C 6 31238886 p.Y195H  
HLA-B 6 31324100 p.R155S  
KCNK17 6 39278695 p.F108del  
PRSS1 7 142460335 p.K170E √ 
KMT2C 7 151945007; 
151945071 
p.G838S; 
p.Y816* 
 
TET1 10 70404588 p.S701N  
CACNA2D4 12 1940199 p.G56S √ 
POLG 15 89876827 p.Q55dup √ 
ABCC1 16 16208631 p.V1030M  
IRX6 16 55363223 p.A445T  
KCNJ12 17 21318867; 
21319208 
p.M71I; 
p.A185V 
 
KCNG2 18 77659680 p.A422V  
COL5A3 19 10084460 p.V1195A  
LILRA6 19 54746051; 
54746081 
p.W69L; 
p.Q59R 
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NBPF10 (Neuroblastoma Breakpoint Family, Member 10) 
NBPF10 is a member of NBPF family, which has 22 genes and pseudogenes. The name 
NBPF was given to this family as one member of this family was disrupted by a 
chromosomal translocation in a neuroblastoma patient. The encoded proteins contain a highly 
conserved domain of unknown function (Vandepoele et al., 2005). Members of this family 
were found to be abundantly expressed in breast, liver, lung and kidney (Vandepoele et al., 
2005). The exact function of the NBPF10 is unknown.  
 
MST1 (Macrophage stimulating 1) 
In view of the identical domain structure of the protein to that of hepatic growth factor 
(HGF), the protein’s alternative name is HGF-like (HGFL) (Han et al., 1991). Hgfl-/- mice 
did not show obvious phenotypical abnormalities (Bezerra et al., 1998).   
 
HAVCR1 (Hepatitis A virus Cellular Receptor 1) 
This gene encodes for the cellular receptor of Hepatitis A virus and is expressed ubiquitously 
with highest expression in kidney and testis.  
 
KMT2C (Lysine-specific methyltransferase 2C) 
This gene is a member of myeloid/lymphoid or mixed-lineage leukemia 3 (MLL3) family. 
The protein methylates ‘Lys-4’ of histone H3. H3’Lys-4’ methylation is a specific event for 
epigenetic transcriptional activation (Daniel et al., 2010).  
 
TET1 (Tet Oncogene family, member 1) 
TET1 is a member of a family of methylcytosine dioxygenases that is required for cytosine 
demethylation and gene activation (Ito et al., 2011).  
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ABCC1 (ATP Binding Cassette, Subfamily C, Member 1) 
This encodes a transporter protein (multidrug resistance protein; MRP) and was found to be 
overexpressed in a multidrug-resistant variant of small cell lung cancer cell line (Cole et al., 
1992). The gene expression analysis detected increased expression in lung, testis and 
peripheral mononuclear cells. MRP-/- mice exhibited reduced dendritic cell migration from 
skin to lymph nodes and reduced mortality from Streptococcus pneumoniae as compared to 
wildtype mice (Robbiani et al., 2000, Schultz et al., 2001).   
 
IRX6 (Iroquois Homeobox Protein 6) 
Members of this gene family are involved during pattern formation in vertebrate embryos 
(Bosse et al., 1997).  
 
KCNJ12 (Potassium channel, Inward rectifying, Subfamily J, Member 12) 
This gene was cloned from human atrial RNA using primers based on the conserved regions 
of inward rectifying K+ channel (Wible et al., 1995). On expression in Xenopus oocytes, the 
encoded protein was shown to be inward rectifying (Wible et al., 1995).  
 
LILRA6 (Leukocyte Immunoglobulin-Like Receptor, Subfamily A, Member 6) 
Based on the similarity of the protein sequence with LILRB4, this is predicted to function as 
a receptor for class 1 MHC (Major Histocompatibility Complex) antigens (Borges et al., 
1997).  
 
COL5A3 (Collagen, Type 5, Alpha-3) 
COL5A3 encodes alpha-3 chain of type 5 collagen, which is a heterotrimer of COL5A1, 
COL5A2 and COL5A3 chains.  
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KCNK17 (Potassium channel, Subfamily K, Member 17) 
KCNK17 is a member of the 2-pore domain superfamily of K+ channels and contribute to the 
resting membrane potential of the cell. KCNK17 is widely expressed with high expression in 
the pancreas and heart (Decher et al., 2001). This gene is discussed in more detail in chapter 
5.  
 
KCNG2 (Potassium channel, voltage-gated, subfamily G, Member 2) 
This gene is highly expressed in the heart and may contribute towards cardiac action potential 
repolarization (Zhu et al., 1999). This gene is also discussed in more detail in chapter 6.  
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3.15	  CLINICAL	  INFORMATION	  (FAMILY	  F)	  
 
Proband F was born at 39+4 weeks of gestation weighing 4600 grams to non-consanguineous 
Caucasian parents. She had transient hypoglycaemia in the neonatal period. Three episodes of 
generalized tonic-clonic seizures associated with low bedside blood glucose level of 
1.7mmol/L resulted in referral to Congenital Hyperinsulinism team at Great Ormond Street 
Hospital. All these episodes happened in the morning before breakfast within a 1week period. 
Her growth was along the 98th centile for weight and height. The pedigree of the family is 
shown in figure 3.15. The results of the controlled diagnostic fast are shown in table 3.17.  
 
Figure 3.15: The pedigree chart of Family F 
 
 
 
 
 
!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!
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She required 10 mg/kg/min of glucose infusion to maintain blood glucose ≥ 3.5mmol/L. No 
response to medical management with diazoxide was seen. Molecular genetic testing 
performed at University Exeter School, Exeter identified a heterozygous non-stop mutation in 
KCNJ11 (c.1171T>C), inherited from the father.  
 
In view of the paternally inherited heterozygous KCNJ11 mutation, an 18F DOPA-PET CT 
scan was performed which identified a focal lesion in the tail of the pancreas. The lesion was 
laparoscopically resected and histological analysis confirmed the focal lesion in the tail. 
Microsatellite analysis of the chromosome 11p15 region of the resected pancreatic tissue 
showed maternal loss of heterozygosity.  
 
Post-resection of the focal lesion, however, the proband continued to have hypoglycaemic 
episodes and could not be weaned off intravenous dextrose fluids. A second 18F DOPA-PET 
CT scan did not identify focal uptake in the pancreas. A second pancreatectomy was done in 
which further pancreatic tissue around the tail (the site of focal lesion) was resected. 
Histological analysis of the pancreatic tissue identified well-demarcated margins of the focal 
lesion. However the pancreatic tissue around the focal lesion did not have normal histological 
appearance. Microsatellite analysis of the chromosome 11p15 region of the pancreatic tissue 
resected in the second pancreatectomy did not show maternal loss of heterozygosity.  
 
The proband continued to have inappropriate fasting tolerance even after the second 
pancreatectomy. She was recommenced on diazoxide, which was gradually increased to the 
maximum dose of 15mg/kg/day. She showed some improvement in her fasting tolerance with 
diazoxide. A repeat 18F DOPA-PET CT scan revealed diffuse uptake throughout pancreas.  
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Table 3.17: Controlled Diagnostic Fast (Proband F) 
Investigations At local 
hospital 
At GOSH After 1st 
surgery 
After 2nd 
surgery 
Blood glucose 
(mmol/L) 
2.5 2.2 2.7 2.5 
Serum Insulin (mU/L) 53 7 12.1 6.8 
C-peptide (pmol/L) 459    
Serum Cortisol 
(nmol/L) 
628  458 604 
Non-esterified fatty 
acids (mmol/L) 
0.4 <0.05 1 1.60 
β-hydroxybutyrate 
(mmol/L) 
<0.1 <0.05 1.41 1.43 
Serum ammonia 
(µmol/L) 
37 22  26 
Serum Lactate 
(mmol/L) 
1.5 1  1.6 
Plasma Acylcarnitine 
profile 
Normal    
Plasma Amino acids Normal    
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3.16	  CLINICAL	  INFORMATION	  (FAMILY	  I)	  
 
The proband I1 was born at term gestation by normal vaginal delivery to Caucasian non-
consanguineous parents weighing 5370g. Her mother’s antenatal period was uneventful. She 
required resuscitation after birth and was ventilated. In the neonatal period, she required high 
glucose infusion to maintain blood glucose above 3.5mmol/L. Her controlled diagnostic fast 
was suggestive of HH (table 3.18). 
 
Table 3.18: Controlled Diagnostic Fast (Proband I) 
Investigation I1 I2 
Blood Glucose (mmol/L) 2.7 0.1 
Serum Insulin (mU/L) <2.0 25.7 
C-peptide (pmol/L) 159  
Serum Cortisol (nmol/L) 433  
Serum Growth hormone 
(ng/mL) 
7.4  
Non-esterified fatty acids 
(mmol/L) 
0.31 <0.05 
Beta-hydroxybutyrate 
(mmol/L) 
<0.05 <0.05 
Serum Ammonia (mmol/L) 29 25 
Serum Lactate (mmol/L) 1.2 1.6 
Plasma Amino acids Normal Normal 
Urine Organic acids Normal Normal 
Serum Carnitine profile Normal Normal 
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She responded well to 3 mg/kg/day of diazoxide. Her HH was transient and she was 
successfully weaned off the medications by 3 months of age.  
The proband’s maternal cousin (proband I2; see figure 3.16 for pedigree) also had transient 
HH. He was born at 31 weeks gestation with a birth weight of 1815g. In view of requirement 
of high glucose infusion rate, a controlled diagnostic fast was done which confirmed HH 
(table 3.18). He was successfully managed with 5mg/kg/day of diazoxide, which could be 
weaned by 8 weeks of age.  
 
Molecular genetic analysis identified a maternally inherited heterozygous ABCC8 mutation 
(c.4547C > T; p.Thr1516Met) in both probands.  
 
Figure 3.16: The pedigree chart of Family I 
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CHAPTER 4 
 
 
 
 
BASIC PRINCIPLES OF PATCH-CLAMP 
ELECTROPHYSIOLOGY 
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4.1	  SUMMARY	  OF	  CHAPTER	  4	  
 
The patch clamp technique is the ‘gold standard’ for studying ion channel function. This 
chapter provides a brief introduction to electrophysiology, followed by a protocol of how the 
experiments were conducted and analyzed. 
 
These electrophysiological experiments were performed at the William Harvey Heart 
Institute, Queen Mary University in Professor Andrew Tinker’s laboratory. Dr Qadeer Aziz 
Hussain, a post-doc in Professor Tinker’s laboratory, supervised these experiments.  
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4.2	  MEMBRANE	  BIOLOGY	  
 
All living cells are enveloped by a plasma membrane, which is mainly constituted of 
phospholipid bilayer. Phospholipids have lipophilic residue (tail) at one end and hydrophilic 
(head) at the other end. In a phospholipid bilayer, these phospholipid molecules arrange 
themselves so that lipophilic residues face each other. This bilayer acts as a barrier between 
the cytoplasm and the extracellular space. Within this bilayer are embedded other membrane 
constituents (ion channel proteins), which allow communication between the cytoplasm and 
the extracellular space.  
 
As shown in table 4.1, there are striking differences in the concentrations of inorganic ions in 
the extracellular and intracellular medium. These concentration differences induce the 
movement of ions along their concentration gradient through the ion channels and generate 
an electrical potential across the plasma membrane.  
 
Table 4.1: Intracellular and extracellular distribution of the main ions 
Ion Intracellular range (mM) Extracellular range (mM) 
Na+ 5-20 130-160 
K+ 130-160 4-8 
Ca2+ 50-1000 nM 1.2-4 
Mg2+ 10-20 1-5 
Cl- 1-60 100-140 
HCO3- 1-3 20-30 
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4.2.1	  Nernst	  equation	  
 
As mentioned in the previous section, the concentration gradients of various ions induce the 
movement from higher to lower concentrations. However as these ions are charged 
molecules, this movement generates an electrical force, opposing this diffusion. When the 
two opposing forces are in equilibrium, there is no net movement of ions. The relation 
describing this equilibrium is described by the following equation: 
−𝑅𝑇  𝐼𝑛 𝑖𝑜𝑛 𝑜𝑖𝑜𝑛 𝑖   = −𝐸𝑧𝐹 
This relation can be rearranged to provide the electrical potential at which a certain ion 
gradient is in equilibrium and there is no net movement.  
𝐸   =   𝑅𝑇𝑧𝐹 𝐼𝑛 𝑖𝑜𝑛 𝑜𝑖𝑜𝑛 𝑖  
• E is the equilibrium potential for the ion under consideration 
• R is the universal gas constant (8.31 Joules mol-1 Kelvin-1) 
• T is the temperature in Kelvin 
• Z is the oxidation state of the ion under consideration 
• F is the Faraday constant (9.65 × 104 Coulombs mol-1) 
• [ion]o and [ion]i are the extracellular and intracellular concentrations of the ion  
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4.2.2	  Membrane	  Potential	  
 
At rest, the inside of all cells is more negatively charged than the outside (resting membrane 
potential). This imbalance is due to differences in the distribution of various ions on either 
side of the membrane and the relative permeability of the plasma membrane to each of the 
ions. The Goldman Hodgkin-Katz (GHK) equation, which takes into account the ion 
concentrations on either side of the membrane as well as the membrane permeability, can be 
used to determine the resting membrane potential.  
𝐸! =   𝑅𝑇𝐹   𝐼𝑛  [𝑃! 𝐾! 𝑜𝑢𝑡 +   𝑃!" 𝑁𝑎! 𝑜𝑢𝑡 +   𝑃!" 𝐶𝑙! 𝑖𝑛𝑃! 𝐾! 𝑖𝑛 + 𝑃!" 𝑁𝑎! 𝑖𝑛 +   𝑃!" 𝐶𝑙! 𝑜𝑢𝑡 ] 
If the plasma membrane was to be permeable only to K+ ions, the resting membrane potential 
of the cell will be equal to the equilibrium potential for potassium ions (EK). This can be 
calculated by the Nernst equation described in the previous section, which is between -80 to -
90 mV. However, plasma membrane is permeable to other ions as well and their equilibrium 
potentials are more positive than EK. Hence the membrane potential is slightly more positive 
than EK and is typically -50 to -80mV.  
 
4.3	  ELECTRICAL	  PROPERTIES	  OF	  THE	  CELL	  MEMBRANE	  
 
4.3.1	  Membrane	  Resistance	  
 
At resting membrane potential, the membrane potential is equivalent to the diffusing force 
and there is no net movement of ions across the cell membrane. As the membrane potential 
moves away from the resting membrane potential, the two forces (diffusing force and 
membrane potential) are not equal and the ions will flow across the membrane. The further 
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the membrane potential is from the resting membrane potential, the greater will be the flow of 
ions. The movement of charge is expressed in current; 
𝐼 =   𝑑𝑄𝑑𝑡  
where I is current in amperes (A) and dQ/dt is the change in charge in coulomb over time. 
The size of current is determined by 
1. Driving force – difference between the membrane potential and equilibrium potential 
2. Resistance of the membrane 
The relation between current, resistance and driving force is described by the following 
equation; 
𝐼 =   𝐸! − 𝐸!"𝑅!  
Where Em – Erm is the driving force and Rm is the membrane resistance.  
 
4.3.2	  Membrane	  Capacitance	  
 
In view of the unequal distribution of charge on the two sides of the membrane, the plasma 
membrane attracts charged particles on either side of the membrane. This storage of charge is 
dependent on the potential difference across the membrane and the physical dimensions of 
the membrane. Consequently, the higher the potential difference across the membrane and the 
larger the size of the cell, the more charge a membrane can store. The ability of the 
membrane to store charge at a given potential is described as capacitance of the cell 
membrane. Measurement of capacitance provides a good estimation of the membrane surface 
area.  
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The membrane capacitance plays an important role in electrophysiological experiments such 
as voltage clamp. Due to membrane capacitance, the voltage clamp will change the 
membrane potential with some delay. Hence it is very important to compensate for the 
capacitance in electrophysiological experiments to accurately measure the current.  
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4.4	  ELECTROPHYSIOLOGY	  
 
Electrophysiological techniques are employed to record ion fluxes across a membrane. There 
are two types of electrophysiological techniques: indirect and direct. Indirect techniques 
include electrograms, encephalograms etc. where the electrodes to measure ion fluxes are 
positioned extracellularly. Direct techniques such as patch clamping require the 
microelectrodes to make contact with the cell of interest.  
4.3.1	  Voltage	  Clamp	  
 
As mentioned before, the movement of ions (through the ion channels across the cell 
membrane) generate a membrane potential. The activity of ion channels can be studied by 
measurement of the changes in membrane potential as a result of ion fluxes. However 
detailed study of the ion channel behavior is difficult by this method as the change in 
membrane potential can itself affect the ion channel activity e.g. many ion channels have 
gating mechanisms which respond to membrane potential changes. It is therefore desirable to 
use a technique called voltage clamp. In voltage clamp, the membrane potential is controlled 
by the experimenter and the current is recorded directly in response to set membrane 
potential.  
 
In voltage clamp, the experimenter sets a series of different voltages (step protocol or 
complicated waveforms) across the membrane. As the set membrane potential is different 
from the actual membrane potential, this results in generation of a driving force for the ions 
across the membrane. The movement of ions (current) is measured and a compensatory 
current equal in size but opposite in direction is instantly injected to keep the membrane 
potential at the potential set by the experimenter. By recording the current required to be 
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injected to keep the membrane potential at the holding potential, the activity of the ion 
channels can be measured.  
 
 
Figure 4.1: The voltage clamp principle in the whole-cell configuration. The holding 
potential and the measured potential between the pipette and bath electrode are continuously 
compared. The difference in the two potentials is instantly corrected by current injection 
using amplifier circuitry.  
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4.5	  PATCH-­‐CLAMP	  CONFIGURATIONS	  
 
Patch clamp technique can be used in various configurations depending upon whether 
individual channels or whole cell need to be studied. Different configurations also allow 
manipulations of the fluids on the extracellular side or the intracellular side of the membrane 
according to the requirements. The various patch-clamp configurations are 
4.5.1	  Cell	  attached	  patch	  mode	  
 
This is the simplest mode of patch-clamp. In this mode, the patch pipette has a very high 
resistance seal (GΩ) with the cell membrane (Rpatch). This configuration is a single channel 
configuration and is used to study the activity of the ion channels in the tiny patch of 
membrane surrounded by the tip of the pipette. Although this configuration is physiological 
as the cell is intact, manipulation of the intracellular media is not possible and extracellular 
media is difficult. During voltage clamp, the membrane potential over the patch cannot be 
measured directly as well.  
4.5.2	  Whole-­‐cell	  patch	  mode	  
 
In whole-cell mode, the patch of the membrane under the tip of the micropipette is ruptured 
and hence the pipette solution and the cytoplasm are in continuity. The rupture results in 
disruption of the membrane potential and dramatic reduction of Rpatch, which in this 
configuration is named as the access resistance Raccess. The series circuit in this configuration 
consists of the pipette resistance Rpipette, the access resistance Raccess and the membrane 
resistance Rm. As Rm is much larger than Rpipette and Raccess, this configuration allows the 
measurement of currents through all activated single channels of the cell. The Raccess and 
Rpipette are also in series with the membrane capacitance (Cm) and form a significant RC 
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circuit. An RC circuit is a circuit where a resistor and a capacitor are present in series. The 
sum of Raccess and Rpipette is referred to as series resistance.  
 
In an RC circuit, the speed of charging and discharging a capacitor upon a change in 
potential, such as seen during voltage clamp, is dependent on the resistor(s) in series with it. 
This series resistance cause delay in voltage changes and need to be compensated. In voltage 
clamp, the problem is reduced by over-injecting current in order to speed up the response.  
 
Electrically, the two electrodes are on either side of the cell membrane: patch electrode on the 
intracellular side and ground electrode on the extracellular side. Hence the membrane 
potential can be directly measured. As there is mixing of the cytoplasm and the pipette 
solution, and the pipette solution volume is much larger than the cell volume, the composition 
of the intracellular fluid can be considered equal to that of the pipette solution.  
 
4.5.3	  Outside-­‐out	  and	  Inside-­‐out	  patch-­‐modes	  
	  
These are single channel configurations that require excising a patch of the membrane from 
the cell. The outside-out patch configuration is obtained by pulling away the patch pipette 
from the whole cell configuration, whereas the inside-out patch is obtained by pulling away 
the pipette from the cell-attached patch configuration. The patch and its ion channels can be 
manipulated both electrically and chemically.  
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4.6	  PROTOCOL	  
 
4.6.1	  The	  Patch-­‐clamp	  set	  up	  (Figure	  4.2)	  
 
The patch-clamp rig, where the electrophysiological experiments were performed, included 
the following elements: 
• A stable platform with vibration dampening properties 
• A microscope (Olympus 1X71) for visualizing the cells 
• Micromanipulators to position the micropipette tip on the cell membrane 
• Superfusion systems – a set of containers containing solutions to bath the cell 
preparation 
The above equipment was all inside a Faraday cage to shield the experiment from 
surroundings.  
The remaining equipment such as fluorescent lamp (for identifying the transfected cells), 
lamp source for visualizing cells under the microscope (Olympus TH-200), AXON CNS 
Digidata 1440A (Molecular Devices; low noise data acquisition system) and AXON CNS 
Multiclamp 700B (Molecular Devices; patch-clamp amplifier which contains the measuring 
and clamping circuitry and controls) were located next to the rig.  
 
 	  
 181 
 
  
 
 
 
 
Figure 4.2: The patch-clamp set up used to make whole-cell recordings for KATP currents. 
The headstage amplifier was placed very close to the pipette holder. The pipette approached 
the cells in the chamber above the objective at an acute angle. The inverted microscope was 
mounted on the air table within the Faraday cage. A tube was attached to the side-port of the 
pipette holder to provide appropriate suction. The recording chamber was constantly 
superfused by solutions by a gravity driven system. A vacuum pump removed the solutions 
from the recording chamber to maintain a constant level. 
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4.6.2	  Cell	  Culture	  
 
HEK293 cells were splitted on to the 10 mm coverslips in the 6 well plates 72 hours before 
the planned experiments in an appropriate dilution depending on the confluency of the cells 
in the T75 flask. After 24 hours, the cells were transfected with the appropriate plasmid 
construct along with eGFP (100ng) using FuGENE HD transfection reagent. The plasmid 
constructs and their amounts used in different experiments performed in this thesis are 
detailed in tables 4.2 and 4.3. 
 
Table 4.2: Transfection Mixtures For Different KATP Channel Experiments 
Experiments	  on	  KATP	  channels	  
 
Wild type  Wild type SUR1 Construct 
Wild type Kir6.2 Construct 
2 µg 
500 ng 
Mutant SUR1 
T1516M 
Mutant T1516M SUR1 Construct  
Wild type Kir6.2 Construct 
2 µg 
500 ng 
Heterozygous SUR1 
T1516M Mutant 
Wild type SUR1 Construct  
Mutant T1516M SUR1 Construct 
Wild type Kir6.2 Construct 
1 µg 
1 µg 
500 ng 
Mutant 
Kir6.2*391Rext*94 
Wild type SUR1 Construct 
Mutant Kir6.2*391Rext*94 Construct 
2 µg 
500 ng 
Heterozygous 
Kir6.2*391Rext*94 
Mutant 
Wild type SUR1 Construct 
Wild type Kir6.2 Construct 
Mutant Kir6.2*391Rext*94 Construct 
2 µg 
250 ng 
250 ng 
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Table 4.3: Transfection Mixtures For Different K2P17 And Kv Channel Experiments 
Experiments	  on	  K2P17	  channels	  
 
Wild type Wild type K2P17 construct 2 µg 
Mutant K2P17 F108del Mutant K2P17 construct 2 µg 
Heterozygous K2P17 F108del Wild type K2P17 construct 
Mutant K2P17 construct 
1 µg 
1 µg 
Experiments	  on	  Kv	  Channels	  
 
Wild type Kv2.1  Wild type Kv2.1 construct 2 µg 
Wild type Kv6.2 Wild type Kv6.2 construct 2 µg 
Mutant Kv6.2 p.A422V Mutant Kv6.2 construct 2 µg 
Wild type Kv2.1 + Wild type 
Kv6.2 
Wild type Kv2.1 construct 
Wild type Kv6.2 construct 
1 µg 
1 µg 
Wild type Kv2.1 + Mutant 
Kv6.2 p.A422V 
Wild type Kv2.1 construct 
Mutant Kv6.2 construct 
1 µg 
1 µg 
Wild type Kv2.1 + Wild type 
Kv6.2 + Mutant Kv6.2 
p.A422V 
Wild type Kv2.1 construct 
Wild type Kv6.2 construct 
Mutant Kv6.2 construct 
1 µg 
500 ng 
500 ng 
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4.6.3	  Intracellular	  (ICS)	  and	  Extracellular	  (ECS)	  solutions	  
 
The composition of the solutions used for whole-cell patch clamping is shown in table 4.4.  
The ICS for patch-clamping experiments on KATP channels was immediately stored in ∼1 ml 
aliquots after preparing. This was then thawed on the day of the experiment and kept on ice 
throughout to prevent degradation of nucleotides. The ICS for patch-clamping experiments 
on K2P17 and Kv channels was stored at +4°C. The ECS for all patch-clamping experiments 
was stored at +4°C. 
Table 4.4: Composition of intracellular (ICS) and extracellular (ECS) solutions for KATP, 
K2P17 and Kv Channel patch-clamping experiments.  
 KATP Channels K2P17 Channels Kv Channels 
ICS 
(mM) 
ECS 
(mM) 
ICS 
(mM) 
ECS 
(mM) 
ICS 
(mM) 
ECS 
(mM) 
KCl 107 5 140 5 140 5 
NaCl - 140 - 140 - 140 
MgCl2  1.2 1 3 1.2 3 1.2 
CaCl2  1 1.8 - 2.6 - 2.6 
EGTA 10 - 10 - 10 - 
HEPES 5 10 10 10 10 10 
MgATP 3 - - - - - 
NaADP 1 - - - - - 
Glucose - - - - - 10 
pH 7.2 (KOH) 7.4 (NaOH) 7.2 (KOH) 7.4 (NaOH) 7.2 (KOH) 7.4 (NaOH) 
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4.6.4	  Patch	  Pipettes	  
 
The thin walled borosilicate glass capillaries were used to make the patch pipettes. The ends 
of the capillaries were fire polished using a bunsen burner. A two-stage pipette puller (Model 
PP-830, Narishige, Japan) was then used to heat and pull the glass into two fine pipettes. In 
the first pull, the capillaries were heated to 62°C. After letting it cool down for few seconds, 
the second pull was applied by heating to 48.8°C. These fine pipettes were filled with ICS for 
whole-cell recordings.  
4.6.5	  Obtaining	  the	  GΩ 	  Seal	  
 
A suitably transfected cell, not touching any neighboring cells, was chosen for whole-cell 
recording. The cell was positioned in the centre of the field of view under the microscope. 
The micropipette, filled with ICS, was loaded on the pipette holder making sure that the tip of 
electrode filament was immersed in the ICS. The micropipette was lowered into the bath 
solution using the coarse manipulator. A small positive pressure was applied with the help of 
1 mL syringe at this stage. Once the micropipette was in the bath solution, the pipette 
resistance could be measured based on the amplitude of the current in response to the test 
pulse. The pipettes with a resistance of ∼2-4 MΩ were generally used. The pipette was 
gradually lowered towards the chosen cell. With the help of manipulators, the position of the 
pipette was adjusted in the horizontal plane so that it touches the centre of the cell on 
lowering. 
 
The current was offset to zero immediately before the pipette made contact with the cell. 
When the pipette was very near to the cell, fine manipulators were used to control the 
movement of the pipette. The pipette was gently touched to the cell membrane so that its 
resistance has increased by ∼1 MΩ. Suction was applied to the pipette through the tubing 
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attached to the side-port of the pipette holder, which increased the seal resistance. Once a seal 
resistance of >1 GΩ was achieved, the cell was in the cell-attached configuration.  
4.6.6	  Whole-­‐cell	  Patch-­‐Clamp	  Recordings	  
 
After establishing the GΩ seal, the capacitance transients were electronically compensated by 
using amplifier circuitry (MultiClamp 700B). Gentle mouth suction was applied to rupture 
the patch of membrane beneath the micropipette tip. The appearance of large capacitance 
spikes denoted the successful rupture of the membrane and attainment of whole-cell 
configuration. These transients are formed by the cell capacitance in series with the Rpipette 
and Raccess (collectively referred to as the series resistance). These transients caused by RC 
circuits can cause large artifacts during voltage clamp.  
 
The capacitance spikes were cancelled and series resistance was compensated electronically 
by using amplifier circuitry (Multiclamp 700B). The series resistance was compensated at 
∼70%. The values of the membrane capacitance (Cm), membrane resistance (Rm) and access 
resistance (Ra) were recorded.  
 
The cells were subsequently subjected to voltage-clamp protocol. Different protocols were 
used for KATP, K2P17 and Kv channels whole-cell recordings.  
 
For K2P17 current recordings, the voltage protocol consisted of a holding potential of -80mV, 
followed by 200 milliseconds pulses at 20 mV increments from -100mV to +60mV with 
inter-pulse interval of 2 seconds. The recordings were performed with different pH 
extracellular solutions after achieving whole-cell configuration. 
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For Kv current recordings, the voltage protocol consisted of a holding potential of -80mV, 
followed by 200 milliseconds pulses at 20 mV increments from -100mV to +80mV with 
inter-pulse interval of 2 seconds. The recordings were performed immediately, 2 and 5 
minutes after attaining whole-cell configuration.  
 
For KATP channel current recordings, the voltage ramp protocol was used. From a holding 
potential of -80mV, cells were ramped from -150mV to +50mVover 1s (200mV/s) and then 
stepped back to -80mV. The recordings were performed in 5K+ bath solution, in 100 µM 
diazoxide solution (to activate KATP currents) and in (100 µM diazoxide + 100 µM 
tolbutamide) solution to block KATP currents.  
 
The data were sampled at 5kHz and filtered at 1kHz with the filter provided in the 
Multiclamp 700B (4 Pole Bessel). Signals were converted from analogue to digital signals by 
Digidata 1440A (Molecular Devices). Recordings were acquired and analyzed using 
pClamp10 and Clampfit 10 (Axon Instruments), respectively.  
 
4.6.7	  Data	  Analysis	  
 
The data for whole-cell recordings were analyzed using the Clampfit 10.4 software, 
Microsoft Excel and Graph Pad Prism 6. The current-voltage (I-V) relationship was plotted 
using the Clampfit 10.4 software. Whole-cell currents were the normalized to the size (Cm) of 
the cell (pA/pF). The mean, standard deviation and standard error were calculated. 
 
Student’s paired t-test was used to calculate the significance of difference between the current 
recordings from the same cell under different conditions. Student’s unpaired t-test with 
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Welch’s correction was used to calculate the difference between the current recordings from 
wild type, mutant and heterozygous mutant channels.  
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CHAPTER 5 
 
 
 
 
 
TWO-PORE DOMAIN POTASSIUM 
CHANNELS (K2P) AND 
ELECTROPHYSIOLOGICAL ANALYSIS 
OF K2P17 WILD TYPE AND p.F108del 
MUTANT  
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5.1	  SUMMARY	  OF	  CHAPTER	  5	  
 
Chapter 5 provides an introduction to two-pore domain potassium channels (K2P) family 
followed by method used to create K2P17 mutant construct and results of whole-cell patch 
clamping. The chapter ends with the discussion of the results in context with the phenotype of 
the patient.  
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5.2	  INTRODUCTION	  
 
The high resting potassium conductance of the plasma membrane has been known for a long 
time and was thought to be due to the presence of background K+ current conducted through 
potassium selective pores in the plasma membrane (Enyedi and Czirjak, 2010, Hodgkin and 
Huxley, 1947). The first member of the molecular entities responsible for the background K+ 
currents, two-pore domain potassium channels, were identified in 1966 long after the 
identification of all the other major K+ channel families (voltage-gated, inwardly rectifying, 
and calcium dependent K+ channels) (Lesage et al., 1996).  
 
The name of the family “two-pore domain” potassium channels (K2P) was given on the basis 
of the topology of the K+ channel subunits. Each subunit contains two K+ channel pore loop-
forming (P) domains (Enyedi and Czirjak, 2010). However other K+ channel families contain 
one P domain per one subunit. Two K2P subunits dimerize to constitute the functional K+ 
selectivity filter containing four pore loop domains (Enyedi and Czirjak, 2010).  
 
Each K2P channel subunit has four transmembrane (TM) segments and thus has a 
characteristic 4TM/2P topology (figure 5.1) (Enyedi and Czirjak, 2010). The probability of 
opening (Po) of these channels is the same at all membrane potentials; K+ current through 
these channels is not voltage dependent. These channels are also time independent; the 
amplitude of the current instantaneously follows the changes of the membrane potential 
(Lesage et al., 1996). In view of these characteristics of K2P channels, a voltage step in a 
voltage-clamp experiment induces a square wave-like K+ current.  
 
The background current through these K2P channels is not rectifying; equal but opposite 
voltage steps induce opposite currents of equal amplitude. The apparent rectification seen in 
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physiological solutions is caused by the unequal K+ concentrations in the intracellular and 
extracellular compartment (Enyedi and Czirjak, 2010).  
 
Many members of K2P channel family encoded by different genes have been found. These 
members have been subdivided into six subfamilies bases on sequence similarity and 
functional resemblance (Enyedi and Czirjak, 2010).  
 
1. TWIK (Tandem of Pore Domains in a Weak Inward Rectifying K+ Channel) 
2. TREK (TWIK-Related K+ channel) 
3. TASK (TWIK-Related Acid-Sensitive K+ Channel) 
4. TALK (TWIK-Related Alkaline pH-Activated K+ Channel) 
5. THIK (Tandem Pore Domain Halothane-Inhibited K+ Channel) 
6. TRESK (TWIK-Related Spinal Cord K+ Channel) 
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Figure 5.1: Schematic transmembrane topology of human two-pore domain potassium (K2P) 
channels. Transmembrane segments are indicated by TMS1-4.  One subunit of the functional 
dimer is depicted. 
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5.2.1	  TALK	  subfamily	  
 
Based on the alkaline range of pH sensitivity, this subfamily has three members: TASK-2 
(K2P5), TALK-1 (K2P16) and TALK-2 (K2P17) (Girard et al., 2001, Decher et al., 2001). The 
first member of this subfamily identified was TASK-2 (Reyes et al., 1998). TALK-1 and 
TALK-2 are more closely related to each other than to TASK-2. 
 
5.2.2	  K2P17	  (TALK-­‐2	  or	  TASK-­‐4)	  
 
Decher et al. cloned full-length cDNA of TASK-4 (TALK-2) channel from adrenal cDNA 
library (Decher et al., 2001). They named it TASK-4 but later on it was reassigned to the 
TALK subfamily. The full length TASK-4 cDNA encoded a protein of 343 amino acids with 
a predicted molecular mass of ≈ 38 kDa. TASK-4 has an extended extracellular M1P1 
interdomain, which is a characteristic of this channel family (Enyedi and Czirjak, 2010). The 
human TASK-4 protein sequence has two consensus sites for N-glycosylation at residues 65 
and 94 within this M1P1 interdomain. The cysteine at residue 68, which is conserved in 
members of K2P channel family, is involved in homodimer formation. TASK-4 does not 
possess a histidine immediately downstream of the “GYG” pore motif. This histidine residue 
mediates proton block in TASK-3.  
 
In addition to cloning TASK-4, Decher et al. also studied the expression of TASK-4 in 
human tissues by RT-PCR. Strongest TASK-4 signals were observed in liver, lung, placenta, 
pancreas, small intestine and aorta. TASK-4 was also detected in human heart where it is 
preferentially expressed in the atrial regions. Expression by insitu hybridization suggested 
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that TALK-2 transcripts are present in acinar cells and not in islets of Langerhans (Decher et 
al., 2001). 
 
Experiments in Xenopus oocytes after injection of TASK-4 cRNA show quasi-instantaneous 
and non-inactivating currents on exposure to alkaline pH (Decher et al., 2001). The current-
voltage (I-V) relationships show outwardly rectifying currents and almost no inward currents 
were recorded with 2mM K+ in the extracellular fluid. Like other members of the TASK 
family, TASK-4 is open at all membrane potentials once extracellular fluid pH is increased. 
At pH 8.5, the classical K+ channel blockers tetraethylammonium (TEA, 3mM), 4-
aminopyridine (4-AP, 2mM) and Cs+ (2mM) are inactive on the recorded currents (Decher et 
al., 2001). Although TASK-4 has potential phosphorylation sites for protein kinase A and 
protein kinase C, it does not appear TASK-4 is regulated by them.  
 
A basic amino acid is conserved at position 242 in TALK-2 (K242). By modeling the 
structure of TALK-2 pore using Kv1.2 as a template, K242 was identified to occupy a 
position at the outermost portion of helix TM4 and close to the pore region. By mutating this 
lysine residue at position 242 to alanine (K242A), it was shown that sizeable currents are 
present at neutral pH. This suggests that lysine at position 242 acts as the pH sensor in 
TALK-2 channels (Niemeyer et al., 2007).  
 
Based on the pH sensitivity, it was postulated that TASK-4 might be of great relevance in 
tissues such as pancreas where physiological pH can range from 7.5 to 8.5. In addition, 
pathophysiological situations can also cause pH shifts. It is also possible that native TASK-4 
channels display a different pH dependency to that observed in heterologous expression 
system.  
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Friedrich et al. reported a heterozygous (c.262G>A; pGly88Arg) mutation in a TASK-4 
channel in a patient with severe cardiac conduction disorder (Friedrich et al., 2014).  With 
quantitative PCR experiments, strongest expression of TASK-4 was found in Purkinje fibers 
and the AV-node, followed by expression in the atrial and sinoatrial (SA)-node. By 
heterologously expressing the G88R mutant TASK-4 channels in Xenopus laevis oocytes and 
recording current voltage relationships of wild-type and mutant TASK-4 channels, threefold 
more outward currents were generated by mutant TASK-4 channels compared to wild-type 
channels. Similar cell surface expression of mutant and wild-type TASK-4 channels was 
shown with a chemiluminometric assay. Further experiments with G88K (p.Gly88Lys), 
G88E (p.Gly88Glu) and G88A (p.Gly88Ala) mutants indicated that a small residue (glycine 
or alanine) at position 88 is essential for normal TASK-4 channel gating.  
 
By transfecting HL-1 cells with wild type or G88R mutants, it was shown that while wild-
type TASK-4 also slowed the action potential frequency as expected from overexpression of 
a tandem K+ channel in cells with less hyperpolarized membrane potential, mutant G88R 
TASK-4 transfection caused a significantly more pronounced slowing of the spontaneous 
beating frequency (Friedrich et al., 2014). Patch clamp experiments of wild type and G88R 
mutant transfected HL-1 cells showed shortening of the action potential duration and more 
pronounced after hyperpolarization following the action potential.  
 
Based on the available biological information about K2P channel family (role in maintaining 
cellular resting membrane potential, strong expression in pancreas and heart, heterozygous 
K2P17 mutation resulting in cardiac arrhythmias, the p.F108del K2P17 mutation, identified in 
whole-exome sequencing of family J with cardiac and hypoglycaemia phenotype, was studied 
in HEK293 cell line by patch-clamping. 
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5.3	  METHODS	  
5.3.1	  Site-­‐Directed	  Mutagenesis	  
 
The construct containing cDNA for human KCNK17 (K2P17) was purchased from 
Thermofisher Scientific Biosciences (pCMV-SPORT6). Mutation (p.F108del) was created by 
site-directed mutagenesis as explained in the methodology chapter. The sequences of the 
mutagenic primers used to create the mutation are shown in table 5.1. The K2P17 cDNA in 
the construct was then sequenced to confirm the creation of the mutation using the primers 
shown in table 5.1. 
 
Table 5.1: Sequences of the mutagenic and sequencing primers for KCNK17 construct  
Mutagenic Primers Primer Sequence 
KCNK17_Primer 1 GCTCGTGGGCTCCTTCTTTTCTGTGTCCACCATCAC 
KCNK17_Primer 2 GTGATGGTGGACACAGAAAAGAAGGAGCCCACGAGC 
Sequencing Primers  
KCNK17_attB1 ACAAGTTTGTACAAAAAAGCAGG 
KCNK17_T7 Promoter AATACGACTCACTATAGGG 
KCNK17_1F CTTCCAGCGCGACAAGTG 
KCNK17_1R AAAGAAGAAGGAGCCCACGA 
KCNK17_2F CCGCCTCTTCTGCATCTTCT 
KCNK17_2R CTGGGAGGGGTTCATTCCAA 
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5.3.2	  Whole-­‐Cell	  Patch	  Clamping	  
 
Pulse protocol was used for measuring currents through two-pore domain potassium channels 
subtype 17 (K2P17) transiently expressed in HEK293 cells. After achieving the whole-cell 
configuration and compensating for capacitance transients and series resistance, currents 
were evoked by stepwise changes in the holding potential. The voltage protocol consisted of 
a holding potential of -80mV, followed by 200 milliseconds pulses at 20 mV increments from 
-100mV to +60mV with inter-pulse interval of 2 seconds. The recordings were performed 
with different pH extracellular solutions after achieving whole-cell configuration. 
 
The patch-clamp amplifier software recorded the whole-cell current (pA) at different voltages 
during the voltage-clamp recordings. The whole-cell current (pA) was normalized for the size 
of the cell (whole-cell capacitance; pF) to calculate the current density (pA/pF) at different 
voltages.   
 
HEK293 cells were transfected with cDNA of wild type K2P 17 (WT K2P17), p.F108del 
K2P17 mutant, and 1:1 mixture of wild type K2P17 and p.F108del K2P17 mutant 
(heterozygous p.108del K2P17 mutant) to measure currents with different pH extracellular 
solutions. 
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5.4	  RESULTS	  
 
The current-voltage relationship, mean current density (pA/pF) at +60 mV and representative 
traces, of wild type K2P17 channels, p.F108del K2P17 mutant channels and heterozygous 
p.F108del K2P17 mutant channels after attaining whole-cell configurations with different pH 
extracellular solutions (pH 7.4, 8.5 and 10.0) are shown in figures 5.2, 5.3 and 5.4 
respectively.  There was significantly reduced current density (pA/pF) at +60mV with 
extracellular solution pH 10.0 with p.F108del K2P17 mutant and heterozygous p.F108del 
K2P17 mutant channels as compared to wild type K2P17 channels (figure 5.5).  
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Figure 5.2. A: Current – Voltage relationships of wild type two-pore domain potassium 
channel subtype 17 (K2P17) with different pH extracellular solution (pH 7.4, 8.5 and 10.0). 
The voltage protocol consisted of a holding potential of -80mV, followed by 200 
milliseconds length pulses at 20mV increments from -100mV to +60mV with inter-pulse 
interval of 2 seconds. B: Graph showing mean current density (pA/pF) at +60mV. Data was 
analyzed using paired t test. *p = 0.006, n = 8. C, D and E: Representative traces for whole-
cell recordings from HEK293 cells transfected with wild type K2P17 with extracellular 
solution pH 7.4 (C), 8.5 (D) and 10.0 (E).  
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Figure 5.3. A: Current – Voltage relationships of p.F108del mutant two-pore domain 
potassium channel subtype 17 (p.F108del K2P17) with different pH extracellular solution (pH 
7.4, 8.5 and 10.0). The voltage protocol consisted of a holding potential of -80mV, followed 
by 200 milliseconds length pulses at 20mV increments from -100mV to +60mV with inter-
pulse interval of 2 seconds. B: Graph showing mean current density (pA/pF) at +60mV. Data 
was analyzed using paired t test. *p = 0.27, n = 7. C, D and E: Representative traces for 
whole-cell recordings from HEK293 cells transfected with p.F108del K2P17 mutant with 
extracellular solution pH 7.4 (C), 8.5 (D) and 10.0 (E). 
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Figure 5.4. A: Current – Voltage relationships of heterozygous p.F108del mutant two-pore 
domain potassium channel subtype 17 (heterozygous p.F108del K2P17) with different pH 
extracellular solution (pH 7.4, 8.5 and 10.0). The voltage protocol consisted of a holding 
potential of -80mV, followed by 200 milliseconds length pulses at 20mV increments from -
100mV to +60mV with inter-pulse interval of 2 seconds. B: Graph showing mean current 
density (pA/pF) at +60mV. Data was analyzed using paired t test. *p = 0.005, n = 10. C, D 
and E: Representative traces for whole-cell recordings from HEK293 cells transfected with 
heterozygous p.F108del mutant K2P17 with extracellular solution pH 7.4 (C), 8.5 (D) and 
10.0 (E). 
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Figure 5.5. A: Current – Voltage relationships of wild type K2P17 channels, p.F108del K2P17 
Mutant channels, heterozygous p.F108del K2P17 mutant channels and untransfected HEK293 
cells with pH 10.0 extracellular solution. B: Graph showing mean current density (pA/pF) at 
+60mV with pH 10.0 extracellular solution. Data was analyzed using unpaired t test with 
Welch’s correction, * p = 0.006, ** p = 0.02.  
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5.5	  DISCUSSION	  
 
The two-pore domain potassium channel subtype 17 (K2P17) belongs to the K2P family. These 
channels are composed of two K2P subunits, each of which contains two pore-forming 
domains. K2P channels family are responsible for the high resting potassium conductance of 
the plasma membrane and contribute to the cellular resting membrane potential (Enyedi and 
Czirjak, 2010). K2P17 is sensitive to alkaline pH and is grouped under TALK (TWIK-Related 
Alkaline pH-Activated K+ Channel) subfamily (Enyedi and Czirjak, 2010). Strong expression 
in human heart and pancreas has been demonstrated with RT-PCR and Northern blot analysis 
(Girard et al., 2001, Decher et al., 2001).  
 
Oocytes expressing TALK-2 (K2P17) displayed almost instantaneous (<10ms) and non-
inactivating currents, which were not present in non-injected oocytes. The current-voltage (I-
V) curves were outwardly rectifying in physiological K+ solution and became linear in 
symmetrical K+ solution (Girard et al., 2001). When expressed in COS cells, the current-
voltage curves were similar to those recorded in oocytes (Girard et al., 2001). The reversal 
potentials measured in physiological K+ (-78 ± 2 mV, n = 16) were strongly shifted towards 
positive values in symmetrical K+ solution (6 ± 1 mV, n = 9) as expected for highly selective 
K+ channels. The recorded currents at +50 mV in physiological K+ solution (216 ± 42 pA, n = 
16) were significantly larger than the small endogenous currents recorded in mock transfected 
cells (101 ± 10 pA, n = 16). Alkalization of the external solution increased TALK-2 (K2P17) 
currents without altering the current kinetics or the voltage dependency (Girard et al., 2001).  
 
In this study, HEK293 cells transfected with wild-type K2P17 channels displayed equivalent 
current to the endogenous HEK293 cell current at +60 mV in physiological K+ solution at pH 
7.4 (25.28 ± 4.45 pA/pF [n = 8] vs. 24.53 ± 6.03 pA/pF [n = 5]; p = 0.11). Alkalinizing the 
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pH of the external solution from 7.4 to 8.5 did not significantly increase the K2P17 current at 
+60 mV in physiological K+ solution (25.28 ± 4.45 pA/pF, n = 8 vs. 30.47 ± 4.54 pA/pF, n = 
8; p = 0.41). However increasing the pH of the external solution further to 10.0 significantly 
increased the K2P17 current at +60 mV in comparison to pH 7.4 external solution (269.6 ± 
61.98 pA/pF, n = 8 vs. 25.28 ± 4.45 pA/pF, n = 8; p = 0.006). 
 
For p.F108del K2P17 mutant channels, increasing the pH of the external solution from 7.4 to 
10.0 did not significantly increase the current density (17.96 ± 1.95 pA/pF, n = 5 vs. 25.78 ± 
4.99 pA/pF, n = 5; p = 0.27).  
 
Although for heterozygous p.F108del K2P17 mutant channels, increasing the pH of the 
external solution from 7.4 to 10.0 increased the current density significantly (22.57 ± 2.89 
pA/pF vs. 85.40 ± 17.61 pA/pF, n = 10; p = 0.005), the current density was significantly less 
than that for wild-type K2P17 channels (85.40 ± 17.61 pA/pF, n = 10 vs. 269.6 ± 61.98 
pA/pF, n = 8; p = 0.02).  
 
These results clearly indicate that p.F108del mutation affects the function of the K2P17 
channel and the mutant K2P17 subunit has a dominant negative effect on the wild type K2P17 
subunit. As K2P17 channels are responsible for the cellular resting membrane potential and 
have a significant expression in the pancreas and heart, it is plausible that the p.F108del 
K2P17 mutation results in unstable resting membrane potential in the pancreatic β-cells and 
conducting system of the heart. Unstable resting membrane potential is possibly predisposing 
these cells to persistent depolarization and action potential. 
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There is very little known about the function of the K2P17 channel in humans, as mice do not 
functionally express K2P17 channels. A heterozygous mutation (p.G88R) in the K2P17 
channel was recently identified in a patient with progressive and severe cardiac conduction 
disorder combined with idiopathic ventricular fibrillation (Friedrich et al., 2014). As opposed 
to p.F108del mutant studied in this thesis, p.G88R K2P17 mutation was a gain-of-function 
mutation and generated threefold increased currents. When p.G88R mutation was expressed 
in spontaneously beating HL-1 cell line, the action potential frequency was reduced and there 
was more pronounced after hyperpolarization following the action potential. Extrapolating 
these observations to a loss-of-function mutation like p.F108del studied in this thesis, 
predisposition to enhanced depolarization would be expected with pF108del mutation. This 
enhanced depolarization can explain the phenotype of cardiac tachyarrhythmia and enhanced 
glucose-induced insulin release from pancreatic β-cells based on the expression pattern of 
K2P17 channels.  
 
Expressing the p.F108del K2P17 mutation in an insulin producing cell line and measuring the 
glucose-stimulated insulin-release in response would help in confirming the role of K2P17 
channels in insulin secretion from pancreatic β-cells. Sequencing KCNK17 in genetically yet 
undiagnosed cases of HH can be another strategy to establish its function.  
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
VOLTAGE GATED POTASSIUM (KV) 
CHANNELS AND 
ELECTROPHYSIOLOGICAL ANALYSIS 
OF p.A422V KV6.2 MUTANT 
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6.1	  SUMMARY	  OF	  CHAPTER	  6	  
 
Chapter 6 provides an introduction to voltage-gated potassium channels (Kv) family, their 
role in insulin secretion followed by method used to create Kv6.2 mutant construct and results 
of whole-cell patch clamping in HEK293 cell line. The chapter ends with the discussion of 
the results in context with the phenotype of the patient.  
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6.2	  INTRODUCTION	  
 
Voltage-gated potassium channels (Kv) are transmembrane channels specific for potassium 
and are sensitive to voltage changes in the plasma membrane potential. Typically, Kv 
channels are tetramers of four identical subunits (alpha subunits) arranged as a ring around a 
pore (Gutman et al., 2005). Each subunit has six membrane spanning hydrophobic α-helical 
sequences (Gutman et al., 2005). These alpha units can be subdivided into 12 classes (Kvα1-
12) on the basis of sequence homology of the hydrophobic transmembrane region. Based on 
the function, the alpha subunits can be grouped into 6 groups. 
 
1. Delayed rectifier 
2. A-type potassium channel 
3. Outward-rectifying 
4. Inward-rectifying 
5. Slowly activating 
6. Modifier/silencer 
 
The delayed rectifier group can be further sub grouped into 5 subgroups based on Kv 
sequence homology.  
1. Kvα1.x – Shaker-related 
2. Kvα2.x – Shab-related 
3. Kvα3.x – Shaw-related 
4. Kvα7.x 
5. Kvα10.x 
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Based on Kv sequence homology, the modifier/silencer group can be sub grouped into 4 
subgroups. 
1. Kvα5.x 
2. Kvα6.x 
3. Kvα8.x 
4. Kvα9.x 
 
The members of the modifier/silence group are unable to form functional channels as 
homotetramers like other groups such as delayed rectifier Kv channels, A-type potassium 
channel etc. Instead the members of this group heterotetramerize with Kvα2 family members 
to form conductive channels (Gutman et al., 2005).  
 
 
Kv channels have a K+ selectivity filter at the narrowest part of the transmembrane pore. The 
amino acid sequence (Thr-Val-Gly-Phe-Gly) or (Thr-Val-Gly-Phe-Gly) is typical to the 
selectivity filter of Kv channels. K+ ions interacts with specific atomic components of Thr-
Val-Gly-Tyr/Phe-Gly sequence from the four channel subunits.  
6.3	  ROLE	  OF	  KV	  CHANNELS	  IN	  REGULATION	  OF	  INSULIN	  SECRETION	  
 
Following action potential due to Ca2+ entry through voltage-dependent Ca2+ channels, action 
potential repolarization results from activation of a delayed outward potassium current, with 
some contribution from Ca2+ activated K+ channels. Kelly et al. from studies on human 
pancreatic islets showed that the delayed outward current activated at about -20mV and 
increased linearly with further depolarization (Kelly et al., 1991). The reversal of current 
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direction at -70mV suggested that this current is carried primarily by potassium ions. By 
replacing internal K+ with impermeant cation N-methyl-D-glucamine (NMG), the authors 
noticed this outward current could be abolished which provide further support to the idea that 
this current is a potassium current (Kelly et al., 1991).  
 
Similar delayed outward K+ current have been described in mouse and rat β-cells and in the 
insulin-secreting cell lines RINm5F and HIT T15. This delayed rectifier current is sensitive to 
tetraethylammonium (TEA), quinine and forskolin, but not to sulfonylureas.  
 
In a study by Henquin JC, low concentrations of TEA, which inhibits voltage sensitive K+ 
channels, produced increase in glucose-induced electrical activity in mouse pancreatic β-
cells. Insulin release was also slightly increased with TEA (Henquin, 1990). He concluded 
that voltage sensitive K+ channels play a role in the repolarization of the spikes of β-cells 
(seen at high concentration of glucose) but not that of the slow waves (Henquin, 1990). 
6.4	  MOLECULAR	  ENTITIES	  RESPONSIBLE	  FOR	  DELAYED	  RECTIFIER	  K+	  
CURRENT	  
 
Of the more than 40 known human voltage-gated potassium channel related genes that have 
been reported, only a subset encodes membrane proteins that produce delayed rectifier 
voltage-sensitive outward K+ currents similar to those found in the β-cells.  They have been 
named according to the single Drosophila gene locus they are most similar to: Shaker 
(Kv1.x), Shab (Kv2.x), and Shaw (Kv3.x).  
 
Using RT-PCR, Roe et al. found the expression of the K+ channel gene Kv2.1 in βTC3-neo 
(transgenically derived insulinoma) cells and β-cells purified from rodent pancreatic islets of 
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Langerhans (Roe et al., 1996). This was confirmed by immunoblotting of the membrane 
proteins in the insulinoma cells with anti-Kv2.1 antibody.  With whole-cell patch clamping, 
they demonstrated the presence of delayed rectifier K+ currents inhibited by TEA and 4-
aminopyridine, with similar Kd values to that of Kv2.1, correlating delayed rectifier gene 
expression with the K+ currents. They also showed that TEA activated large amplitude 
intracellular Ca2+ concentration oscillations and potentiated insulin secretion in the presence 
of glucose in the insulinoma cells (Roe et al., 1996).  
 
In another study, high level protein expression and mRNA transcripts of Kv1.4, Kv1.6 and 
Kv2.1 were detected in rat islets and insulinoma cells (MacDonald et al., 2001). With TEA, 
delayed rectifier current (IDR) decreased by approximately 85% and glucose-stimulated 
insulin secretion increased 2- to 4-fold. With the use of adenovirus-mediated expression of C-
terminal truncated Kv2.1 subunit and Kv1.4 subunit, the authors established that Kv2 and Kv1 
channel homologs mediate the majority of repolarizing delayed rectifier current in HIT-T15 
cells and rat islet cells (MacDonald et al., 2001).  
 
Philipson et al. studied the overexpression of delayed rectifier K+ current in transgenic islets 
and βTC3 insulinoma cells (Philipson et al., 1994). They constructed transgenic mice and 
overexpressed delayed rectifier K+ channel gene, hKv1.5. The hKv1.5 had previously been 
shown to produce TEA-resistant K+ currents (Philipson et al., 1991). With whole-cell patch 
experiments, the authors confirmed the appearance of TEA-resistant K+ currents in transgenic 
islet cells, the expression of which correlated with hyperglycaemia and hypoinsulinaemia 
(Philipson et al., 1994). Stable overexpression of Kv1.5 channel in insulinoma cells attenuated 
glucose-activated increases in intracellular Ca2+ concentration and also prevented the 
induction of TEA-dependent Ca2+ concentration oscillations (Philipson et al., 1994).  
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Zhu et al. cloned rat and human Kv6.2, and noticed the expression of human Kv6.2 mRNA in 
heart, liver, skeletal muscle, kidney and pancreas (Zhu et al., 1999). When expressed alone in 
Xenopus oocytes or Chinese Hamster Ovary (CHO) or HEK 293 cells, no functional Kv6.2 
channels were noticed. However coexpression with Kv2.1 subunits yielded Kv channel 
currents distinct from those of homomultimeric Kv2.1 channels (Zhu et al., 1999).  
 
Yan et al. investigated the expression of 26 subtypes of voltage gated potassium channels in 
human and rhesus pancreatic islets by RT-PCR (Yan et al., 2004). PCR fragments for 17 
channel subtypes (Kv1.3, 1.6, 1.7, 2.1, 2.2, 3.1, 3.2, 3.3, 4.1, 4.4, 6.1, 6.2, 9.1, 9.2, 9.3, 10.1, 
and 11.1) were present in the pancreatic islet preparation. With insitu hybridization and 
immunohistochemistry, the authors showed that Kv2.1 mRNA-positive cells exclusively co-
localized with the insulin-containing cells and confirmed the presence of Kv2.1 in β-cells 
(Yan et al., 2004). On probing the human pancreatic sections with labeled antisense 
oligonucleotides for Kv6.1 and Kv6.2 channels and will cell marker-specific antibodies, the 
authors demonstrated that Kv6.1 colocalized with glucagon and Kv6.2 with insulin containing 
cells (Yan et al., 2004). They hypothesized that as seen in heterologous expression systems, 
silent subunits (Kv6.2 and Kv9.3) coassemble with subunits from either Kv2 or Kv3 families in 
the human β-cells and modify their function (Yan et al., 2004).  
 
Jacobson et al. investigated the role of Kv2.1 in β-cells from a Kv2.1-/- mouse model 
(Jacobson et al., 2007). They demonstrated that Kv2.1 null mice have reduced fasting blood 
glucose levels and elevated serum insulin as compared to control animals. In isolated islets 
from Kv2.1 null mice, they demonstrated that β-cells have reduced Kv currents (83% less at 
+50 mV) as compared with control cells.  
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Another line of evidence of involvement of Kv channels in insulin regulation comes from 
studies on ghrelin. Ghrelin and its receptor (Growth hormone secretagogue-receptor; GHS-R) 
have been shown to be located in pancreatic islets (Dezaki et al., 2004, Gnanapavan et al., 
2002). It has also been shown that ghrelin inhibits insulin release in mice, rats and humans 
(Broglio et al., 2001, Dezaki et al., 2004). Dezaki et al. showed that ghrelin-induced 
attenuation of glucose-induced insulin release was linked to enhanced Kv channel 
conductance in rat islet β-cells (Dezaki et al., 2007).  
 
Glucagon-like peptide-1 (GLP-1) that potentiates glucose-stimulated insulin secretion (GSIS) 
from pancreatic β-cells is hypothesized to mediate its effects through several mechanisms, 
including antagonism of ATP-sensitive K+ channels, potentiation of voltage-dependent Ca2+ 
channels, release of intracellular Ca2+ stores etc. MacDonald et al. reported that GLP-1 
signaling also regulates the activity of β-cell Kv channels (MacDonald et al., 2002). GLP-1 
receptor activation in rat β-cells antagonized Kv currents by 43%. They implicated cAMP 
signaling in GLP-1 receptor modulation of β-cell Kv currents.  
 
Based on the biological information about Kv channels, p.A422V mutation in Kv6.2 modifier 
subunit identified on whole-exome sequencing in family J, may reduce the delayed outward 
potassium current, which repolarize the cell membrane. Impaired repolarization of the 
pancreatic β-cells and heart as a result may result in the combined phenotype of cardiac 
arrhythmia and HH. The p.A422V Kv6.2 mutation was studied by patch clamping. As Kv6.2 
subunits do not form homotetrameric channels, HEK293 cell line was co-transfected with 
Kv2.1 and Kv6.2 subunits to study the impact of p.A422V Kv6.2 mutation on the delayed 
outward potassium current.   
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6.5	  METHODS	  
6.5.1	  Site-­‐Directed	  Mutagenesis	  
 
The construct containing cDNA for human KCNG2 (Kv6.2) was purchased from Origene 
(pCMV-XL4). Mutation (p.A422V) was created by site-directed mutagenesis as explained in 
the methodology chapter. The sequences of the mutagenic primers used to create the mutation 
are shown in table 6.1. The Kv6.2 cDNA in the construct was then sequenced to confirm the 
successful creation of the mutation using the primers shown in table 6.1. The construct 
containing cDNA for rat KCNB1 (Kv2.1) was kindly provided by Professor Michael Tamkun 
from Colorado State University, USA.  
 
Table 6.1: Sequences Of The Mutagenic And Sequencing Primers For KCNG2 Construct 
Mutagenic Primers Primer Sequence 
KCNG2_Primer 1 CAAGGAGCAGCAGCAGCGCGTGGCCAGCCCCGAGCCGGC 
KCNG2_Primer 2 GCCGGCTCGGGGCTGGCCACGCGCTGCTGCTGCTCCTTG 
Sequencing Primers Primer Sequence 
KCNG2_VP1.5 GGACTTTCCAAAATGTCG 
KCNG2_XL39 ATTAGGACAAGGCTGGTGGG 
KCNG2_1F GAGTTCTTCTTCGACCGCAG 
KCNG2_1R GGTCTCCAGCACGAACAGG 
KCNG2_2F CGTGTCCGTGTCCTTCGT 
KCNG2_2R AGGTGTGGAAGATGGAGGTG 
KCNG2_Reverse TCAGCGCCCTGCCCGCACCC 
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6.5.2	  Whole-­‐Cell	  Patch	  Clamping	  
 
Pulse protocol was used for measuring currents through voltage-gated potassium channels. 
After achieving the whole-cell configuration and compensating for capacitance transients and 
series resistance, voltage-activated currents were evoked by stepwise changes in the holding 
potential. The voltage protocol consisted of a holding potential of -80mV, followed by 200 
milliseconds pulses at 20 mV increments from -100mV to +80mV with inter-pulse interval of 
2 seconds.  
 
The patch-clamp amplifier software recorded the whole-cell current (pA) at different voltages 
during the voltage-clamp recordings. The recordings were performed immediately, 2 and 5 
minutes after achieving whole-cell configuration. The whole-cell current (pA) was 
normalized for the size of the cell (whole-cell capacitance; pF) to calculate the current density 
(pA/pF) at different voltages.   
 
HEK293 cells were transfected with following different cDNA combinations of Voltage-
gated potassium channel (Kv) subunits to measure voltage-activated currents. 
1. Kv2.1 subunit only (2µg) 
2. Kv6.2 wild-type subunit only (2µg) 
3. Kv6.2 mutant subunit only (2µg) 
4. Kv2.1 subunit (1µg) plus Kv6.2 wild-type subunit (1µg) 
5. Kv2.1 subunit (1µg) plus Kv6.2 mutant subunit (1µg) 
6. Kv2.1 subunit (1µg) plus Kv6.2 wild-type subunit (500 ng) plus Kv6.2 mutant subunit 
(500 ng) 
7. No transfection (Control) 
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6.6	  RESULTS	  	  
 
The current-voltage relationship and mean current density (pA/pF) at +40 mV, of voltage 
gated potassium channels formed of different combinations of Kv2.1, Kv6.2 WT and Kv6.2 
mutant subunits in HEK293 cells, immediately, 2 and 5 minutes after attaining whole-cell 
configurations are shown in figures 6.1, 6.2 and 6.3 respectively.  There was significantly 
reduced voltage-activated currents seen with voltage-gated potassium channels formed of 
Kv6.2 mutant subunits, as compared to voltage-gated potassium channels formed of Kv6.2 
wild-type subunits (p < 0.05).   
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Figure 6.1. A: Current-Voltage relationships of Voltage-gated Potassium Channels (Kv 
Channels), formed of different combination of subunits (Kv2.1, Kv6.2WT and Kv6.2 
Mutant), expressed in HEK293 cells. The recording was performed immediately after 
attaining whole-cell configuration.  The voltage protocol consisted of a holding potential of -
80mV, followed by 200 milliseconds length pulses at 20 mV increments from -100mV to 
+80mV with inter-pulse interval of 2 seconds. B: Graph showing mean current density 
(pA/pF) at +40 mV. The number of recordings (n) performed for each transfection is shown 
in the brackets along the x-axis. Data was analyzed using unpaired t test with Welch’s 
correction. * p = 0.006 ** p = 0.009. C D E F and G: Representative traces from whole-cell 
patch-clamp recordings for voltage-gated potassium channels formed of Kv2.1 subunit only 
(C), Kv6.2 wild type subunit only (D), 1:1 ratio of Kv2.1 and Kv6.2 wild type subunits (E), 
1:1 ratio of Kv2.1 and Kv6.2 mutant subunits (F) and 2:1:1 ratio of Kv2.1, Kv6.2 wild-type 
and Kv6.2 mutant subunits (G).  Representative traces for untransfected HEK293 cells and 
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cells transfected with Kv6.2 mutant were similar to the representative trace for cells 
transfected with Kv6.2 wild-type subunit.  
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Figure 6.2. A: Current-Voltage relationships of Voltage-gated Potassium Channels (Kv 
Channels), formed of different combination of subunits (Kv2.1, Kv6.2WT and Kv6.2 
Mutant), expressed in HEK293 cells. The recording was performed 2 minutes after attaining 
whole-cell configuration.  The voltage protocol consisted of a holding potential of -80mV, 
followed by 200 milliseconds length pulses at 20 mV increments from -100mV to +80mV 
with inter-pulse interval of 2 seconds. B: Graph showing mean current density (pA/pF) at 
+40 mV. The number of recordings (n) performed for each transfection is shown in the 
brackets along the x-axis. Data was analyzed using unpaired t test with Welch’s correction. * 
p = 0.004 ** p = 0.006. C D E F and G: Representative traces from whole-cell patch-clamp 
recordings for voltage-gated potassium channels formed of Kv2.1 subunit only (C), Kv6.2 
wild type subunit only (D), 1:1 ratio of Kv2.1 and Kv6.2 wild type subunits (E), 1:1 ratio of 
Kv2.1 and Kv6.2 mutant subunits (F) and 2:1:1 ratio of Kv2.1, Kv6.2 wild-type and Kv6.2 
mutant subunits (G).  Representative traces for untransfected HEK293 cells and cells 
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transfected with Kv6.2 mutant were similar to the representative trace for cells transfected 
with Kv6.2 wild-type subunit. 
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Figure 6.3. A: Current-Voltage relationships of Voltage-gated Potassium Channels (Kv 
Channels), formed of different combination of subunits (Kv2.1, Kv6.2WT and Kv6.2 
Mutant), expressed in HEK293 cells. The recording was performed 5 minutes after attaining 
whole-cell configuration.  The voltage protocol consisted of a holding potential of -80mV, 
followed by 200 milliseconds length pulses at 20 mV increments from -100mV to +80mV 
with inter-pulse interval of 2 seconds. B: Graph showing mean current density (pA/pF) at 
+40 mV. The number of recordings (n) performed for each transfection is shown in the 
brackets along the x-axis. Data was analyzed using unpaired t test with Welch’s correction. * 
p = 0.003 ** p = 0.005. C D E F and G: Representative traces from whole-cell patch-clamp 
recordings for voltage-gated potassium channels formed of Kv2.1 subunit only (C), Kv6.2 
wild type subunit only (D), 1:1 ratio of Kv2.1 and Kv6.2 wild type subunits (E), 1:1 ratio of 
Kv2.1 and Kv6.2 mutant subunits (F) and 2:1:1 ratio of Kv2.1, Kv6.2 wild-type and Kv6.2 
mutant subunits (G).  Representative traces for untransfected HEK293 cells and cells 
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transfected with Kv6.2 mutant were similar to the representative trace for cells transfected 
with Kv6.2 wild-type subunit. 
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6.7	  DISCUSSION	  
 
Voltage activated delayed outward potassium currents are responsible for repolarization after 
action potential (Kelly et al., 1991). Inhibition of this voltage-activated outward potassium 
currents by tetraethylammonium (TEA) resulted in increased glucose-induced electrical 
activity in mouse pancreatic β-cells as well as increased insulin secretion.  
 
Expression studies in βTC3-neo (transgenically derived insulinoma) cells and β-cells purified 
from rodent pancreatic islets of Langerhans, and whole-cell patch clamping experiments 
suggested Kv2.1 channels to be responsible for these delayed outwards potassium currents 
(Roe et al., 1996). Other groups also reported the expression of Kv2.1 in human, rhesus and 
rat pancreatic islets as well as insulinoma cells (Yan et al., 2004, MacDonald et al., 2001).  
 
Zhu et al. cloned and functionally characterized Kv6.2 subunit of voltage-gated potassium 
channels (Zhu et al., 1999). The authors demonstrated that when Kv6.2 was coexpressed with 
Kv2.1 subunits, heteromultimeric Kv channels were formed mediating voltage-activated 
delayed-rectifier type outward currents. The kinetics and conductance-voltage relationship 
were different than homomultimeric Kv2.1 channels. Preferential expression of Kv6.2 mRNA 
was seen in rat and human myocardium. Yan et al. reported the expression of Kv6.2 subunits 
in human pancreatic sections and also demonstrated the colocalisation of Kv6.2 with insulin 
containing cells (Yan et al., 2004).  
 
Based on the information from the literature, it is plausible that Kv2.1 and Kv6.2 subunits 
coassemble to form heteromultimeric Kv channels in the pancreatic β-cells and heart, which 
contribute to the repolarization of the action potential. Reduced outward delayed-rectifier 
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potassium current due to loss-of-function mutation in Kv2.1 or Kv6.2 subunits could result in 
prolonged depolarization of the pancreatic β-cells and excessive insulin secretion.  
 
In this study, the Kv channels formed of Kv2.1 wild type and Kv6.2 mutant subunits expressed 
significantly reduced outward potassium current as compared to Kv channels formed of Kv2.1 
wild type and Kv6.2 wild type subunits.  
 
As the Kv channels are formed of four subunits, even the heterozygous mutation is likely to 
result in reduced delayed rectifying outward potassium current as the mutant subunits 
coassemble with the wild type subunits (dominant-negative effect). In this study as well, 
coexpression of the mutation with wild type allele resulted in significantly reduced delayed-
rectifier outward potassium current.   
 
Reduced fasting blood glucose and elevated serum insulin were noticed in Kv2.1-/- mice. The 
β-cells from islets isolated from Kv2.1 null mice had reduced Kv currents as compared to 
control β-cells (Jacobson et al., 2007). Overexpression of delayed-rectifier potassium current 
in transgenic islets and βTC3 insulinoma cells resulted in the opposite phenotype of 
hyperglycaemia and hypoinsulinaemia (Philipson et al., 1994).  
  
Mouse and rat β-cells as well as insulin secreting cell lines RINm5F and HIT T15 show 
similar delayed outward potassium current.  
It is quite clear from the results that heterozygous Kv6.2 mutation resulted in reduced current 
through voltage-activated potassium channels.  
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Chapter 7 
 
 
 
 
EXPRESSION OF KIR6.2 MUTANT 
TRANSCRIPT IN THE PANCREATIC 
TISSUE AND 
ELECTROPHYSIOLOGICAL 
ANALYSIS OF KATP CHANNEL 
MUTATIONS IN HEK293 CELLS 
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7.1	  SUMMARY	  OF	  THE	  CHAPTER	  
 
The results of whole-cell patch-clamping electrophysiology experiments of two KATP channel 
mutants (p.T1516M SUR1 mutant and p.*391Rext*94 Kir6.2 mutant) are discussed in the 
current chapter. The p.*391Rext*94 Kir6.2 mutation replaces the termination codon with the 
amino acid arginine at codon 391 and results in addition of an extra 94 amino acids to the 
carboxyl terminus of Kir6.2 protein. Although it can be assumed that the normal open reading 
frame will simply be extended until the next in-frame stop codon is encountered, only a few 
human nonstop mutations have so far been characterized at either the mRNA or the protein 
level. In view of this, cDNA synthesized from the pancreatic tissue of the patient was 
sequenced as well as Western blot on the pancreatic tissue sample was performed before 
studying the p.*391Rext*94 Kir6.2 mutation electrophysiologically.  
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7.2	  COMPLEMENTARY	  DNA	  (cDNA)	  SEQUENCING	  
 
The RNA sample was extracted from the pancreatic tissue of the patient according to the 
method described in the methodology chapter. The RNA was reverse-transcribed into cDNA 
using random hexamers as described under cDNA synthesis in Section 3.4 using 
SuperScript® III First-Strand Synthesis System (Invitrogen). The cDNA was amplified by 
PCR reaction and sequenced. Pancreatic tissue sample from another patient without KCNJ11 
mutation was used as control. The chromatogram from sequencing is shown in figure 7.1.  
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Chromatogram showing heterozygous T > C change at the termination codon 
(TGA) in the cDNA synthesized from the RNA extracted from the pancreatic sample of the 
patient. Presence of the transcript with nucleotide C at the marker position (arrow) implies 
the incomplete (or no) degradation of the mutant transcript by non-stop decay phenomenon.  
  
 
Control 
Patient 
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7.3	  WESTERN	  BLOTTING	  
 
Along with RNA, protein was also extracted from the pancreatic tissue sample of the patient 
with heterozygous non-stop KCNJ11 mutation according to the method described in the 
methodology chapter. The protein was quantified and 20 µg sample was separated by SDS-
PAGE (8%), transferred to nitrocellulose, probed with primary Kir6.2 antibody (raised in 
goat) followed by horseradish peroxidase (HRP)-conjugated anti-goat secondary antibody, 
and visualized by enhanced chemiluminescence. Protein extracted from control pancreatic 
tissue was run in an adjacent well as a control along with molecular weight markers. The 
molecular weight of Kir6.2 protein is 42kDa and the molecular weight of protein translated 
from KCNJ11 transcript carrying non-stop mutation is predicted to be 52.1kDa. The western 
blot analysis is shown in figure 7.2  
 
 
 
 
 
 
 
 
Figure 7.2: Western blot analysis of Kir6.2 proteins extracted from the pancreatic tissue of 
the patient and control with molecular weight markers. An extra faint band corresponding to 
the molecular weight of Kir6.2 protein with 94 additional amino acids was visualized in the 
patient, which was absent in the control pancreatic tissue. The normal sized Kir6.2 protein 
band was fainter as well in the patient due to translation from only one transcript.   
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7.4	  WHOLE-­‐CELL	  PATCH	  CLAMPING	  
 
The patch-clamp amplifier software recorded the whole-cell current (pA) at different voltages 
during the voltage-clamp recordings. The whole-cell current (pA) was normalized for the size 
of the cell (whole-cell capacitance; pF) to calculate the current density (pA/pF) at different 
voltages.  
The recordings were performed under three different settings:  
1. Immediately after attaining whole-cell configuration,  
2. In the presence of diazoxide only (100 µM). This measured KATP current and 
endogenous HEK293 current, and 
3. In the presence of diazoxide (100 µM) and tolbutamide (100 µM). This measured 
endogenous HEK293 current as the KATP current is inhibited by tolbutamide. 
By subtracting current recorded during recording (3) from recording (2), the tolbutamide 
sensitive current was calculated, which is an indicator of KATP current.  
For steps (2) and (3) recordings, sufficient time was given for the current to reach plateau 
phase. An average of four recording sweeps was used to calculate current density (pA/pF) for 
statistical analysis.  
7.5	  EXPRESSION	  OF	  WT	  AND	  MUTANT	  KATP	  CHANNELS	  IN	  HEK293	  
CELLS	  
 
WT	  SUR1/Kir6.2	  Channels	  Expression	  
 
The whole-cell patch clamp data of HEK293 cells transfected with cDNA of hamster wild 
type SUR1 and mouse Kir6.2 are shown in figure 7.3. The WT KATP channels were activated 
with 100 µM DZX and inhibited by 100 µM TOL, as is evident from figure 7.3B. The 
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reversal potential for the KATP current was approximately -80 mV, which is the reversal 
potential for K+.  
T1516M	  SUR1	  Mutant/WT	  Kir6.2	  Channels	  Expression	  
 
The HEK293 cells transfected with cDNA for hamster T1516M SUR1 mutant and mouse 
WT Kir6.2 showed negligible KATP current (Figure 7.4).  There was no significant change in 
current on exposure to diazoxide suggesting absence of KATP current. The T1516M mutation 
is located in the nucleotide-binding domain 2 (NBD2) region of SUR1 protein.  
 
To simulate the heterozygous expression conditions (as seen in the proband), whole-cell 
patch clamp recordings were done on HEK293 cells transfected with cDNA of WT SUR1 
and T1516M SUR1 mutant in 1:1 ratio along with Kir6.2 (Figure 7.5). The data suggested 
presence of KATP current equivalent to that seen in WT KATP channels (p = 0.28; Figure 7.6).  
WT	  SUR1/p.*391REXT*94	  Kir6.2	  MUTANT	  CHANNELS	  EXPRESSION	  
 
Similar to p.T1516 SUR1 mutant, HEK293 cells transfected with cDNA for hamster WT 
SUR1 and human p.*391Rext*94 Kir6.2 mutant did not show any significant KATP current 
(Figure 7.7). The *391Rext*94 Kir6.2 mutant is the result of a non-stop mutation which 
results in addition of an extra 94 amino acids to the carboxy terminus of Kir6.2 protein.  
 
To simulate the heterozygous expression conditions (as seen in the proband), whole-cell 
patch clamp recordings were done on HEK293 cells transfected with cDNA of WT Kir6.2 
and p.*391Rext94* Kir6.2 mutant in 1:1 ratio along with SUR1 (Figure 7.8). The data 
suggested dominant negative effect of p.*391Rext94* Kir6.2 Mutant on the WT Kir6.2 
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protein, as evidenced by significantly reduced KATP current in the heterozygous conditions as 
compared to that seen in WT KATP channels (p = 0.03; Figure 7.9).   
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Figure 7.3: The effect of diazoxide (DZX) and tolbutamide (TOL) on the activity of wild 
type KATP channels (SUR1/Kir6.2) transiently expressed in HEK293 cells. After attaining 
whole-cell configuration, cells were voltage-clamped. The voltage-clamp protocol consisted 
of a holding potential of -80 mV, after which the cells were ramped from -150 mV to 50 mV 
over 1 second (200mV/s) and then stepped back to -80 mV. Cells were superfused with 5 K+ 
bath solution (CNT), followed by 100 µM DZX to activate KATP currents, and 100 µM DZX 
and 100 µM Tolbutamide (DZX+TOL) to inhibit KATP currents. A: Graph showing mean 
pA/pF at +40 mV. Data was analyzed using Wilcoxon matched-pairs signed rank test, WT n 
= 12, **p = 0.0005. B: Representative trace from whole-cell patch-clamp recordings for WT 
cells.  
Control Diazoxide Diazoxide
and
Tolbutamide
0
100
200
300
400
500
600
pA
/p
F 
at
 +
40
 m
V
Wild Type KATP ChannelsA 
B 
 ** 
-150 -100 -50 50
-200
-100
100
200
300
400
500
600
Voltage (mV)
CNT
DZX
DZX+TOL p
A
/p
F
 234 
 
 
Figure 7.4: The effect of diazoxide (DZX) and tolbutamide (TOL) on the activity of mutant 
KATP channels (T1516M SUR1 Mutant/Kir6.2) transiently expressed in HEK293 cells. After 
attaining whole-cell configuration, cells were voltage-clamped. The voltage-clamp protocol 
consisted of a holding potential of -80 mV, after which the cells were ramped from -150 mV 
to 50 mV over 1 second (200mV/s) and then stepped back to -80 mV. Cells were superfused 
with 5 K+ bath solution (CNT), followed by 100 µM DZX to activate KATP currents, and 100 
µM DZX and 100 µM Tolbutamide (DZX+TOL) to inhibit KATP currents. A: Graph showing 
mean pA/pF at +40 mV. Data was analyzed using Wilcoxon matched-pairs signed rank test, 
WT n = 7, p = 0.58 (not significant [ns]). B: Representative trace from whole-cell patch-
clamp recordings for T1516M SUR1mutant.   
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Figure 7.5: The effect of diazoxide (DZX) and tolbutamide (TOL) on the activity of 
heterozygous mutant KATP channels (Heterozygous T1516M SUR1 Mutant/Kir6.2) 
transiently expressed in HEK293 cells. After attaining whole-cell configuration, cells were 
voltage-clamped. The voltage-clamp protocol consisted of a holding potential of -80 mV, 
after which the cells were ramped from -150 mV to 50 mV over 1 second (200mV/s) and 
then stepped back to -80 mV. Cells were superfused with 5 K+ bath solution (CNT), followed 
by 100 µM DZX to activate KATP currents, and 100 µM DZX and 100 µM Tolbutamide 
(DZX+TOL) to inhibit KATP currents. A: Graph showing mean pA/pF at +40 mV. Data was 
analyzed using Wilcoxon matched-pairs signed rank test, WT n = 12, **p = 0.001. B: 
Representative trace from whole-cell patch-clamp recordings for heterozygous T1516M 
SUR1mutant. 
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Figure: 7.6: Graph showing KATP current at +40 mV from HEK293 cells transfected with 
cDNA of mouse Kir6.2 along with cDNA of WT SUR1, T1516M SUR1 Mutant and 1:1 ratio 
of WT and T1516M SUR1 Mutant. This data was derived by subtracting the current that 
remained after superfusion of cells with (100 µM DZX + 100 µM TOL) from the current seen 
after the superfusion with 100 µM DZX only during whole-cell recordings. Data is presented 
as Mean ± SEM, and was analyzed using Mann-Whitney test, p = 0.28 (not significant [ns]), 
n = 7-12 cells.  
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Figure 7.7: The effect of diazoxide (DZX) and tolbutamide (TOL) on the activity of mutant 
KATP channels (WT SUR1/*391Rext94* Kir6.2 Mutant) transiently expressed in HEK293 
cells. After attaining whole-cell configuration, cells were voltage-clamped. The voltage-
clamp protocol consisted of a holding potential of -80 mV, after which the cells were ramped 
from -150 mV to 50 mV over 1 second (200mV/s) and then stepped back to -80 mV. Cells 
were superfused with 5 K+ bath solution (CNT), followed by 100 µM DZX to activate KATP 
currents, and 100 µM DZX and 100 µM Tolbutamide (DZX+TOL) to inhibit KATP currents. 
A: Graph showing mean pA/pF at +40 mV. Data was analyzed using Wilcoxon matched-
pairs signed rank test, n = 6, p = 0.22 (not significant [ns]). B: Representative trace from 
whole-cell patch-clamp recordings for *391Rext94* Kir6.2 Mutant.  
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Figure 7.8: The effect of diazoxide (DZX) and tolbutamide (TOL) on the activity of 
heterozygous mutant KATP channels (Heterozygous WT SUR1/*391Rext94* Kir6.2 Mutant) 
transiently expressed in HEK293 cells. After attaining whole-cell configuration, cells were 
voltage-clamped. The voltage-clamp protocol consisted of a holding potential of -80 mV, 
after which the cells were ramped from -150 mV to 50 mV over 1 second (200mV/s) and 
then stepped back to -80 mV. Cells were superfused with 5 K+ bath solution (CNT), followed 
by 100 µM DZX to activate KATP currents, and 100 µM DZX and 100 µM Tolbutamide 
(DZX+TOL) to inhibit KATP currents. A: Graph showing mean pA/pF at +40 mV. Data was 
analyzed using Wilcoxon matched-pairs signed rank test, WT n = 12, **p = 0.002. B: 
Representative trace from whole-cell patch-clamp recordings for heterozygous *391Rext94* 
Kir6.2 mutant.   
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Figure: 7.9: Graph showing KATP current at +40 mV from HEK293 cells transfected with 
cDNA of hamster SUR1 along with human cDNA of WT Kir6.2, *391Rext94* Kir6.2 
Mutant and 1:1 ratio of WT and *391Rext94* Kir6.2Mutant. This data was derived by 
subtracting the current that remained after superfusion of cells with (100 µM DZX + 100 µM 
TOL) from the current seen after the superfusion with 100 µM DZX only during whole-cell 
recordings. Data is presented as Mean ± SEM, and was analyzed using Mann-Whitney test, 
**p = 0.03, n = 6-10 cells.  
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7.6	  DISCUSSION	  
 
The p.T1516M SUR1 and p.*391Rext*94 Kir6.2 mutants under homozygous expression 
conditions did not show any response to diazoxide or tolbutamide. However under 
heterozygous expression, the HEK293 cells transfected with p.T1516M SUR1 mutant 
displayed equivalent KATP current as that seen with the wild type KATP channels. In 
comparison, HEK293 cells transfected with p.*391Rext*94 Kir6.2 mutant under 
heterozygous expression conditions displayed significantly reduced KATP current as 
compared to the WT KATP channels. These results correlate well with the clinical phenotype 
observed in the patients carrying these two KATP channel mutations.  In the family with 
p.T1516M SUR1 mutation, HH resolved in both the patients (recruited in this thesis) within 
the first few weeks of life, which suggests that the wild type SUR1 subunits was able to 
rescue the function of p.T1516M SUR1 mutant subunits. The other explanation could be that 
the KATP channels under heterozygous conditions were formed by only wild type SUR1 
subunits, and the mutant p.T1516M SUR1 subunits were retained in the endoplasmic 
reticulum and not trafficked to the plasma membrane.  
 
With regard to the Kir6.2 mutant (p.*391Rext*94 mutation), the WT Kir6.2 subunits were 
able to rescue the function of mutant subunits but not completely as the KATP current under 
simulated heterozygous conditions was significantly reduced as compared to WT KATP 
channels. To exclude the possibility of complete degradation of the mutated transcript by 
nonstop mRNA decay and no translation from the mutated transcript, RNA and protein was 
extracted from the pancreatic tissue of the patient with heterozygous nonstop Kir6.2 
mutation.  
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Non-stop mRNA decay is a cellular mechanism of mRNA surveillance to detect mRNA 
molecules lacking a stop codon and prevent these mRNAs from translation (Frischmeyer et 
al., 2002). In yeast, nonstop mRNAs are recognized by the protein Ski7 on ribosomes that 
have become stalled at the 3´ ends of the mRNAs (van Hoof et al., 2002). These RNAs are 
then targeted by exosome-mediated degradation (van Hoof et al., 2002). Precisely how 
effective nonstop mRNA decay is in humans is unclear. Evidence points towards this to be a 
gene- and mutation-dependent process (Danckwardt et al., 2008).  
 
With the techniques of cDNA synthesis and sequencing, and Western blotting, the presence 
of mutated transcript and protein in the pancreatic tissue was established before conducting 
electrophysiological experiments in the HEK293 cells transfected with the Kir6.2 mutants.  
 
The significantly reduced KATP current under the heterozygous expression conditions of 
p.*391Rext*94 Kir6.2 mutant as compared to wild type KATP channels suggest dominant 
negative effect of the mutant. However the reduced KATP current under the heterozygous 
expression conditions could be due to haploinsufficiency. 
 
Dominantly inherited KATP mutant subunits usually traffic normally to the plasma membrane. 
Pinney et al studied the surface expression and functional properties of 14 KATP channel 
mutants (ABCC8 – 11; KCNJ11 – 3) in COSm6 cells using immunofluorescence staining and 
quantitative chemiluminescence assay (Pinney et al., 2008). The authors observed that the 
surface expression of the various KATP channel mutants varied between 64.7 ± 12.9 % to 
126.7 ± 7.5% relative to the WT KATP channel expression. A number of mutants studied by 
the authors (E1507K, I1512T, and R1539E) were located very near to the location of 
T1516M mutant studied in this thesis, suggesting that the trafficking of T1516M mutant to 
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the plasma membrane surface would be unaffected. However the surface expression of 
T1516M mutant was not studied in this thesis.  
 
Huopio et al described the first dominantly inherited SUR1 mutation, E1506K, which caused 
CHI (Huopio et al., 2000). However, the authors used a different numbering system and 
according to the 1582 amino acid transcript (NM_000352.3), this mutation actually is 
E1507K. To avoid confusion, the E1506K mutation will be referred as E1507K from here 
onwards.  The authors studied the function of the mutant by two-electrode voltage-clamp 
studies in the oocytes of Xenopus laevis. They noticed that although metabolic poisoning 
induced little effect on the currents recorded from oocytes injected with Kir6.2/SUR1-
E1507K, subsequent addition of diazoxide activated currents that were blocked by 
tolbutamide. These results indicated that SUR1-E1507K subunits were capable of forming 
functional KATP channels with Kir6.2.  The authors also observed that the failure of 
Kir6.2/SUR1-E1507K channels to respond to metabolic inhibition was not a consequence of 
an altered ATP sensitivity, but possibly due to lack of MgADP activation.  
 
When Huopio et al coexpressed Kir6.2 with a 1:1 mixture of wild type and mutant SUR1 
subunits, they observed that the amplitude of KATP currents activated by metabolic inhibition 
in oocytes expressing Kir6.2 and a 1:1 mixture of wild type and mutant SUR1 was 
approximately half that found for oocytes expressing wild type Kir6.2/SUR1 channels 
(Huopio et al., 2000). The authors did not perform statistical analysis to look whether the 
difference in the KATP current between wild type Kir6.2/SUR1 channels and those channels 
with Kir6.2 and 1:1 mixture of wild type and mutant SUR1 subunits was statistically 
significant. They concluded that E1507K mutation does not have a dominant negative effect.  
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Thornton et al functionally characterized a trinucleotide deletion in SUR1 exon 34 
(delSer1387) (Thornton et al., 2003). The authors reconstituted mutant SUR1 subunits with 
wild type Kir6.2 to form mutant KATP channels in COSm6 cells. By photolabeling the cells 
with a high affinity sulfonylurea ligand [125I]azido-glibenclamide and surface 
immunofluorescence studies, the authors demonstrated that delSer1387 SUR1 mutant KATP 
channels trafficked normally to the plasma membrane, similar to wild-type. On 
glibenclamide-inhibitable [86Rb+] efflux studies, no rubidium efflux was noticed in response 
to metabolic inhibition and in the presence of diazoxide, indicating that the mutant KATP 
channels were non-functional.  
 
However expression studies with equimolar mixtures of wild type and delSer1387 SUR1 
resulted in rubidium efflux similar to control. The authors commented that the mechanism of 
hyperinsulinism associated with heterozygosity for the delSer1387 mutation remains 
speculative. It might be due to reduction in the number of active KATP channels to a point that 
the plasma membrane is partly, but not completely depolarized. Patients with heterozygous 
SUR1 mutants that traffic normally to the plasma membrane would be predicted to have only 
1/16 the normal number of channels, as compared to ½ expected with mutations that result in 
defective trafficking to the plasma membrane surface. Significantly less number of normal 
KATP channels in dominantly acting mutations could result in partial depolarization of the β-
cell plasma membrane. However what is puzzling is that when the heterozygous conditions 
are simulated in vitro by using equimolar mixture of wild type and mutant subunits, the KATP 
current observed is equivalent to wild type KATP channels.  
Recently, the same group from Philadelphia reported 13 different dominant SUR1 mutations 
causing diazoxide-unresponsive CHI in 15 families (Macmullen et al., 2011). Twelve of the 
13 mutations were novel. Expression of mutations in COSm6 cells revealed normal 
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trafficking of channels but severely impaired responses to diazoxide or MgADP. Of these 13 
mutations studied, they reported results under simulated heterozygous conditions for only 
S1387Y mutant. The MgADP response and diazoxide response (calculated as the current in 
K-INT solution plus 0.1mmol/L ATP, 0.5mmol/L ADP or 0.2mmol/L diazoxide, and 1 
mmol/L free Mg2+ relative to that in plain K-INT solution) was approximately 10 and 25% 
respectively. The difference between homozygous and heterozygous expression was not as 
pronounced as one would expect from only 1/16th normal number of channels in dominant 
acting SUR1 mutations. The authors mentioned that their previous speculation of “spare 
normal channels” is not sufficient in light of their data. Other non-genetic factors such as 
chance exposure to fasting stress or protein meals, or possibly epigenetic modifiers might 
play a role.  
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7.7	  CONCLUSIONS	  
 
Under homozygous expression, both the KATP mutants (p.T1516M SUR1 and p.*391Rext*94 
Kir6.2) studied in this thesis were disease causing mutants. Under heterozygous expression 
conditions, wild type SUR1 subunits were able to rescue the function of p.T1516M SUR1 
subunits, and generate KATP current equivalent to wild type KATP channels. These results are 
partly consistent with the clinical phenotype of transient HH with heterozygous p.T1516M 
SUR1 mutation. However, it is unclear how in the first few weeks, heterozygous p.T1516M 
mutation resulted in reduced KATP current in the pancreatic β-cell to cause HH. There is likely 
to be involvement of other genetic (epigenetic modifiers) or non-genetic factors.  
 
The p.*391Rext*94 Kir 6.2 mutant, under heterozygous expression, displayed significantly 
reduced KATP current as compared to wild-type KATP channels. These results are in keeping 
with the phenotype of diazoxide-responsive HH in the patient. However, this patient earlier 
was diazoxide-unresponsive and had a focal HH on 18F DOPA PET scan, which was removed 
surgically and confirmed histologically and by microsatellite markers analysis. The focal 
lesion would have the p.*391Rext*94 Kir6.2 mutation in a homozygous state due to loss of 
the normal maternal allele. The KATP currents measured under homozygous p.*391Rext*94 
Kir6.2 mutant expression is indicative of the state of the pancreatic β-cells in the focal lesion. 
As no KATP currents were present under homozygous p.*391Rext*94 Kir6.2 mutant 
expression, not surprisingly the patient was diazoxide-unresponsive before the focal lesion 
was removed. To summarize, the clinical phenotype and whole-cell patch clamping data 
suggest p.*391Rext*94 Kir6.2 mutation to be both recessive and dominant acting KATP 
channel mutation.  
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CHAPTER 8 
 
 
 
GENERAL DISCUSSION 
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8.1	  GENERAL	  DISCUSSION	  
 
Hyperinsulinaemic hypoglycaemia (HH) is the most common cause of persistent and severe 
hypoglycaemia in neonates, infants and children (Aynsley-Green et al., 2000). Mutations in 
nine different key genes involved in insulin secretion have been found as a cause of HH 
(Arya et al., 2014). Mutations in ABCC8 and KCNJ11 account for the majority of the cases in 
which genetic aetiology is identified (Kapoor et al., 2013, Snider et al., 2013). ABCC8 and 
KCNJ11 encode SUR1 and Kir6.2 subunits of ATP-sensitive potassium channel (KATP 
channel) respectively, which are present on the surface of pancreatic β-cells. KATP channels 
play an important role in regulating insulin secretion from pancreatic β-cells.  
 
Diazoxide, a KATP channel agonist, is the first line of treatment for HH (Aynsley-Green et al., 
2000).  Based on responsiveness to diazoxide, HH can be classified into two broad groups – 
diazoxide-responsive HH and diazoxide-unresponsive HH. Mutations in KATP channel genes 
(ABCC8 and KCNJ11) are identified in >90% of diazoxide-unresponsive HH (Kapoor et al., 
2013, Snider et al., 2013). However, the underlying genetic aetiology is not identified in the 
majority of diazoxide-responsive HH (Kapoor et al., 2013, Snider et al., 2013). Both 
recessive and dominant acting KATP channel mutations have been described.  
 
Histologically, there are two types of HH – diffuse and focal. In diffuse HH, the islets 
throughout the pancreas are enlarged and contain distinctly hypertrophied insulin producing 
β-cells. In focal HH, there is focal nodular hyperplasia of islet-like cell clusters, including 
ductuloinsular complexes and giant β-cell nuclei surrounded by a histologically and 
functionally normal pancreatic tissue. These two types have different underlying genetic 
mechanisms (Kapoor et al., 2009c).  
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Mutations in GLUD1 and HADH are characterized by a unique clinical phenotype of protein 
sensitive HH (Kapoor et al., 2009b, Palladino and Stanley, 2010). Serum ammonia is mildly 
elevated in GLUD1 mutations, whereas HADH mutations are characterized by abnormal 
plasma acylcarnitine profile and urine amino acid analysis (Clayton et al., 2001).  
 
In a cohort of more than 300 congenital HH patients enrolled under Professor Khalid Hussain 
at Great Ormond Street Hospital, genetic aetiology was identified in only 47.6% of the 
patients (Kapoor et al., 2013). This cohort included patients with complex phenotypes such as 
protein sensitive HH with normal serum ammonia, HH with cardiac arrhythmias, and siblings 
from consanguineous and non-consanguineous families with unidentified genetic aetiology. 
A selection of these patients was studied by whole-exome sequencing.  
 
Whole-exome sequencing is a new and powerful technique to identify genetic basis of a 
disease (Bamshad et al., 2011). It involves sequencing of the protein coding regions of the 
genome.  Whole-exome sequencing has successfully identified the causal alleles for several 
Mendelian disorders (Bilguvar et al., 2010, Johnson et al., 2010, Walsh et al., 2010).  
 
Whole-exome sequencing identified two potential disease-causing variants in a family with 
HH and cardiac arrhythmias. Whole-exome sequencing was performed on two affected 
members of this family (proband and her mother). Filtering whole-exome sequence data for 
novelty against polymorphisms available in public databases (dbSNP, 1000 Genome Project, 
and Exome Variant Server) identified 19 heterozygous potential disease-causing variants. 
Based on the biological information available about these genes in the literature, two variants 
(p.F108del K2P17 and p.A422V Kv6.2) were strong candidates for the disease phenotype.  
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Whole-exome sequencing in the other families (protein sensitive HH with normal serum 
ammonia and families with two affected siblings) did not identify any variants in the genes 
after filtering, which could be considered strong candidates based on the biological 
information about them in the literature. This could either be due to a number of reasons. 
Firstly, the capture method used in the project could only capture approximately 80% of the 
target region and it is possible that the disease-causing variant was hence not sequenced. 
Secondly, may be the disease-causing variant was eliminated due to the contamination of 
pathogenic alleles in the public SNP databases (Bamshad et al., 2011). Last but not the least, 
clinical and locus heterogeneity may have accounted for the absence of potential disease-
causing variants in the other families (Kapoor et al., 2012).  
 
The K2P17 (two-pore potassium channel subtype 17) is a K2P family member and dimerize to 
form K2P17 channels (Enyedi and Czirjak, 2010). These channels are responsible for the 
cellular resting membrane potential and are sensitive to alkaline pH (Enyedi and Czirjak, 
2010, Girard et al., 2001, Decher et al., 2001). Previous studies have established strong 
expression of K2P17 in human heart and pancreas (Decher et al., 2001, Girard et al., 2001). In 
heterologous system, p.F108del K2P17 mutant channels (in homozygous as well as 
heterozygous expression) generated significantly less current as compared to wild type K2P17 
channels. Hence heterozygous p.F108del K2P17 mutant channels could result in unstable 
resting membrane potential in the pancreatic β-cells and heart, and contribute/account for the 
clinical phenotype of HH and cardiac arrhythmias.  
 
Kv6.2 subunit belongs to the modifier/silencer group of the voltage-gated potassium channels, 
which are tetramers arranged as a ring around a pore (Gutman et al., 2005).  These subunits 
do not form homotetramers but form heterotetramers with Kvα2 (Kv2.1 or Kv2.2) family 
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members to form conductive channels (Zhu et al., 1999). The expression in heart and 
pancreas of human Kv6.2 is well established (Yan et al., 2004, Zhu et al., 1999). Yan et al. 
also demonstrated the colocalisation of Kv6.2 with insulin containing cells in the human 
pancreatic sections.  
 
Kv2.1 homotetrameric channels account for the delayed rectifier potassium current seen in 
βTC3-neo (transgenically derived insulinoma) cells, HIT-T15 cells and β-cells purified from 
rodent pancreatic islets of Langerhans (Roe et al., 1996, MacDonald et al., 2001). As Kv6.2 
subunit is expressed in the heart and pancreas and can form channels with Kv2.1 subunits, it 
is plausible that Kv2.1/Kv6.2 heterotetrameric channels account for the delayed rectifier 
potassium current as well (Zhu et al., 1999, Yan et al., 2004).  Inhibition of delayed rectifier 
potassium current resulted in increased glucose-induced insulin secretion in the insulinoma 
cells (MacDonald et al., 2001, Roe et al., 1996). Overexpression of delayed rectifier 
potassium current in transgenic islets and βTC3 insulinoma cells correlated with 
hypoinsulinaemia and hyperglycaemia (Philipson et al., 1994). The β-cells isolated from 
Kv2.1-/- mice have reduced Kv currents and Kv2.1-/- mice show a phenotype of reduced fasting 
blood glucose and elevated serum insulin as compared to control animals (Jacobson et al., 
2007).  
 
In this study, Kv2.1/p.A422V Kv6.2 mutant heterotetrameric channels generated significantly 
reduced Kv currents as compared to Kv2.1/wild type Kv6.2 heterotetrameric channels. This 
reduction in Kv current due to p.A422V Kv6.2 mutation is expected to result in increased 
glucose-induced insulin secretion from pancreatic β-cells, similar to as was observed by 
inhibition of Kv delayed rectifier current by TEA in HIT-T15 and rat islet cells (Roe et al., 
1996, MacDonald et al., 2001).  
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In addition to identification of novel genetic mechanisms for congenital HH by whole-exome 
sequencing of patients with unidentified genetic aetiology, two KATP channel mutations 
associated with a unique clinical phenotype were molecularly characterized. The p.T1516M 
SUR1 heterozygous mutation was associated with transient HH in two cousins, whereas 
p.*391Rext*94 Kir6.2 heterozygous mutation was associated with a combined diffuse and 
focal HH phenotype.  
 
When p.T1516M SUR1 mutant was expressed in homozygous conditions with wild type 
Kir6.2 in HEK293 cell line, no KATP currents were recorded, indicating that the p.T1516M 
SUR1 mutation was a pathogenic mutation. However under heterozygous expression 
conditions, KATP currents equivalent to wild type KATP channels were recorded. This 
indicated that either the wild type SUR1 subunits were able to rescue the function of 
p.T1516M SUR1 mutant subunits or the KATP channels in simulated heterozygous conditions 
were formed only by wild type SUR1 subunits. However for KATP channels to be formed only 
of wild type SUR1 subunits, mutant p.T1516M subunits would need to be retained in the 
endoplasmic reticulum. Whereas, dominant KATP mutations studied so far have been reported 
to traffic to the plasma membrane normally (Pinney et al., 2008, Thornton et al., 2003, 
Macmullen et al., 2011). The trafficking of p.T1516M mutation was not studied in this thesis.  
 
Under simulated heterozygous conditions for dominant acting KATP mutations previously 
reported, authors have found results similar to control. Expression studies with equimolar 
mixtures of wild type and delSer1387 SUR1 mutant resulted in rubidium efflux similar to 
control (Thornton et al., 2003).  
 
 252 
 
Based on these results, it is difficult to explain HH with heterozygous p.T1516M SUR1 
mutation in the first few weeks of life. It has been suggested that non-genetic factors such as 
chance exposure to fasting or possibly epigenetic modifiers play a role (Macmullen et al., 
2011, Pinney et al., 2008). Possibly, high KATP currents are required in the newborn period to 
suppress insulin secretion from pancreatic β-cells. A small reduction in KATP current as seen 
in heterozygous p.T1516 SUR1 mutation might be enough to cause HH in the neonatal 
period. 
 
When p.*391Rext*94 Kir6.2 mutant was expressed in homozygous conditions with wild type 
SUR1 in HEK293 cell line, no KATP currents were recorded, indicating that the 
p.*391Rext*94 Kir6.2 mutation was a pathogenic mutation. Under heterozygous expression 
conditions, significantly less KATP current was recorded with wild type SUR1/ 
p.*391Rext*94 Kir6.2 mutant channels as compared to wild type KATP channels. The 
reduction in KATP current is likely to be due to dominant negative effect of p.*391Rext*94 
Kir6.2 mutant rather than haploinsufficiency as the Western blotting and cDNA sequencing 
from the pancreatic tissue of the patient with  p.*391Rext*94 Kir6.2 mutation showed the 
presence of the protein and transcript from both alleles. These results correlate well with the 
patient’s phenotype of combined diazoxide-unresponsive focal and diazoxide-responsive 
diffuse HH.  
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8.2	  CONCLUSIONS	  
 
In this project, a novel molecular mechanism of HH and cardiac arrhythmia phenotype was 
identified. Whole-exome sequencing identified two strong causative variants in a family with 
a phenotype of HH and cardiac arrhythmia. Electrophysiological analysis of the variants 
(p.F108del K2P17 and p.A422V Kv6.2) proved both to be pathogenic in heterozygous 
expression. Strong expression of both the genes has previously been shown in pancreas and 
heart.  
 
K2P17 contribute to the cellular resting membrane potential, whereas Kv6.2 in combination 
with Kv2.1 subunits form heterotetrameric voltage gated potassium channels responsible for 
delayed rectifier repolarizing potassium currents. Inactivating mutations in K2P17 and Kv6.2 
are likely to result in increased glucose-induced insulin secretion (HH) and cardiac 
arrhythmias. Screening of more patients with the described phenotype is needed. 
 
In this project, the molecular basis of a transient type of HH and a novel combined phenotype 
of focal and diffuse HH was also identified. The heterozygous SUR1 (p.T1516M) mutation 
was associated with transient HH, whereas Kir6.2 (p.*391Rext*94) mutation was associated 
with combined diffuse and focal HH phenotype. The p.*391Rext*94 Kir6.2 mutation was a 
non-stop mutation. The transcripts containing non-stop mutations are at risk of non-stop 
mRNA decay. Analysis of pancreatic tissue from the patient by cDNA sequencing and 
Western blotting established presence of transcript and protein with non-stop mutation. 
Electrophysiological analysis of p.T1516M SUR1 and p.*391Rext*94 Kir6.2 mutants was 
indicative of pathogenic nature of the mutation.  
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8.3 FUTURE	  WORK	  
 
Based on the results from this project, Sanger sequencing KCNG2 and KCNK17 in more 
patients with similar phenotype (HH and cardiac arrhythmias) is planned to establish the 
causality. Expressing the WT and mutant KCNG2 and KCNK17 in an insulin-producing cell 
line and studying the resultant effect on basal as well as glucose-induced insulin release 
would be another strategy to clarify the potential role of KCNG2 and KCNK17 in insulin 
release.  
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Human and Hamster ABCC8 Alignment 
 
 
humanAbcc8        CGGGGCCCGGGGGGCGGGGGCCTGACGGCCGGGCCGGGCGGCGGAGCTGCAAGGGACAGA 60 
hamsterabcc8      ------------------------------------------------------------ 
                                                                               
 
humanAbcc8        GGCGCGGCAGGCGCGCGGAGCCAGCGGAGCCAGCTGAGCCCGAGCCCAGCCCGCGCCCGC 120 
hamsterabcc8      ------------------------------------------------------------ 
                                                                               
 
humanAbcc8        GCCGCCATGCCCCTGGCCTTCTGCGGCAGCGAGAACCACTCGGCCGCCTACCGGGTGGAC 180 
hamsterabcc8      ------ATGCCCTTGGCCTTCTGCGGTACCGAGAACCACTCGGCCGCCTACCGGGTGGAC 54 
                        ****** ************* * ******************************* 
 
humanAbcc8        CAGGGGGTCCTCAACAACGGCTGCTTTGTGGACGCGCTCAACGTGGTGCCGCACGTCTTC 240 
hamsterabcc8      CAGGGCGTCCTCAACAACGGCTGCTTCGTGGACGCGCTCAACGTGGTGCCGCACGTTTTC 114 
                  ***** ******************** ***************************** *** 
 
humanAbcc8        CTACTCTTCATCACCTTCCCCATCCTCTTCATTGGATGGGGAAGTCAGAGCTCCAAGGTG 300 
hamsterabcc8      CTGCTCTTCATCACCTTCCCCATCCTCTTCATCGGATGGGGCAGCCAGAGCTCCAAGGTG 174 
                  ** ***************************** ******** ** *************** 
 
humanAbcc8        CACATCCACCACAGCACATGGCTTCATTTCCCTGGGCACAACCTGCGGTGGATCCTGACC 360 
hamsterabcc8      CACATCCACCACAGCACCTGGCTGCACTTTCCAGGGCACAACCTGCGCTGGATCCTTACC 234 
                  ***************** ***** ** ** ** ************** ******** *** 
 
humanAbcc8        TTCATGCTGCTCTTCGTCCTGGTGTGTGAGATTGCAGAGGGCATCCTGTCTGATGGGGTG 420 
hamsterabcc8      TTCATTTTGCTCTTCGTCCTTGTGTGTGAGATCGCTGAGGGCATCCTGTCTGATGGGGTG 294 
                  *****  ************* *********** ** ************************ 
 
humanAbcc8        ACCGAATCCCACCATCTGCACCTGTACATGCCAGCCGGGATGGCGTTCATGGCTGCTGTC 480 
hamsterabcc8      ACAGAATCCCGCCACCTCCACCTGTACATGCCAGCCGGGATGGCGTTCATGGCTGCCATC 354 
                  ** ******* *** ** **************************************  ** 
 
humanAbcc8        ACCTCCGTGGTCTACTATCACAACATCGAGACTTCCAACTTCCCCAAGCTGCTAATTGCC 540 
hamsterabcc8      ACCTCTGTAGTCTACTATCATAACATCGAGACCTCCAACTTCCCCAAGCTTTTGATCGCT 414 
                  ***** ** *********** *********** *****************  * ** **  
 
humanAbcc8        CTGCTGGTGTATTGGACCCTGGCCTTCATCACCAAGACCATCAAGTTTGTCAAGTTCTTG 600 
hamsterabcc8      CTGCTCATCTATTGGACCCTGGCCTTCATCACGAAGACCATCAAGTTTGTCAAGTTCTAT 474 
                  *****  * *********************** *************************   
 
humanAbcc8        GACCACGCCATCGGCTTCTCGCAGCTACGCTTCTGCCTCACAGGGCTGCTGGTGATCCTC 660 
hamsterabcc8      GACCACGCCATCGGCTTCTCCCAGCTGCGCTTCTGCCTCACGGGGCTTCTGGTGATCCTG 534 
                  ******************** ***** ************** ***** ***********  
 
humanAbcc8        TATGGGATGCTGCTCCTCGTGGAGGTCAATGTCATCAGGGTGAGGAGATACATCTTCTTC 720 
hamsterabcc8      TATGGGATGTTGCTGCTTGTGGAGGTCAACGTCATCAGAGTGAGGAGGTACATCTTCTTC 594 
                  ********* **** ** *********** ******** ******** ************ 
 
humanAbcc8        AAGACACCGAGGGAGGTGAAGCCTCCCGAGGACCTGCAAGACCTGGGGGTACGCTTCCTG 780 
hamsterabcc8      AAGACGCCACGGGAGGTGAAGCCCCCTGAGGACCTGCAGGACCTGGGTGTGCGCTTTCTG 654 
                  ***** **  ************* ** *********** ******** ** ***** *** 
 
humanAbcc8        CAGCCCTTCGTGAATCTGCTGTCCAAAGGCACCTACTGGTGGATGAACGCCTTCATCAAG 840 
hamsterabcc8      CAGCCCTTCGTTAACCTGCTGTCAAAGGGGACCTATTGGTGGATGAATGCCTTCATCAAG 714 
                  *********** ** ******** ** ** ***** *********** ************ 
 
humanAbcc8        ACTGCCCACAAGAAGCCCATCGACTTGCGAGCCATCGGGAAGCTGCCCATCGCCATGAGG 900 
hamsterabcc8      ACGGCCCACAAGAAGCCCATCGACCTGCGGGCCATCGCGAAGCTGCCCATCGCCATGAGA 774 
                  ** ********************* **** ******* *********************  
 
 
humanAbcc8        GCCCTCACCAACTACCAACGGCTCTGCGAGGCCTTTGACGCCCAGGTGCGGAAGGACATT 960 
hamsterabcc8      GCCCTCACCAACTATCAGCGCCTCTGCGTGGCCTTCGATGCTCAGGCGCGGAAGGACACA 834 
                  ************** ** ** ******* ****** ** ** **** ***********   
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humanAbcc8        CAGGGCACTCAAGGTGCCCGGGCCATCTGGCAGGCACTCAGCCATGCCTTCGGGAGGCGC 1020 
hamsterabcc8      CAGAGCCCACAGGGTGCCCGGGCCATCTGGAGGGCTCTATGCCATGCCTTTGGGAGACGC 894 
                  *** ** * ** ******************  *** **  ********** ***** *** 
 
humanAbcc8        CTGGTCCTCAGCAGCACTTTCCGCATCTTGGCCGACCTGCTGGGCTTCGCCGGGCCACTG 1080 
hamsterabcc8      CTGATCCTCAGCAGCACATTCCGCATCCTGGCTGACCTGTTGGGCTTCGCTGGACCACTC 954 
                  *** ************* ********* **** ****** ********** ** *****  
 
humanAbcc8        TGCATCTTTGGGATCGTGGACCACCTTGGGAAGGAGAACGACGTCTTCCAGCCCAAGACA 1140 
hamsterabcc8      TGCATCTTTGGGATCGTGGACCACCTGGGGAAGGAGAACCACGTCTTCCAGCCCAAGACA 1014 
                  ************************** ************ ******************** 
 
humanAbcc8        CAATTTCTCGGGGTTTACTTTGTCTCATCCCAAGAGTTCCTTGCCAATGCCTACGTCTTA 1200 
hamsterabcc8      CAGTTTCTCGGGGTTTACTTCGTCTCTTCTCAAGAGTTCCTTGGCAATGCCTACGTCTTG 1074 
                  ** ***************** ***** ** ************* ***************  
 
humanAbcc8        GCTGTGCTTCTGTTCCTTGCCCTCCTACTGCAAAGGACATTTCTGCAAGCATCCTACTAT 1260 
hamsterabcc8      GCCGTGCTTCTGTTCCTTGCCCTGCTACTGCAAAGGACATTCCTGCAAGCCTCATACTAC 1134 
                  ** ******************** ***************** ******** ** *****  
 
humanAbcc8        GTGGCCATTGAAACTGGAATTAACTTGAGAGGAGCAATACAGACCAAGATTTACAATAAA 1320 
hamsterabcc8      GTCGCCATTGAAACTGGAATTAACCTGAGAGGAGCAATCCAGACCAAGATTTACAATAAA 1194 
                  ** ********************* ************* ********************* 
 
humanAbcc8        ATTATGCACCTGTCCACCTCCAACCTGTCCATGGGAGAAATGACTGCTGGACAGATCTGT 1380 
hamsterabcc8      ATCATGCACATGTCCACCTCCAACCTGTCAATGGGGGAAATGACTGCTGGGCAGATCTGC 1254 
                  ** ****** ******************* ***** ************** ********  
 
humanAbcc8        AATCTGGTTGCCATCGACACCAATCAGCTCATGTGGTTTTTCTTCTTGTGCCCAAACCTC 1440 
hamsterabcc8      AACCTGGTGGCCATCGACACAAACCAGCTCATGTGGTTCTTCTTTCTGTGCCCAAACCTC 1314 
                  ** ***** *********** ** ************** *****  ************** 
 
humanAbcc8        TGGGCTATGCCAGTACAGATCATTGTGGGTGTGATTCTCCTCTACTACATACTCGGAGTC 1500 
hamsterabcc8      TGGACGATGCCAGTACAGATCATTGTGGGCGTGATCCTTCTCTACTACATCCTTGGGGTC 1374 
                  *** * *********************** ***** ** *********** ** ** *** 
 
humanAbcc8        AGTGCCTTAATTGGAGCAGCTGTCATCATTCTACTGGCTCCTGTCCAGTACTTCGTGGCC 1560 
hamsterabcc8      AGTGCCTTGATTGGAGCAGCTGTCATCATTCTGCTGGCTCCTGTACAGTACTTTGTGGCC 1434 
                  ******** *********************** *********** ******** ****** 
 
humanAbcc8        ACCAAGCTGTCTCAGGCCCAGCGGAGCACACTGGAGTATTCCAATGAGCGGCTGAAGCAG 1620 
hamsterabcc8      ACCAAGCTCTCCCAGGCACAGCGGACGACCTTGGAGCACTCCAACGAGAGGCTGAAGCAG 1494 
                  ******** ** ***** *******  **  ***** * ***** *** *********** 
 
humanAbcc8        ACCAACGAGATGCTCCGCGGCATCAAGCTGCTGAAGCTGTACGCCTGGGAGAACATCTTC 1680 
hamsterabcc8      ACCAACGAGATGCTCCGGGGCATGAAGCTGCTCAAACTGTATGCGTGGGAGAGCATCTTC 1554 
                  ***************** ***** ******** ** ***** ** ******* ******* 
 
humanAbcc8        CGCACGCGGGTGGAGACGACCCGCAGGAAGGAGATGACCAGCCTCAGGGCCTTTGCCATC 1740 
hamsterabcc8      TGCTCCAGGGTGGAGGTGACTCGCAGGAAGGAGATGACCAGCCTGAGGGCGTTTGCTGTC 1614 
                   ** *  ********  *** *********************** ***** *****  ** 
 
humanAbcc8        TATACCTCCATCTCCATTTTCATGAACACGGCCATCCCCATTGCAGCTGTCCTCATAACT 1800 
hamsterabcc8      TACACTTCCATCTCCATCTTCATGAACACAGCCATCCCCATTGCTGCCGTCCTCATCACC 1674 
                  ** ** *********** *********** ************** ** ******** **  
 
humanAbcc8        TTCGTGGGCCACGTCAGCTTCTTCAAAGAGGCCGACTTCTCGCCCTCCGTGGCCTTTGCC 1860 
hamsterabcc8      TTCGTGGGCCACGTCAGCTTCTTCAAAGAGTCGGACTTGTCACCCTCGGTGGCCTTTGCC 1734 
                  ****************************** * ***** ** ***** ************ 
 
humanAbcc8        TCCCTCTCCCTCTTCCATATCTTGGTCACACCGCTGTTCCTGCTGTCCAGTGTGGTCCGA 1920 
hamsterabcc8      TCCCTCTCTCTCTTCCACATCCTGGTCACTCCACTGTTCCTGCTGTCTAGCGTGGTTCGG 1794 
                  ******** ******** *** ******* ** ************** ** ***** **  
 
humanAbcc8        TCTACCGTCAAAGCTCTAGTGAGCGTGCAAAAGCTAAGCGAGTTCCTGTCCAGTGCAGAG 1980 
hamsterabcc8      TCCACTGTCAAAGCCCTGGTGAGCGTGCAAAAACTGAGCGAGTTCCTGTCTAGTGCAGAG 1854 
                  ** ** ******** ** ************** ** ************** ********* 
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humanAbcc8        ATCCGTGAGGAGCAGTGTGCCCCCCATGAGCCCACACCTCAGGGCCCAGCCAGCAAGTAC 2040 
hamsterabcc8      ATCCGTGAGGAGCAGTGTGCCCCCCGAGAGCCTGCACCCCAAGGCCAAGCCGGCAAGTAC 1914 
                  *************************  *****  **** ** **** **** ******** 
 
humanAbcc8        CAGGCGGTGCCCCTCAGGGTTGTGAACCGCAAGCGTCCAGCCCGGGAGGATTGTCGGGGC 2100 
hamsterabcc8      CAGGCAGTGCCCCTCAAGGTTGTGAACCGCAAACGCCCAGCCCGGGAAGAGGTCCGGGAC 1974 
                  ***** ********** *************** ** *********** **    **** * 
 
humanAbcc8        CTCACCGGCCCACTGCAGAGCCTGGTCCCCAGTGCAGATGGCGATGCTGACAACTGCTGT 2160 
hamsterabcc8      CTCCTGGGCCCACTGCAGAGGCTGGCCCCTAGCATGGACGGGGATGCTGACAACTTCTGT 2034 
                  ***   ************** **** *** **    ** ** ************* **** 
 
humanAbcc8        GTCCAGATCATGGGAGGCTACTTCACGTGGACCCCAGATGGAATCCCCACACTGTCCAAC 2220 
hamsterabcc8      GTCCAGATCATCGGAGGCTTCTTCACCTGGACCCCTGATGGAATCCCCACTCTGTCCAAC 2094 
                  *********** ******* ****** ******** ************** ********* 
 
humanAbcc8        ATCACCATTCGTATCCCCCGAGGCCAGCTGACTATGATCGTGGGGCAGGTGGGCTGCGGC 2280 
hamsterabcc8      ATCACCATCCGTATTCCCCGAGGTCAGCTAACCATGATTGTGGGGCAGGTGGGCTGCGGC 2154 
                  ******** ***** ******** ***** ** ***** ********************* 
 
humanAbcc8        AAGTCCTCGCTCCTTCTAGCCGCACTGGGGGAGATGCAGAAGGTCTCAGGGGCTGTCTTC 2340 
hamsterabcc8      AAGTCCTCGCTCCTCCTCGCCACCCTGGGGGAGATGCAGAAGGTGTCGGGGGCCGTCTTC 2214 
                  ************** ** *** * ******************** ** ***** ****** 
 
humanAbcc8        TGGAGCAGC---CTTCCTGACAGCGAGATAGGAGAGGACCCCAGCCCAGAGCGGGAGACA 2397 
hamsterabcc8      TGGAACAGCAACCTTCCGGACAGCGAGGGAGAGGACCCCAGCAGCCCAGAGCGGGAGACA 2274 
                  **** ****   ***** *********  **  **   *  ******************* 
 
humanAbcc8        GCGACCGACTTGGATATCAGGAAGAGAGGCCCCGTGGCCTATGCTTCGCAGAAACCATGG 2457 
hamsterabcc8      GCAGCTGGCTCGGATATCAGGAGCAGAGGCCCCGTGGCCTACGCATCTCAGAAACCATGG 2334 
                  **  * * ** ***********  ***************** ** ** ************ 
 
humanAbcc8        CTGCTAAATGCCACTGTGGAGGAGAACATCATCTTTGAGAGTCCCTTCAACAAACAACGG 2517 
hamsterabcc8      CTGCTAAACGCCACCGTGGAAGAGAACATCACCTTCGAGAGTCCCTTCAATAAGCAGCGG 2394 
                  ******** ***** ***** ********** *** ************** ** ** *** 
 
humanAbcc8        TACAAGATGGTCATTGAAGCCTGCTCTCTGCAGCCAGACATCGACATCCTGCCCCATGGA 2577 
hamsterabcc8      TACAAGATGGTCATCGAAGCCTGCTCCCTGCAGCCGGACATAGACATCCTGCCCCACGGA 2454 
                  ************** *********** ******** ***** ************** *** 
 
humanAbcc8        GACCAGACCCAGATTGGGGAACGGGGCATCAACCTGTCTGGTGGTCAACGCCAGCGAATC 2637 
hamsterabcc8      GACCAGACTCAGATTGGGGAACGGGGCATCAACCTGTCTGGTGGTCAGCGTCAGCGTATC 2514 
                  ******** ************************************** ** ***** *** 
 
humanAbcc8        AGTGTGGCCCGAGCCCTCTACCAGCACGCCAACGTTGTCTTCTTGGATGACCCCTTCTCA 2697 
hamsterabcc8      AGTGTGGCCAGAGCCCTCTACCAGCAGACCAATGTCGTCTTCTTGGATGACCCCTTCTCA 2574 
                  ********* ****************  **** ** ************************ 
 
humanAbcc8        GCTCTGGATATCCATCTGAGTGACCACTTAATGCAGGCCGGCATCCTTGAGCTGCTCCGG 2757 
hamsterabcc8      GCTTTGGATGTCCATCTGAGTGACCACCTGATGCAGGCCGGCATCCTTGAGCTGCTCCGG 2634 
                  *** ***** ***************** * ****************************** 
 
humanAbcc8        GACGACAAGAGGACAGTGGTCTTAGTGACCCACAAGCTACAGTACCTGCCCCATGCAGAC 2817 
hamsterabcc8      GATGACAAGAGGACAGTGGTCTTGGTGACCCACAAGCTACAGTATCTGCCTCATGCAGAC 2694 
                  ** ******************** ******************** ***** ********* 
 
 
humanAbcc8        TGGATCATTGCCATGAAGGATGGCACCATCCAGAGGGAGGGTACCCTCAAGGACTTCCAG 2877 
hamsterabcc8      TGGATCATTGCCATGAAGGATGGGACCATTCAGAGGGAAGGGACGCTCAAGGACTTCCAG 2754 
                  *********************** ***** ******** ** ** *************** 
 
humanAbcc8        AGGTCTGAATGCCAGCTCTTTGAGCACTGGAAGACCCTCATGAACCGACAGGACCAAGAG 2937 
hamsterabcc8      AGGTCCGAGTGCCAGCTCTTTGAGCACTGGAAGACCCTCATGAACCGGCAGGACCAAGAG 2814 
                  ***** ** ************************************** ************ 
 
humanAbcc8        CTGGAGAAGGAGACTGTCACAGAGAGAAAAGCCACAGAGCCACCCCAGGGCCTATCTCGT 2997 
hamsterabcc8      CTGGAGAAGGAGACAGTCATGGAGAGGAAAGCCTCAGAGCCATCTCAGGGCCTGCCCCGT 2874 
                  ************** ****  ***** ****** ******** * ********  * *** 
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humanAbcc8        GCCATGTCCTCGAGGGATGGCCTTCTGCAGGATGAGGAAGAGGAGGAAGAGGAGGCAGCT 3057 
hamsterabcc8      GCCATGTCCTCCAGAGACGGCCTTCTGCTGGATGAGGAAGAGGAGGAAGAGGAGGCAGCC 2934 
                  *********** ** ** ********** ******************************  
 
humanAbcc8        GAGAGCGAGGAGGATGACAACCTGTCGTCCATGCTGCACCAGCGTGCTGAGATCCCATGG 3117 
hamsterabcc8      GAAAGCGAGGAAGATGACAACTTATCTTCAGTGCTGCATCAGCGAGCTAAGATCCCCTGG 2994 
                  ** ******** ********* * ** **  ******* ***** *** ******* *** 
 
humanAbcc8        CGAGCCTGCGCCAAGTACCTGTCCTCCGCCGGCATCCTGCTCCTGTCGTTGCTGGTCTTC 3177 
hamsterabcc8      CGAGCCTGCACTAAGTATCTGTCCTCTGCTGGCATTCTGCTCCTGTCCCTGCTTGTCTTC 3054 
                  ********* * ***** ******** ** ***** ***********  **** ****** 
 
humanAbcc8        TCACAGCTGCTCAAGCACATGGTCCTGGTGGCCATCGACTACTGGCTGGCCAAGTGGACC 3237 
hamsterabcc8      TCCCAGCTGCTCAAGCACATGGTCTTGGTGGCCATTGATTATTGGCTGGCCAAGTGGACG 3114 
                  ** ********************* ********** ** ** *****************  
 
humanAbcc8        GACAGCGCCCTGACCCTGACCCCTGCAGCCAGGAACTGCTCCCTCAGCCAGGAGTGCACC 3297 
hamsterabcc8      GACAGTGCCCTGGTCCTGAGCCCCGCTGCCAGGAACTGTTCGCTCAGCCAGGAATGTGAC 3174 
                  ***** ******  ***** *** ** *********** ** *********** **   * 
 
humanAbcc8        CTCGACCAGACTGTCTATGCCATGGTGTTCACGGTGCTCTGCAGCCTGGGCATTGTGCTG 3357 
hamsterabcc8      CTGGACCAGTCTGTCTATGCCATGGTATTCACCTTGCTCTGCAGCCTGGGTATCGTGCTG 3234 
                  ** ****** **************** *****  **************** ** ****** 
 
humanAbcc8        TGCCTCGTCACGTCTGTCACTGTGGAGTGGACAGGGCTGAAGGTGGCCAAGAGACTGCAC 3417 
hamsterabcc8      TGCCTGGTCACCTCTGTCACTGTGGAGTGGACGGGACTGAAGGTGGCCAAGAGGCTACAC 3294 
                  ***** ***** ******************** ** ***************** ** *** 
 
humanAbcc8        CGCAGCCTGCTAAACCGGATCATCCTAGCCCCCATGAGGTTTTTTGAGACCACGCCCCTT 3477 
hamsterabcc8      CGCAGCCTGCTCAACCGCATCATCCTGGCCCCCATGAGGTTCTTTGAGACCACACCCCTC 3354 
                  *********** ***** ******** ************** *********** *****  
 
humanAbcc8        GGGAGCATCCTGAACAGATTTTCATCTGACTGTAACACCATCGACCAGCACATCCCATCC 3537 
hamsterabcc8      GGGAGTATCCTGAACAGATTTTCATCCGACTGTAACACCATTGACCAGCACATCCCATCC 3414 
                  ***** ******************** ************** ****************** 
 
humanAbcc8        ACGCTGGAGTGCCTGAGCCGCTCCACCCTGCTCTGTGTCTCAGCCCTGGCCGTCATCTCC 3597 
hamsterabcc8      ACGCTGGAGTGTCTGAGCCGGTCCACCCTGCTGTGTGTCTCCGCCCTGACTGTCATCTCC 3474 
                  *********** ******** *********** ******** ****** * ********* 
 
humanAbcc8        TATGTCACACCTGTGTTCCTCGTGGCCCTCTTGCCCCTGGCCATCGTGTGCTACTTCATC 3657 
hamsterabcc8      TATGTCACACCCGTGTTCCTCGTGGCCCTCTTACCCCTAGCTGTTGTGTGCTACTTCATT 3534 
                  *********** ******************** ***** **  * **************  
 
humanAbcc8        CAGAAGTACTTCCGGGTGGCGTCCAGGGACCTGCAGCAGCTGGATGACACCACCCAGCTT 3717 
hamsterabcc8      CAGAAGTACTTCCGAGTGGCATCCAGGGACCTGCAGCAGCTGGACGACACGACGCAGCTC 3594 
                  ************** ***** *********************** ***** ** *****  
 
humanAbcc8        CCACTTCTCTCACACTTTGCCGAAACCGTAGAAGGACTCACCACCATCCGGGCCTTCAGG 3777 
hamsterabcc8      CCGCTCGTCTCACACTTTGCTGAAACTGTGGAGGGACTCACCACCATCCGTGCCTTCAGG 3654 
                  ** **  ************* ***** ** ** ***************** ********* 
 
humanAbcc8        TATGAGGCCCGGTTCCAGCAGAAGCTTCTCGAATACACAGACTCCAACAACATTGCTTCC 3837 
hamsterabcc8      TACGAGGCCCGGTTCCAGCAGAAGCTTCTAGAATATACCGACTCCAACAACATCGCCTCC 3714 
                  ** ************************** ***** ** ************** ** *** 
 
humanAbcc8        CTCTTCCTCACAGCTGCCAACAGATGGCTGGAAGTCCGAATGGAGTACATCGGTGCATGT 3897 
hamsterabcc8      CTCTTCCTCACGGCAGCCAACAGATGGCTGGAAGTCTGCATGGAGTACATCGGAGCGTGC 3774 
                  *********** ** ********************* * ************** ** **  
 
humanAbcc8        GTGGTGCTCATCGCAGCGGTGACCTCCATCTCCAACTCCCTGCACAGGGAGCTCTCTGCT 3957 
hamsterabcc8      GTGGTACTCATTGCGGCTGCCACCTCCATCTCCAACTCCCTGCACAGGGAACTTTCTGCT 3834 
                  ***** ***** ** ** *  ***************************** ** ****** 
 
humanAbcc8        GGCCTGGTGGGCCTGGGCCTTACCTACGCCCTAATGGTCTCCAACTACCTCAACTGGATG 4017 
hamsterabcc8      GGCCTGGTGGGCCTGGGCCTCACCTATGCCTTGATGGTCTCCAACTACCTCAACTGGATG 3894 
                  ******************** ***** *** * *************************** 
 
 
300 
 
humanAbcc8        GTGAGGAACCTGGCAGACATGGAGCTCCAGCTGGGGGCTGTGAAGCGCATCCATGGGCTC 4077 
hamsterabcc8      GTGAGGAACCTGGCGGACATGGAGATCCAGCTGGGGGCTGTGAAGAGGATCCACGCACTC 3954 
                  ************** ********* ******************** * ***** *  *** 
 
humanAbcc8        CTGAAAACCGAGGCAGAGAGCTACGAGGGGCTCCTGGCACCATCGCTGATCCCAAAGAAC 4137 
hamsterabcc8      CTGAAAACCGAGGCGGAGAGCTATGAGGGGCTCCTGGCGCCGTCGTTGATCCCCAAGAAC 4014 
                  ************** ******** ************** ** *** ******* ****** 
 
humanAbcc8        TGGCCAGACCAAGGGAAGATCCAGATCCAGAACCTGAGCGTGCGCTACGACAGCTCCCTG 4197 
hamsterabcc8      TGGCCAGACCAAGGGAAGATCCAAATTCAGAACCTGAGCGTGCGCTATGACAGCTCCCTG 4074 
                  *********************** ** ******************** ************ 
 
humanAbcc8        AAGCCGGTGCTGAAGCACGTCAATGCCCTCATCGCCCCTGGACAGAAGATCGGGATCTGC 4257 
hamsterabcc8      AAGCCAGTGCTGAAGCATGTCAACACCCTCATCTCCCCGGGGCAGAAGATCGGGATCTGC 4134 
                  ***** *********** *****  ******** **** ** ****************** 
 
humanAbcc8        GGCCGCACCGGCAGTGGGAAGTCCTCCTTCTCTCTTGCCTTCTTCCGCATGGTGGACACG 4317 
hamsterabcc8      GGCCGCACAGGCAGCGGGAAGTCCTCCTTCTCCCTGGCCTTTTTCCGAATGGTGGACATG 4194 
                  ******** ***** ***************** ** ***** ***** ********** * 
 
humanAbcc8        TTCGAAGGGCACATCATCATTGATGGCATTGACATCGCCAAACTGCCGCTGCACACCCTG 4377 
hamsterabcc8      TTTGAAGGACGCATCATCATTGATGGCATCGACATCGCCAAGCTGCCACTTCACACGCTG 4254 
                  ** ***** * ****************** *********** ***** ** ***** *** 
 
humanAbcc8        CGCTCACGCCTCTCCATCATCCTGCAGGACCCCGTCCTCTTCAGCGGCACCATCCGATTT 4437 
hamsterabcc8      CGCTCACGCCTGTCCATCATCCTACAGGACCCCGTCCTCTTCAGCGGCACGATCAGATTC 4314 
                  *********** *********** ************************** *** ****  
 
humanAbcc8        AACCTGGACCCTGAGAGGAAGTGCTCAGATAGCACACTGTGGGAGGCCCTGGAAATCGCC 4497 
hamsterabcc8      AACCTGGACCCCGAGAAGAAATGCTCAGACAGCACACTGTGGGAGGCCCTGGAGATCGCC 4374 
                  *********** **** *** ******** *********************** ****** 
 
humanAbcc8        CAGCTGAAGCTGGTGGTGAAGGCACTGCCAGGAGGCCTCGATGCCATCATCACAGAAGGC 4557 
hamsterabcc8      CAGCTGAAGCTGGTAGTGAAGGCACTGCCAGGAGGCCTAGATGCCATCATCACAGAAGGA 4434 
                  ************** *********************** ********************  
 
humanAbcc8        GGGGAGAATTTCAGCCAGGGACAGAGGCAGCTGTTCTGCCTGGCCCGGGCCTTCGTGAGG 4617 
hamsterabcc8      GGGGAGAATTTTAGCCAGGGCCAGAGGCAGCTGTTCTGCCTGGCCCGGGCCTTCGTGAGG 4494 
                  *********** ******** *************************************** 
 
humanAbcc8        AAGACCAGCATCTTCATCATGGACGAGGCCACGGCTTCCATTGACATGGCCACGGAAAAC 4677 
hamsterabcc8      AAGACCAGCATCTTCATCATGGATGAAGCAACCGCCTCCATCGACATGGCTACGGAGAAC 4554 
                  *********************** ** ** ** ** ***** ******** ***** *** 
 
humanAbcc8        ATCCTCCAAAAGGTGGTGATGACAGCCTTCGCAGACCGCACTGTGGTCACCATCGCGCAT 4737 
hamsterabcc8      ATCCTCCAGAAGGTGGTGATGACAGCCTTCGCAGACCGCACGGTGGTCACCATCGCGCAT 4614 
                  ******** ******************************** ****************** 
 
humanAbcc8        CGAGTGCACACCATCCTGAGTGCAGACCTGGTGATCGTCCTGAAGCGGGGTGCCATCCTT 4797 
hamsterabcc8      CGTGTGCACACCATCCTGAGTGCAGACCTGGTGATGGTCCTCAAGAGGGGTGCTATCCTG 4674 
                  ** ******************************** ***** *** ******* *****  
 
humanAbcc8        GAGTTCGATAAGCCAGAGAAGCTGCTCAGCCGGAAGGACAGCGTCTTCGCCTCCTTCGTC 4857 
hamsterabcc8      GAGTTTGACAAGCCAGAGACGCTCCTCAGCCAGAAGGACAGCGTGTTCGCCTCCTTTGTC 4734 
                  ***** ** ********** *** ******* ************ *********** *** 
 
humanAbcc8        CGTGCAGACAAGTGACCTGCCAGAGCCCAAGTGCCATCCCACATTCGGACCCTGCCCATA 4917 
hamsterabcc8      CGTGCGGACAAGTGA--------------------------------------------- 4749 
                  ***** *********                                              
 
humanAbcc8        CCCCTGCCTGGGTTTTCTAACTGTAAATCACTTGTAAATAAATAGATTTGATTATTTCCT 4977 
hamsterabcc8      ------------------------------------------------------------ 
                                                                               
 
humanAbcc8        A 4978 
hamsterabcc8      - 
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Clinical, Biochemical and Genetic Mechanisms of Hyperinsulinaemic Hypoglycemia. 
 
Consultant Paediatric Endocrinologist: Dr Khalid Hussain (02079052128 or 
K.Hussain@ich.ucl.ac.uk) 
Consultant Molecular Geneticist:  Prof S. Ellard (01392-402910 or Sian.Ellard@rdeft.nhs.uk) 
 
Please contact Dr Ved Bhushan Arya, Clinical Research Fellow at the Institute of Child 
Health (07737672273, 
0207 2429789/ Extn 2864, v.arya@ucl.ac.uk) as soon as diagnosis is established. 
Please fill in as fully as possible and circle Yes/ No where appropriate. 
  
Patient details     Requestor details 
Surname..............................….. ……….  Clinician 
name................................................... 
First name(s).......................…….........  Telephone 
....................................................... 
Date of birth........................……………..  Email 
Address……………………………………………………………………  
Gender...............................…… ……….  Address for 
report............................................... 
Hospital No.........................……………… 
 ................................................................……. 
Address………………………...........………………. 
Tel No………………………………………………………..  Type of Test:    Diagnostic    
 Research     
Ethnic origin........................………………       
 
Clinical information 
Age at presentation (weeks): ......................    Duration of 
hyperinsulinism:……………………………………. 
Any suggestion of protein sensitivity (episodes of hypoglycaemia post protein rich meals): 
Yes/No/Not known 
Any syndromic features (e.g. Beckwith Weidemann Syndrome). Please give details: 
………………….. 
 
Any other medical problems? : .................................................... 
 
Neonatal History 
Birth weight (g): ………….……             Gestation (weeks): ............. 
IUGR: Yes/No                                   Perinatal Asphyxia: Yes/No 
Maternal details:  Pre-eclampsia    Yes/No 
                           Gestational diabetes  Yes/No 
                           Other significant maternal history  …………………………………………………… 
Details of Treatment 
 Current Treatment and Dose (mg/kg/d): ………………………….. 
 Responsive to current treatment? : Yes/No 
           Diazoxide responsive? Yes/No/Not tried 
            Any other medications tried? Please give details (name of drug, duration 
tried): ………………………. 
18F-DOPA/PET CT scan performed? : Yes/No 
 If yes, focal/diffuse/atypical disease: ……………………..  
Pancreatectomy performed? : Yes/No 
 If yes, focal/diffuse disease: …………………………….. 
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Family history 
Are parents related? If yes – how? : ............................   
Any family history of hypoglycaemia? : 
............................………………………………………………  
Any family history of diabetes? Please give details of affected family members (age of 
onset, treatment and duration of diabetes): 
............................……………………………………………………………………………………........…………... 
…………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………… 
(NB.  A pedigree showing clinical details of affected family members would be very 
helpful).  
 
 
 
 
 
Biochemical information 
Insulin level: ……….. (mU/l) C-peptide: ............. (pmols/l) Glucose level: ………… 
(mmol/l)  
Hyperammonaemia? : Yes/No/Not known  If Yes,ammonia level …………………………. 
Acyl Carnitine profile? : Normal/Abnormal/Not done. If abnormal, 
result?…………………………………………………………… 
…………………………………………………………………………………………………………………………………………………
…………… 
Lactate, if done : ………………………..  Pyruvate,if done : ………………………….. 
Plasma amino acids : …………………………… 
Urine organic acids result: …………………………………. 
 
Special Investigations 
 
Oral Glucose Tolerance test done? Yes/No. If yes, result……………………………………….. 
 
 
Oral Protein Loading test done? Yes/No. If yes, result…………………………………………… 
 
 
Oral Leucine Loading test done? Yes/No. If yes, result………………………………………….. 
 
 
 
Any other 
information?...............................................................................................
........... 
…………………………………………………………………………………………………………………………………………………
………………………. 
…………………………………………………………………………………………………………………………………………………
………… 
Testing required (If no boxes are ticked, testing will be performed according to the clinical 
information provided) 
SUR1 sequencing      KCNJ11 (gene encoding Kir6.2) sequencing        GCK (glucokinase) 
sequencing    
GLUD1 sequencing    LOH analysis for 11p15 (paraffin-embedded pancreatic tissue 
required + blood DNA)     
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Consent form  
 
Consent by parent or guardian for genetic testing to determine the cause of 
hypoglycemia in a child less than 16 years old  
 
Date:…………………………………………………………... 
 
Child’s full name:…………………………………………….. 
 
Date of birth:………………………………………………….. 
 
Parent or guardian’s full name:……………………………………….. 
 
 
I have given permission for a blood sample to be taken from my child to allow genetic 
testing to be performed.  I understand that this testing will be only for the purpose of 
determining the cause of hypoglycaemia in my child or a member of my family.  The 
sample will not be used for any other purpose.  The testing will be performed in the 
molecular genetic laboratory, Peninsula Medical School, Exeter UK.  
 
The details of the testing have been explained by ……………………………………. 
  
 
 
Signed ………………………………………………… 
 
Consent for genetic testing to determine the cause of hypoglycemia (patient) 
 
Date:…………………………………………………………... 
 
Name of the person:…………………………………………….. 
 
Date of birth:………………………………………………….. 
 
 
I have given a blood sample to allow genetic testing to be performed on my blood.  I 
understand that this testing will be only for the purpose of determining the cause of 
hypoglycaemia that affects myself or a member of my family.  The sample will not be used 
for any other purpose.  The testing will be performed in the molecular genetic laboratory, 
Peninsula Medical School, Exeter UK.  
 
The details of the testing have been explained by ……………………………………. 
  
 
 
Signed ………………………………………………… 
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If samples from other family members have been sent previously please give details: 
 
...............................................................................................................
...……………………………………..  
Consent for genetic testing to determine the cause of hypoglycemia (family member, if 
applicable) 
 
I have given a blood sample to allow genetic testing to be performed on my blood.  I 
understand that this testing will be only for the purpose of determining the cause of 
hypoglycaemia that affects a member of my family.  The sample will not be used for any 
other purpose.  The testing will be performed in the molecular genetic laboratory, 
Peninsula Medical School, Exeter UK.  
 
The details of the testing have been explained by ……………………………………. 
 
1) Name of the person:……………………………………… 
 
Date of birth:………………………………………………… 
 
Relationship with the patient:……………………………….. 
 
Signed …………………………Date………………………. 
 
 
2) Name of the person:……………………………………… 
 
Date of birth:………………………………………………… 
 
Relationship with the patient:………………………………. 
 
Signed …………………………Date………………………. 
 
 
3) Name of the person:……………………………………… 
 
Date of birth:………………………………………………… 
 
Relationship with the patient:………………………………. 
 
Signed …………………………Date………………………. 
 
 
4) Name of the person:……………………………………… 
 
Date of birth:………………………………………………… 
 
Relationship with the patient:………………………………. 
 
Signed …………………………Date………………………. 
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Samples taken 
The samples should be labeled with name and date of birth and can either be: 
1. Our preferred option is Blood 3-5 mls: taken in tubes containing EDTA and couriered 
fresh (not frozen). This should be sent in a package with at least two layers of wrapping 
and include absorbent material to absorb any blood that leaks out of the tube. 
2. Or made into DNA and 2-10 micrograms (to allow repeats) sent at room temperature. 
Again please make sure the tube is very securely sealed. 
 
Where should samples be sent? 
Please discuss with Dr Ved Bhushan Arya (v.arya@ucl.ac.uk/ 07737672273/ 02072429789, 
Ex 2864) before sending samples.  
The samples should be sent to: 
Dr. Ved Bhushan Arya 
Clinical Research Fellow 
Institute of Child Health 
Clinical & Molecular Genetics Unit 
Developmental Endocrinology Research 
30, Guildford Street 
London 
WC1N 1EH 
Email:  v.arya@ucl.ac.uk  
 
Other questions 
Please do contact me if there are any other questions.  We would be very keen to help in 
any way we can. 
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                    Parent/Guardian Information Sheet – January 2012 
Project Title: Clinical, Biochemical and Genetic Mechanisms of Hyperinsulinaemic 
Hypoglycemia. 
 
1. The aim of the study 
The aim of this project is to investigate the genetic causes of hypoglycemia (low blood 
glucose) in newborns, infants and children. 
Previous research has already identified a number of abnormalities in certain genes that can 
cause excessive amounts of insulin (hyperinsulinism) to be made causing hypoglycemia, but 
we still don’t know the cause in the majority of children. Recently, we found a new genetic 
cause of this condition and the aim of this study is to characterize this novel type of 
hyperinsulinism along with trying to unravel further genetic causes. 
2. Why is the study being done? 
A normal blood glucose level is important for brain function. Hypoglycemia (low blood 
glucose levels) can cause significant brain injury. We currently have very little understanding 
as to the genetic mechanisms that cause hypoglycemia in childhood.  This study will allow us 
to understand why hypoglycemia develops in some children and the genetic basis of this.  
This will have important implications for the future treatment of our children.  
3. How is the study being done? 
If you agree to participate in this study, your child will have an additional blood sample taken 
when they are having their routine investigations. We will use this blood sample to extract 
DNA (genetic material). The DNA will then be used to analyze certain genes. The extra 
blood sample that we take will do no harm to your child, as the amount of blood that we will 
take is extremely small (a few tea spoonfuls).  As a part of the study, we might request blood 
samples from you or other related family members; especially if there is a family member 
affected with diabetes mellitus/ hypoglycemia. This blood sample will be used to extract 
DNA that will be used only for the purpose of establishing a genetic cause for hypoglycemia. 
4. What are the risks and discomfort? 
No risk to the child can be foreseen.  Your child might have a cannula inserted for routine 
medical treatment and we will then take the blood sample from the cannula. There is 
discomfort from the insertion of the cannula but we would normally numb the skin anyway 
with a local anaesthetic cream.  
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5. Who will have access to the case/research records? 
Only the researchers and a representative of the Research Ethics Committee will have access 
to the data collected during this study. 
6. What are the arrangements for compensation? 
An independent Research Ethics Committee who believes that it is of minimal risk to your 
child has approved this research.  However, research can carry unforeseen risks and we are 
required to tell you that if your child is harmed and this is due to someone’s negligence, you 
may have grounds for legal action for compensation in respect of any harm arising out of 
participation in the study. 
7. What are the potential benefits? 
This study will not bring any immediate benefits to your child.  However, if we find the 
genetic mechanism that is causing the hypoglycemia in your child we will explain this to you 
and it will give us a better understanding of why some children do develop this condition. 
8. Do I have to take part in this study? 
If you decide, now or at a later stage, that you do not wish to participate in this research 
project, that is entirely your right and will not in any way prejudice any present or future 
treatment. 
9. Who do I speak to if problems arise? 
If you have any complaints about the way in which this research project has been, or is being 
conducted, please, in the first instance, discuss them with the researcher (Dr.Ved Bhushan 
Arya: 07737672273; 02072429789/ Extn 2864; v.arya@ucl.ac.uk).  
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CASE REPORT Open Access
Congenital hyperinsulinism: clinical and molecular
characterisation of compound heterozygous
ABCC8 mutation responsive to Diazoxide therapy
Ved Bhushan Arya1†, Qadeer Aziz2†, Azizun Nessa3, Andrew Tinker2 and Khalid Hussain1,4*
Abstract
Background: Mutations in ABCC8 and KCNJ11 are the most common cause of congenital hyperinsulinism (CHI).
Recessive as well as dominant acting ABCC8/KCNJ11 mutations have been described. Diazoxide, which is the first
line medication for CHI, is usually ineffective in recessive ABCC8 mutations. We describe the clinical and molecular
characterisation of a recessive ABCC8 mutation in a CHI patient that is diazoxide response.
Clinical case: A term macrosomic female infant presented with symptomatic persistent hypoglycaemia confirmed
to be secondary to CHI. She exhibited an excellent response to moderate doses of diazoxide (10 mg/kg/day).
Molecular genetic analysis of the proband confirmed a biallelic ABCC8 mutation – missense R526C inherited from
an unaffected mother and a frameshift c.1879delC mutation (H627Mfs*20) inherited from an unaffected father.
Follow-up highlighted persistent requirement for diazoxide to control CHI. Functional analysis of mutants confirmed
them to result in diazoxide-responsive CHI, consistent with the clinical phenotype.
Conclusion: Biallelic ABCC8 mutations may result in diazoxide-responsive CHI. Irrespective of the molecular genetic
analysis results, accurate assessment of the response to diazoxide should be undertaken before classifying a patient
as diazoxide-responsive or unresponsive CHI.
Keywords: Congenital hyperinsulinism, Hypoglycaemia, ABCC8, Diazoxide
Background
Congenital hyperinsulinism (CHI) is due to an inappro-
priate insulin secretion by the β-cells of the islets of
Langerhans [1]. It usually presents with severe hypoketo-
tic hypofattyacidaemic hypoglycaemia [2]. The majority
of the affected newborns are macrosomic at birth and re-
quire high intravenous glucose administration to maintain
plasma glucose above 3.5 mmol/l [3].
Mutations in ABCC8 and KCNJ11, which encode the
SUR1 and Kir6.2 subunits of pancreatic ATP-sensitive
potassium channel (KATP), are by far the most common
cause of CHI and are estimated to account for 36%-69%
of all cases [4-6]. KATP channels are octameric protein
complexes composed of four pore-forming Kir6.2 sub-
units and four sulfonylurea receptor 1 (SUR1) subunits,
and form a link between cellular metabolism and mem-
brane excitability [7,8]. It is thought that the β-cells in
patients with CHI are persistently depolarized because
of abnormally modulated or absent KATP channels. This
depolarisation opens the voltage-gated calcium channels
and leads to unregulated insulin exocytosis. Although
dominant acting ABCC8/KCNJ11 mutations have been
reported, recessively inherited mutations are more com-
mon [4,5,9,10].
Diazoxide, which binds to the SUR1 subunit of the
KATP channel and reduces insulin secretion by hyperpo-
larisation of the pancreatic β-cell plasma membrane, is
the first line of treatment for CHI [1]. However, reces-
sive inactivating mutations in ABCC8 and KCNJ11 usu-
ally cause severe diazoxide-unresponsive CHI due to
defects in channel biogenesis, turnover, trafficking or
regulation [11].
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We describe a unique genotype-phenotype correlation
with diazoxide responsive CHI in a patient with compound
heterozygous ABCC8 mutation. Functional work on the mu-
tants was consistent with the observed clinical phenotype.
Case presentation
Clinical case
A term large-for-gestational age (birth weight 4500 g
at 39 weeks gestation) female infant born to non-
consanguineous Caucasian parents presented with
symptomatic hypoglycaemia on first day of life. There
was no history of gestational diabetes mellitus in the
mother. The proband developed tonic clonic seizures
associated with laboratory blood glucose of 0.4 mmol/l at
22 hours of age. The infection and metabolic screen was
negative. She required infusion of high concentration glu-
cose (glucose infusion rate 16 mg/kg/minute) to maintain
blood glucose above 3.5 mmol/l.
A controlled hypoglycaemia screen established the diag-
nosis of CHI (serum Insulin 44.5 mU/l associated with lab
glucose of 2.3 mmol/l and undetectable non-esterified
fatty acids and β-hydroxybutyrate). Her serum cortisol
was 570 nmol/l during the hypoglycaemia screen. The rest
of the hypoglycaemic screen including insulin like growth
factor-1 (IGF1), and insulin-like growth factor binding
protein-3 (IGFBP3), serum ammonia, lactate, acylcarnitine
profile, plasma amino acids and urine organic acids was
within normal reference range (results not shown).
Molecular genetic analysis for CHI was performed after
informed consent from the parents (see below). She was
commenced on diazoxide (5 mg/kg/day in three divided
doses) and the dose was gradually increased to 10 mg/kg/
day. Chlorothiazide was given along with diazoxide to
counteract the side effect of fluid retention. On 10 mg/kg/
day of diazoxide, she was successfully weaned off intraven-
ous glucose administration. She demonstrated age appro-
priate fasting tolerance on diazoxide before discharge.
Blood glucose monitoring performed at home demon-
strated satisfactory glycaemic control on diazoxide. No ad-
justment in diazoxide dose was required with her growth.
At 9 months of age, a trial off diazoxide therapy resulted
in recurrence of hypoglycaemia with fasting tolerance of
only 3½ hours. Diazoxide was recommenced at 5 mg/kg/
day, which led to disappearance of hypoglycaemia and age
appropriate fasting tolerance.
At the time of writing, the proband is 15 months old and
is able to fast for 12 hours without developing hypoglycaemia
on a low dose of diazoxide (5 mg/kg/day). Neurodevelop-
mental assessment did not identify any abnormality.
Genetic analysis
Methods
Genomic DNA was extracted from peripheral blood leu-
kocytes using standard procedures. The single exon of
the KCNJ11 gene was amplified in 3 overlapping frag-
ments and sequenced. When no mutations were identi-
fied in KCNJ11, the 39 exons of the ABCC8 gene were
amplified by polymerase chain reaction (PCR). The prod-
ucts were sequenced using Big Dye Terminator cycler
sequencing Kit v3.1 (Applied Biosystems, Warrington,
UK) and sequencing reactions were analysed on an
ABI3730 (Applied Biosystems, Warrington, UK). Se-
quences were compared to the reference sequence (NM_
000352.2) using Mutation Surveyor software (SoftGenetics,
Pa., USA).
Results
Sequence analysis identified biallelic ABCC8 mutation in
the proband – a missense mutation, R526C, inherited
from an unaffected mother and a frameshift mutation,
c.1879delC (H627Mfs*20), inherited from an unaffected
father. Both R526C and c.1879delC (H627Mfs*20) muta-
tions have previously been reported as recessive acting
mutations in patients with focal CHI [5].
Functional analysis of mutant channels
Methods
Single point mutations (R526C and c.1879delC) were in-
troduced into the hamster SUR1 clone by PCR using the
Strategene XL Mutagenesis Kit according to the manu-
facturer’s instructions.
Human Embryonic Kidney (HEK) 293 cells were transi-
ently transfected with Kir6.2/SUR1, Kir6.2/SUR1c1879delC,
Kir6.2/SUR1R526C or Kir6.2/SUR1c1879C + SUR1R526C
(together with a small amount of eGFP (Green Fluorescence
Protein) expressing plasmid to enable identification of
transfected cells using epifluorescence) using FuGENE
HD (Roche Diagnostics, UK) as per the manufacturers’ in-
structions and cells were subjected to whole cell patch-
clamp 48 hours after transfection.
Whole-cell patch-clamp recordings were performed as
previously described [12]. Capacitance transients and series
resistance in whole-cell recordings were compensated elec-
tronically by using amplifier circuitry (Multiclamp 700B).
Data were filtered at 1 kHz using the filter provided
with the Multiclamp 700B (4 pole Bessel) and sampled
at 5 kHz using a Digidata 1440 (Axon Instruments). Cur-
rents were acquired and analysed using pClamp 10.4
(Axon Instruments). The intracellular (pipette) solution
contained (mM); 140 KCl, 1.2 MgCl2, 1 CaCl2, 10 EGTA
and 5 HEPES, 0.1 mM Na.ATP and 1 mM Na.ADP,
pH 7.2 using KOH. The bath solution contained (mM); 5
KCl, 140 NaCl, 2.6 CaCl2, 1.2 MgCl2 and 5 HEPES
(pH 7.4). Pipette resistances were between 2–4 mΩ. Diaz-
oxide and Tolbutamide were obtained from Sigma Aldrich
(Poole, UK). Agents were applied to the bath using a
gravity-driven perfusion system.
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Results
Whole-cell patch-clamp recordings from HEK 293 cells
transfected with wild-type (WT) Kir6.2/SUR1 cDNA
showed normal KATP currents which was activated by
the KATP channel opener diazoxide (100 μM) and inhib-
ited by the KATP blocker tolbutamide (100 μM) (control,
144.77 ± 25.57 pA/pF; diazoxide, 382.7 ± 37.67 pA/pF;
diazoxide + tolbutamide, 98.05 ± 28.05 pA/pF, n = 5 cells,
P < 0.05). Currents from cells transfected with the frameshift
mutation SUR1c1879delC were unresponsive to diazoxide
and tolbutamide (control, 85.26 ± 12.7 pA/pF; diazoxide,
91.98 ± 14.36 pA/pF; tolbutamide, 79.57 ± 11.57 pA/pF, n = 7
cells, P > 0.05). In contrast, currents from cells transfected
with the missense mutation, SUR1R526C, activated in
the presence of diazoxide albeit to a lesser extent when
compared to WT (control, 76.55 ± 8.2 pA/pF; diazoxide,
175.2 ± 16.47 pA/pF; tolbutamide, 64.55 ± 8.88 pA/pF, n = 5
cells, P < 0.05).
Interestingly, co-expression of SUR1c1879delC and
SUR1R526C (to mimic the compound heterozygous ABCC8
(R256C/H627Mfs*20) mutation) rescued the diazoxide-
sensitive KATP current which was absent when SUR1c1879-
delC was expressed alone (control, 62.9 ± 9.3 pA/pF;
diazoxide, 223.11 ± 60.21 pA/pF; tolbutamide, 52.26 ± 11.36
pA/pF, n = 5 cells, P < 0.05). These data are shown in Figure 1.
The diazoxide-sensitive KATP current in the double mutant
transfected cells was significantly greater as compared to
SUR1c1879delC transfected cells (160.2 ± 52.9 vs 8.72 ±
4.41 pA/pF, P = 0.01) and equivalent to WT Kir6.2/SUR1
transfected cells (160.2 ± 52.9 vs 237.9 ± 59.1 pA/pF, P = 0.33).
Figure 1 Functional characterisation of KATP channels with a heterozygous ABCC8 R526C/H627Mfs*20 compound mutation. A, Representative
whole-cell time-current density traces at +40 mV recorded from HEK293 cells expressing Kir6.2/SUR1, Kir6.2/SUR1c1879delC, Kir6.2/SUR1R526C and
Kir6.2/SUR1R526C + SUR1C1879delC showing the effects of diazoxide (DZX) and tolbutamide (in the presence of diazoxide) (TOL). Current
were recorded using a 1 s ramp protocol (−150 mV to 50 mV). B, Summary of the mean current-densities at +40 mV. Values are mean ±
S.E.M from 5–7 cells, *P < 0.05, **P < 0.01 compared to control
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There was no statistically significant difference in the
KATP current seen in cells transfected with SUR1R256C
alone and cells co-transfected with SUR1R256C and
SUR1c1879delC (p = 0.291).
Discussion
We describe a patient with diazoxide responsive CHI due
to compound heterozygous ABCC8 mutation. The pro-
band was macrosomic at birth (consistent with foetal hy-
perinsulinism) and presented with severe hypoketotic
hypoglycaemia requiring high glucose infusion (16 mg/kg/
minute). Investigations confirmed CHI and compound
heterozygous ABCC8 (R256C/H627Mfs*20) mutation.
Surprisingly, the proband showed an excellent response to
moderate doses of diazoxide (10 mg/kg/day). Subsequent
follow-up revealed persistent requirement for diazoxide
to control CHI. Functional analysis of the mutant KATP chan-
nel subunits confirmed a phenotype of diazoxide-responsive
CHI in association with ABCC8 R526C/H627Mfs*20 com-
pound heterozygous mutation.
Mutations in ABCC8 and KCNJ11, both monoallelic
and biallelic, account for the majority of CHI patients
[4,5]. Although monoallelic ABCC8/KCNJ11 mutations
can cause both diazoxide-responsive as well as diazoxide-
unresponsive CHI, nearly all biallelic ABCC8/KCNJ11mu-
tations result in diazoxide unresponsive CHI [9,10,13,14].
In two recent large studies comprising more than 700
patients with CHI, there was no patient reported with
diazoxide responsive CHI due to biallelic ABCC8/KCNJ11
mutation [4,5].
However, Dekel et al. reported a patient with a com-
pound heterozygous ABCC8 mutation (c.3992-9G > A/
F1388del) who responded to diazoxide [15]. However,
no functional work was done to correlate with the clin-
ical observations.
Previous functional work on compound heterozygous
ABCC8 mutations has shown that mutations may inter-
act to modify KATP channel function and influence dis-
ease severity. Muzyamba et al. showed that single SUR1
mutants (D1193V or R1436Q) trafficked to the plasma
membrane whereas the double mutant (SUR1D1193V/
R1436Q) was retained in the endoplasmic reticulum
[16].
Both SUR1 R526C and H627Mfs*20 mutations have
been described previously as presumed recessive acting
mutations in association with CHI. Snider et al. reported
one patient each with both these mutations in associ-
ation with focal CHI [5]. No functional work had been
done on either of these mutations. The H627Mfs*20 mu-
tation is a frameshift mutation and is severely damaging
to the protein function as shown by our functional work.
When the SUR1H627Mfs*20 mutant was co-expressed
with Kir6.2, there was no increase in current with the ap-
plication of diazoxide indicating either absence of KATP
channels on the plasma membrane surface and\or severely
dysfunctional KATP channel. With the SUR1R526C mutant,
there was reduced current flow under basal conditions as
compared to wild-type. However, importantly, there was an
increase in current with the application of diazoxide which
persisted when the two mutants (SUR1R526C/H627Mfs*20)
were expressed in combination, suggesting this variant to
be diazoxide-responsive.
As the frameshift mutation H627Mfs*20 results in a
premature termination codon and is likely to be degraded
by non-sense mediated decay, it is possible that the KATP
channels in double mutant SUR1R256C/H627Mfs*20 will
contain SUR1 subunits produced by allele carrying R526C
mutation only and hence the response shown by the
SUR1R256C/H627Mfs*20 resembles that of SUR1R256C
mutant. However non-sense mediated decay cannot
be reproduced in the expression studies as that re-
quires replication of intronic and exonic structure of
the gene whereas the plasmids can only accommodate
cDNA of the gene.
Although we used 100 μM diazoxide to assess the re-
sponsiveness of SUR1 mutants, to our knowledge there
is no data in the literature as to what concentration of
diazoxide is achieved at the cellular level with the standard
doses of diazoxide used for medical management of CHI.
However, assuming a distribution volume of ~0.2 L/kg,
the dose of diazoxide administered orally to this proband
is likely to result in a concentration higher (~2×) than the
100 μM we used for our studies at the cellular level [17].
Our functional data, however, is not consistent with
the previous observation of diazoxide-unresponsive focal
CHI in association with paternally inherited heterozygous
ABCC8 R526C mutation [5]. Marked intrafamilial clinical
heterogeneity in four haploidentical siblings harbouring
the identical ABCC8 homozygous c.3992-9G >A mutation
was also highlighted by Kapoor et al. [18]. This difference
in clinical expression may be due to background genetic
factors and other unknown factors involved in regulating
gene expression.
Conclusion
In conclusion, although the majority of biallelic ABCC8/
KCNJ11 mutations result in diazoxide-unresponsive CHI,
occasional biallelic and particularly compound heterozy-
gous ABCC8 mutations may lead to a diazoxide-responsive
phenotype. Accurate clinical assessment would avoid the
need for near-total pancreatectomy in such cases.
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Abstract
Context: Congenital hyperinsulinism (CHI) has two main histological types: diffuse and focal. Heterozygous paternally
inherited ABCC8/KCNJ11 mutations (depending upon whether recessive or dominant acting and occurrence of somatic
maternal allele loss) can give rise to either phenotype. However, the relative proportion of these two phenotypes in a large
cohort of CHI patients due to paternally inherited heterozygous ABCC8/KCNJ11 mutations has not been reported.
Objective: The purpose of this study is to highlight the variable clinical phenotype and to characterise the distribution of
diffuse and focal disease in a large cohort of CHI patients due to paternally inherited heterozygousABCC8/KCNJ11mutations.
Design: A retrospective chart review of the CHI patients due to heterozygous paternally inherited ABCC8/KCNJ11mutations
from 2000 to 2013 was conducted.
Results: Paternally inherited heterozygous ABCC8/KCNJ11 mutations were identified in 53 CHI patients. Of these, 18 (34%)
either responded to diazoxide or resolved spontaneously. Fluorine-18 L-3, 4-dihydroxyphenylalanine positron emission
tomography computerised tomography (18F DOPA–PET CT) scanning in 3/18 children showed diffuse disease. The remaining
35 (66%) diazoxide-unresponsive children either had pancreatic venous sampling (nZ8) or 18F DOPA–PET CT (nZ27). Diffuse,
indeterminate and focal disease was identified in 13, 1 and 21 patients respectively. Two patients with suspected diffuse
disease were identified to have focal disease on histology.
Conclusions: Paternally inherited heterozygous ABCC8/KCNJ11 mutations can manifest as a wide spectrum of CHI
with variable 18F DOPA–PET CT/histological findings and clinical outcomes. Focal disease was histologically confirmed in
24/53 (45%) of CHI patients with paternally inherited heterozygous ABCC8/KCNJ11 mutations.
European Journal of
Endocrinology
(2014) 171, 685–695
Introduction
Congenital hyperinsulinism (CHI) is one of the main
causes of hypoglycaemia and is characterised by inap-
propriate insulin secretion (1). Mutations in nine different
genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1,
UCP2, HNF4A and HNF1A) have been reported so far as
the genetic causes of CHI (1, 2). The pancreatic b-cell ATP-
sensitive potassium channel (KATP channel) regulates
glucose-mediated insulin release and is composed of two
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subunits: Kir6.2 encoded by KCNJ11 and SUR1 encoded
by ABCC8 gene (2). Both genes are localised in the 11p15.1
region and mutations in these accounts for the majority
of CHI patients (3, 4, 5, 6, 7, 8, 9, 10, 11).
There are two main forms of CHI (focal and diffuse)
that are clinically identical but differ in histology,
underlying genetic mechanism and management. In
diffuse CHI, histologically there is an increase in the
b-cell nuclear size throughout the pancreas. Diffuse CHI is
genetically heterogeneous and most commonly due to
mutations in ABCC8 or KCNJ11 genes (3, 12, 13, 14, 15).
Diazoxide, an agonist that targets the SUR1 subunit, is
usually ineffective in patients with autosomal recessive
form of ABCC8 or KCNJ11 mutations. The management of
the medically unresponsive diffuse CHI patients involves
near-total pancreatectomy.
The focal lesions are characterised by nodular hyper-
plasia of islet-like cell clusters with ductuloinsular
complexes and scattered giant b-cell nuclei with normal
surrounding tissue (16). The focal CHI results from
a paternally inherited heterozygous ABCC8/KCNJ11
mutation together with a somatic loss of the maternal
chromosome in the 11p15 region (most likely caused by
paternal isodisomy) (16, 17). The resulting loss of
heterozygosity (LOH) renders the b-cells biallelic for the
abnormal foci, altering the KATP channel and resulting
in dysregulated insulin secretion within the focal lesion
(16, 17, 18). The consequent imbalance in the expression
of adjacent imprinted genes implicated in cell prolifer-
ation (such as CDKN1C and H19 normally expressed from
the maternal allele and IGF2 paternally expressed) within
the 11p15.5 region leads to focal islet cell adenomatous
hyperplasia (19, 20, 21, 22). Focal CHI is usually medically
unresponsive, although diazoxide-responsive focal CHI
has been recently described (23). Targeted surgical
removal of the lesion will cure the patient.
Fluorine-18 L-3, 4-dihydroxyphenylalanine positron
emission tomography computerised tomography (18F
DOPA–PET CT) scan can help to differentiate the focal
from diffuse forms of CHI and aids in the clinical
management of these patients (24). Before the advent
of 18F DOPA–PET CT, pancreatic venous sampling (PVS)
and selective pancreatic arterial calcium stimulation with
hepatic venous sampling (ASVS) were used to differentiate
between the two subtypes (25, 26). A recent systematic
review and meta-analysis has found 18F DOPA–PET CT
to be far superior to PVS and ASVS in diagnosing and
localising focal CHI (27).
Patients with CHI associated with heterozygous
paternally inherited ABCC8/KCNJ11 mutations may or
may not have the second hit of somatic maternal allele
loss in the pancreatic b-cell. Accordingly, these patients
can either have focal or diffuse disease. Furthermore,
diffuse disease can either be diazoxide-responsive or
unresponsive depending on the underlying molecular
basis of the mutation and other unclear genetic or
environmental influences (28). There are isolated case
reports of heterozygous paternally inherited ABCC8/
KCNJ11 mutations leading to diffuse CHI in the literature
(3, 10, 29, 30). The proportion of patients with paternally
inherited heterozygous ABCC8/KCNJ11 mutations who
develop focal CHI has not been reported in any study so
far. Herein, we describe the heterogeneous clinical
presentation and the histological basis of a relatively
large cohort of patients with heterozygous paternally
inherited ABCC8/KCNJ11 mutations. We also report the
proportion of focal and diffuse disease in a large cohort of
CHI patients with paternally inherited heterozygous
ABCC8/KCNJ11 mutations.
Subjects and methods
The study was approved by the Ethics Committee of Great
Ormond Street Children’s Hospital and the Institute
of Child Health. Informed written consent was obtained
from the parents of children enrolled for molecular
genetic testing for CHI (ABCC8/KCNJ11 sequencing).
This is a descriptive study of the clinical characteristics
of children with CHI due to paternally inherited hetero-
zygous ABCC8/KCNJ11 mutations. Clinical presentation,
disease course and outcome for consecutive patients with
CHI associated with paternally inherited heterozygous
ABCC8/KCNJ11 mutations between the years 2000 and
2013 were retrospectively reviewed.
CHI was diagnosed by a controlled fasting test that
demonstrated an inappropriately detectable serum insulin
and/or C-peptide concentration and/or inappropriately
low b-hydroxybutyrate and non-esterified fatty acids
concentrations in the presence of hypoglycaemia (plasma
glucose concentration !3.0 mmol/l). The patients with
confirmed diagnosis of CHI underwent molecular genetic
analysis after informed consent (see below). Diazoxide
(5–15 mg/kg per day in three divided doses) was com-
menced as the first-line medical treatment. The patients
were defined as diazoxide unresponsive if age appropriate
fasting tolerance could not be achieved by treat-
ment with 15 mg/kg per day diazoxide for a minimum
of 5 days. Diazoxide-unresponsive patients associated
with paternally inherited heterozygous ABCC8/KCNJ11
mutation underwent further investigations (PVS or
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18F DOPA–PET CT) to differentiate between focal and
diffuse disease. PVS was performed and interpreted as
described previously by de Lonlay-Debeney et al. (26). The
detailed protocol used for 18F DOPA–PET CT and analysis of
the images has already been described (31).
Diazoxide-unresponsive diffuse disease was managed
by octreotide injections (5–30 mg/kg per day in three to four
divided doses)Gnear-total pancreatectomy along with
carbohydrate-rich feeds. The focal disease was managed
with the resection of the focal lesion or partial pancrea-
tectomy. Post-surgery, glycaemic control was periodically
assessed by 24-h blood glucose profile and controlled fast
to ensure cure of the focal CHI and appropriate control of
diffuse CHI.
Genetic testing
Genomic DNA was extracted from peripheral leukocytes
using standard procedures. The single-coding exon of the
KCNJ11 gene and the 39 exons of the ABCC8 gene were
amplified using the PCR. Unidirectional sequencing was
performed using universal M13 primers and a Big Dye
Terminator Cycle Sequencing Kit v3.1 (Applied Biosys-
tems) according to the manufacturer’s instructions. The
reactions were analysed on an ABI 3730 Capillary
Sequencer (Applied Biosystems) and the sequences were
compared with the reference sequences (NM_000525
and NM_000352.2) using Mutation Surveyor v3.24
(SoftGenetics, PA, USA). Dosage analyses by multiplex
ligation-dependent probe amplification were done in
patients with a heterozygous ABCC8/KCNJ11 mutation
and diffuse disease on 18F DOPA–PET scan/PVS (32).
LOH was investigated by microsatellite analysis of
DNA extracted from paraffin-embedded pancreatic tissue
and peripheral leukocytes, mainly when there was a
discrepancy between the histology and 18F DOPA–PET
CT/PVS result. Six markers (D11S2071, D11S1964,
D11S419, D11S1397, D11S1888 and D11S4138) spanning
chromosome 11p15.1–11p15.5 were amplified by PCR and
allele peak heights were compared using GeneMarker
v1.85 (SoftGenetics).
Results
Over a period of 14 years (2000–2013), more than 300
children with confirmed biochemical and genetic
diagnosis of CHI were managed in our centre. Of these,
53 children had paternally inherited heterozygous
ABCC8/KCNJ11 mutation (ABCC8, 42 and KCNJ11, 11).
Of the 35 different ABCC8 mutations seen in 42 patients,
19 affected a single amino acid (missense or in-frame
deletion/insertion). Of the ten different KCNJ11 mutations
seen in 11 patients, eight affected a single amino acid
(missense or in-frame deletion/insertion), one was a frame
shift mutation and one was a non-stop codon mutation
resulting in extension of the Kir6.2 protein sequence by
three amino acids (Fig. 1). As shown in Fig. 1, mutations
occurred throughout SUR1 and Kir6.2.
Extracellular
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Figure 1
Paternal mutations mapped onto the SUR1 and Kir6.2 protein. All SUR1 intronic splice site mutation mutants have been highlighted
in red. All mutants with * are responsive to diazoxide (transmembrane domain (TMD) and nucleotide-binding domain (NBD)). A full
colour version of this figure available via http://dx.doi.org/10.1530/EJE-14-0353.
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study V B Arya, M Guemes and
others
Paternal heterozygous
ABCC8/KCNJ11 mutations
171 :6 687
www.eje-online.org
Ta
b
le
1
C
li
n
ic
a
l
a
n
d
b
io
ch
e
m
ic
a
l
ch
a
ra
ct
e
ri
st
ic
s,
m
u
ta
ti
o
n
a
l
a
n
a
ly
si
s
a
n
d
cl
in
ic
a
l
o
u
tc
o
m
e
o
f
5
3
p
a
ti
e
n
ts
w
it
h
p
a
te
rn
a
ll
y
in
h
e
ri
te
d
A
B
C
C
8
/K
C
N
J1
1
m
u
ta
ti
o
n
s.
P
a
ti
e
n
t
ID
G
A
(w
e
e
k
s)
,
b
ir
th
w
e
ig
h
t
(g
)
G
e
n
d
e
r
A
g
e
a
t
p
re
se
n
ta
ti
o
n
(w
e
e
k
s)
B
lo
o
d
g
lu
co
se
(m
m
o
l/
l)
S
e
ru
m
in
su
li
n
(m
U
/l
)
M
u
ta
ti
o
n
p
ro
te
in
d
e
sc
ri
p
ti
o
n
(D
N
A
d
e
sc
ri
p
ti
o
n
)
L
O
H
D
zx
R
e
sp
P
E
T
C
T
/P
V
S
O
u
tc
o
m
e
A
B
C
C
8
1
4
0
,
3
1
5
0
M
a
le
5
2
2
.4
4
.3
L1
4
3
1
F/
N
(c
.4
2
9
1
C
O
T
/N
)
Y
e
s
–
O
n
D
zx
a
t
6
.4
ye
a
rs
2
4
0
,
4
0
0
0
M
a
le
2
2
.4
1
.9
p
.?
/N
(c
.2
6
9
7
C
4
A
O
T
/N
)
Y
e
s
–
O
ff
D
zx
a
t
2
ye
a
rs
3
4
0
,
5
0
1
0
Fe
m
a
le
!
1
2
.6
8
.6
E
1
5
0
7
K
/N
(c
.4
5
1
9
G
O
A
/N
)
Y
e
s
–
O
n
D
zx
a
t
2
.3
ye
a
rs
4
4
0
,
5
6
0
0
M
a
le
!
1
2
.0
7
.5
A
1
5
0
8
P
/N
(c
.4
5
2
2
G
O
C
/N
)
Y
e
s
–
O
n
D
zx
a
t
1
2
ye
a
rs
5
3
7
,
4
8
2
0
M
a
le
!
1
2
.0
9
.0
A
1
1
5
3
T
/N
(c
.3
4
5
7
G
O
A
/N
)
Y
e
s
–
O
n
D
zx
a
t
4
ye
a
rs
6
3
8
,
3
6
3
0
Fe
m
a
le
7
2
3
.1
!
2
A
1
1
5
3
T
/N
(c
.3
4
5
7
G
O
A
/N
)
Y
e
s
–
O
n
D
zx
a
t
2
ye
a
rs
8
3
5
,
2
8
2
0
M
a
le
!
1
1
.2
1
2
.9
A
1
1
8
5
V
/N
(c
.3
5
5
4
C
O
T
/N
)
Y
e
s
–
O
ff
D
zx
a
t
8
m
o
n
th
s
9
3
6
,
4
4
5
0
M
a
le
!
1
2
2
8
.5
p
.?
/N
(c
.3
9
9
2
-9
G
O
A
/N
)
Y
e
s
–
O
ff
D
zx
a
ft
e
r
4
.5
m
o
n
th
s
1
0
4
1
,
2
7
8
0
Fe
m
a
le
!
1
1
9
.3
D
1
4
7
2
N
/N
(c
.4
4
1
4
G
O
A
/N
)
Y
e
s
–
O
ff
D
zx
a
ft
e
r
1
0
m
o
n
th
s
1
1
3
8
,
3
7
5
0
M
a
le
!
1
2
.6
5
.9
0
V
6
0
1
I/
N
(c
.1
8
0
1
G
O
A
/N
)
Y
e
s
–
O
ff
D
zx
a
ft
e
r
1
4
m
o
n
th
s
1
3
4
0
,
4
1
6
0
Fe
m
a
le
!
1
2
.4
1
4
.8
V
1
8
5
fs
/N
(c
.5
5
4
d
e
lT
/N
)
N
o
D
if
fu
se
O
ff
o
ct
re
o
ti
d
e
a
t
5
ye
a
rs
1
4
3
7
,
3
0
9
0
M
a
le
!
1
0
.6
1
2
.4
p
.?
/N
(c
.3
9
9
2
-9
G
O
A
/N
)
N
o
Fo
ca
l
O
n
o
ct
re
o
ti
d
e
a
t
9
.5
ye
a
rs
1
5
4
0
,
3
6
0
0
M
a
le
!
1
2
.7
6
.7
H
6
2
7
fs
/N
(c
.1
8
7
9
d
e
lC
/N
)
N
o
D
if
fu
se
O
ff
o
ct
re
o
ti
d
e
a
t
1
8
m
o
n
th
s
1
6
4
0
,
4
7
0
0
Fe
m
a
le
!
1
2
.0
!
2
E
1
5
0
7
K
/N
(c
.4
5
1
9
G
O
A
/N
)
N
A
–
N
o
tr
e
a
tm
e
n
t
re
q
u
ir
e
d
1
7
4
0
,
4
2
0
0
M
a
le
!
1
1
.0
!
2
D
1
0
3
1
N
/N
(c
.3
0
9
1
G
O
A
/N
)
N
A
–
N
o
tr
e
a
tm
e
n
t
re
q
u
ir
e
d
1
8
4
1
,
4
8
5
0
M
a
le
!
1
1
.2
1
0
.1
M
1
V
/N
(c
.1
A
O
G
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
1
9
3
8
,
2
4
0
0
M
a
le
!
1
2
.1
1
6
.3
D
1
1
9
4
V
;
R
1
4
3
7
Q
/N
(c
.3
5
8
1
A
O
T;
c.
4
3
1
0
G
O
A
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
2
0
4
0
,
4
5
8
0
Fe
m
a
le
!
1
1
.1
1
0
3
A
1
4
9
3
T
/N
(c
.4
4
7
7
G
O
A
/N
)
Y
e
sa
N
o
D
if
fu
se
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
2
1
4
0
,
4
6
0
0
M
a
le
!
1
1
.2
2
2
.5
K
8
9
0
fs
/N
(c
.2
6
6
9
_2
6
7
5
d
e
l/
N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
2
2
4
0
,
4
3
3
5
M
a
le
!
1
2
.6
3
.4
p
.?
/N
(c
.3
9
9
2
-9
G
O
A
/N
)
Y
e
s
N
o
Fo
ca
l
P
a
rt
ia
l
p
a
n
cr
e
a
te
ct
o
m
y
2
3
4
0
,
3
0
3
0
M
a
le
!
1
1
.8
1
5
.6
p
.?
/N
(c
.3
9
9
2
-9
G
O
A
/N
)
Y
e
s
N
o
Fo
ca
l
P
a
rt
ia
l
p
a
n
cr
e
a
te
ct
o
m
y
2
4
4
0
,
2
7
7
0
M
a
le
!
1
2
.2
3
.4
p
.?
/N
(c
.5
8
0
-1
G
O
C
/N
)
N
o
In
d
e
te
rm
i-
n
a
te
(P
V
S)
P
a
rt
ia
l
p
a
n
cr
e
a
te
ct
o
m
y
–
fo
ca
l
le
si
o
n
o
n
h
is
to
lo
g
y
2
5
4
1
,
4
2
9
0
M
a
le
2
2
.3
4
.3
2
E
1
2
8
K
/N
(c
.3
8
2
G
O
A
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
2
7
4
0
,
5
0
9
5
M
a
le
!
1
2
.0
1
0
.5
L1
1
7
1
X
/N
(c
.3
5
1
2
d
e
lT
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
2
9
3
7
,
3
5
6
0
M
a
le
!
1
1
.6
2
1
.8
p
.?
/N
(c
.1
6
2
9
-2
A
O
C
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
3
0
4
0
,
2
7
5
0
M
a
le
!
1
1
.5
1
6
.4
G
1
1
1
R
/N
(c
.3
3
1
G
O
A
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
3
1
3
7
,
3
3
4
0
M
a
le
!
1
2
.1
1
5
H
6
2
7
fs
/N
(c
.1
8
7
9
d
e
lC
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
3
2
4
1
,
4
9
5
0
M
a
le
!
1
1
.2
1
1
.9
5
R
9
3
4
X
/N
(c
.2
8
0
0
C
O
T
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
3
3
4
0
,
3
0
8
0
Fe
m
a
le
1
2
1
.5
4
.6
S1
2
X
/N
(c
.3
5
C
O
A
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
3
4
3
9
,
3
6
0
0
M
a
le
!
1
2
.5
8
R
1
4
9
4
W
/N
(c
.4
4
8
0
C
O
T
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
3
7
3
6
,
3
4
1
0
M
a
le
!
1
0
.9
1
7
.4
2
R
1
4
9
4
W
/N
(c
.4
4
8
0
C
O
T
/N
)
N
o
Fo
ca
l
P
a
rt
ia
l
p
a
n
cr
e
a
te
ct
o
m
y
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study V B Arya, M Guemes and
others
Paternal heterozygous
ABCC8/KCNJ11 mutations
171 :6 688
www.eje-online.org
Ta
b
le
1
C
o
n
ti
n
u
e
d
P
a
ti
e
n
t
ID
G
A
(w
e
e
k
s)
,
b
ir
th
w
e
ig
h
t
(g
)
G
e
n
d
e
r
A
g
e
a
t
p
re
se
n
ta
ti
o
n
(w
e
e
k
s)
B
lo
o
d
g
lu
co
se
(m
m
o
l/
l)
S
e
ru
m
in
su
li
n
(m
U
/l
)
M
u
ta
ti
o
n
p
ro
te
in
d
e
sc
ri
p
ti
o
n
(D
N
A
d
e
sc
ri
p
ti
o
n
)
L
O
H
D
zx
R
e
sp
P
E
T
C
T
/P
V
S
O
u
tc
o
m
e
3
8
3
9
,
4
9
0
0
Fe
m
a
le
!
1
1
.4
2
3
.6
1
A
1
1
3
V
/N
(c
.3
3
8
C
O
T
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
3
9
3
6
,
3
2
1
0
M
a
le
!
1
0
.6
1
1
4
M
o
sa
ic
Q
5
4
X
(c
.1
6
0
C
O
T
)
N
o
D
if
fu
se
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
4
0
4
1
,
4
3
0
0
Fe
m
a
le
!
1
2
.1
1
7
Q
9
5
4
X
/N
(c
.2
8
6
0
C
O
T
/N
)
N
o
D
if
fu
se
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
4
1
3
6
,
2
7
3
0
M
a
le
!
1
?
?
p
.?
/N
(c
.1
3
3
3
-1
0
1
3
A
O
G
/N
)
Y
e
s
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
4
2
3
7
,
4
4
8
0
Fe
m
a
le
!
1
1
.7
5
.6
A
1
2
6
3
T
/N
(c
.3
7
8
7
G
O
A
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
4
5
3
9
,
3
9
6
0
M
a
le
!
1
2
.4
2
3
.6
p
.?
/N
(c
.1
-?
_c
.1
1
7
6
C
1
?/
N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
4
6
3
4
,
3
8
0
0
M
a
le
!
1
0
.8
2
0
1
D
8
5
5
E
/N
(c
.2
5
6
5
C
O
A
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
4
7
4
1
,
4
7
8
0
M
a
le
!
1
2
.4
1
5
.9
M
4
2
9
X
/N
(c
.1
2
5
4
_1
2
8
4
d
u
p
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
4
8
4
0
,
3
8
0
0
Fe
m
a
le
!
1
2
.4
5
.9
M
4
2
9
X
/N
(c
.1
2
5
4
_1
2
8
4
d
u
p
/N
)
N
o
D
if
fu
se
O
n
o
ct
re
o
ti
d
e
a
t
7
m
o
n
th
s
4
9
4
0
,
4
1
0
0
M
a
le
!
1
0
.8
9
.1
R
7
4
W
/N
(c
.2
2
0
C
O
T
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
5
1
3
8
,
3
7
3
0
Fe
m
a
le
!
1
1
.9
2
1
.6
E
9
9
5
X
(c
.2
9
8
3
G
O
T
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
K
C
N
J1
1
7
3
8
,
3
7
8
0
Fe
m
a
le
!
1
1
.7
2
9
.6
M
2
0
9
I/
N
(c
.6
2
7
G
O
A
/N
)
Y
e
s
D
if
fu
se
O
n
D
zx
a
t
2
.8
ye
a
rs
1
2
4
0
,
3
4
5
0
M
a
le
!
1
2
6
.7
R
5
4
H
/N
(c
.1
6
1
G
O
A
/N
)
Y
e
s
–
O
ff
D
zx
a
ft
e
r
4
m
o
n
th
s
2
6
3
6
,
3
8
8
0
M
a
le
!
1
!
1
.0
6
.1
E
2
9
2
K
/N
(c
.8
7
4
G
O
A
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
2
8
4
0
,
4
6
0
0
M
a
le
!
1
1
.3
3
8
.8
7
R
1
3
6
fs
/N
(c
.4
0
5
d
u
p
G
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
3
5
3
8
,
4
1
2
0
Fe
m
a
le
!
1
2
.2
1
2
.0
T
2
9
4
M
/N
(c
.8
8
1
C
O
T
/N
)
N
o
D
if
fu
se
(P
V
S)
N
e
a
r-
to
ta
l
p
a
n
cr
e
a
te
ct
o
m
y
(9
5
%
)
3
6
3
7
,
3
9
6
0
M
a
le
!
1
1
.9
7
.0
G
3
1
2
C
/N
(c
.9
3
4
G
O
T
/N
)
N
o
Fo
ca
l
H
yp
o
g
ly
ca
e
m
ia
re
so
lv
e
d
a
ft
e
r
re
m
o
va
l
o
f
fo
ca
l
le
si
o
n
4
3
4
0
,
4
1
0
0
Fe
m
a
le
!
1
1
.0
3
5
I2
8
4
d
e
l/
N
(c
.8
5
0
_8
5
2
d
e
lA
T
C
/N
)
Y
e
s
D
if
fu
se
O
ff
D
zx
a
t
4
ye
a
rs
o
f
a
g
e
4
4
4
0
,
4
5
8
0
Fe
m
a
le
3
2
2
.2
7
p
.*
3
9
1
R
e
xt
*
9
4
/N
(c
.1
1
7
1
T
O
C
/N
)
N
o
Fo
ca
l
P
a
rt
ia
l
p
a
n
cr
e
a
te
ct
o
m
y,
cu
r-
re
n
tl
y
o
n
D
zx
5
0
3
7
,
3
9
8
0
M
a
le
!
1
0
.5
2
.9
T
6
2
M
/N
(c
.1
8
5
C
O
T
/N
)
Y
e
s
–
O
ff
D
zx
a
t
1
m
o
n
th
5
2
4
0
,
5
1
9
0
M
a
le
!
1
2
.5
8
.4
R
1
7
7
W
/N
(c
.5
2
9
A
O
T
/N
)
Y
e
s
D
if
fu
se
O
n
D
zx
a
t
3
m
o
n
th
s
o
f
a
g
e
5
3
4
0
,
3
9
2
0
M
a
le
!
1
2
.1
9
.2
E
2
9
2
K
/N
(c
.8
7
4
G
O
A
/N
)
Y
e
s
D
if
fu
se
O
ff
D
zx
a
t
5
m
o
n
th
s
o
f
a
g
e
D
zx
,
d
ia
zo
xi
d
e
;
P
E
T,
p
o
si
tr
o
n
e
m
is
si
o
n
to
m
o
g
ra
p
h
y;
P
V
S,
p
a
n
cr
e
a
ti
c
ve
n
o
u
s
sa
m
p
li
n
g
;
G
A
,
g
e
st
a
ti
o
n
a
l
a
g
e
;
W
t,
w
e
ig
h
t;
LO
H
,
lo
ss
o
f
h
e
te
ro
zy
g
o
si
ty
;
R
e
sp
,
re
sp
o
n
si
ve
n
e
ss
.
a
T
h
is
p
a
ti
e
n
t
h
a
d
g
ia
n
t
fo
ca
l
le
si
o
n
a
n
d
vi
rt
u
a
ll
y
o
cc
u
p
ie
d
th
e
w
h
o
le
o
f
p
a
n
cr
e
a
s.E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study V B Arya, M Guemes and
others
Paternal heterozygous
ABCC8/KCNJ11 mutations
171 :6 689
www.eje-online.org
Clinical and biochemical characteristics
The mean (G2 S.D.) gestational age and birth weight of
our cohort was 38.9 (G1.8) weeks and 3980 (G760) g
respectively. Of these, 19 infants (36%) were macrosomic
(birth weightO2 S.D.) at birth. The gender distribution was
37 males and 16 females. The majority of patients in our
cohort were of Caucasian descent. Only one proband was a
product of the consanguineous marriage. There were two
pairs of two siblings and the rest of the cohort was
unrelated. The median age of presentation with hypogly-
caemia was !1 week (range !1–130 weeks). More than
85% (46/53) patients presented with hypoglycaemia
within first week of life. The mean (GS.D.) serum insulin
during hypoglycaemia was 21.1 (G34.2) mU/l. In three
infants in whom serum insulin was undetectable,
C-peptide level was inappropriately elevated for the blood
glucose measurement. The serum ammonia was within
normal range and b-hydroxybutyrate/non-esterified fatty
acids were inappropriately low in all children (Table 1).
Clinical course, 18F DOPA–PET CT and PVS findings
and final outcome
Diazoxide-responsive group " In two (4%) patients
(Table 1: patients 16 and 17), CHI resolved spontaneously
within few weeks before investigations were repeated in
our centre (Fig. 2). Previous functional work has estab-
lished milder disease phenotype with a mutation seen in
one of these two patients (ABCC8 (E1507K)) (33). The
mutation identified in the second patient (ABCC8
(D1031N)) is not reported in dbSNP and predicted to be
disease causing (Table 2).
Sixteen patients (30%) with presumably diffuse CHI
responded to diazoxide treatment (Fig. 2). In three
patients from diazoxide-responsive group who under-
went 18F DOPA–PET CT, diffuse uptake throughout the
pancreas was noticed. Nine patients (17%) successfully
managed to come off diazoxide treatment after a variable
period of time. The remaining seven (13%) patients were
on diazoxide for a median duration of 2.8 years (range
3 months–12 years) at the time of writing.
The mutations in this subgroup are predicted to be
pathogenic by various mutation prediction programmes
(Table 2) (34, 35).
Diazoxide-unresponsive group " The remaining 35
(66%) patients were unresponsive to maximum doses of
diazoxide and were investigated either by using PVS (nZ8)
or 18F DOPA–PET CT scan (nZ27).
PVS was suggestive of diffuse disease in seven patients
and no differentiation between focal and diffuse was
CHI due to paternally inherited KATP
mutation (n=53)
Diazoxide
responsive
(n=16)
Off diazoxide
(n=9)
18F DOPA–PET
CT (n=2)
diffuse disease
Still on diazoxide
(n=7)
18F DOPA–PET
CT (n=1)
diffuse disease
No treatment
required
(n=2)
Diazoxide
unresponsive
(n=35)
Pancreatic venous
sampling
(n=8) 
Diffuse disease
(histology–focal
1 and Diffuse, 7)
18F DOPA–PET
CT
(n=27)
Focal disease
(n=21)
Diffuse disease
(n=6)
Figure 2
Clinical course, 18F DOPA–PET CT/pancreatic venous sampling findings and outcome.
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possible in one patient. The suspected diffuse disease
patients were managed with near-total pancreatectomy.
Although histology confirmed diffuse disease in six
patients, there was one patient who had focal adenoma-
tous hyperplasia which was presumably missed on PVS.
The patient with indeterminate PVS underwent partial
pancreatectomy and focal lesion was seen on the histology
of the resected pancreas.
Of the 27 patients who were investigated with 18F
DOPA–PET scan, focal uptake was seen in 21 and diffuse
uptake in six patients (Fig. 3). The focal lesion was
successfully managed either with lesionectomy (nZ16)
or partial pancreatectomy (nZ4). One patient was
managed successfully with octreotide injections.
The patients with diffuse tracer pancreatic uptake were
either managed with near-total pancreatectomy (nZ3)
or octreotide injections (nZ3). One patient from this
subgroup had atypical histology with pancreatic b-cell
enlargement in parts of body and head of the pancreas due
to mosaic interstitial paternal uniparental isodisomy for
chromosome 11p15.1 (36).
Discussion
This study reports the proportion of focal disease in a large
cohort of patients with CHI associated with paternally
inherited heterozygous ABCC8/KCNJ11 mutations. In
addition, it highlights the clinical and histological
heterogeneity of CHI associated with paternally inherited
heterozygous ABCC8/KCNJ11 mutation.
Mutations in the ABCC8/KCNJ11, which account
for the majority of genetically confirmed CHI cases, can
either be biallelic or monoallelic (3, 4, 37). Biallelic
ABCC8/KCNJ11 mutations result in diffuse CHI, whereas
monoallelic mutations can either be asymptomatic
Table 2 In silico pathogenicity prediction of diazoxide-responsive patients’ mutations.
Mutation
Prediction
Mutation
previously reportedFound in dbSNP Provean SIFT MutationTaster
ABCC8
L1431F (c.4291COT) No Deleterious Damaging Disease causing (38)a
p.? (c.2697C4AOT) No Not available Not available Disease causing Novel
E1507K (c.4519GOA) Yes Deleterious Damaging Disease causing (32)
A1508P (c.4522GOC) No Deleterious Damaging Disease causing (38)a
A1153T (c.3457GOA) No Deleterious Damaging Disease causing Novel
A1185V (c.3554COT) No Neutral Damaging Disease causing Novel
p.? (c.3992-9GOA) No Not available Not available Disease causing (5)a
D1472N (c.4414GOA) Yes Deleterious Damaging Disease causing (24)a
V601I (c.1801GOA) No Neutral Tolerated Disease causing Novela
V185fs (c.554delT) Yes Not available Not available Disease causing Novel
H627fs (c.1879delC) No Not available Not available Disease causing (9)a
D1031N (c.3091GOA) No Neutral Tolerated Disease causing Novel
M1V (c.1AOG) No Neutral Damaging Disease causing (6)a
A1493T (c.4477GOA) Yes Deleterious Damaging Disease causing (14)a
R1494W (c.4480COT) Yes Deleterious Damaging Disease causing (25)a
KCNJ11
M209I (c.627GOA) No Neutral Damaging Disease causing Novel
R54H (c.161GOA) No Deleterious Damaging Disease causing Novela
E292K (c.874GOA) No Deleterious Damaging Disease causing Novel
T62M (c.185COT) No Deleterious Damaging Disease causing (4)
R177W (c.529AOT) No Deleterious Damaging Disease causing Novel
aThese patients were included in reference (3).
Diffuse tracer uptake
throughout the pancreas
–0.03
Figure 3
18F DOPA–PET CT image of patient 40 showing diffuse tracer
uptake throughout the pancreas in a patient with paternally
inherited heterozygous ABCC8 mutation. Full colour version of
this figure available via http://dx.doi.org/10.1530/EJE-14-0353.
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(recessive acting), or lead to focal CHI (if paternally
inherited and associated with loss of somatic maternal
11p allele) or diffuse CHI (dominant acting). Diazoxide, a
KATP channel opener, which is the first-line management
for CHI, is usually ineffective in biallelic disease and
monoallelic focal disease (3, 4). However, recently a case of
diazoxide-responsive focal CHI was described (23). It may
be possible that as more diazoxide-responsive CHI patients
are investigated with 18F DOPA–PET CT scan, more
diazoxide-responsive focal lesions are identified. However,
currently diazoxide responsiveness in our institution is
generally considered equivalent to excluding monoallelic
focal disease and this group of patients are not usually
considered as suitable candidates for further investigations
with 18F DOPA–PET CT. On the other hand, diazoxide-
unresponsive subgroup, particularly associated with
paternally inherited monoallelic ABCC8/KCNJ11
mutations or no identified ABCC8/KCNJ11 mutations, is
investigated with 18F DOPA–PET CT to identify focal or
diffuse subtype before proceeding with definitive treat-
ment as the treatment for focal (limited pancreatectomy)
and diffuse CHI (near-total pancreatectomy) is drastically
different (38).
In our cohort of 53 CHI patients associated with
paternally inherited monoallelic ABCC8/KCNJ11 muta-
tions, 18 (33%) patients either responded to diazoxide or
resolved spontaneously and are likely to have dominant
acting CHI. Mutations in these 18 patients are predicted
to be pathogenic by different mutation prediction
programmes (Table 2). Functional work has already
established some of these mutants to be dominant acting
and exerting their effect by a dominant-negative
mechanism (33, 39, 40). Although there was no history
of hypoglycaemia in the fathers of our cohort, formal
evaluation with controlled provocation fasting studies has
not been done. Other studies also have reported parents to
be asymptomatic carriers of dominant acting mutations
(41). In view of severe diazoxide side effects and parental
request, three patients from this subgroup underwent 18F
DOPA–PET CT imaging to avoid long-term treatment with
diazoxide. This was in the hope that these patients could
be managed with removal of focal lesion if found to be the
underlying cause for CHI. However, as suspected from the
phenotype of diazoxide-responsiveness, 18F DOPA–PET CT
identified diffuse tracer uptake throughout the pancreas.
Evaluation with 18F DOPA–PET CT in 27 diazoxide-
unresponsive patients with paternally inherited hetero-
zygous ABCC8/KCNJ11 mutations identified focal disease
in 21 (78%) patients. Majority of these patients presented
within the first week of life. There was no difference in the
age of presentation between those who were diagnosed
with diffuse or focal CHI. Apart from one patient who was
managed with octreotide therapy, these patients were
either managed with resection of the focal lesion or partial
pancreatectomy. Follow-up assessment highlighted age-
appropriate fasting tolerance and resolution of hypogly-
caemia in all except one (19/20; 95%) after the removal of
the focal lesion. Similar to our results, Lord et al. (42)
recently reported that 94% of their cohort of focal CHI
after pancreatectomy remained euglycaemic and required
no treatment for blood glucose abnormalities. In the
cohort reported by Beltrand et al. (43), 91.4% (43/47)
patients with focal CHI had complete resolution of
hypoglycaemia post-surgery. One patient in whom the
evidence of CHI persisted despite the removal of a
histologically confirmed focal lesion was managed with
diazoxide and regular feeds. A repeat 18F DOPA–PET CT
revealed diffuse tracer uptake in the remaining pancreas.
Molecular basis for CHI in this particular patient is unclear
and further studies are in progress.
In six (21%) diazoxide-unresponsive patients investi-
gated with 18F DOPA–PET CT, diffuse tracer uptake
throughout the pancreas was noticed (Fig. 3). Three of
these patients were managed with near-total pancreatect-
omy and in one of these patients, histology and
microsatellite analysis was suggestive of giant focal lesion
(44). Diffuse uptake in this particular patient was due to
the size of the focal lesion, which occupied nearly the
whole pancreas. Diffuse CHI has been described in the
literature with paternally inherited ABCC8/KCNJ11
mutations. Fernandez-Marmiesse et al. (10) reported five
patients with paternally inherited KATP mutations and
whose post pancreatectomy pathology result was not
consistent with that of focal lesion. Similar findings have
been reported by other studies (1, 21, 27, 30).
There are a number of possible mechanisms as to how a
heterozygous ABCC8/KCNJ11 mutation can lead to diffuse
disease. For example there could be a post-zygotic second hit
within the pancreas or a maternally inherited mutation may
reside within a non-coding regulatory/intronic region of the
ABCC8/KCNJ11 gene. Recently, in a patient with focal CHI
but no exonic or splice site ABCC8/KCNJ11 mutation, next-
generation sequencing identified a deep intronic ABCC8
mutation inherited fromtheunaffected father,whichcreated
a cryptic spice site and an out of frame pseudoexon (32). A
third possibility is allelic drop-out due to a rare poly-
morphism within a primer binding site. In this scenario, a
maternally inherited coding mutation could escape detec-
tion by Sanger sequencing. Besides, some of the missense
mutations may be dominantly acting (dominant negative).
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As compared with recessive acting mutations where there is
defective biogenesis or trafficking of KATP channel to the
b-cell membrane, the dominant acting mutants traffic
normally to the plasma membrane but show impaired
responsiveness to the channel agonists, MgADP and diaz-
oxide (45). Diazoxide-unresponsive mutations produce a
more severe impairment in the expressed channel response
to activation by diazoxide and MgADP as compared with
diazoxide-responsive mutations (28).
A novel genetic mechanism of diffuse disease due to
mosaic paternal uniparental isodisomy in a patient with
heterozygous ABCC8/KCNJ11 mutations was recently
described (36). Lastly, it could also very rarely be due to
failure of Sanger sequencing to detect the second
ABCC8/KCNJ11 mutation or a missed histological diag-
nosis of focal CHI in these patients. Although ABCC8 and
KCNJ11 are not known to be imprinted genes, they
are next to the 11p15.5 imprinted region, so another
hypothesis could be the involvement of epigenetic
mechanisms.
In summary, of the 53 patients associated with
paternally inherited ABCC8/KCNJ11 mutations, 29 (55%)
patients had diffuse CHI (18 (34%) patients – diazoxide-
responsive; 11 (21%) patients – diazoxide-unresponsive)
and 24 (45%) patients had confirmed focal CHI either
based on histology or LOH studies. One patient had
giant focal lesion based on histology and LOH studies,
confusing the interpretation of 18F DOPA–PET CT.
From our results, it is clear that paternally inherited
heterozygous ABCC8/KCNJ11 mutations can manifest as a
wide spectrum of CHI with focal disease in 45% patients.
This heterogeneous clinical picture could be due to
modifying genes or other unknown factors, e.g. environ-
mental, that influence the expression of the phenotype
in CHI patients.
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Abstract
Context: Congenital hyperinsulinism (CHI), the commonest cause of persistent hypoglycaemia, has two main histological
subtypes: diffuse and focal. Diffuse CHI, if medically unresponsive, is managed with near-total pancreatectomy. Post-
pancreatectomy, in addition to persistent hypoglycaemia, there is a very high risk of diabetes mellitus and pancreatic
exocrine insufficiency.
Setting: International referral centre for the management of CHI.
Patients: Medically unresponsive diffuse CHI patients managed with near-total pancreatectomy between 1994 and 2012.
Intervention: Near-total pancreatectomy.
Main Outcome Measures: Persistent hypoglycaemia post near-total pancreatectomy, insulin-dependent diabetes mellitus,
clinical and biochemical (faecal elastase 1) pancreatic exocrine insufficiency.
Results: Of more than 300 patients with CHI managed during this time period, 45 children had medically unresponsive
diffuse disease and were managed with near-total pancreatectomy. After near-total pancreatectomy, 60% of children had
persistent hypoglycaemia requiring medical interventions. The incidence of insulin dependent diabetes mellitus was 96% at
11 years after surgery. Thirty-two patients (72%) had biochemical evidence of severe pancreatic exocrine insufficiency
(Faecal elastase 1,100 mg/g). Clinical exocrine insufficiency was observed in 22 (49%) patients. No statistically significant
difference in weight and height standard deviation score (SDS) was found between untreated subclinical pancreatic
exocrine insufficiency patients and treated clinical pancreatic exocrine insufficiency patients.
Conclusions: The outcome of diffuse CHI patients after near-total pancreatectomy is very unsatisfactory. The incidence of
persistent hypoglycaemia and insulin-dependent diabetes mellitus is very high. The presence of clinical rather than
biochemical pancreatic exocrine insufficiency should inform decisions about pancreatic enzyme supplementation.
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Introduction
Congenital hyperinsulinism (CHI) is a major cause of persistent
and recurrent hypoglycaemia in the neonatal and infancy periods
[1]. It is characterized by inappropriate and unregulated secretion
of insulin from pancreatic b-cells in relation to the blood glucose
concentration. CHI is a heterogeneous disease in terms of clinical
presentation, histological subgroups and underlying molecular
genetics. There are 2 main histological subtypes: diffuse (60%–
70% of patients) and focal (30%–40% of patients) [2]. Typically
children with diffuse CHI have homozygous recessive or
compound heterozygous mutations in the ABCC8 or KCNJ11
genes (which encode the SUR1 and Kir6.2 proteins respectively –
the two components of the ATP-sensitive K+ (KATP) channel of the
pancreatic b-cell) [3,4].
Focal CHI is sporadic in inheritance and requires two
independents events: inheritance of a paternal mutation in the
ABCC8 or KCNJ11 gene, and somatic loss of maternal 11p allele
within the focal lesion [5]. Focal CHI is managed with
lesionectomy, whereas first line of treatment for diffuse CHI is
medical management (diazoxide, octreotide and continuous
feeding). If unresponsive to maximum medical management,
children with diffuse CHI are managed with near-total pancre-
atectomy (with high risk of diabetes mellitus).
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e98054
A significant percentage of children undergoing near-total
pancreatectomy continue to experience recurrent hypoglycaemia
as well as develop diabetes mellitus eventually [6,7]. Near-total
pancreatectomy is also associated with the risk of pancreatic
exocrine insufficiency. Small studies evaluating long term pancre-
atic exocrine function (using pancreozymin-secretin stimulation
test or 72 hour stool collection) following 85–95% or subtotal
pancreatectomy for CHI have been done [8,9,10,11]. There are a
number of pancreatic function tests available but measurement of
faecal elastase-1 is the currently preferred pancreatic function test
[12].
There are very few studies reporting the long term glucose
metabolism in a large cohort of diffuse CHI patients managed with
near-total pancreatectomy and no large studies assessing pancre-
atic exocrine function after near-total pancreatectomy. We
describe the immediate and long term pancreatic exocrine and
endocrine function in a large cohort of diffuse CHI patients who
underwent near-total pancreatectomy over an 18-years period.
Materials and Methods
The study was approved by the Ethics Committee of Great
Ormond Street Hospital for Children and the Institute of Child
Health, University College London. Informed written consent was
obtained from parents of enrolled children for molecular genetic
testing for CHI (ABCC8/KCNJ11 sequencing).
Among more than 300 patients with CHI managed during this
time period, 45 children had medically unresponsive diffuse
disease and were included in this study. The detailed data about
clinical presentation and management, molecular genetic analysis
results, and post-pancreatectomy periodic assessment of glucose
homeostasis were retrospectively collected by medical case-notes
review.
CHI was diagnosed based on critical blood sample taken during
an episode of spontaneous or provoked hypoglycaemia. Before
2000 when our centre started performing trans-hepatic pancreatic
venous sampling (PVS) for differentiation between diffuse and
focal CHI, all medically unresponsive CHI patients were managed
with near-total pancreatectomy (95% pancreatectomy), the
resection being identical in all patients. Medically unresponsive
diffuse disease was defined as persistent hypoglycaemia with
normal feeding schedule on diazoxide 20 mg/kg/d and/or
octreotide 30 mcg/kg/d and carbohydrate enriched feeds. After
May 2006, we started performing positron emission tomography
using isotope Fluroine-18 L-3, 4-dihydroxyphenyalanine [18F-
DOPA-PET]) to differentiate between diffuse and focal disease.
Biopsies were taken during surgery from various parts of pancreas
and analysed contemporaneously to confirm the diffuse disease
before resection, if not already suspected by genetic analysis. The
diagnosis was subsequently confirmed on histology.
Genetic testing
Genomic DNA was extracted from peripheral leukocytes using
standard procedures. The single-coding exon of the KCNJ11 gene
and the 39 exons of the ABCC8 gene were amplified using the
polymerase chain reaction. Unidirectional sequencing was per-
formed using universal M13 primers and a Big Dye Terminator
Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington,
UK) according to the manufacturer’s instructions. Reactions were
analysed on an ABI 3730 Capillary sequencer (Applied Biosys-
tems, Warrington, UK) and sequences were compared to the
reference sequences (NM_000525 and NM_000352.2) using
Mutation Surveyor v3.24 (SoftGenetics, PA, USA).
Loss of heterozygosity was investigated by microsatellite analysis
of DNA extracted from paraffin-embedded pancreatic tissue and
peripheral leukocytes. Six markers (D11S2071, D11S1964,
D11S419, D11S1397, D11S1888 and D114138) were amplified
by PCR and allele peak heights were compared using GeneMarker
v1.85 (SoftGenetics, PA, USA).
Pancreatic endocrine assessment
Post-pancreatectomy, periodic 24-hr blood glucose profile,
controlled fast and/or oral glucose tolerance tests were performed
in our centre to assess glucose homeostasis, starting before hospital
discharge after pancreatectomy (immediate outcome). Recurrent
or persistent hypoglycaemia (blood glucose ,3 mmol/l) post-
pancreatectomy was managed with addition of extra carbohydrate
in the feeds, continuous feeds and/or medical therapy with
diazoxide or octreotide. Second pancreatectomy was undertaken if
normoglycaemia could not be achieved with medical manage-
ment. Controlled fast was used to inform decisions about regular
daytime feeds, overnight continuous feeds and extra carbohydrate
in the feeds. Multiple readings of hyperglycaemia (blood glucose.
11 mmol/L) on 24-hour profile was investigated with oral glucose
tolerance test. Diabetes mellitus was diagnosed according to World
Health Organisation criteria. Episodes of postprandial hypergly-
caemia were managed with dietary management. Insulin therapy
was considered when patient developed pre- and postprandial
hyperglycaemia and started in low doses to avoid hypoglycaemia
due to residual endogenous insulin production.
Pancreatic exocrine assessment and Anthropometry
Within 3 months of pancreatectomy, faecal elastase 1 was
measured by sandwich ELISA method utilizing two monoclonal
antibodies highly specific for human pancreatic elastase 1
(ScheBo). A single random stool sample (about 100 mg) was
required. The sample was prepared and analysed according to
manufacturer’s instruction. The detection range was 15 to 500 mg
E1/g stool.
In addition to measurement of faecal elastase 1, patients were
also monitored for clinical symptoms of pancreatic exocrine
insufficiency including pale stools, abdominal discomfort, excessive
flatulence, and poor weight gain. Patients manifesting these
symptoms were managed with pancreatic enzyme replacement
(Creon Micro [Abbott Healthcare, Maidenhead, UK] 100 mg
before each feed or equivalent). Resolution of symptoms on
pancreatic enzyme supplements was used as criteria for clinical
pancreatic exocrine insufficiency.
In patients not requiring pancreatic enzyme supplementation,
faecal elastase 1 was measured annually or at the onset of clinical
pancreatic exocrine insufficiency. In those patients already
commenced on pancreatic enzyme supplementation during
previous assessment, only clinical monitoring was performed.
Correlation between clinical and biochemical pancreatic exocrine
insufficiency was made.
Weight and height from the last clinical assessment was
converted to weight and height standard deviation score (SDS).
Statistical analysis
Data analysis was conducted by using SPSS statistics software,
version 22.0 (IBM SPSS Statistics 22). The normality of the data
was assessed by Shapiro-Wilk test. The medians were compared
using Mann-Whitney U test. A P value,0.05 was considered
statistically significant. The evolution of diabetes mellitus post-
pancreatectomy was estimated using Kaplan-Meier analysis.
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Results
From 1994 to 2012, 45 children underwent near-total
pancreatectomy for management of medically unresponsive diffuse
CHI (table 1). These patients presented with severe hypoketotic,
hypofattyacidaemic hypoglycaemia, biochemical hallmark of
inappropriate insulin secretion. Five patients presented between
1994 and 2000, and underwent near-total pancreatectomy without
undergoing PVS or 18F-DOPA-PET. All five patients had diffuse
disease on histology. Later genetic analysis confirmed four patients
to have biallelic ABCC8 mutation, and one patient to have
paternally inherited monoallelic ABCC8 mutation.
Nine patients with medically unresponsive CHI who presented
between 2000 and May 2006 were diagnosed to have diffuse CHI
on PVS. The remaining medically unresponsive CHI patients who
presented after May 2006 were diagnosed as diffuse CHI either on
the basis of 18F-DOPA-PET or molecular genetic analysis (biallelic
mutations).
Apart from one international patient who developed diabetes
mellitus immediately post-pancreatectomy and was lost to follow-
up, all patients were regularly followed up in our centre at least
until they developed diabetes mellitus.
Pancreatic Endocrine function
Figure 1 shows immediate post-operative pancreatic endocrine
function outcome following near-total pancreatectomy.
Hypoglycaemia
Post-pancreatectomy, 27 children (60%) continued to have
episodes of hypoglycaemia. Hypoglycaemia was less severe as
compared to before pancreatectomy and was successfully managed
with octreotide in 15 (33.3%), diazoxide in 3 (6.6%) and regular
daytime and overnight feeds in 7 (15.6%). Second pancreatectomy
was required in 2 children (4.4%). Over a mean (6 S.D.)/median
(range) follow up period of 6.71 (64.75)/6.52 (0.1–17.5) years,
episodes of hypoglycaemia resolved in 12 children (27%) and the
medical treatments were successfully stopped. Episodes of hypo-
glycaemia persisted up to the age of 7 years in some children. In
the remaining 15 children, the median fasting tolerance was
5 hours (range 3–14 hours) on the current treatment.
Hyperglycaemia
Over a mean (6 S.D.)/median (range) follow up period of 6.71
(64.75)/6.52 (0.1–17.5) years, twenty-two (49%) children devel-
oped hyperglycaemia requiring insulin treatment. Ten children
(22%) developed hyperglycaemia requiring insulin therapy imme-
diately after pancreatectomy. Four of these required insulin
treatment transiently for a period of 6–12 months. The incidence
of hyperglycaemia requiring definitive insulin therapy increased
from 13% immediately post-pancreatectomy to 77% at 7 years
and then to 96% at 11 years post-surgery (figure 2).
Table 1. Characteristics of 45 children managed with near-total pancreatectomy.
Demographics Patients (n) 45
Boys/Girls (n) 20/25
Birth weight (g)* 40896805
Gestational age (weeks)* 3862
Age at presentation (days)# 1 (1–56)
Hypoglycaemia screen Serum glucose (mmol/l)* 1.860.7
Serum Insulin (mU/l)* 34.3642.9
Age at surgery (n) 0–4 weeks 5
5–12 weeks 24
13–52 weeks 12
.52 weeks 4
ABCC8/KCNJ11 mutation analysis (n) Homozygous 10
Compound heterozygous 15
Dominant heterozygous 12
Contiguous gene deletion (Usher’s syndrome) 3
No mutation 5
*Mean6S.D.
#Median (Range).
doi:10.1371/journal.pone.0098054.t001
Figure 1. Immediate outcome of 45 children with medically
unresponsive diffuse CHI managed with near-total pancrea-
tectomy.
doi:10.1371/journal.pone.0098054.g001
Pancreatic Endocrine and Exocrine Function
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e98054
Pancreatic Exocrine function and Anthropometry
Of these 45 children, 32 (72%) had faecal elastase 1 either
undetectable (,15 mg/g of stools) or suggestive of severe
pancreatic exocrine insufficiency (15–100 mg/g of stools). Clinical
pancreatic exocrine insufficiency was diagnosed in 22/45 (49%)
patients. The sensitivity and specificity of faecal elastase 1 for
predicting clinical pancreatic exocrine insufficiency in our series
was 95% and 52% respectively.
In the biochemical pancreatic exocrine insufficiency group
(n = 32), no statistically significant difference was found in age,
weight SDS and height SDS on comparison between subgroups
with treated clinical pancreatic exocrine insufficiency (n = 19) and
untreated subclinical pancreatic exocrine insufficiency (n = 13)
(figure 3).
Discussion
CHI is a heterogeneous disease with regards to responsiveness
to medical treatment. A significant proportion of children require
surgical resection of the pancreas to control the CHI. Most
published series report an unacceptably high incidence of
recurrent hyperinsulinemia following ,95% pancreatectomy,
with need for up to a 98% pancreatectomy in refractory cases
[13,14,15]. In addition to persistent hypoglycaemia, these children
are also at high risk of developing severe pancreatic exocrine
insufficiency and diabetes mellitus.
In our large single centre cohort, 27/45 (60%) children had
persistent hypoglycaemia after near-total pancreatectomy. Meiss-
ner et al published on long-term follow-up of 114 patients with
CHI of all types (focal and diffuse; diazoxide responsive and
unresponsive) [16]. More than half patients in this series (63/114;
55%) required pancreatic surgery comprising of partial (3%),
subtotal (37%) or near-total (15%) pancreatectomy. Persistent
hypoglycaemia was observed in 40% of patients after pancreatic
surgery. However as the data was collected by survey of different
hospitals, there is likely to be an unknown reporting bias in their
study as compared to robust high quality single centre data
presented here.
Similar to our study, Beltrand et al. recently published on
glucose metabolism in 105 children and adolescents with CHI
managed with pancreatectomy, 58 of whom had diffuse CHI and
underwent near-total pancreatectomy. Of these 58 children, 59%
had persistent but mild hypoglycaemia after surgery [6]. As we
report very similar outcome from another large centre, these
findings become of heightened clinical interest and highlight the
consideration for alternative treatment strategies in this disease
such as prolonged intensive medical and nutritional treatment,
with high dose medication.
Leibowitz et al. evaluated endocrine pancreatic function in 14
patients with persistent hyperinsulinaemic hypoglycaemia of
infancy 6.5–21 years after diagnosis, eight of which have been
managed with early subtotal pancreatectomy [17]. In this study,
the insulin response to glucose was blunted in all pancreatecto-
mized patients, and six developed overt diabetes mellitus during
puberty.
Figure 2. Cumulative incidence of definitive insulin therapy in
45 medically unresponsive diffuse CHI patients managed with
near-total pancreatectomy.
doi:10.1371/journal.pone.0098054.g002
Figure 3. Comparison of weight and height SDS between untreated (no pancreatic enzyme supplementation) subclinical group and
treated (appropriate pancreatic enzyme supplementation) clinically symptomatic group using Mann-Whitney U test.
doi:10.1371/journal.pone.0098054.g003
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Cade et al. evaluated six children after pancreatectomy for
persistent hyperinsulinaemic hypoglycaemia of infancy and
reported diabetes mellitus in the only child who had entered
puberty [8]. In our cohort, nearly one-quarter of the patients (10/
45; 22%) developed hyperglycaemia in the days after surgery. Of
these 10 patients with hyperglycaemia after pancreatectomy, 4
(9%) required insulin therapy transiently. The incidence of
definitive insulin therapy increased from 13% postoperatively to
80% at 8 years and then 96% at 11 years post pancreatectomy. As
compared to the study by Beltrand et al., twice number of patients
in our cohort required definitive insulin therapy by 8 years post
pancreatectomy (80% vs 42%). Surprisingly, the incidence of
insulin-dependent diabetes mellitus in a study by Meissner et al.
was only 28% by the mean age of 14 years [16]. This is likely to be
due to more patients undergoing sub-total rather than near-total
pancreatectomy or perhaps healthy remaining pancreatic b-cells
not undergoing apoptosis. The incidence of diabetes mellitus in the
study by Meissner et al. rose to 71% after re-operation for
persistent HH [16].
Fourteen (31%) patients in our study achieved stable euglycae-
mia for more than 2 years duration after pancreatectomy without
the development of hyperglycaemia. Meissner et al. reported
stable long-term euglycaemia after surgery without the need of
further surgery or the development of hyperglycaemia in 27% of
all operated patients [16]. However for this cohort of patients,
surgery was performed without prior investigation for differenti-
ating between focal and diffuse CHI. The authors acknowledged
that focal lesions in the head of the pancreas may have been
missed by blind pancreatic resections. Although equivalent
number of patients achieved stable euglycaemia in our series,
the slightly better outcome as compared to the study by Meissner
et al. could be because of the exclusion of focal lesions in the head
before surgery in our cohort.
Few small studies which have evaluated pancreatic exocrine
function using different methods in this clinical setting have
reported subclinical deficiency rather than clinical exocrine
dysfunction in these patients [8,9,11]. Dunger et al. reported low
trypsin, amylase and bicarbonate concentrations with cholecysto-
kinin-secretin test in approximately two-thirds of their patients
who had 95% pancreatectomy whereas Rother et al. reported
normal pancreatic exocrine function based on clinical history and
72-h stool collection in eight children after subtotal pancreatec-
tomy for CHI [9,11]. Though cholecystokinin-secretion test or one
of its modifications are the gold standard for pancreatic exocrine
function, they have drawbacks of being time consuming, invasive
and not being routinely available in clinical practice. In addition,
there are no standardized enzyme cut-off values or agreement
between centres as to which parameter is the most specific for the
assessment of pancreatic function.
Measurement of faecal elastase 1 is the currently preferred
pancreatic function test and is the new gold standard for non-
invasive pancreatic function testing. Faecal elastase 1 is a
pancreas-specific proteolytic enzyme that binds to bile salts and
is not degraded during its passage through the gut, unlike other
pancreatic enzymes [18]. Studies have shown that measurement of
faecal elastase 1 correlates well with pancreatic output of elastase-1
and other pancreatic enzymes such as amylase, lipase and trypsin
[19]. A faecal elastase 1 value of ,200 mg/g of stool is the cut-off
for pancreatic exocrine insufficiency. To the best of our
knowledge, there are no studies assessing pancreatic exocrine
function following pancreatectomy utilizing measurement of faecal
elastase 1. It is unclear whether subclinical pancreatic exocrine
deficient patients will benefit from pancreatic enzyme supplemen-
tation.
In our cohort, nearly three-quarter patients (32/45; 72%) had
either undetectable faecal elastase 1 or in the severe pancreatic
exocrine insufficiency range. Clinical pancreatic exocrine insuffi-
ciency was evident in 22/45 (49%) patients requiring pancreatic
enzyme supplementation. In nearly one-quarter of the patients
(12/45; 27%), no correlation between the biochemical and clinical
pancreatic exocrine insufficiency was observed. No statistically
significant difference was observed in weight and height SDS
between treated subclinical pancreatic exocrine deficient patients
and treated clinical pancreatic exocrine insufficiency patients
(figures 3).
We acknowledge that faecal elastase 1 is an indirect pancreatic
function test and is likely to be more prone to errors than the direct
pancreatic function tests but because of its simple technique is used
most often in the setting likely to result in pancreatic exocrine
insufficiency such as post-pancreatectomy. With the increased
awareness of CHI, need for appropriate management to avoid
poor neurological outcome (near-total pancreatectomy in medi-
cally unresponsive diffuse disease), and advancement in the
radiological (18F DOPA-PET CT) and laparoscopic surgical
techniques, clinicians are likely to come across post-pancreatecto-
my biochemical pancreatic exocrine insufficiency scenario. Our
results highlight that faecal elastase-1 has poor specificity and
should be cautiously interpreted in absence of clinical pancreatic
exocrine insufficiency to inform clinical decisions about pancreatic
enzyme replacement treatment.
In our cohort, although a number of patients had monoallelic
ABCC8/KCNJ11 mutations which usually results either in mild
diazoxide responsive CHI or focal CHI if paternally inherited and
associated with somatic loss of maternal 11p allele, detailed
evaluation did not show response to medical therapy and histology
showed diffuse disease. Diazoxide unresponsive diffuse CHI has
been reported in association with dominant heterozygous ABCC8/
KCNJ11 mutations [20]. Another plausible hypothesis is that some
of these patients may have a deep intronic mutation on the second
allele that was not identified on Sanger sequencing or have a
different mechanism of diffuse CHI [21].
A limitation of this study is its retrospective nature. In addition,
the data presented here span a period of nearly two decades
during which there were a number of significant advances in the
management of CHI (introduction of PVS and 18F DOPA-PET
CT) and hence changes in the algorithms for the management.
Despite these limitations, our robust single centre data on a large
cohort of a complex group of CHI patients highlights the need for
research for alternative treatment strategies in this disease.
Conclusions
In conclusion, long-term follow up a large cohort of medically
unresponsive diffuse CHI patients has shown that milder
hypoglycaemia persisted in 60% patients in this CHI subgroup
after near-total pancreatectomy. The incidence of insulin depen-
dent diabetes mellitus was nearly 100% after 11 years post-
pancreatectomy. There seems to be poor correlation between the
biochemical (faecal elastase 1) and clinical evidence of pancreatic
exocrine insufficiency. Untreated subclinically pancreatic exocrine
deficient children thrive as well as treated clinically pancreatic
exocrine deficient children.
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Abstract
Objective: Congenital hyperinsulinism (CHI) is the commonest cause of hyperinsulinaemic hypoglycaemia in the neonatal,
infancy and childhood periods. Its clinical presentation, histology and underlying molecular biology are extremely
heterogeneous. The aim of this study was to describe the clinical characteristics, analyse the genotype–phenotype
correlations and describe the treatment outcome of Turkish CHI patients.
Design and methods: A total of 35 patients with CHI were retrospectively recruited from four large paediatric endocrine
centres in Turkey. Detailed clinical, biochemical and genotype information was collected.
Results: Diazoxide unresponsiveness was observed in nearly half of the patients (nZ17; 48.5%). Among
diazoxide-unresponsive patients, mutations in ABCC8/KCNJ11 were identified in 16 (94%) patients. Among
diazoxide-responsive patients (nZ18), mutations were identified in two patients (11%). Genotype–phenotype correlation
revealed that mutations in ABCC8/KCNJ11 were associated with an increased birth weight and early age of presentation.
Five patients had p.L1171fs (c.3512del) ABCC8 mutations, suggestive of a founder effect. The rate of detection of
a pathogenic mutation was higher in consanguineous families compared with non-consanguineous families
(87.5 vs 21%; P!0.0001).
Among the diazoxide-unresponsive group, ten patients were medically managed with octreotide therapy and carbohydrate-
rich feeds and six patients underwent subtotal pancreatectomy. There was a high incidence of developmental delay and
cerebral palsy among diazoxide-unresponsive patients.
Conclusions: This is the largest study to report genotype–phenotype correlations among Turkish patients with CHI.
Mutations in ABCC8 and KCNJ11 are the commonest causes of CHI in Turkish patients (48.6%). There is a higher
likelihood of genetic diagnosis in patients with early age of presentation, higher birth weight and from consanguineous
pedigrees.
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Introduction
Hyperinsulinaemic hypoglycaemia (HH) is the common-
est cause of hypoglycaemia in the neonatal, infancy and
childhood periods (1, 2, 3). It occurs due to the
unregulated secretion of insulin from pancreatic b-cells
leading to severe and persistent hypoglycaemia. HH can be
congenital (congenital hyperinsulinism, CHI) or transient
due to risk factors such as perinatal asphyxia, intrauterine
growth restriction (IUGR) and maternal diabetes mellitus
(gestational or non-gestational) (1, 2, 3).
CHI refers to a group of conditions that are extremely
heterogeneous in terms of clinical presentation, histo-
logical subgroups and underlying molecular biology. The
molecular basis of CHI involves genetic defects in nine
different genes (ABCC8, KCNJ11, GLUD1, GCK, HADH,
SLC16A1, HNF4A, HNF1A and UCP2) that are involved in
regulating insulin secretion from b-cells (1, 3). Mutations
in the ABCC8 and KCNJ11 genes that encode the two
subunits (SUR1 and Kir6.2) of ATP-sensitive potassium
(KATP) channel are the commonest cause of CHI (4, 5).
At a histological level, two major subtypes of CHI
(diffuse and focal) have been described. The differentiation
of these two histological subtypes is important from the
management point of view (6). The diffuse form may
require a near-total pancreatectomy (with the risk of
diabetes mellitus and pancreatic exocrine insufficiency),
whereas the focal form will only require a limited focal
lesionectomy. The frequency of focal disease has been
reported to be 30–40% of all CHI patients in different series
(7, 8). Genetic analysis and specialised positron emission
tomography scan using the isotope Fluorine 18 L-3,4-
dihydroxyphenyalanine (18F-DOPA-PET) can be helpful in
differentiating focal and diffuse diseases (9, 10). PET scan
can also localise the focal lesions within the pancreas.
Regarding their underlying genetic basis, the diffuse form
is inherited in an autosomal recessive (or dominant)
manner, whereas the focal form is sporadic in inheritance.
Besides differentiation of focal and diffuse diseases,
documentation of protein sensitivity constitutes another
important issue in the management of CHI. Mutations in
GLUD1 and HADH are associated with protein-sensitive
CHI (11, 12). Protein-restricted diet may increase the
success of medical therapy (13).
Although the incidence of CHI in the general
population is one in 35 000–40 000, it rises to one in
2500 in the communities with the high rates of con-
sanguinity (14). Turkey also has a high rate of consangui-
neous marriage (15). Thus, interpretation of clinical
characteristics, genetic basis and phenotype–genotype
relation of Turkish patients with CHI could bring a new
perspective in understanding genetic basis, genotype–
phenotype correlation andmanagement of CHI. However,
to our knowledge, to date, except for two small studies
reporting the clinical and genetic characteristics offive and
13 Turkish patients with CHI, there is no large-scale study
reporting clinical and genetic characteristics of Turkish
children with CHI (16, 17). In this study, we describe
clinical characteristics, genetic results and treatment
outcome of a large cohort of CHI patients from Turkey.
Subjects and methods
Patients
Patients presenting with CHI to four large paediatric
endocrine centres in Turkey were included in this study.
CHI was defined as a detectable insulin level (R2 mU/l)
during an episode of spontaneous or provoked hypo-
glycaemia (blood glucose !3.0 mmol/l). Patients with
secondary HH due to IUGR, evidence of perinatal asphyxia
and maternal diabetes mellitus were excluded. Detailed
clinical and biochemical information was collected from
the responsible clinician of these patients.
Written informed consent was obtained from parents
of all participants for genetic mutation analysis. Diazoxide
(5–15 mg/kg per day) was commenced as first line for the
management of CHI. In diazoxide-unresponsive patients,
octreotide (5–40 mg/kg per day) was tried. Patients unre-
sponsive to medical therapy were managed with open
near-total pancreatectomy. As 18F-DOPA-PET–CT is not
currently available in Turkey, a near-total pancreatectomy
was performed for all patients who required surgical
therapy irrespective of the results of molecular genetic
analysis.
Mutation analysis
Genomic DNA was extracted from peripheral leukocytes
using standard procedures and the coding regions and
intron/exon boundaries of the ABCC8 and KCNJ11 genes
were amplified by PCR (primers available on request) in all
patients. Amplicons were subsequently sequenced using
the Big Dye Terminator Cycler Sequencing Kit v3.1
(Applied Biosystems) according to the manufacturer’s
instruction and reactions were analysed on an ABI 3730
Capillary sequencer (Applied Biosystems). Sequences were
compared with the reference sequences (NM_000525.3
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and NM_000352.3) using the Mutation Surveyor v3.24
software (SoftGenetics, State College, PA, USA). If no
mutations in ABCC8 and KCNJ11 were identified, the
coding regions of HADH (only in diazoxide-responsive
patients and those with abnormal acylcarnitine and/or
urine organic acid profile) and HNF4A were amplified and
sequenced as described previously (18, 19).
Statistical analyses
IBM SPSS statistics 21.0 for Windows software package
program was used for statistical analyses. The Kolmo-
gorov–Smirnov test was used to test normality for
distribution of data. The independent samples t-test was
used to compare mean of normally distributed data and
the Mann–Whitney U test for non-normally distributed
data. The c2-test was used to compare the ratios. A P value
of !0.05 was considered statistically significant.
Results
A total of 35 patients presented with CHI between April
2002 and October 2013. The clinical and biochemical
characteristics at presentation are summarised in Table 1.
The median follow-up period for this cohort of patients
was 2 years and 3 months (range: 1 month–10.5 years).
Mutation analysis, genotype–phenotype relation and
treatment outcome
Mutation analysis " Molecular genetic analysis ident-
ified pathogenic mutations in 51.4% of Turkish CHI
patients (18/35; ABCC8 (14 patients), KCNJ11 (three
patients) and HADH (one patient)) (Table 2). The KATP
channel mutations included homozygous (13),
compound heterozygous (2) and paternally inherited
heterozygous (1) mutations. Maternal DNA was unavail-
able for testing to confirm the inheritance pattern in one
patient with heterozygous ABCC8 mutation.
While a mutation was identified in 14 out of 16
patients (87.5%) from consanguineous families, it was
identified only in four out of 19 patients (21%) from
non-consanguineous families (P!0.0001).
In 40% (14/35) of the CHI patients, eight different
ABCC8mutations were identified. One of the commonest
mutations in our cohort was p.L1171fs (c.3512del), a
frameshift mutation on exon 28 of ABCC8 gene (five
patients). Four unrelated patients from consanguineous
families were homozygous for this mutation and one
was heterozygous (inherited from unaffected father).
Another common mutation identified was c.3554COA
(p.Ala1185Glu). This was a novel mutation identified in
the homozygous state in four first cousins and a second
unrelated proband.
The remaining six ABCC8 mutations, p.R168C,
p.N188S, p.L533P, p.W232G, p.R842Q and p.F591L were
each identified in a single patient. Among these, p.L533P
and p.W232G were novel mutations. These novel variants
are not listed in various sequence variant databases
(dbSNP, Exome Variant Server and 1000 Genomes) and
the nucleotide at this position is conserved across all
species. Additionally, in silico analysis by SIFT, PolyPhen2,
AlignGVGD and Grantham distance predicts these novel
variants to be likely pathogenic.
In 8.6% (3/35) of the CHI patients, three different
KCNJ11 mutations were identified. These included two
missense (p.E126K, and p.R34H) and one nonsense
(p.W91X) mutation. Among these, p.E126K was a novel
mutation. The p.E126K mutation was identified in two
probands in our cohort. Conservation across species,
in silico analysis and comparison with various sequence
databases predict this variant to be likely pathogenic.
The remaining two mutations in KCNJ11, p.W91X and
p.R34H, were identified in trans in a single patient and
have been reported previously (20).
A previously described homozygous nonsense
mutation in exon 6 of HADH (p.R236X) was identified in
one patient. A protein-loading test showed protein-
sensitive HH in this patient.
Sequencing of ABCC8, KCNJ11, HNF4A and HADH
did not identify a causative mutation in the remaining
15 patients.
Table 1 Clinical characteristics of CHI patients.
Clinical characteristics Results
Number of patients, n 35
Males, n (%) 20 (57.1)
Gestational age (weeks)a 38 (29–40)
Birth weight (g)b 3407G789
Large for gestational age
(O90th percentile), n (%)
14 (40)
Age at presentation (weeks)a 1 (1–48)
Presentation within
first week of life, n (%)
19 (58)
Consanguinity, n (%) 16 (45.7)
Family history of CHI, n (%) 7 (20)
Hypoglycaemia screenb
Blood glucose (mmol/l) 1.7G0.5
Serum insulin (mU/l) 32.7G35.9
Hyperammonaemiac 0
aMedian (range).
bMeanGS.D.
cSerum ammonia more than twice the normal upper limit.
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Genotype–phenotype correlation " Comparison
between KATP mutation-positive and KATP mutation-
negative groups highlighted a statistically significant
increased birth weight and younger age of presentation
in KATP mutation-positive group as compared with KATP
mutation-negative patients (Table 3).
Rate of detection of a pathogenic mutation in
diazoxide-unresponsive patients (16/17; 94.1%) was
higher than that of diazoxide-responsive group (2/18,
11.1% (P!0.0001) (Fig. 1).
Treatment outcome " Of the total number of patients,
18 (51.4%; median age 22 months (range 3–128 months))
were responsive to diazoxide treatment (Fig. 1). Children
were defined as being diazoxide responsive if they
demonstrated age-appropriate fasting tolerance or evi-
dence of appropriate hyperketonaemia before developing
hypoglycaemia on diazoxide at doses!15 mg/kg per day.
Administration of diazoxide could be successfully stopped
in four of the diazoxide-responsive CHI patients at a
median age of 3.5 months (range, 3–15 months). Of these,
a pathogenic mutation was identified in only two patients
(monoallelic ABCC8 – 1 and biallelic HADH – 1).
Of the diazoxide-unresponsive group (17), six patients
underwent pancreatectomy (five subtotal and one near-
total) and ten patients were managed with octreotide
treatment. One patient was lost to follow-up and
represented at a later age with severe learning disability
due to uncontrolled severe hypoglycaemia. A pathogenic
mutation was identified in 16 out of 17 patients (94.1%;
biallelic KATP – 15 and paternally inherited KATP – 1).
The median age at pancreatectomy was 1.5 months
(range 1–2 months). Histological examination identified
typical diffuse disease (abnormal large b-cell nuclei in
pancreatic islets and low nuclear crowding in the whole
pancreas) in all of these patients. After pancreatectomy, one
patient unfortunately diedbecause of sepsis and four patients
required octreotide treatment to maintain euglycaemia. In
only one patientwho underwent near-total pancreatectomy,
normoglycaemia was achieved without the need for
additional medical therapy. There was no correlation
between the type of mutation and the severity of CHI.
Long-term neurological sequelae such as develop-
mental delay, cerebral palsy and epilepsy were higher in
diazoxide-unresponsive patients (9/17) as compared with
diazoxide-responsive (3/18) patients (52.9 vs 16.6%;
PZ0.035).This is likely tobedue todifficulties incontrolling
hypoglycaemia in the diazoxide-unresponsive group.
Table 3 Clinical characteristics of CHI patients with and
without mutation at presentation. Data are presented as
meanGS.D.
Characteristics
Mutation
positive
Mutation
negative P value
Birth weight (g) 3725G664 3070G788 0.012
Gestational age
(weeks)
38.6G1.6 37.6G3.1 0.532
Age of presentation
(weeks)
3.1G6.8 10.3G13.8 0.032
Serum insulin (mU/l) 36.1G34.4 29.2G38.1 0.355
Blood glucose level
(mmol/l)
1.7G0.5 1.8G0.6 0.456
P!0.05 was considered statistically significant.
Patient with CHI
(n=35)
Mutation negative
(n=1; 5.9%)
Diazoxide responsive No (n=17)Yes (n=18)
Mutation positive
(n=2; 11.1%)
Mutation negative
(n=16; 88.9%)
Mutation positive
(n=16; 94.1%)
Surgical management
(n=2)
Medical management
(n=9)
ABCC8 mutation
(n=13; 76.5%)ABCC8 mutation(n=1; 5.5%)
HADH mutation
(n=1; 5.5%1)
KCNJ11 mutation
(n=3; 17.6%)
Surgical management
(n=4)
Medical management
(n=1)
Medical management
(n=1)
Medical management
(n=1)
Figure 1
Mutation analysis results and treatment choices for patients with diazoxide-responsive CHI vs diazoxide-unresponsive CHI.
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Discussion
In this study, 18 out of 35 patients (51.4%) had a genetically
confirmed diagnosis of CHI (biallelic – 15 andmonoallelic –
3). In two recent large studies of patients with CHI, genetic
mutations were identified in 45.3 and 78.8% (21, 22).
Mutations in the KATP channel genes were the commonest
identifiable cause in our cohort (biallelic ABCC8 – 12,
monoallelic ABCC8 – 2 and biallelic KCNJ11 – 3).
All patients with biallelic KATP channel mutations in
our cohort (nZ15; 43%) were unresponsive to diazoxide
treatment. Despite high doses of diazoxide for an adequate
period of time, these patients could not be weaned off
high-concentration dextrose fluids and experienced ran-
dom episodes of hypoglycaemia. Similar findings have
been reported by other investigators (Table 4). In the
studies by Kapoor et al. (21) and Snider et al. (22), all
patients with biallelic KATP mutations (63/300 (21%) and
84/417 (20%)) were unresponsive to diazoxide. The
prevalence of homozygous KATP mutations in these studies
(15 and 3.6%) was less when compared with our study
(42.8%), possibly due to high consanguinity in our cohort.
The studies by Kapoor et al. (21) and Snider et al. (22)
have not mentioned the percentage of patients born of
consanguineous marriage in their cohorts.
Five patients with biallelic KATP mutations were treated
with near-total pancreatectomy and the remaining patients
were treated with s.c. octreotide injections and carbo-
hydrate-rich feeds. All the patients with biallelic KATP
channelmutationswhowerepancreatectomisedhaddiffuse
disease onhistological examination of the pancreatic tissue.
Of the two patients with monoallelic ABCC8
mutations, the mutation was paternally inherited in one
patient (p.Leu1171fs). This patient was medically unre-
sponsive and was treated with near-total pancreatectomy.
The histology of the resected pancreatic tissue showed
diffuse disease, although it is likely that the focal lesion
could have been missed. As this particular ABCC8
mutation was present in monoallelic state in clinically
unaffected parents (although not biochemically evalu-
ated) of four different patients in our cohort and it is a null
mutation, it seems likely that this was a recessive ABCC8
mutation which has been unmasked by paternal unipar-
ental disomy within the pancreas. Although there is no
family history of hyperinsulinism or early-onset diabetes
mellitus on the maternal side, the milder clinical
phenotype (diazoxide responsiveness) of the second
patient with monoallelic non-paternal ABCC8 mutation
(maternal DNA unavailable for testing) was suggestive of
dominant ABCC8 mutation. Ta
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The other interesting observation in our study was the
low prevalence of monoallelic KATP mutation (2/35; 5.7%).
This is in sharp contrast to observations from genetic
analysis of patients fromKorea and Japan, where the single
mutation rate was between 50 and 60% (Table 4) (20, 23).
In the study by Kapoor et al., monoallelic KATP mutation
was present in 14.6% of patients, whereas 48% of
patients had monoallelic KATP mutation in the study by
Snider et al. (21, 22).
In our cohort, about half of the patients were
diazoxide responsive (nZ18). Only two patients from
this group had a pathogenic mutation (monoallelic
ABCC8 – 1 and biallelic HADH – 1). No mutation could
be identified in the remaining 16 out of 18 (88.9%)
diazoxide-responsive patients. The mutation detection
rate in diazoxide-responsive category in our cohort is less
when compared with other studies (21, 22). This may be
due to the fact that sequencing of GLUD1, GCK andHADH
genes was not performed in these patients unless indicated
by the clinical phenotype. Novel genetic mechanisms
might be responsible for CHI in these patients.
In our study, the majority of diazoxide-unresponsive
patients (16/17; 94.1%) had a KATP channel mutation. This
has been established in large cohort studies by Kapoor
et al. (21) and Snider et al. (22) (87.6 and 91% respectively).
Our results are in line with these larger studies.
This study identified a number of novel ABCC8 and
KCNJ11 mutations (Table 2). One particular novel ABCC8
missensemutation (p.A1185E, c.3554COA), co-segregating
withdisease in the family,was found in four affected cousins
from one family and another unrelated patient. In addition
to this mutation, another ABCC8 mutation (p.L1171fs,
c.3512delT) was also detected in five patients from four
different families, possibly suggesting a founder effect.
In this study, integration of the clinical findings and
genetic results suggests the likelihood of KATP mutations
in patients with CHI in the presence of increased birth
weight and earlier age of presentation. It was striking that
those patients with KATP channel mutations presented
earlier and had a higher birth weight when compared with
patients without a KATP channel mutation. Previous
studies have shown that there may be an overlap between
birth weight and age of presentation between patients
with HNF4A and KATP channel mutations (21). However,
our study clearly showed the difference in age of
presentation and birth weight between KATP channel-
positive and -negative groups. These observations can be
very helpful in the clinical management of patients with
CHI, especially if the clinicians do not have access to
urgent molecular genetic analysis.
Lastly, in our cohort, 12 out of 35 (34%) patients had
long-term neurological sequelae such as developmental
delay, cerebral palsy and epilepsy. This is similar to what
has been reported in the recent literature from Turkey (24).
The likelihood of adverse neurological sequelae was
significantly higher in the diazoxide-unresponsive group.
Conclusions
In conclusion, in this largest Turkish cohort with CHI,
KATP channel mutations were detected in 48.6% (17/35) of
the patients studied. The likelihood of long-term neuro-
logical sequelae was higher in the diazoxide-unresponsive
group, highlighting the need for management of these
complex patients in highly specialised centres. Additional
research to identify novel genetic mechanisms for patients
with diazoxide-responsive CHI is required.
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Abstract
Background Hepatocyte nuclear factor 4a (HNF4A) is a member of the nuclear receptor family of ligand-activated
transcription factors. HNF4A mutations cause hyperinsulinaemic hypoglycaemia in early life and maturity-onset
diabetes of the young. Regular screening of HNF4A mutation carriers using the oral glucose tolerance test has been
recommended to diagnose diabetes mellitus at an early stage. Glucagon-like peptide-1 and glucose-dependent
insulinotropic polypeptide are incretin hormones, responsible for up to 70% of the secreted insulin after a meal in
healthy individuals. We describe, for the first time, gradual alteration of glucose homeostasis in a patient with HNF4A
mutation after resolution of hyperinsulinaemic hypoglycaemia, on serial oral glucose tolerance testing. We also
measured the incretin response to a mixed meal in our patient.
Case report Our patient was born with macrosomia and developed hyperinsulinaemic hypoglycaemia in the neonatal
period. Molecular genetic analysis confirmed HNF4A mutation (p.M116I, c.317G>A) as an underlying cause of
hyperinsulinaemic hypoglycaemia. Serial oral glucose tolerance testing, after the resolution of hyperinsulinaemic
hypoglycaemia, confirmed the diagnosis of maturity-onset diabetes of the young at the age of 10 years. Interestingly, the
intravenous glucose tolerance test revealed normal glucose disappearance rate and first-phase insulin secretion. Incretin
hormones showed a suboptimal rise in response to the mixed meal, potentially explaining the discrepancy between the
oral glucose tolerance test and the intravenous glucose tolerance test.
Conclusions Maturity-onset diabetes of the young can develop as early as the first decade of life in persons with an
HNF4A mutation. Impaired incretin response might be contributory in the early stages of HNF4A maturity-onset
diabetes of the young.
Diabet. Med. 31, e11–e15 (2014)
Introduction
Hepatocyte nuclear factor 4a (HNF4A) is a member of the
steroid/thyroid hormone receptor superfamily and is most
highly expressed in the liver, kidney, pancreatic islets and
intestine [1,2]. HNF4A is a major activator of hepatocyte
nuclear factor 1a (HNF1A), which in turn activates the
expression of a large number of liver-specific genes, including
those involved inglucose, cholesterol and fatty acidmetabolism
[3]. Specifically in the pancreatic islets,HNF4Ahasbeen shown
to control the expression of genes involved in glucose-stimu-
lated insulin secretion [4,5]. HNF4A mutations cause hype-
rinsulinaemic hypoglycaemia and maturity-onset diabetes of
the young (MODY) [6–8]. Annual screening of HNF4A-
mutation carriers with oral glucose tolerance testing was
recommended todiagnosediabetesmellitus at an early stage [7].
Glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide are incretin hormones, which
augment the magnitude of meal-stimulated insulin secretion
from islet b-cells in a glucose-dependent manner [9].
We describe, for the first time, the gradual alteration in
glucose homeostasis and development of MODY in the
HNF4A-mutation carrier after resolution of hyperinsulinae-
mic hypoglycaemia, on prospective follow-up with an annual
oral glucose tolerance test. We also report the GLP-1 and
glucose-dependent insulinotropic polypeptide response to the
mixed-meal test at the onset of diabetes mellitus.
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Research design and methods
KCNJ11, ABCC8 and HNF4A sequencing
Genomic DNA was extracted from peripheral leukocytes
using standard procedures, and the coding exons and intron/
exon boundaries of the ABCC8, KCNJ11 and HNF4A genes
were amplified by polymerase chain reaction (PCR). HNF4A
analysis included the coding exons 1d–10 and the P2
pancreatic promoter. PCR products were sequenced using
standard methods on an ABI 3730 sequencer (Applied
Biosystems, Warrington, UK) and were compared with the
published sequence NM_000457.3 (exons 2–10) and
AY680697 (exon 1d only) using Mutation Surveyor v3.2
(SoftGenetics, State College, PA, USA) [10].
Oral glucose tolerance test
An oral glucose tolerance test (glucose load 1.75 g/kg) was
performed in accordancewith standard recommendations and
the results were interpreted according to published World
Health Organization (WHO) diagnostic criteria [11,12].
Intravenous glucose tolerance test
After an overnight fast of 12 h, 0.5 g/kg of glucose as a 20%
solution was infused within 2 min through an intravenous
catheter in the antecubital region. Blood samples were
obtained at –10, –5, 0, 1, 3, 5, 10, 15, 20, 30, 45 and 60 min
through a second intravenous catheter for estimation of blood
glucose and serum insulin. The glucose disappearance rate K
(%/min) was calculated according to 0.693 9 100/t1/2 (in min),
where t1/2 was the time span (min) required for glucose to fall
by 50% from its level at 10 min [12]. The first-phase insulin
releasewas calculated by the area under the insulin stimulation
curve between 0 and 10 min [12].
Mixed-meal tolerance test
The mixed-meal tolerance test was performed after an
overnight fast of 12 h. A standardized breakfast was ingested
over 10 min, calculated by a dietician based on the total
caloric needs of the patient (25–30% of their daily caloric
intake; 50% of the calories as carbohydrates, 33% lipids and
17% proteins). Blood samples were collected at 0, 15, 30, 45
and 60 min for estimation of blood glucose, serum insulin,
total glucose-dependent insulinotropic polypeptide and
active GLP-1. The area under curve was estimated by the
linear trapezoidal method from the concentration time curve.
Measurement of GLP1 and glucose-dependent insulinotropic
polypeptide
Blood was collected in chilled EDTA-treated tubes containing
DPP-4 inhibitor (10 ll/ml blood:Millipore,Watford, UK) and
aprotonin (trasylol 5000 KIU/ml blood: Bayer, Newbury,
UK). Blood was processed according to the manufacturers’
instructions for the measurement of hormones using commer-
cially available assays. Total glucose-dependent insulinotropic
polypeptide and active GLP-1 were determined using
commercially available human ELISA kits according to the
manufacturer’s guidelines (Millipore). All samples were
performed in duplicate.
Case report
We describe a male Caucasian patient, who was born with
macrosomia [birthweight 4060 g at 39 weeks of gestation;
+1.44 standard deviation score (SDS)] and who developed
neonatal hypoglycaemia requiring a high glucose infusion
rate (18.5 mg kg–1 min–1) to maintain normoglycaemia.
There was no family history of diabetes mellitus. Investiga-
tions revealed inappropriately elevated serum insulin and
inappropriately low b-hydroxybutyrate and non-esterified
fatty acids during an episode of hypoglycaemia on three
occasions, confirming hyperinsulinaemic hypoglycaemia.
Serum cortisol, lactate, ammonia, plasma aminoacids,
carnitine profile and urine organic acids were normal.
Molecular genetic testing for mutation in ABCC8/KCNJ11
was negative. Hyperinsulinaemic hypoglycaemia was suc-
cessfully managed with diazoxide. A 24-h blood glucose
profile and controlled fasting studies were carried out at
regular intervals until the age of 18 months, at which age his
hyperinsulinaemic hypoglycaemia resolved.
At the age of 5 years, after HNF4A mutations were first
reported as a cause of macrosomia and neonatal hyperins-
ulinaemic hypoglycaemia, he underwent molecular genetic
testing and was identified to have a de novo heterozygous
HNF4A mutation (p.M116I, c.317G>A) [13].
Oral glucose tolerance test
Annual monitoring with an oral glucose tolerance test
revealed impaired glucose tolerance and development of
diabetes mellitus according to WHO diagnostic criteria
(Table 1) [11]. At the diagnosis of diabetes mellitus, he
was prepubertal with a bilateral testicular volume of 2 ml.
His HbA1c was 40 mmol/mmol (5.8%) and autoantibodies
What’s new?
• This study reports the first patient with an HNF4A
mutation to have been serially monitored from the
diagnosis of hyperinsulinaemic hypoglycaemia to matu-
rity-onset diabetes of the young.
• We describe, for the first time, incretin response in a
patient with HNF4A maturity-onset diabetes of the
young, which has the potential to influence the man-
agement of these patients.
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(GAD 65 and islet-cell) were negative. His serial BMI and
BMI SDS were normal (Table 1).
Intravenous glucose tolerance test
An intravenous glucose tolerance test (Fig. 1) revealed
normal glucose disappearance rate (1.38% per min; normal
response > 1.2% per min) and first-phase insulin secretion
(2.7 nmol l1 min1 normal 1.4–5.3 nmol l–1 min–1), which
were not indicative of insulin secretion defect [12].
Mixed-meal tolerance test
To understand the reasons for the discrepancy between
diabetic oral glucose tolerance test response and normal
intravenous glucose tolerance test response, we measured the
incretin hormones in response to the mixed-meal tolerance
test (Fig. 2). The 30-min areas under the curve for active
GLP-1 and total glucose-dependent insulinotropic polypep-
tide were 350.9 and 740.2 pmol/l, respectively, which are
lower than the sparse data on these hormones in the
literature in this age group.
Discussion
MODY is a genetically heterogeneous monogenic form of
diabetes mellitus, characterized by early onset, usually before
25 years of age and often in adolescence or childhood, and
by autosomal dominant inheritance [14]. Heterozygous
mutations in the genes encoding the glycolytic enzyme
glucokinase and the transcription factors, HNF-1a, HNF-4a
and HNF1b have been shown to cause MODY. Clinical
studies have shown normal insulin sensitivity, but reduced
glucose-stimulated insulin secretion in subjects with pre-
diabetes with HNF-4A MODY, suggesting that pancreatic
b-cell dysfunction rather than insulin resistance is the
primary defect in this disorder [15].
Recently, HNF4A mutations have been shown to cause
macrosomia and hyperinsulinaemic hypoglycaemia (tran-
sient and persistent) in early life [7,8]. Hence, in HNF4A
mutation carriers, there would need to be a switch from
increased insulin secretion in utero and neonatal life to
decreased glucose-stimulated insulin secretion in later
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Table 1 Oral glucose tolerance test
Age 7 years 8 years 9 years 10 years
BMI,
kg/m2
(SDS)
15.25
(–0.22)
15.8
(+0.05)
17.6
(+0.75)
19.9
(+1.17)
Time
Blood glucose
(mmol/l)
Serum
insulin
(mU/l)
Blood
glucose
(mmol/l)
Serum
insulin
(mU/l)
Blood
glucose
(mmol/l)
Serum insulin
(mU/l) Blood glucose (mmol/l)
Serum
insulin (mU/l)
C-peptide
(pmol/l)
–30 min 4.0 < 2.0 4.0 < 2.0 4.3 < 2.0
0 min 3.6 < 2.0 3.9 < 2.0 4.2 < 2.0 4.8 5.6 440
30 min 8.8 39.8 8.6 39.6 6.9 23 9.2 47.1 1903
60 min 7.7 39.1 8.5 26.4 9.5 30 11.7 66.7 2522
90 min 6.7 22.5 6.8 17.0 8.5 21 11.5 44.1 2214
120 min 6.8 23.6 8.3 28.9 9.3 26 12.3 35.9 1956
150 min 3.4 6.6 6.2 13.8 13.3 36.3 1926
180 min 3.1 < 2.0 3.2 < 2.0 8.4 17.0 1202
ª 2014 The Authors.
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life. The molecular basis for the differential aspects of
HNF-4a deficiency on b-cell function and insulin secretion
in neonates and later in life and the exact timing of the
switch from hyperinsulinaemia to hypoinsulinaemia are
unknown.
We describe the first patient with an HNF4A mutation to
have been serially monitored with oral glucose tolerance
testing through to MODY from hyperinsulinaemic hypo-
glycaemia. The patient was macrosomic at birth and exhib-
ited hyperinsulinaemic hypoglycaemia in the neonatal period
and infancy. Annual oral glucose tolerance test monitoring
highlighted gradually worsening glucose tolerance (impaired
oral glucose tolerance test). At age 10 years, he fulfilled the
WHO oral glucose tolerance test criteria for diabetes mellitus
[11].
Surprisingly, intravenous glucose tolerance testing demon-
strated a normal glucose disappearance rate (K) and first-
phase insulin secretion, contradictory to what one would
expect in MODY (K 1.38% per min; normal response
> 1.2%, first-phase insulin secretion 2.7 nmol l–1 min–1;
normal 1.4–5.3 nmol l–1 min–1). Similar to our results, when
assessed by intravenous glucose tolerance test, Herman et al.
[15] did not find any significant difference in insulin secretion
in HNF4A mutation carriers without diabetes as compared
with control subjects either. As our patient has been
diagnosed at a very early stage of MODY, it is possible that
his insulin secretion as assessed by intravenous glucose
tolerance test is still preserved.
As our patient had a diabetic response to the oral glucose
tolerance test and a relatively normal response to the
intravenous glucose tolerance test, we hypothesized a
suboptimal glucose-dependent insulinotropic polypeptide
and GLP-1 rise in response to oral glucose/meal in HNF4A
mutation carriers. Glucose-dependent insulinotropic poly-
peptide and GLP-1 are peptide hormones, responsible for up
to 70% of the secreted insulin after a meal in healthy
individuals [16].
In response to a mixed-meal tolerance test, the 30-min
areas under the curve for GLP-1 and glucose-dependent
insulinotropic polypeptide were 350.9 and 740.2 pmol/l,
respectively. Rask et al. reported a 30-min area under
the curve for GLP-1 and glucose-dependent insulino-
tropic polypeptide after oral glucose as 460  60 and
1491  136 pmol/l, respectively, in subjects with impaired
glucose tolerance [17]. Huml et al. measured GLP-1 and
glucose-dependent insulinotropic polypeptide in healthy
children, but at a single time point of 90 min after the
standardized breakfast [18]. Unfortunately, there are no
normative data on GLP-1 and glucose-dependent insulino-
tropic polypeptide in healthy control children. Comparing
the results, it does seem that our patient mounted a lower
GLP-1 and glucose-dependent insulinotropic polypeptide
response to the mixed-meal tolerance test, potentially
explaining the discrepancy for responses to the oral glucose
tolerance test and intravenous glucose tolerance test.
However, there are limitations to comparing our results
with adult subjects with impaired glucose tolerance from
another cause.
From our data, it is plausible that incretin response might
be impaired and contributory to glucose intolerance in the
preclinical stages in some patients with HNF4A MODY.
Once glucose intolerance sets in, chronic exposure to
supraphysiologic concentrations of glucose over several
months can lead to gradual loss of insulin gene expression
[19,20].
In conclusion, we report the first patient with HNF4A
hyperinsulinaemic hypoglycaemia to have switched to
maturity-onset diabetes of the young on serial oral glucose
tolerance testing. Impaired glucose tolerance can develop
within the first decade of life in these patients. Our findings
suggest a possibility of impaired incretin response and this
is an exciting area to be explored in HNF4A maturity-onset
diabetes of the young. More HNF4A-positive subjects with
pre-diabetes and diabetes need to be studied to understand
the impact of the HNF4A mutation on incretin effect.
Funding sources
The genetic testing was funded by a Medical Council Grant
award.
Competing interests
None declared.
Acknowledgements
The authors would like to acknowledge the family. The
genetic testing was funded by a Medical Council Grant
award to KH and SE. SE is a Wellcome Trust Senior
Investigator. KH is the guarantor for the manuscript.
References
1 Xanthopoulos KG, Prezioso VR, Chen WS, Sladek FM, Cortese R,
Darnell JE Jr. The different tissue transcription patterns of genes for
HNF-1, C/EBP, HNF-3, and HNF-4, protein factors that govern
liver-specific transcription. Proc Natl Acad Sci U S A 1991; 88:
3807–3811.
2 Sladek FM, Zhong WM, Lai E, Darnell JE Jr. Liver-enriched
transcription factor HNF-4 is a novel member of the steroid
hormone receptor superfamily. Genes Dev 1990; 4: 2353–2365.
3 Kuo CJ, Conley PB, Chen L, Sladek FM, Darnell JE Jr, Crabtree
GR. A transcriptional hierarchy involved in mammalian cell-type
specification. Nature 1992; 355: 457–461.
4 Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ,
Murray HL et al. Control of pancreas and liver gene expression by
HNF transcription factors. Science 2004; 303: 1378–1381.
5 Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim
CB. Hepatocyte nuclear factor 4a regulates the expression of
pancreatic b-cell genes implicated in glucose metabolism and
nutrient-induced insulin secretion. J Biol Chem 2000; 275:
35953–35959.
e14
ª 2014 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
DIABETICMedicine HNF4A hyperinsulinaemic hypoglycaemia, MODY, and incretins  V. B. Arya et al.
6 Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ et al.
Mutations in the hepatocyte nuclear factor-4a gene in matu-
rity-onset diabetes of the young (MODY1). Nature 1996; 384:
458–460.
7 Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP et al.
Macrosomia and hyperinsulinaemic hypoglycaemia in patients with
heterozygous mutations in the HNF4A gene. PLoS Med 2007; 4:
e118.
8 Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT
et al. Persistent hyperinsulinemic hypoglycemia and maturity-onset
diabetes of the young due to heterozygous HNF4A mutations.
Diabetes 2008; 57: 1659–1663.
9 Drucker DJ. The role of gut hormones in glucose homeostasis.
J Clin Invest 2007; 117: 24–32.
10 Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE,
Ellard S. Mutations in the genes encoding the transcription factors
hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset
diabetes of the young and hyperinsulinemic hypoglycemia. Hum
Mutat 2013; 34: 669–685.
11 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and
classification of diabetes mellitus provisional report of a WHO
consultation. Diabet Med 1998; 15: 539–553.
12 Heinze E, Holl RW. Test of b-cell function in childhood and
adolescence. In: Ranke MB ed. Diagnostics of Endocrine Function
in Children and Adolescents, 3rd ed. Basel: Karger, 2003:
318–338.
13 Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B
et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused
by HNF4A gene mutations. Eur J Endocrinol 2010; 162: 987–992.
14 Fajans SS. Maturity-onset diabetes of the young (MODY).Diabetes
Metab Rev 1989; 5: 579–606.
15 Herman WH, Fajans SS, Ortiz FJ, Smith MJ, Sturis J, Bell GI et al.
Abnormal insulin secretion, not insulin resistance, is the genetic or
primarydefect ofMODYin theRWpedigree.Diabetes1994;43: 40–46.
16 Herzberg-Schafer S, Heni M, Stefan N, Haring HU, Fritsche A.
Impairment of GLP1-induced insulin secretion: role of genetic
background, insulin resistance and hyperglycaemia. Diabetes Obes
Metab 2012; 14: S85–90.
17 Rask E, Olsson T, Soderberg S, Holst JJ, Tura A, Pacini G et al.
Insulin secretion and incretin hormones after oral glucose in
non-obese subjects with impaired glucose tolerance. Metab Clin
Exp 2004; 53: 624–631.
18 Huml M, Kobr J, Siala K, Varvarovska J, Pomahacova R,
Karlikova M et al. Gut peptide hormones and pediatric type 1
diabetes mellitus. Physiol Res 2011; 60: 647–658.
19 Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preserva-
tion of insulin mRNA levels and insulin secretion in HIT cells by
avoidance of chronic exposure to high glucose concentrations.
J Clin Invest 1992; 90: 320–325.
20 Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic
exposure of HIT cells to high glucose concentrations paradoxically
decreases insulin gene transcription and alters binding of insulin
gene regulatory protein. J Clin Invest 1993; 92: 514–519.
ª 2014 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. e15
Case report DIABETICMedicine
Clinical and molecular characterisation of
hyperinsulinaemic hypoglycaemia in infants
born small-for-gestational age
Ved Bhushan Arya,1 Sarah E Flanagan,2 Anitha Kumaran,1 Julian P Shield,3
Sian Ellard,2 Khalid Hussain,1 Ritika R Kapoor1
1Developmental Endocrinology
Research Group, Molecular
Genetics Unit, London Centre
for Paediatric Endocrinology
and Metabolism, Great
Ormond Street Hospital for
Children NHS Trust, and The
Institute of Child Health,
University College London,
London, UK
2Institute of Biomedical and
Clinical Science, University
of Exeter Medical School,
Exeter, UK
3Department of Child Health,
University of Bristol, and Bristol
Royal Hospital for Children,
Bristol, UK
Correspondence to
Dr Ritika R Kapoor,
Developmental Endocrinology
Research Group, Molecular
Genetics Unit, Institute of Child
Health, University College
London, 30 Guilford Street,
London WC1N 1EH, UK;
sejjrik@ucl.ac.uk
Received 23 August 2012
Revised 3 January 2012
Accepted 4 January 2013
Published Online First
29 January 2013
▸ http://dx.doi.org/10.1136/
fetalneonatal-2012-302546
To cite: Arya VB,
Flanagan SE, Kumaran A,
et al. Arch Dis Child Fetal
Neonatal Ed 2013;98:
F356–F358.
ABSTRACT
Objective To characterise the phenotype and genotype
of neonates born small-for-gestational age (SGA; birth
weight <10th centile) who developed hyperinsulinaemic
hypoglycaemia (HH).
Methods Clinical information was prospectively
collected on 27 SGA neonates with HH, followed by
sequencing of KCNJ11 and ABCC8.
Results There was no correlation between the maximum
glucose requirement and serum insulin levels. Serum insulin
level was undetectable in ﬁve infants (19%) during
hypoglycaemia. Six infants (22%) required diazoxide
treatment >6 months. Normoglycaemia on diazoxide <5 mg/
kg/day was a safe predictor of resolved HH. Sequencing of
KCNJ11/ABCC8 did not identify any mutations.
Conclusions Serum insulin levels during hypoglycaemia
taken in isolation can miss the diagnosis of HH. SGA
infants may continue to have hypofattyacidaemic
hypoketotic HH beyond the ﬁrst few weeks of life.
Recognition and treatment of this group of patients are
important and may have important implications for
neurodevelopmental outcome of these patients.
INTRODUCTION
Hyperinsulinaemic hypoglycaemia (HH) is charac-
terised by the unregulated secretion of insulin from
pancreatic β-cells in relation to the blood glucose
concentration. It is the commonest cause of severe
and persistent hypoglycaemia in the neonatal and
infancy periods.1 The genetic basis of congenital
forms of HH involves defects in key genes (com-
monest—ABCC8 and KCNJ11 encoding the two
subunits SUR1 and Kir6.2, respectively), which
regulate insulin secretion from pancreatic β-cells.1
HH may be secondary to certain risk factors (such
as maternal diabetes mellitus, perinatal asphyxia
and small-for-gestational age (SGA)). In 1984,
Collins and Leonard ﬁrst described transient HH in
SGA infants.2 It has not previously been documen-
ted whether the HH observed in infants born SGA
is due to defects in the ABCC8/KCNJ11 genes. The
phenotype of a large cohort of SGA neonates who
developed HH has not been studied previously.
The purpose of the present study was to report on
the phenotype, clinical course and results of the
sequencing of ABCC8/KCNJ11 in a cohort of
infants born SGAwho developed HH.
PATIENTS AND METHODS
We prospectively studied the clinical and biochem-
ical features of 27 SGA (deﬁned as birth weight
<10th centile) neonates with HH who were
admitted to two tertiary paediatric referral centres
(Great Ormond Street Hospital and Bristol Royal
Hospital for Children). Neonates with history of
perinatal asphyxia, Rhesus isoimmunisation and
syndromic forms such as Beckwith-Wiedemann
syndrome were excluded from the study. All were
investigated at the time of clinical and biochemical
hypoglycaemia to establish the diagnosis of HH
and were commenced on diazoxide (5–20 mg/kg/
day). Diazoxide responsiveness was deﬁned as
ability to come off intravenous glucose and main-
tain normoglycaemia during a physiological fast.
Following discharge, they were followed up at
3-monthly intervals in outpatient clinic, where
glycaemic control and diazoxide dose were
reviewed. These infants were readmitted for a
24-h glucose proﬁle and a controlled fast after
stopping diazoxide for 3 days, if home glucose
monitoring indicated no recurrence of hypogly-
caemia on <5 mg/kg/day of diazoxide.1 If home
glucose monitoring revealed hypoglycaemic epi-
sodes, the dose of diazoxide was adjusted and the
trial off diazoxide was postponed until the dose
was <5 mg/kg/day.
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What is already known on this topic
▸ Infants born small-for-gestational age are at an
increased risk to develop transient
hyperinsulinaemic hypoglycaemia (HH).
▸ Mutations in ABCC8/KCNJ11 genes are the
commonest cause of congenital HH.
What this study adds
▸ This largest series of small-for-gestational age
infants who developed hyperinsulinaemic
hypoglycaemia (HH) highlights that
hypofattyacidaemic hypoketotic HH may persist
beyond the ﬁrst few weeks of life.
▸ HH in these infants is diazoxide responsive and
not identiﬁed to be due to mutations in
ABCC8/KCNJ11 genes in this series.
▸ Withdrawal of diazoxide treatment when
glycaemic control is maintained at a dose of
<5 mg/kg/day can be safely recommended.
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Genetics
Genomic DNA was extracted from peripheral leukocytes using
standard procedures and the coding regions and intron/exon
boundaries of the ABCC8 and KCNJ11 genes were ampliﬁed
by PCR (primers available on request). Amplicons were subse-
quently sequenced using the Big Dye Terminator Cycler
Sequencing Kit V.3.1 (Applied Biosystems, Warrington, UK)
according to manufacturer’s instruction and reactions were ana-
lysed on an ABI 3730 Capillary sequencer (Applied Biosystems,
Warrington, UK). Sequences were compared with the reference
sequences (NM_000525.3 and NM_000352.3) using Mutation
Surveyor v3.24 software (SoftGenetics, State College,
Pennsylvania, USA).
RESULTS
Clinical characteristics and course
The phenotypic details of 27 SGA infants with HH are sum-
marised in table 1.
The plasma insulin levels were inappropriately elevated during
hypoglycaemia in 22 infants (81%). The remaining ﬁve infants
(19%) had inappropriately low β-hydroxybutyrate and non-
esteriﬁed fatty acids during hypoglycaemia as supportive biochem-
ical evidence of HH. All infants required glucose infusion rate of
≥8 mg/kg/min to maintain normoglycaemia (median 15.6 mg/kg/
min). There was no correlation found between maximum glucose
infusion rate to maintain normoglycaemia and plasma insulin level
during hypoglycaemia (ﬁgure 1). Most (89%) responded to mild–
moderate doses of diazoxide (5–10 mg/kg/day), with three infants
(11%) needing high doses (15–20 mg/kg/day).
Glucose proﬁle and fasting responses at resolution of
hyperinsulinism
In all, 17 infants (63%) underwent a 24 h glucose proﬁle and con-
trolled fast after stopping diazoxide to demonstrate resolution of
hyperinsulinism. None of these infants recorded hypoglycaemia
during a 24-h glucose proﬁle. All infants maintained blood glucose
concentrations above 3.0 mmol/l at the end of fast appropriate for
their age, with 13 infants maintaining blood glucose concentra-
tions >3.5 mmol/l. All infants showed appropriate plasma insulin
suppression and elevation of plasma β-hydroxybutyrate/non-
esteriﬁed fatty acids as evidence of resolution of HH.
Genetic results
Sequencing did not reveal mutations in ABCC8/KCNJ11 genes
in 25/27 DNA samples analysed.
DISCUSSION
This is the largest case series of SGA neonates with HH that
reports the clinical characteristics and ABCC8/KCNJ11 sequen-
cing results in a cohort of 27 subjects. Collins et al ﬁrst
described transient HH in three SGA infants and subsequently
reported HH in ﬁve of 27 SGA neonates studied, suggesting it is
common in SGA neonates.2 3 It is important to recognise this as
neonates with HH are especially prone to the complications of
hypoglycaemia because of their inability to generate alternative
fuels, such as ketone bodies.
In our study, despite other evidence of hyperinsulinism,
plasma insulin levels were undetectable during hypoglycaemia in
5/27 SGA neonates. We did not ﬁnd any correlation between
the maximum glucose infusion rate required to maintain normo-
glycaemia and plasma insulin levels. This is explained by the
short half-life of insulin of 4–5 min and rapid clearance by the
liver before it reaches peripheral circulation. In a study by Hoe
et al,4 plasma insulin was inappropriately elevated in only 11 of
24 neonates who had transient prolonged neonatal hyperinsu-
linism. Our results corroborate these ﬁndings and highlight the
value of other parameters (apart from plasma insulin) in the
diagnosis of HH.
In this case study of SGA infants referred to two tertiary hos-
pitals with HH, all infants responded to diazoxide, though the
dose was variable ranging from 5 to 20 mg/kg/day. Diazoxide
was successfully stopped in 21 (78%) patients by 6 months of
age. In the remaining six infants, ﬁve needed diazoxide until
10 months of age and one infant needed prolonged treatment
until 22 months. In a study of 26 neonates with hyperinsulinism
which included 7 SGA neonates, HH resolved by a median age
of 181 days (range, 18–403 days).4 Fafoula et al5 also reported
prolonged transient HH up to 9 months in SGA infants.
In our cohort, no recurrence of HH was noticed after stop-
ping diazoxide. This highlights that with the management proto-
col whereby diazoxide was stopped when good glycaemic
control was maintained with diazoxide dose <5 mg/kg/day, the
risk of recurrence of hypoketotic hypoglycaemia brain injury to
these vulnerable infants is avoided.
To our knowledge, no previous study has reported on the
genetic results of SGA neonates who developed HH. In our
study, no mutations in ABCC8/KCNJ11 were identiﬁed in these
SGA infants. However, rarer genetic causes of HH due to muta-
tions in GLUD1, HADH, GCK and HNF4Awere not excluded.
CONCLUSIONS
SGA infants may continue to have hypofattyacidaemic hypoke-
totic HH beyond the ﬁrst few weeks of life. Recognition and
Table 1 Clinical characteristics of 27 small-for-gestational age
infants with hyperinsulinaemic hypoglycaemia
Age at presentation (days)
Median (range) 1 (1–14)
Gestational age (weeks)
Median (range) 37 (32–42)
Birth weight (g)
Median (range) 2300 (1100–3100)
Male (%) 66.6
Ethnic origin (n)
Caucasian 17
Afro-Caribbean 6
Asian 2
Mixed 2
Diazoxide responsive (%) 100
Glucose infusion rate (mg/kg/min)
Median (range) 15.6 (8.0–20.8)
Figure 1 Figure demonstrating the lack of correlation between
maximum glucose infusion rate and plasma insulin concentrations.
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treatment of this group of patients are important and may have
important implications for neurodevelopmental outcome of
these patients. Plasma insulin levels during hypoglycaemia taken
in isolation can miss the diagnosis of HH and hence other para-
meters (such as glucose infusion rates and production of free
fatty acids/ketone bodies during hypoglycaemia) must be consid-
ered in the diagnosis. Withdrawal of diazoxide treatment when
glycaemic control is maintained at a dose of <5 mg/kg/day can
be safely recommended.
Finally, the genetic aetiology of HH in SGA infants is not
understood and, in this study, mutations in the common genes
implicated in the aetiology of congenital hyperinsulinism were
not identiﬁed. Further studies are required to understand the
underlying mechanism of HH in these infants.
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